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This thesis describes the design and synthesis of a library of novel 3-D fragments for use in 
drug discovery. Chapter 1 explains the process of fragment based drug discovery in detail, 
as well as why the synthesis of novel 3-D fragments is needed and the previous work carried 
out in the group to design and select 33 initial 3-D fragments.  These fragments were 
designed to fit industry-recommended guidelines on physicochemical properties and their 3-
D shape was analysed using principal moments of inertia (PMI) plots to demonstrate that 
they occupied under-explored areas of 3-D space. Chapter 2 describes synthetic efforts 
towards four of these fragments, A-D.  Fragments A and B were successfully synthesised 
using a 1,3-dipolar cycloaddition with an alkyne followed by hydrogenation to introduce the 
desired stereochemistry. Fragments C and D could only be synthesised as a mixture of 
diastereomers. However, while exploring a new approach to synthesise fragment D, four 
analogues, fragments E-H were prepared. 
 
Chapter 3 details a new approach that was devised in order to synthesise 3-D fragments that 
contained greater functional group variation. This route focussed on the triflation, Suzuki-
Miyaura cross-coupling, hydrogenation and derivatisation of β-ketoesters to give 3-D 
fragments. Using this route, 24 novel 3-D fragments were synthesised. 
 
Finally, Chapter 4 contains an analysis of both the physicochemical properties and the 3-D 
shapes of the 1st and 2nd generation 3-D fragments. These properties are compared to both 
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INTRODUCTION 
 
Drug discovery is a huge and many-faceted industry, with different companies using 
different approaches at every stage of the process. Within the initial screening process, a 
variety of techniques including high throughput screening, DNA encoded libraries, and 
target-focussed libraries are used. All of these offer their own pros and cons and all have led 
to drug discovery programmes. The idea of screening smaller molecules than those used in 
the techniques listed above in order to start the drug discovery process with highly efficient 
hits started in the early 1980s,1 but the technology required for the detection of weakly-
binding molecules meant that the concept was not used practically until the late 1990s. In 
1996, work by Fesik et al. kickstarted the field of fragment based drug discovery (FBDD). 
Since its inception 23 years ago, FBDD has resulted in three FDA approved drugs (Figure 
1.1) and dozens of clinical candidates, proving it to be a valuable technique. 
 
Figure 1.1: Current FDA-approved drugs derived from fragment based drug discovery 
Since the publication of the landmark paper ‘Escape from Flatland’ in 2007, attention has 
turned to the synthesis of 3-D fragment libraries, the topic of this thesis. This Chapter 
includes an overview of FBDD (Section 1.1), explanation of methods used to quantify 3-D 
shape (Section 1.2), a review of recent literature on the synthesis of 3-D fragments (Section 
1.3) and previous work in the group on this topic (Section 1.4) before describing the aims of 
this project (Section 1.5).  
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1.1  Fragment Based Drug Discovery 
1.1.1 Overview of Fragment Based Drug Discovery 
Fragment based drug discovery (FBDD) is a method of drug discovery which screens 
smaller molecules than other approaches in order to provide small, highly efficient starting 
points for drug discovery programmes. Screening smaller molecules gives a number of 
important advantages including greater hit rates, better sampling of chemical space and 
increased ligand efficiency. These advantages have allowed the field of FBDD to grow 
rapidly, from its first empirical use in 1996 by Fesik et al.2 to providing three clinically 
approved drugs and numerous clinical candidates just over twenty years later.3–5 A 
representation of the FBDD process is shown in Scheme 1.1, demonstrating how the reduced 
complexity of fragments results in increased hit rate compared to HTS compounds.  
 
Scheme 1.1: Schematic representation of the FBDD process 
Fragment libraries are relatively small, with libraries typically numbering 1,000-20,000 
compounds. The small size of the library is made possible by the fact that these smaller 
compounds better sample chemical space. Consider Scheme 1.1, where the HTS-type 
compounds possess the requisite groups to bind but are unable to do so. As molecules 
become more complex, the chance that those groups are all correctly oriented decreases 
exponentially, hence the need to screen larger collections. Once the fragment hits are 
obtained, there are three possible strategies for developing a hit compound: growing, linking 
and merging. Should multiple hits be obtained in close but not identical binding locations 
then either merging or building a linker between two or more different fragments offers a 
very attractive way to increase potency quickly. Often though, this cannot be performed as 
multiple sites are not found, in which case fragment growing is used. The aim of all three of 
HTS-type compounds 
Pick Target  Fragment Library Screen Fragments 
Fragment Hits  
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these techniques is to identify a molecule that has both high enough potency and good 
enough physicochemical properties to function as a starting point for a full drug discovery 
programme. 
Fragment based drug discovery is a relatively new field, with the first key theoretical 
contribution published in 1981 and no breakthroughs until 1996. In 1981, Jencks detailed 
the factors involved in the binding of small molecules and the potential for merging initial 
small molecule hits into larger compounds.1 The idea of the binding of small molecules was 
then further explored6,7 before the first practical results were reported in 1996 by Fesik et 
al.2 Fesik’s group describes the screening of a relatively small compound library (around 
10,000 compounds) with an average molecular weight of just 213 Da. Two hits were 
identified that bound in close but separate locations in the target protein. Optimisation of 
these two fragments led to ligands 1 and 2, with mM and μM potencies. The two ligands 
were then linked to give ligand 3 which displayed substantially improved affinity over its 




This ability to synthesise a low nM affinity ligand for the target protein from a library of 
10,000 small molecules initiated the field of FBDD. Since its inception, improvement in the 
sensitivity of various screening methods has made hit detection easier. Hit detection has 
always been a significant issue with FBDD, as such small molecules typically only bind very 
weakly to target proteins. However, over the past two decades, new methods have evolved 
for the screening of fragments and other methods, such as NMR screening techniques, have 
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improved to the point where FBDD is now a substantial part of the drug discovery landscape. 
Key advances include work from Nienaber et al.8 on the use of X-ray crystallography as a 
screening technique as well as the development of techniques such as weak affinity 
chromatography (WAC),9 surface plasmon resonance (SPR)10 and isothermal titration 
calorimetry (ITC).11 
1.1.2 Properties of Fragments 
Although the concept of FBDD had been around for more than twenty years, there were 
initially no criteria set to define what a fragment actually was. The understanding was that 
fragments were smaller than lead-like compounds used in typical HTS programmes, but it 
took until 2003 for fragment space to be defined. Congreve et al. from Astex proposed a 
fragment ‘rule of three’,12 based on Lipinski’s ‘rule of five’ for orally-available drugs.13 It 
contained five criteria: molecular weight (MW) ≤ 300, three or fewer rotatable bonds, H-
bond donors and H-bond acceptors and values of cLogP ≤ 3. This rule remains popular today, 
in part because of its simplicity and the broadness of its criteria. 
In 2015, researchers from Astex aimed to streamline the ‘rule of three’ into tighter guidelines 
based on their own successes and experience in FBDD programmes. Table 1.1 shows a 
comparison of the initial ‘rule of three’ and the more recent updated guidelines for X-ray 
screening. Although Astex proposed other criteria which are more difficult to quantify, such 
as the importance of multiple synthetically accessible vectors to allow for fragment growth, 
the most notable guidelines were the tight range of desired molecular weight and cLogP. 
These were in part due to Astex’s focus on X-ray crystallography as a primary screening 
technique with molecules adhering to these criteria providing a greater chance of 
progressible hits. 
 
Property ‘Rule of Three’ Updated Guidelines 
Molecular Weight (Da.) ≤ 300 140-230 
Heavy Atom Count (HAC) N/A 10-16 
cLogP ≤ 3 0-2 
Rotatable Bonds ≤ 3 ≤ 3 
H-Bond Donors ≤ 3 N/A 
H-Bond Acceptors ≤ 3 N/A 
l 
Table 1.1: Fragment space guidelines 
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1.1.3 Fragment Based Drug Discovery versus High Throughput Screening 
FBDD is most commonly compared to the technique from which it evolved, high throughput 
screening (HTS). HTS functions very similarly to FBDD but both the molecules (MW 300-
500) and the libraries in HTS tend to be significantly larger. In particular, HTS focusses on 
lead-like compounds, which have less strict guidelines and tend to aim for properties within 
Lipinski’s ‘rule of five’.13 The difference in size between these two classes of compounds 
causes some marked differences during screening, including hit rate, ease of screening, 
ligand efficiency and library size. A review of recent literature on FBDD programmes 
performed by Johnson et al.14 compared the properties of fragment hits reported in 2015-
2017 with the lead compounds that resulted from those hits (Figure 1.2). The differences 
between compounds that are considered ‘lead-like’ and ‘fragment-like’ were evident, 
particularly in terms of molecular weight. For the purpose of the analysis, fragments were 
defined as having MW ≤ 300, but they did not have to comply with other ‘rule of three’ 
criteria. The spread in cLogP values is particularly notable given that 5% of fragment hits 
disobeyed the ‘rule of three’ based on cLogP while only 60% conformed to the more 
stringent updated guidelines. 
 
 
Figure 1.2: Figure from Johnson et al. comparing fragment hits and the resulting lead 
compounds14 
The differences in potency, hit rate and ease of screening between fragments and lead-like 
compounds are inextricably linked. Lead-like compounds, being both larger and typically 
more lipophilic, usually form several key interactions with a target during a binding event. 
This results in strong binding with the protein, particularly when compared to a smaller 
molecule that may only have one or two interactions. However, the binding groups must be 
in a near-perfect alignment for the interactions to take place, otherwise the lead-like 
compound cannot bind properly and the enthalpy of one binding interaction would be 
Introduction 
 6  
counteracted by the significant entropy loss of binding a large molecule. Furthermore, even 
if all the binding groups are perfectly oriented, a single group out of place elsewhere in the 
molecule may cause steric clashing that prevents the molecule from binding. Hit rates in 
HTS are therefore very low, with libraries numbering hundreds of thousands or even millions 
of compounds being screened in order to provide serviceable leads for drug discovery 
programmes. In contrast, FBDD focusses on using typically one or two binding groups in a 
molecule. This gives a much better chance for binding, as the groups are more likely to be 
correctly oriented to bind, and the small molecule means that there is much less chance of 
steric clashing. The size of the molecule also reduces the entropy cost on binding. However, 
even this lower cost can be difficult to overcome with only one or two binding interactions 
with the target protein. Fragments therefore tend to have a better hit rate, with 2% often the 
expectation, but the hits obtained are of substantially lower potency. Indeed, it was the low 
potency of the hits that caused FBDD to only become a viable process within the last 25 
years. This has now been overcome though with the wealth of screening techniques that are 
now available.  
Whereas HTS libraries feature hundreds of thousands of compounds, fragment libraries 
typically contain only a few thousand compounds. This is due to both the greater hit rate 
with fragments and the ability of smaller molecules to more effectively sample chemical 
space. Reymond has done extensive work on enumerating the number of possible molecules 
that contain a certain number of medicinally relevant heavy atoms (carbon, oxygen, nitrogen, 
and fluorine).15,16 In work with Fink, it was shown that there are approximately 26.4 million 
realistic compounds consisting of 11 or fewer carbon, oxygen, nitrogen and fluorine atoms 
(plus hydrogen).15 This does not take into account other medicinally relevant but less 
common atoms such as sulfur and chlorine. Of these 26.4 million compounds, almost exactly 
half (13.2 million) were ‘rule of three’ compliant. When this paper was published in 2007, 
the authors lacked the computational power to move beyond 11 heavy atoms. However, in 
2015, Reymond detailed the enumeration of all possible realistic structures of molecules up 
to 17 heavy atoms containing carbon, nitrogen, oxygen, sulfur and the halogens. The number 
of possible structures was a staggering 166.4 billion. For comparison, there are only 977 
million possible structures with up to 13 heavy atoms using the same parameters. Although 
still a huge number, and far beyond any current synthetic capabilities, this library is just 
0.6% of the size of the 17 heavy atom library. Hence, a library of 10,000 lead-like 
compounds consisting of 17 heavy atoms would cover the same percentage of chemical 
space as a library of only 60 fragments. This, combined with the higher hit rate that also 
Introduction 
 7  
allows for the synthesis and screening of fewer compounds, is part of what makes FBDD 
such a promising area, and also what makes it so well suited for academic collaborations. 
The last key advantage that FBDD has over HTS is the versatility of fragment hits. As shown 
in Figure 1.3 from Churcher et al.,17 molecular weight and cLogP tend to increase as a hit is 
developed into a viable clinical candidate. By starting with smaller, more hydrophilic 
compounds, there is more room during the optimisation process to improve potency without 
compromising lipophilicity. Increasing lipophilicity has been shown to correlate with 
increased chance of failure during development due to off-target effects,18,19 meaning that 
starting with hit compounds that have low cLogP is very attractive to pharmaceutical 
companies. 
 
Figure 1.3: Figure from Churcher et al. showing the progression towards drug-like space17 
1.1.4 Fragment Based Drug Discovery Successes 
Since its inception in 1996, FBDD has resulted in over 30 clinical candidates20 and three of 
these have gone on to become approved drugs: Vemurafenib, Venetoclax and Erdafitinib 
(see Figure 1.1).3–5 All three are anti-cancer drugs, targeting melanoma, lymphoma and 
bladder cancer respectively. As is evident from the size of their structures, the approved 
drugs derived from FBDD have grown significantly from the fragments they were likely 
derived from. An abbreviated scheme showing the discovery process for Vemurafenib is 
shown in Scheme 1.3. The initial hit, fragment 4, was a simple aza-indole, with early 
optimisation focussing on the linker and the linked phenyl ring. The additional methoxy 
group in the evolved fragment 5 formed a key hydrogen bonding interaction that improved 
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potency 100-fold as well as the selectivity. Further optimisation of the same aromatic ring 
lead to another 100-fold potency increase in the clinical candidate 6 before a chlorophenyl 
group was added to the azaindole to give the final compound, Vemurafenib. The structure 
of the initial fragment hit has been almost entirely preserved in the final compound in order 
to maintain the key binding interactions and the shape of the compound in the binding 
pocket. 
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1.2 Quantifying 3-D Shape 
Although comparing the 3-D shape of different molecules is relatively easy to do 
qualitatively, it is much more difficult to do quantitatively. A number of methods have been 
developed in an attempt to do so, each with their own pros and cons. As such, no one method 
has been agreed upon universally as the best method for quantifying 3-D shape, although 
several are commonly used. Four of the most common techniques are described in this 
Section. 
The simplest method is to calculate the fraction of sp3 carbons (Fsp3) which is the number 
of sp3 hybridised carbons divided by the total number of carbons (Equation 1). This gives a 
number between 0 and 1. Despite being created as recently as 2009 by Lovering et al.,21 Fsp3 
has already become one of the most popular methods for assessing 3-D character. 
𝐹𝑠𝑝3 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝3 ℎ𝑦𝑏𝑟𝑖𝑑𝑖𝑠𝑒𝑑 𝑐𝑎𝑟𝑏𝑜𝑛𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑟𝑏𝑜𝑛𝑠
    (1) 
Fsp3 has proved popular for two main reasons: its ease of calculation and its proven 
usefulness. Unlike other methods, Fsp3 is quick to calculate and gives a single number value 
that can be easily compared to other libraries. Furthermore, in the seminal paper ‘Escape 
from Flatland’ that proposed the use of Fsp3, Lovering et al. showed that increasing Fsp3 
correlated with reduced clinical attrition rate. As shown in Figure 1.4, the average Fsp3 
values increased at every stage in the process since compounds with lower Fsp3 were more 
likely to fail. Drugs failing in the clinic cost pharmaceutical companies huge amounts of 
money every year, so finding a molecular property that correlates with clinical success was 
seen as a major breakthrough. 
 
Figure 1.4: Graph showing the average Fsp3 of molecules at each stage of the drug 
discovery process from Lovering et al.21 
However, Fsp3 does have some drawbacks. Chief among these is its use as a measure of 3-
D shape. Although being easy to calculate is a significant advantage, Blagg et al. pointed 
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out in 2012 that two molecules with the same Fsp3 value can have vastly different shapes. 
They used the example of molecules 7 and 8, both of which have Fsp3 = 0. However, whereas 




Figure 1.5: Demonstration of the limited correlation between Fsp3 and 3-D shape from 
Blagg et al.22 
Fsp3 is therefore useful as an easy to calculate figure that gives some indication of 3-D shape 
and allows for rapid comparison of different libraries. It is important to note though that it 
only gives an indication of 3-D character – a library of compounds with an Fsp3 value of 0.5 
is highly likely to be more 3-D than one with an average Fsp3 of 0.1. 
In 1986, Meyer23 described a number of ways to quantify 3-D shape using a concept he 
called ‘globularity’ after a term first used by Timmermans in 1954.24 Two of these methods 
could be deemed as forerunners to plane of best fit (PBF) and principal moments of inertia 
(PMI) plots: one method measured the cross-sectional area of a molecule along a plane 
whereas the other compared the ratios of the moments of inertia along each axis. These will 
not be described here as they have been improved upon since by Blagg et al. (PBF)22 and 
Sauer and Schwarz (PMI).25 The third method is substantially different and compares the 
computationally generated surface area of a molecule with the surface area of a sphere with 
the same volume. First, the lowest energy conformation of a molecule is computationally 
generated. Then, the van der Waals radius sphere is traced around each atom to give the 
shape of the molecule. The surface area of this shape is then calculated to give the actual 
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surface area, Aact. Then, the ideal surface area is calculated by using the total van der Waals 






3 ≈  4.84𝑉𝑣𝑑𝑤
2
3    (2) 
With the actual and the van der Waals surface area calculated, the ratio of the two is taken. 
Dividing the van der Waals area by the actual surface area then gives a number between 0 
and 1. A value of 1 indicates that both surface areas are identical and the molecule is 
therefore spherical, whereas a value closer to 0 indicates a flatter molecule. 
This method of calculating globularity shares some of the same benefits as Fsp3, namely that 
the process gives out a single value between 0 and 1 that allows for quick and easy 
comparison between compounds and libraries. It is a better quantifier of 3-D shape than Fsp3 
as the data uses the conformation of the molecule. However, this process has several 
drawbacks. Since it focusses on surface area, atoms with large van der Waals radii cause 
significant distortion. In addition, a molecule with several planar sections will have the same 
globularity value irrespective of the orientation of those planar sections. Biphenyl 9, for 
example, could have the two rings in-plane or twisted 90° to each other (Figure 1.6). These 
planar sections will have minimal overlap, and both conformations will have similar 
globularity values despite one being planar and the other not.  
 
Figure 1.6: Conformations of biphenyl 
Since its introduction in 2012, plane of best fit (PBF) has proved to be a very popular method 
for quantifying 3-D shape. Conceptually simple, PBF fits a 2-D plane through a 3-D 
molecule. The method involves initial calculation of the lowest energy conformation. The 
plane is then computationally optimised to ensure that it has the smallest possible deviation 
from the atoms of the calculated conformation (Figure 1.7). The average deviation of the 
heavy atoms from that plane is then given as the deviation from planarity (DFP) value. 
 
Figure 1.7: Figure from Blagg et al. showing the PBF for cyclohexane and its deviations 
from planarity22 
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The higher the DFP value, the further a molecule is from being 2-D and thus the more 3-D 
it is. Although in theory the DFP value has no upper limit, in practise Blagg et al. showed 
that drug-like molecules rarely exceed a DFP value of 2 and proteins have an upper limit of 
around 10. PBF should therefore not be used to compare molecules of significantly different 
size, but this is not an issue for fragment libraries where fragments are typically capped at a 
MW of 300 Da. Blagg et al.22 compared the PBF values for a given set of compounds with 
other methods of quantifying 3-D shape. They showed a clear correlation between PBF and 
globularity, but no correlation with Fsp3, confirming that Fsp3 is not a good measure of 3-D 
shape.  
The final method for quantifying 3-D shape described here is principal moments of inertia 
(PMI), which is represented graphically by PMI plots. PMI focusses on the moments of 
inertia of a molecule along three principal axes and requires the computational calculation 
of the ground state conformation of a molecule. Then, the moments of inertia in the x, y and 
z axes are calculated. The calculated moments of inertia are then sorted in ascending order 
from I1 to I3. These three moments of inertia are then normalised using Equations 3 and 4 to 








       (4) 
The NPR values are then plotted on a graph which gives a representation of their 3-D shape. 
Figure 1.8 shows an example PMI plot. If all three moments of inertia of a compound’s 
conformation are equal (I1 = I2 = I3) then the compound will have NPR values of (1,1) and 
it will be spherical. An example of this is as adamantane. A compound that is disc-like such 
as benzene will have NPR values of (0.5,0.5) and be located at the bottom of the plot. Finally, 
a rod-like compound such as a polyalkyne will have NPR values of (0,1) and be located at 
the top left corner. One of the key advantages of PMI plots is that the data are very easy to 
visualise. Compounds that are more spherical are closer to the top-right corner of the plot 
whereas flatter compounds are closer to the ‘rod-disc axis’, the term used for the left-hand 
side of the triangle. Another advantage is that PMI can be used to generate a single value for 
each conformation of a compound that describes its 3-D character, enabling easy comparison 
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Figure 1.8: Example PMI plot with structures of 1-D, 2-D and 3-D compounds and ∑NPR 
values added 
In order to help assess 3-D shape further, the plot can be divided into the ten sections shown 
in Figure 1.8. Each section is delineated by a line corresponding to a single ∑NPR value. 
∑NPR, simply calculated by adding the NPR1 and NPR2 values, is a number between 1 and 
2 where 1 is the rod-disc axis and 2 is spherical. These ∑NPR values are shown along the 
top of the PMI plot in Figure 1.8. Blagg et al compared PBF with PMI plots to see if the two 
methods correlated.22 PBF value was plotted against ∑NPR for a library of ~4 million 
compounds, using ∑NPR > 1.07 and PBF > 0.6 to define a compound as being 3-D. 
Importantly, the two methods clearly correlated well, with increasing PBF score 
corresponding to increasing ∑NPR, although there were a significant number of compounds 
that were deemed 3-D by one method but not by the other. 
Overall, Fsp3 remains the most popular metric, but it is important to recognise that Fsp3 does 
not correlate with other 3-D shape metrics and so should not be used to classify a molecule 
as 3-D or not.22 Of the other three methods, PBF and PMI plots are by far the most popular 
and the strong correlation between the two shows that either can be used, although PMI plots 
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1.3 Recent Approaches to the Generation or Synthesis of 3-D Fragments 
Since Lovering et al. published ‘Escape from Flatland’ in 2009, there has been significant 
interest in the synthesis of 3-D fragments from both academia and industry. A number of 
different approaches have been taken to synthesise libraries of 3-D fragments, including: 
• Diversity-oriented synthesis (DOS), in which one or two poised and versatile 
intermediates are transformed using a range of reactions to give a library of 
compounds containing a variety of different scaffolds 
• Computational generation of shape-diverse libraries based on lists of commercially 
available compounds followed by purchasing a representative set. This is often 
carried out to start a library before synthesis of other fragments which are added to 
the library. 
• Degradation of natural products to give their constituent fragments. This can either 
be done computationally, breaking natural products down to their constituent parts 
and then purchasing or synthesising these parts, or chemically, where natural 
products are reacted in order to obtain constituent fragments. 
• Diversification of specific scaffolds to give a fragment set. Unlike DOS, where 
multiple scaffolds are synthesised, a popular approach is to synthesise a limited 
number of scaffolds featuring several synthetic handles and then to use these handles 
to diversify the scaffolds into a library of fragments. 
• Use of a single piece of synthetic methodology in order to access a range of 
fragments. Here, the diversity comes from being able to use a range of substrates in 
a single key reaction to give good variation in the fragments formed. This can overlap 
with the previous method, where some variation is introduced in the key reaction 
then further diversification is carried out. 
All of these methods have led to the successful creation of 3-D fragment libraries. In this 
section, examples where these methods have been employed to obtain 3-D fragments 
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1.3.1 Diversity-Oriented Synthesis 
The first example where diversity-oriented synthesis (DOS) was used to create a small 
library of 3-D fragments was reported by Young et al.26 The aim was to create a library of 
fragments featuring diverse scaffolds and high 3-D character as quantified by PMI plots. 
Previously, DOS and FBDD had been seen as two opposing methods due to the relatively 
large molecules that are typically produced by DOS.27 However, in this study, DOS was 
used to synthesise molecules with MW ≤ 300. Using a build/couple/pair (B/C/P) approach 
starting with either 2,4- or 2,2-disubstituted pyrrolidines, a variety of fused bicyclic and 
spirocyclic fragments were synthesised. Scheme 1.4 shows one example where pyrrolidine 
10 was ‘built’, then a group containing a terminal alkene was ‘coupled’ on to the pyrrolidine 
nitrogen to give sulfonamide 11 and finally the two alkenes were ‘paired’ using Grubbs 
metathesis. Subsequent transformations gave fragment 12. Using this method, 35 fragments 
containing a variety of ring sizes were synthesised. 
 
Scheme 1.4 
3-D shape analysis was performed on the 35 fragments and compared to an analysis of 
18,534 fragments from the ZINC database. Figure 1.9 shows the resulting PMI plot with the 
synthesised compounds shown in red and a selection of fragment structures shown 
alongside. The blue shaded area represents a ∑NPR value approximately ≤ 1.2 and 75% of 
the ZINC database compounds are in this region. 
  
Figure 1.9: PMI plot and example fragments from Hung et al.26 
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This strategy was also used by Nelson, Marsden et al. in 2015 to synthesise compounds 
based on disubstituted amino acids. Although the paper focussed on the synthesis of 
scaffolds which could be turned into a large library of lead-like compounds, the scaffolds 
themselves would all be interesting 3-D fragments if deprotected. Starting with allyl 
substituted proline methyl ester 13, phenylalanine or the azetidine and piperazine analogues, 
a wide variety of scaffolds were prepared. First, a variety of groups were attached to the 
nitrogen, for example the acyl urea in 14 (Scheme 1.5). These attached groups were then 
either coupled with the allyl group (as in compound 15) or with the ester (compound 16) to 
give the different scaffolds. In total, 22 scaffolds were synthesised this way, all with very 




The use of DOS to synthesise a fragment library was described by Spring et al. in 2018.28 
Starting with the versatile, functionalised amine 17, each of the three synthetic handles 
(amine, alkyne and ester) were either further functionalised or coupled with each other in a 
variety of combinations. Ultimately, 25 different scaffolds were synthesised using this 
process with good variation of ring size, functionality and binding vectors (Scheme 1.6). 
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Scheme 1.6 
A library of 40 fragments was synthesised from the different scaffolds and their 3-D shape 
was assessed using PMI analysis (Figure 1.10). As well as these 40 fragments, the PMI plot 
also shows a virtual library of phenyl derivatives of the 40 fragments and a commercially 
available 1000 fragment library (from Maybridge). Using ∑NPR > 1.1 as their criteria for 
classifying a compound as 3-D, 37 of the 40 synthesised compounds were deemed to be 3-
D as opposed to only 28% of the Maybridge library. 
 
Figure 1.10: PMI plot of compounds from Spring et al.28 
A similar approach was taken by the same group in 2019 using amines 18 as the starting 
point.29 This time the focus was on building a library of spirocyclic compounds. For 
example, a series of tetramic acid spirocycles with various ring sizes of cycloalkene were 
synthesised (Scheme 1.7). The ability to synthesise a range of alternatives to the tetramic 
acid ring was also demonstrated. Oxazolidones, oxazolines and morpholinones were formed 
in one or two steps from a key N-Boc amino alcohol intermediate (Scheme 1.7). 
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The alkenes in the scaffolds in Scheme 1.7 were then diversified to add alcohol, epoxide, 
aziridine, difluorocyclopropane, ketone and dibromo functionality to the fragments. In total, 
28 fragments were synthesised with attractive physicochemical properties that fitted within 
the updated fragment guidelines. Furthermore, PMI analysis showed that the compounds 
exhibited substantially higher average ∑NPR values than a library of 1000 commercially 
available fragments from Maybridge, including no compounds with ∑NPR < 1.1 (Figure 
1.11). 
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1.3.2 Computational Generation of Shape-Diverse Libraries 
In 2013, work was published by a consortium of academic and industrial collaborators on 
the creation of a library of 3-D fragments.30 Industry partners in the consortium had 
identified a lack of compounds with good 3-D shape in their libraries and sought to rectify 
this through this project. The PMI plot in Figure 1.12 (left) shows a collection of 1000 
fragments belonging to one of the industrial collaborators and is notable for the high 
concentration of compounds along the rod-disc axis. To kick-start the project, a process was 
devised to take an initial list of 13.4 million compounds available from e-molecules or the 
ZINC database and narrow it down to a library of just 200 fragments that were highly shape 
diverse, had good physicochemical properties and would be available for purchase. Initial 
filters to remove compounds which did not fit typical fragment properties (9-18 heavy atoms, 
XlogP < 3, total polar surface area < 3, number of rotatable bonds < 4) and/or contained 
PAINS motifs (functional groups likely to cause false hits) left 180,000 potential 
compounds. These were then passed through an algorithm to select a set of 5,000 compounds 
which covered 3-D space (based on PMI analysis) as evenly as possible. Finally, each 
compound within this set was reviewed by medicinal chemists in industry to assess the 
attractiveness of each compound as an addition to their fragment libraries to give a set of 
200 compounds. Of these, 20 were unavailable, 10 failed QC and the remaining 170 
fragments formed the initial library. The PMI plot in Figure 1.12 (right) shows these 170 
fragments and their even coverage of 3-D space, a clear improvement on the industry 
fragment collection. However, it is worth noting that in attempting to cover 3-D space 
evenly, a substantial number of these fragments have a ∑NPR value < 1.1 despite this area 
already being well populated by other libraries.  
 
Figure 1.12: PMI plots of 1,000 fragments from an industry collection (left) and the 170 
fragments from the 3-D fragment consortium library (right)30 
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Another example of computationally generating a library of compounds which could then 
be purchased was described by Nelson, Marsden et al.31 They sought to combine 60 
purchased fragments with 20 synthesised fragments (based on a few synthetic routes) to give 
a library of 80 fragments that covered 3-D space as evenly as possible. Four routes were 
selected for syntheses, giving 63 potential scaffolds and, after decoration, a total of 66,000 
potential compounds. Both these and the 12.7 million compound ZINC database were first 
put through a filter to ensure that heavy atom count (HAC) was between 18 and 22. This is 
an interesting choice since typical fragment libraries have a lower average HAC. The authors 
comment that this allowed them to select more of their potential scaffolds, but it did result 
in around 40% of the compounds after the HAC filter having a MW > 300, which are not 
‘rule of three’ compliant fragments. Selection of 100,000 of the successful ZINC fragments 
at random followed by further filtering for AlogP between –1 and 3 narrowed the field down 
to approximately 9,000 synthesisable fragments and 67,000 ZINC fragments. These were 
then passed through an algorithm to select a shape-diverse set of fragments which resulted 
in 20 synthesisable fragments and 60 ZINC fragments. The PMI plot of the resulting library, 
as well as the structures of some of the synthesised fragments, is shown in Figure 1.13. 
 
Figure 1.13: PMI plot of the library from Nelson, Marsden et al. with synthesised 
fragments in blue, ZINC fragments in grey and successful hits circled32 
As evidenced by the structures in Figure 1.13, one criticism of this fragment library would 
be the high levels of complexity in these fragments, with multiple binding groups within 
each fragment. The library was tested against Aurora-A kinase using high-throughput X-ray 
crystallography screening. Four of the 80 fragments were hits, all with highly diverse shapes 
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1.3.3 Degradation of Natural Products 
Natural products have historically been an excellent source of drug and drug-like 
molecules.33 One approach to harnessing some of the potential of natural products is to break 
down natural products into their constituent fragments and then screen these fragments 
against targets. With typically high Fsp3 values and number of stereogenic centres, natural 
product-based fragments have shown promise in their ability to generate highly shape-
diverse libraries. Two key approaches have been taken towards natural product-based 
fragment libraries. Natural products can either be deconstructed computationally into their 
constituent fragments, which are then purchased or synthesised, or they can be degraded 
chemically to give fragments directly.  
In 2014, Waldmann et al.34 published their work on the computational deconstruction of 
natural products into their constituent fragments, which were then purchased in order to form 
a fragment library. Starting from a set of 180,000 natural products, an algorithm that 
sequentially removed sections of the natural product was used to generate 750,000 potential 
fragments. After filtering using various criteria, namely Alog P < 3.5, MW 120–350 Da, ≤3 
hydrogen bond donors, ≤6 hydrogen bond acceptors and ≤6 rotatable bonds in addition to 
PAINS filters, 160,000 potential fragments were identified. Although these criteria are more 
generous than those typically used for fragments, it has previously been noted that a higher 
proportion of successful natural product-like fragments are non‘rule of three’ compliant .35 
Further filtering to remove macrocycles and structures with a high number of rings or 
bridged carbons reduced the count to 110,000 fragments. From these, a set of 2,000 with 
representative pharmacophores were then selected. Scheme 1.8 shows an example of the 
potential fragments resulting from a natural product using this methodology. In this case, 
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Scheme 1.8 
The group then tested this virtual library of 2,000 fragments in a screening programme. From 
this screen, 193 compounds that were either identical or very similar to compounds in the 
virtual library were purchased and screened against p38α MAP kinase. Crystal structures 
were obtained for 9 of these compounds bound with the kinase and, interestingly, several 
different binding locations were observed. Notably, two compounds bound in an allosteric 
site. Synthesis of further related fragments resulted in two fragments that formed a novel 
class of inhibitor for this protein, stabilising its inactive form and showing the value of sp3-
rich natural product-like fragments.  
Lizos et al. took an alternative approach to natural product-derived fragments in their 2017 
work,36 focussing on direct chemical reactions of natural products in order to either fragment 
large natural products or modify smaller natural products. First, computational analysis of a 
library of 17,000 natural products was used to select suitable compounds which could easily 
be chemically degraded to give fragments. Of the 66,000 possible degradation products, 
9,000 passed fragment property filters (MW 150-300 and cLogP < 3). A PMI plot of these 
9,000 potential fragments showed almost complete coverage of the plot, demonstrating the 
value of natural product-like structures in exploring 3-D space. The 9,000 potential 
fragments were then assessed for their availability, functional groups, similarity to Novartis’ 
current fragment library and 3-D shape before being purchased or synthesised for addition 
to the library. An example of the degradation approach is shown in Scheme 1.9. TBS 
protection of the alcohols in Tacrolimus followed by ozonolysis gave access to the top two 
fragments after deprotection and oxidation/reduction. Alternatively, retro-aldol reactions 
caused fragmentation to give access to the bottom two fragments. Although these fragments 
contain more stereogenic centres than typical fragments, the unique method of their 
synthesis means that they are easily accessible as single enantiomers. 
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Scheme 1.9 
At the time of publishing, 150 fragments generated by this approach had been added to the 
Novartis collection, filling underrepresented space in their library both in terms of fragments 
with high natural product-likeness and high Fsp3 values (most fragments from this 
methodology had Fsp3 > 0.7). 
1.3.4 Scaffold Diversification 
One of the most popular routes for library design is the synthesis of a limited number of 
scaffolds which can then be diversified using a toolkit of well-known reactions. This 
approach is attractive for a number of reasons including its ability to develop large numbers 
of fragments very quickly and its use to showcase novel methodology by using it to produce 
a library of medicinally-relevant compounds.  
Two examples of this approach were reported by Bull et al.37,38 In both, a small scaffold was 
produced in just a few steps using new methodology and the scaffolds were diversified at 
multiple points to create a library of fragments. For example, the synthesis of 2-(aryl-
sulfonyl)oxetane scaffold was achieved as shown in Scheme 1.10. The aryl group was varied 
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Three different approaches for diversification are shown in Scheme 1.11. Oxetane 19 was 
synthesised with a 4-chlorophenyl group, with the chlorine then able to take part in coupling 
reactions. Both alkyl and aryl groups were able to be attached, using either iron-mediated 
cross-coupling or classical Suzuki-Miyaura cross-coupling. Alternatively, a variety of 
groups in the position α to the sulfone and oxetane could be attached using lithiation/trapping 
methodology (Scheme 1.11). 
 
Scheme 1.11 
In addition, disubstituted oxetanes such as 20 were subjected to sulfone-directed ortho-
metallation. This resulted in the addition of a methyl group in the ortho- position of the 
aromatic ring (Scheme 1.12). 
 
Scheme 1.12 
Bull et al. used a similar approach to synthesise a library of disubstituted cyclopropanes.38 
A variety of different cyclopropanes were synthesised, including potential fragments, larger 
lead-like compounds and building blocks that contained key groups including boronic acids. 
The work focussed on cyclopropanes 21. After extensive investigation, a cobalt-catalysed 
reaction was used to give large amounts of both cis-21 and trans-21. Cyclopropanes 21 were 
then diversified either via the ester or the sulfide. Hydrolysis of the ester followed by amide 
couplings resulted in the synthesis of a wide variety of amides, whereas oxidation of the 
sulfide to the sulfoxide allowed for the sulfoxide to then be turned into a Grignard reagent. 
This Grignard reagent could then be reacted with a range of electrophiles to give fragments 
including those shown in Scheme 1.13. 
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Scheme 1.13 
In 2016, Spring et al. reported a scaffold diversification approach that focussed on partially 
saturated heteroaromatic bicyclic fragments.39 Two key scaffolds were developed based on 
either bicyclic pyrazoles or pyridines (Scheme 1.14). Synthesis of pyrazole scaffold 22 
involved the attachment of two alkene-containing groups to a pyrazole ring followed by the 
use of metathesis to join the alkenes and synthesise the second ring.  By varying the chain 
length of the second alkene-containing substituent either 5-, 6- or 7-membered rings could 
be fused with the initial pyrazole. Synthesis of the pyridine scaffold involved a very similar 
approach. Two alkenes, the second of which contained a variable chain length linker, were 
attached to the pyridine using Suzuki-Miyaura coupling and a benzylic lithiation reaction. 
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Importantly, both bicyclic scaffolds 22 and 23 contained an alkene in the second ring. This 
alkene was functionalised using either one, two or three steps to create a library of fragments 
(examples shown in Figure 1.14). In total, 42 fragments were synthesised, all of which 
showed excellent physicochemical properties. Fraction of aromatic carbons and number of 
stereogenic centres were calculated instead of the more common Fsp3 values. In these 
categories, the library compared unfavourably with the reference commercially-available 
libraries, although this does not necessarily mean that the fragments are less 3-D.  
 
Figure 1.14: Example fragment structures from Spring et al.39 
 
1.3.5 Versatile Methodology for Fragment Synthesis 
The final approach to 3-D fragments is the use of a single, versatile reaction in which various 
substrates can be used to give a diverse range of products. In the previously described 
strategy, a significant number of synthetic steps from starting material to fragment is often 
needed due to the need to synthesise a core scaffold and then perform further reactions on it. 
In contrast, the examples in this Section show a selection of different synthetic routes that 
turn relatively simple molecules into a more complex fragment in a few steps, often in a one-
pot process. 
An example of this strategy, using C-H activation to synthesise small bicyclic compounds, 
was described by Fagnou et al.40 Rees et al. refer to it as an example of an approach that 
demonstrates ideal characteristics of fragment synthesis.41 Key points in favour of this 
approach included its use of new chemistry (rhodium-mediated C-H activation), the ability 
to elaborate the fragment in all positions and vectors, the mix of aromatic and unsaturated 
carbons and the potential to include heterocycles. The key reaction involves the activation 
of an ortho C-H bond in the aromatic ring of 24 using rhodium. An alkene group was then 
attached between the aryl ring and the amide nitrogen (Scheme 1.15). 
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Scheme 1.15 
By varying the alkene, groups could be added at either end to add diversity. Furthermore, a 
variety of aromatic groups were used including heteroaromatics and aromatics with synthetic 
handles to allow for further derivatisation. However, a number of less desirable properties 
of this approach were noted. Polar groups were not well tolerated and substantially lower 
yields were obtained with pyridine or free amine groups. Also, the reaction could not be 
performed in water as the solvent. However, it is important to consider the properties detailed 
when designing a new fragment synthesis. 
The Willand group have published two papers using the versatile methodology approach to 
synthesise fragments.42,43 The use of 1,3-dipolar cycloadditions to prepare isoxazoline 
fragments was described in 2015.42 An aldoxime was first chlorinated and the desired alkene 
then added. A wide variety of alkenes were used, particularly exocyclic alkenes as these 
would generate spirocycles. Addition of base caused the chloro-oxime to collapse, 
generating the desired 1,3-dipole, a nitrile oxide. Subsequent cycloaddition gave the target 
fragments directly after purification (Scheme 1.16). Using this method, 21 fragments were 
synthesised including 5,4- 5,5- 5,6- and 5,7-spirocycles as well as some monocyclic 
compounds. A good variety of functional groups were tolerated on the alkene, allowing for 
the inclusion of amines, nitriles, esters and aromatics. 
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Scheme 1.16 
As well as ensuring that the fragments were appropriately sized (MW range of 140-291), the 
fragments also showed good solubility in buffer solution and high Fsp3 values (0.25-0.92). 
The 3-D shape of the fragments was determined using PMI analysis. The 21 isoxazoline 
fragments had an average ∑NPR = 1.19 ± 0.08, substantially better than the figure of 1.09 ± 
0.07 that the group calculated for their library of commercially available fragments. The 
compounds clustered slightly in the top left corner of the PMI plot, which is to be expected 
for a library containing a common framework, but the spread was still enough to ensure that 
a significant amount of 3-D space was covered. 
The other work published by Willand et al. in this area focussed on the synthesis of 
spirohydantoin fragments.43 Similar methodology had been developed previously for the 
synthesis of hydantoins,44 but the reaction required large amounts of potassium cyanide to 
work, which was highly undesirable. By performing the reaction in a microwave, the group 
were able to reduce the amount of cyanide required to 1.5 equivalents and the reaction was 
complete in just ten minutes. A variety of cyclic ketones could be used to deliver a diverse 




In total, 27 fragments were synthesised using this methodology. PMI analysis was used to 
assess the 3-D character of the synthesised compounds. These compounds showed a similar 
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level of 3-D character to those from the group’s previous work. There was a small amount 
of clustering in the top left corner but these fragments were better spread overall and made 
a valuable addition to the group’s fragment library. 
Cycloaddition reactions work well as a method to synthesise fragment libraries due to the 
ease of varying the substrates and their ability to create complex molecules from simple 
starting materials. Mykhailiuk et al. leveraged these advantages to synthesise a library of 
spirocyclic pyrrolidine fragments.45 Amine 25, a well-known ylid precursor,46 was reacted 
with a variety of electron-deficient alkenes featuring a 4-membered ring to synthesise 
fragments quickly. Two sets of conditions were used to ensure the best yields for the target 
fragments (Scheme 1.18). In total, 20 cycloaddition products were synthesised using this 




The potential of these cycloaddition products was then demonstrated by derivatising both 
the ester and nitrogen. Furthermore, they were able to obtain single enantiomers of the 
products using either HPLC, kinetic resolution or chiral auxiliaries. Although fragments are 
typically screened as racemates to increase the potential for hits, chiral fragments will have 
to be synthesised as single enantiomers at some point in the process. Thus, demonstrating 
that this is possible makes these fragments more attractive.  
Erdman et al. also designed a library of 3-D pyrrolidine fragments based on a cycloaddition 
strategy.47 Chiral amine 27 was reacted with aromatic aldehydes 26 to give an iminium ion. 
This then formed a metallo-azomethine ylid with either copper or silver and this ylid 
underwent a cycloaddition with the cyanoalkene to give trisubstitiuted pyrrolidines (Scheme 
1.19). A variety of heteroaromatics including pyridines, pyrazoles, imidazoles and indoles 
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were used and the directing camphorsultam group could easily be converted into either the 
ester or alcohol. In total, 48 Fragments were synthesised using this methodology and both 
PBF and PMI analysis was performed. The fragments showed an even spread of ∑NPR 
values from ∑NPR = 1.06-1.37 and these correlated well with the PBF scores. 
 
Scheme 1.19 
Marsden, Nelson et al.48 synthesised a library of fragments based on twisted bicyclic 
lactams. The key reaction, shown in Scheme 1.20, used dibutyltin oxide to close the ring, 
resulting in the bicyclic lactams shown. This reaction gives fragments directly, although 
lactam 28 is a versatile intermediate which could be further diversified. The four fragments 
shown in Scheme 1.20 are all derived from lactam 28, by either reduction of the ketone, 
chlorination then Suzuki-Miyaura coupling of the amide or annulation of an aromatic ring. 
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3-D Shape analysis was performed on the 22 fragments, with the resulting PMI plot shown 
in Figure 1.15. The fragments demonstrated excellent 3-D shape with no compounds on the 
rod-disc axis and a good spread across 3-D space 
 
Figure 1.15: PMI plot of 22 fragments from Marsden, Nelson et al.48 
Recently, Grainger et al. reported the synthesis of α-substituted saturated nitrogen 
heterocycle fragments using C-H activation methodology.49 Aryl C-H bonds and C-H bonds 
α- to N-Boc groups were activated using an iridium photocatalyst. A wide variety of 
saturated nitrogen heterocycles and heteroaromatic groups were coupled in this way to give 
23 polycyclic compounds in generally good yields (Scheme 1.21). The reaction was shown 
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1.4 Previous Group Work towards the Creation of a 3-D Fragment Library 
In 2012, the O’Brien group embarked on a project to design and synthesise a library of 3-D 
fragments based on saturated heterocycles. The project, led by PhD student Mary Wheldon, 
focussed on the design of families of disubstituted heterocyclic fragments, from which the 
most 3-D would be selected and synthesised. This Section describes the design and selection 
of the 3-D fragments. 
1.4.1 3-D Shape Analysis 
A reliable protocol was required for the generation of molecular conformations and the 
analysis of their 3-D shape. As demonstrated in Section 1.2, there are several methods of 
quantifying 3-D shape including globularity,23 plane of best fit (PBF)22 and principal 
moments of inertia (PMI) plots.25 From these, PMI plots were selected as the primary method 
of 3-D shape quantification, due to their ease of use, their prevalence in the literature and the 
easy visualisation of the data.26,32,36,50 The conformational generation protocol was 
developed using Pipeline Pilot. Pipeline Pilot is a tool that allows for the streamlining of 
several processes and contains features including computational conformer generation, 
effectively using a ‘ball and springs’ model. Molecules submitted to the Pipeline Pilot 
protocol were ionised to physiological pH (pH 7.4) and then passed into the conformation 
generation software. The BEST method algorithm was used for the computational generation 
of conformers, with all conformations up to 20.0 kcal mol–1 above the energy of the ground 
state conformation being calculated. The data outputted by Pipeline Pilot included molecular 
properties such as heavy atom count, rotatable bond count and polar surface area for each 
conformation as well as 3-D shape.  
1.4.2 PMI Analysis of a Commercially Available Fragment Library 
A commercially available library was run through the Pipeline Pilot protocol to provide a 
point of comparison for the proposed structures. A sample library of 1000 commercially 
available fragments from Maybridge was selected. Although all of the conformations up to 
20 kcalmol–1 were calculated, only the ground state energies were plotted due to the high 
number of conformations. As shown by the PMI plot in Figure 1.16, the library is dominated 
by compounds along or near to the rod-disc axis (the line that corresponds to ∑NPR = 1.0). 
Using ∑NPR values, shown by the diagonal lines in Figure 1.16, it can be seen that the 
majority of molecules in the Maybridge fragment library exhibit ground state conformations 
with ∑NPR ≤ 1.1 and a large amount of compounds lie directly on the rod-disc axis. 
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Figure 1.16: PMI plot of 1,000 fragments from the Maybridge Library 
This result was encouraging since it emphasised how under-explored the more 3-D region 
of the PMI plot was (∑NPR >1.3). The target of the project was therefore to synthesise 
fragments with high ∑NPR values and thus contribute to this under-used area. 
1.4.3 Fragment Design and Selection 
Initially, the group decided to focus on fragments containing saturated nitrogen-based 
heterocycles. Piperidines and pyrrolidines are the second and seventh most common rings 
found in drug molecules.51 This, combined with the group’s experience in the synthesis of 
nitrogen-based heterocycles, made it a logical place to start construction of the York 3-D 
fragment library.52–57 It was anticipated that disubstituted compounds would give interesting 
3-D shapes whilst not providing too large an entropic barrier on binding. To prevent the 
fragments from having too many pharmacophores, which would reduce the hit rate by 
increasing the potential for unfavourable interactions, or becoming too polar, one of these 
groups was selected to be a methyl group. The methyl group would change the 3-D shape of 
the molecule while having minimal impact on the MW, rotatable bond count or lipophilicity. 
The other group was selected to be either an ester or an alcohol. Both were simple 
pharmacophores that are frequently found in drug molecules. Furthermore, one is a hydrogen 
bond acceptor and the other a hydrogen bond donor, giving more variety in the library. Two 
families of compounds were therefore selected: a disubstituted pyrrolidine scaffold 29 and a 
disubstituted piperidine scaffold 30 (Figure 1.17). The proposed compounds would all be 
synthesised as racemates. It was envisioned that synthesising the racemates would be easier 
and it provides two potentially active compounds. Should any fragments be hits, synthesis 
of single enantiomers would then be considered. 
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Figure 1.17: Proposed Fragment Structures 
The final decision in compound design was then to decide on the capping groups for the 
nitrogen. NH, methyl, acetyl and methanesulfonyl groups were selected due to their low 
molecular weight, their prevalence in medicinal chemistry and the different hybridisation 
states of the nitrogen atom. It was anticipated that the N-acetyl and sulfonyl groups would 
cause the nitrogen to form a flat sp2 centre, giving a different shape. The steric bulk of the 
sulfonyl group would also potentially force substituents on the neighbouring carbons into an 
axial position, again changing the shapes of the molecules. With the two families of 
fragments designed, all the possible isomers and compounds were then enumerated. This 
gave 14 possible isomers of the pyrrolidine system (Figure 1.18), resulting in 56 possible 
compounds.  
 
Figure 1.18: The 14 proposed pyrrolidine isomers 
The piperidines were then also enumerated to give 23 isomers and 92 potential compounds 
after the capping groups were attached (Figure 1.19). 
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Figure 1.19: The 23 isomers of the proposed piperidine system 
Before moving on to 3-D shape analysis, the physicochemical properties of these compounds 
were calculated computationally, and their properties compared to fragment guidelines from 
the literature. Table 1.1 shows the properties of the proposed fragments alongside the two 
well-known sets of guidelines (see Section 1.1.2). As shown in Table 1.1, the proposed 
fragments fitted very well with the fragment guidelines. All proposed fragments fitted 
completely with the ‘rule of three’, while all except the NH piperidines fitted the updated 
guidelines on molecular weight and HAC due to having MW < 140. The calculated 
lipophilicity values were slightly lower than the updated guidelines recommended, although 
the two were measured using different metrics (cLogP vs AlogP) and later calculations 
showed that the cLogP values fell almost entirely within the updated guidelines. The 
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properties of the library were therefore deemed to fit sufficiently within both sets of 
guidelines and were taken forward on to selection and synthesis. 
 
Property ‘Rule of Three’ Updated Guidelines Our Fragments 
Molecular Weight (Da.) ≤ 300 140-230 129-221 
Heavy Atom Count 
(HAC) 
N/A 10-16 9-14 
logPa ≤ 3 0-2 –1.18-0.36 
Rotatable Bonds ≤ 3 N/A 1-2 
aBoth sets of guidelines are reported as cLogP values but initially only AlogP values were available for the York fragments. 
Later calculations showed that the cLogP values for the York fragments were –0.18-1.32 
 
Table 1.2: Comparison of Proposed Fragment Properties with Literature Guidelines 
1.4.4 Fragment Selection 
With the structures of the potential pyrrolidine and piperidine fragments set, fragments were 
selected for synthesis. The compounds were run through Pipeline Pilot to check them for 3-
D shape. All conformations up to 20 kcal mol–1 were initially calculated in the process, but 
compounds so high in energy above the ground state would be very unlikely to be binding 
conformations as they would be almost completely unpopulated. Most examples of PMI 
plots in the literature use only the ground state conformations,26,32,36,50 but this is also 
problematic as other low energy conformations will be significantly populated and 
compounds do not always bind in their ground state conformations. It was therefore decided 
to implement a limit of 1.5 kcal mol–1 above the ground state, with all conformations ≤ 1.5 
kcal mol–1 above the ground state being plotted. This corresponds to approximately a 12:1 
occupation ratio of the ground state to the higher energy state and seemed an appropriate 
limit to ensure that most of the possible binding conformations would be included without 
diluting the dataset with unlikely conformations. The PMI plots of the 92 piperidine 
compounds with just the ground states (left) and all conformations up to 1.5 kcal mol–1 
(right) are shown in Figure 1.20. 
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Colour             
Energy above ground 
state /kcalmol–1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
 
Figure 1.20: PMI plots of the ground state (left) and low energy (right) conformations of 
the 92 piperidines 
The PMI plot of all the low energy conformations in Figure 1.20 showed that these 
piperidines had a significant number of conformations with interesting 3-D shape, and no 
conformations on the rod-disc axis. It was then considered how to select which of these 
piperidines should be synthesised. A cut-off at a particular ∑NPR value was decided on, 
where all compounds with at least one conformation above that ∑NPR value would be 
synthesised. The cut-off was set at a level to select an appropriate number of compounds for 
synthesis while also maintaining good 3-D shape. For the piperidines, this cut-off was set at 
∑NPR = 1.38, and 19 of the 92 possible piperidines were selected (Figure 1.21). 
 
Figure 1.21: PMI plot of the proposed piperidines with the cut-off at ∑NPR = 1.38 shown 
The PMI plot of the 19 selected compounds is shown in Figure 1.22. The PMI plot showed 
an excellent spread of conformations across 3D space, with conformers reaching as far as 
∑NPR = 1.68. Only one conformation exists below ∑NPR = 1.1 and the conformations show 
minimal clustering, which was pleasing given the structural similarities of these piperidines. 
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Figure 1.22: PMI plot of the selected 19 piperidines 
The structures of the selected piperidines are shown in Figure 1.23. Despite being selected 
purely by shape, the piperidines showed a good variety of substitution patterns. The 
compounds selected also contained all four nitrogen groups, giving good diversity within 
the target fragments. 
 
Figure 1.23: Structures of the 19 selected piperidines 
With the 19 piperidines selected, the same process was applied to the pyrrolidines. Both the 
ground state and low energy conformation PMI plots of the pyrrolidines displayed a wide 
range of 3-D conformations. The ground state (Figure 1.24, left) conformations showed 
almost no clustering, while the low energy conformations (Figure 1.24, right) did display 
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some clustering in the upper right corner. However, it was expected that once the less 3-D 
compounds were removed, the clustering would become significantly less. 
      
Figure 1.24: PMI plots of the ground state (left) and low energy (right) conformations of 
the 56 proposed pyrrolidines 
The ∑NPR cut-off for the pyrrolidine fragments was set at ∑NPR ≥ 1.36 (Figure 1.25, left). 
14 Of the possible 56 pyrrolidines were selected for synthesis. As the PMI plot of the selected 
pyrrolidines shows, the clustering was no longer an issue and the selected compounds 
displayed an excellent spread of conformations over the PMI plot (Figure 1.25, right). 
      
Figure 1.25: PMI plots of the 56 pyrrolidines showing the ∑NPR cut-off (left) and the 14 
selected pyrrolidines (right) 
The structures of the 14 selected pyrrolidines are shown in Figure 1.26. Pleasingly, a wide 
variety of structures was chosen, including 8 of the possible 14 isomers and examples of 
each of the nitrogen groups. This gave a total of 33 pyrrolidine and piperidine 3-D fragments. 
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Figure 1.26: Structures of the 14 pyrrolidine fragments 
With the compounds selected, synthetic efforts towards these 33 fragments began. Initial 
work from two members of the group resulted in the synthesis of a few pyrrolidine and 
piperidine fragments before more researchers joined the project. When more people, 
including myself, joined the project the fragments were divided among the group for 
synthesis. Chapter 2 of this thesis will deal with the synthesis of the fragments I was tasked 
with making, trans-37 and cis-37 and cis-42 and cis-43. 
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1.5  Project Outline 
The primary aim of the project was to aid in the completion of the synthesis of the 33 
pyrrolidine and piperidine 3-D fragments selected as described in the previous Section. My 
contribution to this would be to synthesise four of the pyrrolidine fragments: trans-37, cis-
37, cis-42 and cis-43 (Figure 1.27). Our efforts on the synthesis of these 3-D fragments is 
detailed in Chapter 2.  
 
Figure 1.27: Structures of the four pyrrolidine fragments for synthesis 
Once synthetic efforts towards these four fragments was completed, the plan was to design 
and synthesise a 2nd generation of fragments with good 3-D shape to add to the library. As 
the synthesis of the first-generation shape-selected fragments proved difficult, an alternative 
approach to fragment synthesis was sought. Focussing on the versatile methodology 
approach, a synthetic route was designed that could use a variety of β-ketoesters and aryl 
boronic acids to synthesise cis-3,4-disubstituted 5- and 6- membered ring fragments cis-44 
(Scheme 1.22). Diversification of the ester group would allow for three different points of 
diversification and/or further growth. The design and synthesis of these new, 2nd generation 
3-D fragments is discussed in Chapter 3. 
  
Scheme 1.22 
Finally, Chapter 4 contains a detailed analysis of both the physicochemical and 3-D shape 
properties of all of the synthesised fragments in the York 3-D fragment library.  Separate 
analysis of the 1st generation and 2nd generation fragments as well as the whole library is 
included. In addition, the 3-D shape properties were compared to a selection of other 
available 3-D fragment libraries. 
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SYNTHESIS OF PYRROLIDINE 3-D FRAGMENTS 
 
In this Chapter, the synthetic work towards 3-D fragments cis-42, cis-43, trans-37 and cis-
37 (Figure 2.1) is detailed. Section 2.1 covers the synthesis of the two 3,4-disubstituted 
pyrrolidines cis-42 and cis-43. This includes a literature survey on the synthesis of similar 
molecules before describing the different routes that were explored. Similarly, the relevant 
literature background on the synthesis of the two 2,4-disubstituted pyrrolidines trans-37 and 
cis-37 and our synthetic efforts are described in Section 2.2.   
 
 Figure 2.1: Structures of the four target fragments 
During the development of routes to 2,4-disubstituted pyrrolidines trans-37 and cis-37, a 
highly diastereoselective approach to cis-2,4-disubstituted pyrrolidines was optimised. Thus, 
the synthesis of four t-butyl ester-substituted cis-2,4-disubstituted pyrrolidine fragments, 
namely cis-45, cis-46, cis-47 and cis-48 (Figure 2.2), is described (Section 2.3).  
 
Figure 2.2: Structures of the four t-butyl ester fragments 
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2.1  Synthesis of 3,4-Disubstituted Pyrrolidine Fragments 
This Section describes our efforts towards the synthesis of 3,4-disubstituted pyrrolidines cis-
42 and cis-43. The selection of these 3-D fragments as targets was described in Section 1.4. 
The PMI plots for each fragment cis-42 and cis-43 are shown in Figure 2.3. Given that the 
two fragments only differ at the N-substituent, the same route would be used to prepare both 
fragments.   
                
   
Figure 2.3: Structures and PMI plots of fragments cis-42 and cis-43 
2.1.1 Overview of Previous Synthetic Routes to 3,4-Disubstituted Pyrrolidines 
The synthesis of cis-3,4-disubstituted monocyclic pyrrolidines is relatively uncommon and 
there are few synthetic routes available to access them. There are many examples of the 
synthesis of cis-3,4-pyrrolidines which are part of bicyclic systems but there are fewer 
examples if the substituents are separate. trans-3,4-Pyrrolidines are more common in the 
literature due to the increased number of synthetic routes available.  
The most common route to 3,4-disubstituted pyrrolidines was pioneered by Achiwa et al. in  
1985,46 where an azomethine ylid was generated in situ from easily accessible ylid precursor 
25.58 The ylid can react with alkenes to give a range of pyrrolidines. For example, treatment 
of ylid precursor 25 with catalytic TFA in the presence of dimethyl maleate cis-49 gave 
pyrrolidine cis-50 in 94% yield (Scheme 2.1). TFA converts the hemiaminal in 25 into an 
iminium and the resulting methoxide can then attack the trimethylsilyl group. This generates 
the azomethine ylid which undergoes the 1,3-dipolar cycloaddition. One of the key 
advantages of 1,3-dipolar cycloadditions is that the pericyclic nature of the reaction means 
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This strategy has been widely employed since the initial report with a variety of electron 
poor alkenes being utilised. Aromatic groups on the alkene are popular. For example, the 
use of p-bromophenyl alkene trans-51 gave pyrrolidine trans-52 in 85% yield (Scheme 
2.2).59 The cycloaddition is typically performed using alkenes with two electron 
withdrawing groups attached. However, it can be performed on alkenes with an alkyl group 
and an electron withdrawing group. Under standard TFA conditions, alkene cis-53 reacted 
with ylid precursor 25 to give pyrrolidine cis-54 in 41% yield (Scheme 2.2), a significantly 




Catalytic TFA with CH2Cl2 as solvent has remained the most popular method for 1,3-dipolar 
cycloadditions using precursor 25, although others have used fluoride to activate ylid 
precursor 25. This was first reported by Dent et al. in 1987,60 where LiF or CsF in MeCN 
were used. Fluoride caused the decomposition of precursor 25 into the ylid which underwent 
the 1,3-dipolar cycloaddition with dimethyl maleate cis-49 to give pyrrolidine cis-50 
(Scheme 2.3).  
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Scheme 2.3 
More recently, Lupton et al.61 used benzoyl fluoride as a sacrificial source of fluoride and 
catalytic DMAP to affect a wide variety of 1,3-dipolar cycloadditions, including reaction 
with methyl cinnamate trans-55 to give pyrrolidine trans-56 (Scheme 2.4). The reaction 
proceeds via attack of DMAP into benzoyl fluoride to generate fluoride which can then aid 
the decomposition of ylid precursor 25. 
 
Scheme 2.4 
Lupton’s work also provided a first example of performing a 1,3-dipolar cycloaddition using 
precursor 25 with some form of enantioselectivity.61 Ylid precursor 25 was reacted with 
alkene trans-57 and a chiral isothiourea catalyst to give enantioenriched pyrrolidine trans-
56 in 35% yield and 14% ee (Scheme 2.5). The chiral catalyst adds into the acyl fluoride, 
generating the fluoride necessary to activate the ylid precursor. The ylid then has two 
options: either to react with the starting alkene trans-57 or to react with the generated acyl 
thiourea trans-58. The acyl thiourea trans-58 showed similar reactivity to the acyl fluoride 
trans-57, allowing for some enantioselectivity, but the two pathways were too similar in rate 
to generate higher levels of enantioselectivity. 
 
Scheme 2.5 
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Other ylids can also be generated for use in 1,3-dipolar cycloadditions towards pyrrolidines. 
N-Benzyl hydroxylamine has been reacted with formaldehyde and, under basic conditions, 
deprotonated to create an ylid. The resulting ylid then performed a 1,3-dipolar cycloaddition 
with dihydropyrrole 59 to synthesise bicycle 60 (Scheme 2.6).62 Hydrogenation of bicyclic 




Apart from the 1,3-dipolar cycloaddition strategy, there are few other routes towards 
monocyclic 3,4-cis-disubstituted pyrrolidines. One of those is a route designed by Smith et 
al.63 where simple 3,4-cis-disubstituted pyrrolidines were synthesised as single enantiomers. 
The strategy involved the synthesis of building block 63 from acids 62 via ozonolysis and 
Wittig olefination or Grubbs metathesis. Intermediates 63 then underwent cyclisation to an 
intermediate bicycle by enolate conjugate addition and subsequent tetramisole-assisted 
lactone formation. The bicycle readily ring-opens to give pyrrolidines cis-64 (Scheme 2.7). 
While this process can be telescoped using the Grubbs route and the enantioselectivity is 
good, the key limitation of this route is that pyrrolidines cis-64 represent the simplest 
pyrrolidine that can be synthesised using this methodology. 
 
Scheme 2.7 
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Alternative routes to synthesise 3,4-disubstituted pyrrolidines with similar substituents 
include the zinc–based strategy of Chemla et al.64 The zinc-mediated cyclisation of amines 
such as amine 65 can be used to generate a variety of  trans-3,4-pyrrolidines in moderate 
yields. Treatment of amine 65 with LDA and ZnBr2 gave pyrrolidine trans-66 in 40% yield 
(Scheme 2.8). Zinc coordinates to the alkene, allowing for enolate addition into the alkene 
and generation of the pyrrolidine. The coordination of the zinc locks the conformation to 
give high diastereoselectivity in the cyclisation. 
 
Scheme 2.8 
Rinaldi et al. used enolate alkylation of 4-substituted pyrrolidine-2-ones to generate a 3,4-
substitution pattern and then reduced out the lactam carbonyl to generate trans-3,4-
pyrrolidines.65 For example, pyrrolidinone 67 was deprotonated and then trapped with i-
butyl iodide to synthesise pyrrolidinone 68, which was then reduced with LiAlH4 to give the 
desired pyrrolidine trans-69 (Scheme 2.9). This approach is attractive due to the high level 
of diastereoselectivity.  
 
Scheme 2.9 
Epoxidation followed by ring opening and Mitsunobu reaction is a popular alternative 
strategy to synthesise both cis- and trans-3,4-disubstituted pyrrolidines.66,67 An example of 
this methodology is shown in Scheme 2.10.68,69 Epoxide 70 was ring-opened with a vinyl 
cuprate to give pyrrolidine trans-71. The versatility of hydroxypyrrolidines such as trans-71 
was then demonstrated as the alcohol was converted directly into a fluoro-pyrrolidine by 
treatment with perfluorobutanesulfonyl fluoride to give pyrrolidine cis-72.69 
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Scheme 2.10 
Another strategy to 3,4-trans-pyrrolidines proceeded via dihydropyrrole 74 (Scheme 2.11).70 
Reduction of oxopyrrolidine 73 with NaBH3CN gave the hydroxypyrrolidine, which was 
then eliminated using Mitsunobu conditions to give dihydropyrrole 74 in 90% yield over 
two steps. Dihydropyrrole 74 then acted as a Michael acceptor to synthesise pyrrolidine 
trans-75 albeit in only 13% yield after chromatography. 
 
Scheme 2.11 
Other methods for the synthesis of simple 3,4-cis-pyrrolidines include the use an Upjohn 
dihydroxylation, which gave diol cis-77 from dihydropyrrole 76 (Scheme 2.12).71 These 




During the course of this thesis, Bull et al. released work detailing a novel approach to the 
synthesis of 3,4-disubstituted pyrrolidines using C-H activation via palladium catalysis and 
a directing group.72 The aminoquinoline amide in pyrrolidine 78 directed the palladium to 
perform a C-H insertion both regio and diastereoselectively. This then coupled with the aryl 
iodide to give pyrrolidine cis-79 (Scheme 2.13). It was shown that a wide variety of aryl 
groups could be used, including heteroaryl groups. In addition, the directing group could be 
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removed to give a variety of medicinally-relevant functional groups including alcohols, 
esters, acids and amides. 
 
Scheme 2.13 
Perhaps surprisingly, pyrrole reduction or hydrogenation is not used in the synthesis of 
simple 3,4-disubstituted pyrrolidines. However, reduction has been used in the synthesis of 
pyrrolidines with different or more complex substitution patterns such as pyrrolidine cis-81. 
In this case, Birch reduction of pyrrole 80 with lithium in ammonia followed by trapping of 
the resultant enolate intermediates with alkyl iodides gave access to 3,3,4,4-tetrasubstituted 
pyrrolidines in good yield (Scheme 2.14). 
 
Scheme 2.14 
2.1.2 1,3-Dipolar Cycloaddition Route 
After considering a number of potential synthetic routes towards the 3,4-cis-disubstituted 
fragments, it was decided to first explore a 1,3-dipolar cycloaddition route. Initially, it was 
proposed to synthesise fragments cis-42 and cis-43 from benzylated pyrrolidine cis-82. 
Pyrrolidine cis-82 would be synthesised via a cycloaddition involving silyl methoxyamine 
25 and cis-methyl crotonate. This route would yield fragment cis-42 in just two steps from 
25. However, some initial work on this route performed by another group member revealed 
that the required alkene was volatile and difficult to work with, as well as not being 
commercially available.73 They were able to synthesise only a small amount of fragment cis-
42 via this diastereospecific route, although this could be used to confirm the stereochemistry 
of later syntheses. An alternative route was therefore proposed, using the corresponding 
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alkyne instead of the alkene. Use of an alkyne in the cycloaddition would give 
dihydropyrrole 83 and would add no extra steps to the synthesis, as it was anticipated that 
both the hydrogenation of the alkene and the hydrogenolysis of the benzyl group could be 
performed in one step (Scheme 2.15). 
 
Scheme 2.15 
To start, silyl methoxyamine 25 was synthesised via a simple two-step process. The first step 
was the reaction of benzylamine with chloromethyl trimethylsilane to give intermediate 85. 
Using a procedure from Yarovskaya et al.,74 benzylamine was reacted with 
(chloromethyl)trimethylsilane 84 in MeCN to give silyl amine 85 in 42% yield after 
chromatography (Scheme 2.16).  Although the reaction was successful, an alternative route 
was sought due to the low yield. Sieburth et al. had reported the use of DMSO as solvent.58 
Performing the reaction by heating silane 84 and benzylamine at 80 ºC for 18 h in DMSO, 
followed by purification via chromatography gave silyl amine 85 in 73% yield (Scheme 
2.16). Silyl amine 85 was then reacted with stoichiometric formaldehyde and methanol at rt 
for 4 h to yield methoxyamine 25 as a sufficiently pure crude product in 79% yield (Scheme 
2.16). Both reactions proved amenable to scaling up, allowing for the synthesis of more than 
5 g of silyl methoxyamine 25 in one run. 
 
Scheme 2.16 
With intermediate 25 in hand, it was now possible to investigate the key 1,3-dipolar 
cycloaddition step. Initial attempts used conditions reported by Yarovskaya et al.74 Alkyne 
86 was added dropwise to methoxyamine 25 and TFA at 0 ºC then stirred at rt for 16 h. 
Work-up and purification yielded the desired dihydropyrrole 83 in 32% yield (Scheme 2.17). 
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Scheme 2.17 
Hydrogenation of dihydropyrrole 83 was expected to result in saturation of the double bond 
and removal of the N-benzyl protecting group. Hydrogenation of dihydropyrrole 83 was 
undertaken with 10% Pd/C under an H2 atmosphere at rt for 16 h. After filtering through 
Celite and solvent removal, 1H NMR spectroscopy showed evidence of the desired fragment 
cis-42. However, mass recovery was poor and attempts to remove the last traces of solvent 
resulted in no product cis-42 being recovered (Scheme 2.18). 
 
Scheme 2.18 
Now knowing that the hydrogenation would require optimisation, alternative reaction 
conditions for the cycloaddition were sought to increase the yield and bring through larger 
quantities of material. There was a report of carrying out the reaction in THF75 instead of 
CH2Cl2, with otherwise identical conditions and on similar scale (<200 mg). Pleasingly, this 
improved the yield from 32% to 48% (Scheme 2.19). Further optimisation to improve the 
yield of the cycloaddition and hydrogenation was desired, so it was decided to use alkyne 
87 with an ethyl ester, which was substantially less expensive. Performing the same dipolar 
cycloaddition using the ethyl ester gave dihydropyrrole 88 in a 56% yield (Scheme 2.19). 
 
Scheme 2.19 
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With the reaction in THF appearing promising the reaction was scaled up. However, it 
quickly became apparent that on larger scale (≥ 0.5 g), the yields of the cycloaddition 
dropped significantly to 20-25% for both ethyl ester dihydropyrrole 88 and methyl ester 
dihydropyrrole 83. The reactions were repeated a number of times with similar results. 
During purification by chromatography, a significant amount of a by-product was isolated. 
1H NMR spectroscopy showed a mixture of three compounds that displayed trimethylsilyl, 
aromatic and methoxy peaks but we were unable to assign the structures of any of these 
compounds. The signals in the 1H NMR spectrum indicated that these by-products were 
formed from side-reactions of the methoxyamine 25. 
With this reaction not working as well as expected on scale, alternative conditions were 
explored. Lupton et al. had reported the use of DMAP and a sacrificial source of fluoride to 
give high yields in these types of dipolar cycloadditions (see Scheme 2.4).61  It was decided 
to repeat the literature example with alkyne 89, which was reported to give a 90% yield of 
dihydropyrrole 90. In our hands, reaction of alkyne 89 with methoxyamine 25 using benzoyl 
fluoride and catalytic DMAP in THF gave an 86% yield of dihydropyrrole 90 (Scheme 2.20). 
Now confident with these conditions, they were then used with methyl-substituted alkyne 
86. However, purification by chromatography proved difficult as TLC showed that at least 
eight different compounds were present in the reaction mixture and 1H NMR spectroscopy 
of the crude product showed no evidence of the desired product 83 (Scheme 2.20). 
 
Scheme 2.20 
It was hypothesised that the reason the cycloaddition step was proving so difficult was the 
electron density of the alkyne compared to other examples in the literature. There are no 
known examples of alkynes used in these 1,3-dipolar cycloadditions that contain at least one 
simple alkyl substituent. Aryl, ester, CF3 and SF5 substituents have been used previously, all 
of which help reduce the electron density on the alkyne. The most similar example of this 
reaction to ours was performed by both Achiwa et al.46 and at UCB.76 In the hands of Achiwa 
et al., alkyne 91 reacted with methoxyamine 25 to give dihydropyrrole 92 in 58% yield 
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(Scheme 2.21). At UCB, the reaction was performed on larger scale (40 mmol of alkyne 91) 
for a slightly shorter time and a significantly lower yield of 29% was obtained (Scheme 
2.21). These examples also give further evidence of the reduced yields in dipolar 
cycloadditions when the scale is increased. 
 
Scheme 2.21 
It was therefore decided to stop further optimisation of the cycloaddition step and move on 
to the hydrogenation.  Transfer hydrogenation with ammonium formate has been used by 
our group with success in the past, so it was decided to attempt the hydrogenation of 
dihydropyrrole 83 using the group conditions.77 Ammonium formate and Pd(OH)2 were 
added to dihydropyrrole 83 and the mixture refluxed in methanol for 4 h (Scheme 2.22). 
However, after the reaction only ammonium formate was recovered. 
 
Scheme 2.22 
Through the evaporation of solvent and drying on the high vacuum line in both this reaction 
and the hydrogenation shown in Scheme 2.22, it was realised that the desired pyrrolidines 
cis-42 and cis-43 were volatile. Now knowing this, and with the intermediate 
dihydropyrroles 83 and 88 being valuable compounds, it was decided to optimise the 
hydrogenation conditions on a model system. 
Proline derivative (S)-94 was chosen as the model system due to its availability and 
similarity to dihydropyrrole 83 both in molecular weight and functionality. Using a literature 
procedure,78 synthesis of (S)-94 proceeded via esterification of proline (S)-93 with acetyl 
chloride and methanol followed by protection of the nitrogen with benzyl bromide (Scheme 
2.23).  
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Scheme 2.23 
With pyrrolidine (S)-94 now in hand, conditions were considered that would allow for 
handling of the volatile product. Two strategies were identified: immediate hydrochloride 
salt formation to yield salt (S)-95•HCl or immediate Boc protection to give a non-volatile, 
isolable compound followed by deprotection to form the same salt (S)-95•HCl. In both 
routes, pyrrolidine (S)-94 would be subjected to transfer hydrogenolysis by Pd(OH)2 in 
methanol and then filtered through Celite to remove the catalyst. The solution would then 
either be subjected to HCl in Et2O or Boc protection conditions (Scheme 2.24). 
 
Scheme 2.24 
The Boc protection route was attempted first. Pyrrolidine (S)-94 was stirred with ammonium 
formate and 5% Pd(OH)2 at reflux for 3 h in methanol and then filtered through Celite. 
Reaction with Boc2O and Et3N (1.3 eq) at rt for 16 h gave very poor mass recovery and there 
was no evidence of N-Boc pyrrolidine (S)-96 by 1H NMR spectroscopy. Surprised at the lack 
of mass recovery, the reaction was re-attempted while increasing the number of equivalents 
of Et3N in the Boc protection step from 1.3 to 6 eq and adding catalytic DMAP. Under the 
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Transfer hydrogenation of pyrrolidine (S)-94 and hydrochloride salt formation using HCl in 
Et2O was attempted next. However, this resulted in a mixture of a small amount of product 
(S)-95 and ammonium formate, as shown by 1H NMR spectroscopy (Scheme 2.26). It was 
therefore decided to proceed via formation of the N-Boc pyrrolidine (S)-96 as the reaction 
was working in excellent yield and forming the N-Boc as opposed to the NH system meant 




The new protocol was then applied to the real system. Scaling the cycloaddition up to 0.5 g 
of methoxyamine 25 resulted in the reaction giving a 24% yield of dihydropyrrole 83. 
Hydrogenation of dihydropyrrole 83 followed by Boc protection gave a 90:10 mixture (by 
1H NMR spectroscopy) of desired pyrrolidine cis-97 and dihydropyrrole 98 after 
chromatography. Interestingly, this indicated that under these conditions the alkene 
hydrogenation was occurring slower than the N-debenzylation. The 90:10 mixture was then 
subjected to Pd/C and H2 in MeOH for 16 h to complete the hydrogenation and gave N-Boc 
pyrrolidine cis-97 in 77% yield from dihydropyrrole 83 (Scheme 2.27). 
 
Scheme 2.27 
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With the N-Boc pyrrolidine cis-97 now in hand, it was possible to deprotect and form one of 
the desired fragments, cis-42. Adding HCl in Et2O to cis-97 in CH2Cl2 and stirring at rt for 
16 h allowed for deprotection to form fragment cis-42•HCl in 97% yield (Scheme 2.28). The 
1H NMR spectrum of cis-42•HCl displayed broad signals, but there was only one doublet 
corresponding to the methyl group, suggesting that no epimerisation had occurred. 
 
Scheme 2.28 
Unfortunately, compound cis-42 proved to be unstable as the hydrochloride salt. This issue 
occurred with several other fragments synthesised early on in the project. The fragments 
were shown to be degrading when stored as the HCl salt. It was therefore decided to store 
fragments as the more stable acetic acid salts in the future. 1H NMR spectra were taken at 
different time intervals of all fragments to check that no epimerisation or degradation was 
occurring. 
In order to synthesise fragment cis-42 as the acetic acid salt, it was proposed to synthesise 
dihydropyrrole 83 on a large scale and then hydrogenate using Pd/C and H2 to give fragment 
cis-42 directly, which could then be converted into the acetic acid salt. Performing the 
reactions on large scale would help minimise the volatility issues, although the dipolar 
cycloaddition yield would likely suffer when performed on large scale. 
Free base fragment cis-42 was prepared by another member of the group on a large scale 
(~20 g of methoxyamine 25) using the optimised route . Despite starting with 20 g of 
methoxyamine 25, after purification, only 550 mg (3% yield over 3 steps) of fragment cis-
42•AcOH was isolated. However, this was sufficient to both add the fragment to the library 
and to give enough material to perform N-methylation in order to prepare fragment cis-42. 
Conditions had been optimised in the group for the effective methylation of pyrrolidine 
fragments using aqueous formaldehyde, sodium triacetoxyborohydride and MgSO4 in 3:1 
CH2Cl2–AcOH. Using these reductive amination conditions followed by aqueous work-up 
and stirring of the resulting organic layer with acetic acid, a 75:25 ratio of acetic acid and 
fragment cis-43•AcOH was isolated. Importantly, the acetic acid was added to the organic 
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layer before removing the solvent, ensuring that minimal loss occurred due to volatility. 
Despite repeated drying on the high vacuum line, the remaining acetic acid could not be 
completely removed, so a yield of 41% for the step was calculated, taking into account the 
remaining acetic acid (Scheme 2.29).  
 
Scheme 2.29 
2.1.3 Enol Triflate/Michael Addition Route 
An alternative route to fragments cis-42 and cis-43 was also investigated. In particular, we 
focussed on a route that had the potential to be more readily scaled up. As outlined in Scheme 
2.30, it was envisioned that fragments cis-42 and cis-43 could be synthesised from 
dihydropyrrole 98. Dihydropyrrole 98 would be generated from triflate 99, the product of 
trapping β-ketoester 100 as the enol triflate. β-Ketoester 100 can in turn be synthesised in 
one step from N-Boc glycine using a literature procedure.79 
 
Scheme 2.30 
The synthesis of oxopyrrolidines such as 100 via a tandem Michael addition/Dieckmann 
cyclisation of an N-carbamyl amino acid ester and an acrylate ester is well described in the 
literature.79,80 It was first performed by Rigo et al.80 using an N-ethylcarbamate system 102 
and later by Schmidt et al.79 using N-Boc glycine methyl ester 101 (Scheme 2.31). In each 
case, the N-protected glycine was first deprotonated on the nitrogen. The reaction then 
proceeded via aza-Michael addition to give a diester such as 103 which underwent a 
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Dieckmann cyclisation. The synthesis of pyrrolidinones 104 and 100 proceeded in ≥ 85% 
yield with the Dieckmann cyclisation occurring completely regioselectively. 
 
Scheme 2.31 
To start our synthetic efforts, glycine methyl ester hydrochloride was Boc protected in near-
quantitative yield to give 101, which was subjected to the same conditions reported by 
Schmidt et al.79 Work-up and purification by flash column chromatography gave the desired 
oxopyrrolidine 100 in 90% yield (Scheme 2.32). The 1H NMR spectrum of oxopyrrolidine 
100 was complicated and difficult to interpret. The complexity arises from the fact that 
oxopyrrolidine 100 actually exists as a mixture of keto tautomer 100 and enol tautomer 100a, 
and the spectrum is further complicated by N-Boc rotamers. Interpretation was made 
possible by comparison with the literature data79 and it was concluded that a 50:50 mixture 
of tautomers 100 and 100a were formed. 
 
Scheme 2.32 
The next step involved conversion of oxopyrrolidine 100 into enol triflate 99. Burton et al. 
had reported using triflic anhydride and Hünig’s base to successfully triflate cyclopentane 
β-keto ester in 92% yield.81 Using these conditions, reaction of oxopyrrolidine 100 with 
Hünig’s base and triflic anhydride at –78 °C and then at rt gave enol triflate 99 in 71% yield 
after chromatography (Scheme 2.33).  
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Scheme 2.33 
The key step in the proposed fragment synthesis was the triflate substitution reaction. There 
is precedent for performing cuprate additions on similar triflates. For instance, Tius et al.82 
showed that reaction of enol triflate 105 with CuCN and MeLi gave ester 106 in 48% yield 
(Scheme 2.34). There was no cuprate addition to the product 106, which could potentially 
also function as a Michael acceptor. A similar reaction was also performed by Fallis et al. 
on triflate 107. The cuprate was preformed from MeLi and CuI at 0 °C before reacting with 




Using the conditions reported by Tius et al., an alkyl cuprate was generated by premixing of 
1.4 equivalents of methyl lithium and copper(I) cyanide. Reaction with enol triflate 99 was 
carried out at –50 °C. 1H NMR spectroscopy of the crude product was very promising, 
appearing to show an 80:20 mixture of the desired product 98 and detriflated product 109 
(Scheme 2.35). 
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Scheme 2.35 
Determination of the ratio of the products was performed by comparison of the diagnostic 
signals in the 1H NMR spectrum: dihydropyrrole 98 showed a methyl singlet at 2.1 ppm, 
whereas dihydropyrrole 109 had an alkene signal at 6.7 ppm. Disappointingly, 
chromatography of the crude mixture did not yield either compounds 98 or 109. Despite 
flushing the column, there was little trace of either compound and only half of the crude 
mass could be recovered which was a mixture of complex products. 
With compound 98 proving either unstable on silica or when stored, it was decided to repeat 
the cuprate addition and attempt to hydrogenate the crude product directly. The cuprate 
addition gave an 80:20 crude mixture (by 1H NMR spectroscopy) of compounds 98 and 109 
after filtration through Celite. This mixture was then treated with 10% Pd/C and H2 in MeOH 
at rt for 16 h. However, 1H NMR spectroscopy of the crude product showed the presence of 
only dihydropyrroles 98 and 109. The mixture was therefore treated with 10% Pd(OH)2/C 
and H2 in MeOH. 
1H NMR spectroscopy of the crude product showed a mixture of products 
including starting dihydropyrrole 98 and desired pyrrolidine cis-97 in an 85:15 ratio as well 
as other minor products (Scheme 2.36). 
 
Scheme 2.36 
Another member of the group attempted a Negishi coupling on dihydropyrrole triflate 99 
using Me2Zn and Pd(PPh3)4 based on a reaction on a tetrahydropyran enol triflate from a 
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patent by Novartis.83,84 Treatment of enol triflate 99 with Me2Zn and Pd(PPh3)4 successfully 
gave the desired dihydropyrrole 98 in 81% yield. However, the hydrogenation step proved 
more challenging. Reaction with 10% Pd/C and H2 in MeOH for 16 h showed no conversion 
of dihydropyrrole 98 into the desired pyrrolidine cis-97 (Scheme 2.37). 
 
Scheme 2.37 
At this point, due to our lack of success, this approach to fragments cis-42 and cis-43 was 
abandoned. Further work could have been focussed on the hydrogenation step. However, 
since the 1,3-dipolar cycloaddition route described in Section 2.1.2 had been successful, no 
further work was carried out on the synthesis of fragments cis-42 and cis-43. 
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2.2  Synthesis of 2,4-Disubstituted Pyrrolidine Fragments 
The structures of two 2,4-disubstituted pyrrolidines to be synthesised (trans-37 and cis-37) 
are shown in Figure 2.4. 
 
      
Figure 2.4: The two 2-4 disubstituted pyrrolidines to be synthesised and their PMI plots 
Despite the fact that fragments trans-37 and cis-37 both appear relatively simple, they were 
both novel compounds and would therefore require carefully chosen synthetic routes. 
Initially, it was uncertain whether the best approach would be to synthesise a mixture of the 
two diastereomers, which would then be separated by chromatography, or to attempt to 
synthesise each fragment selectively by a separate route. A third potential strategy would be 
to synthesise one of the two diastereomers and then explore epimerisation to access the other. 
A detailed literature review was therefore undertaken to assess which strategy would be most 
attractive. 
2.2.1 Overview of Previous Synthetic Routes to 2,4-Disubstituted Pyrrolidines 
2,4-Disubstituted pyrrolidines are a relatively uncommon substitution pattern, despite such 
compounds having been shown to be useful proline-type chiral catalysts.85 The synthesis of 
2,4-disubstituted pyrrolidines with an ester at the 2-position often starts from derivatives of 
pyroglutamic acid such as 110, which is commercially available as either enantiomer. 
Enolate chemistry can then be used to attach substituents at the 4-position. For instance, 
deprotonation of pyroglutamate 110 using LHMDS followed by trapping with methyl iodide 
gave a separable mixture of pyrrolidinone trans-111, pyrrolidinone cis-111 and 
pyrrolidinone 112 (Scheme 2.38).86 The slight trans-selectivity potentially arises from the 
alkylation occurring on the less sterically hindered face, opposite to the ester. 
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Scheme 2.38 
A different approach was used to synthesise pyrrolidinone cis-115.87 Reaction of 
pyroglutamate 113 with Bredereck’s reagent gave intermediate enamine 114. 
Mechanistically, Bredereck’s reagent works by generating tBuO- which can then 
deprotonate the pyrrolidinone. The enolate then adds into the generated amidinium cation 
and the resulting aminal then breaks down to give enamine 114. Hydrogenation of enamine 
114 gave pyrrolidinone cis-115 (Scheme 2.38). Presumably, enamine hydrogenation, E1cB-
type elimination of the NMe2 group, and then hydrogenation of the so-generated alkene on 
the face opposite to the ester group accounts for the formation of cis-115. 
 
Scheme 2.38 
Another popular starting material for the synthesis of 2,4-disubstituted pyrrolidines is 4-
hydroxyproline or derivatives thereof. The hydroxy group has been used in Mitsunobu 
reactions to introduce a variety of groups stereospecifically. For example, 
diphenylphosphoryl azide is a source of azide which, under Mitsunobu conditions, reacted 
with pyrrolidine cis-116 to give pyrrolidine trans-117 (Scheme 2.39, yield not given).88 
Pyrrolidine trans-116 is also available and can be subjected to similar reactions. For 
example, electrophilic fluorination of pyrrolidine trans-116 with DAST generated 4-
fluoropyrrolidine cis-118 in quantitative yield (Scheme 2.39).89 
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Scheme 2.39 
4-Hydroxyproline trans-119 has been used in the synthesis of pyrrolidine trans-124 via a 
long synthetic route. The synthesis from Barbas et al. is shown in Scheme 2.40 and shows a 
variety of intermediate 2,4-disubstituted pyrrolidines en route to pyrrolidine trans-124.85 
Key steps included the inversion of pyrrolidine trans-120 to pyrrolidine cis-121 using TsCl 
and NH4OAc followed by a second inversion which used mesyl chloride and sodium cyanide 
to form pyrrolidine trans-123 from pyrrolidine cis-122. The synthesis of trans-124 occured 




Structurally-related pyrrolidines, such as trans-127 and cis-127, can be synthesised using a 
Claisen condensation approach. Trapping of the enolate derived from N-benzyl 
pyrrolidinone 125 using ethyl chloroformate generated intermediate pyrrolidinones 126, 
which were then globally reduced using LiAlH4 to give pyrrolidines cis-127 and trans-127 
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(Scheme 2.41).90 The lack of diastereoselectivity could be due to enolisation of the acidic 
‘malonate-type’ proton of pyrrolidinone 126 leading to facile epimerisation. 
 
Scheme 2.41 
Similarly, Claisen condensation of N-Boc pyrrolidinone 128 using ethyl chloroformate was 
used in the synthesis of pyrrolidines 130.91 Pyrrolidinone 128 was subjected to LHMDS 
followed by ethyl chloroformate trapping to give pyrrolidinones 129. Selective reduction of 
pyrrolidinones such as 129 can be difficult due to the presence of carbamate, amide and ester 
carbonyl groups. In this case, the Boc group was removed and the amide O-alkylated using 
Meerwein’s salt before reduction. This process gave a 50:50 mixture of diastereomeric 
pyrrolidines 130 in 74% yield over 3 steps (Scheme 2.42).  
 
Scheme 2.42 
In 2017, some time after we had begun our attempts at the synthesis of the target 3-D 
fragments trans-37 and cis-37, Tanaka et al. showed that 2-alkyl-4-carboxypyrrolidines such 
as cis-124 could be synthesised in a simple two-step process.92 Stereocontrolled nitro-aldol 
addition of nitromethane to Michael acceptor 131 using a chiral thiourea catalyst generated 
intermediate 132 in 75% yield and an impressive 97% ee. Hydrogenation of intermediate 
132 with Pd/C and H2 then gave pyrrolidine cis-124 in 90% yield (Scheme 2.43). The 
hydrogenation first reduces the nitro group to an amine, which then cyclised onto the pendant 
ketone. This gives a cyclic imine that can also be hydrogenated, allowing for the rapid 
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generation of 2,4-disubstituted pyrrolidines. The reason for such high diastereoselectivity 
was not commented on in the paper. 
 
Scheme 2.43 
Other concise methods for the synthesis of 2,4-disubstituted pyrrolidines include the use of 
zirconium to transform N-tosyl carbamates such as 133a and 133b into pyrrolidines.93 
Treatment of carbamate 133a with ZrCp2 and iodine gave intermediate iodide 134a. Iodide 
134a could not be purified and was directly cyclised in the presence of K2CO3 to give a 2:1 
mixture of pyrrolidines cis-135a and trans-135a in 48% yield (Scheme 2.44). However, 
when a propyl group was used in place of a methyl group, the intermediate iodide 134b 
could be purified and cyclisation gave the corresponding pyrrolidine 135b in 80% yield with 
much higher diastereoselectivity. A proposed mechanism for some of the key steps in the 
ZrCp2/I2 reaction is shown in Scheme 2.45. The zirconium co-ordinates to the alkene in 
carbamate 133 and then adds into the carbonyl group. The resulting bicycle can rearrange to 
form an intermediate 7-membered ring, which then breaks down in the presence of an 
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Scheme 2.45 
Another noteworthy route for the synthesis of 2,4-disubstituted pyrrolidines is the use of 
pyrrole hydrogenation. Although uncommon, there are some limited examples of 
pyrrolidines such as cis-138 and trans-138 being synthesised by hydrogenation. For 
example, hydrogenation of a mixture of pyrrole 136 and 2-chloropyrrole 137 gave a 75:25 
mixture of diastereomeric pyrrolidines cis-138 and trans-138 (Scheme 2.46, yield not 
given).94 However, high pressures and long reaction times are typically required for these 
types of hydrogenations. 
 
Scheme 2.46 
2.2.2 Claisen Condensation Route 
The first route considered for the synthesis of fragments trans-37 and cis-37 was based on 
installing the ester using a Claisen condensation, similar to the examples shown in Scheme 
2.41 and Scheme 2.42.90,91 It was proposed that target fragments 37 could be synthesised by 
chemoselective reduction of the corresponding pyrrolidinone 139. Pyrrolidinone 139 would 
be derived from a Claisen condensation of N-methyl pyrrolidinone 140 (Scheme 2.47). 
 
Scheme 2.47 
The Claisen condensation of N-alkyl pyrrolidin-2-ones is a well-known reaction.95,96,97 For 
example, Takeda and Toyota showed that N-methyl pyrrolidinone 141 could be deprotonated 
with LDA at –78 °C and then trapped with methyl chloroformate to give pyrrolidinones 142 
in 86% yield (Scheme 2.48). Tanaka et al. performed a similar reaction on a 2-substituted 
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pyrrolidinone 143. Deprotonation this time was performed at rt to give the enolate which 




To start our synthetic work, the Claisen condensation of pyrrolidinone 140 with methyl 
chloroformate was attempted. Deprotonation of pyrrolidinone 140 with KHMDS (1.1 eq) in 
THF at –78 ºC was followed by reaction with methyl chloroformate. This gave a 77:23 
mixture (by 1H NMR spectroscopy) of starting pyrrolidinone 140 and double addition 
product 145 after work-up and chromatography. From the mass of the mixture, a 9% yield 
of pyrrolidinone 145 was calculated (Scheme 2.49). There was no evidence of the desired 
pyrrolidinones 139. Any that had formed underwent a second Claisen condensation. 
 
Scheme 2.49 
Due to this discouraging result, we turned our attention to N-Boc pyrrolidinones which also 
have good literature precedent for Claisen condensations and have different electronics.98–
100 Bogle et al. had reported the successful condensation of N-Boc pyrrolidinone 146 with 
methyl chloroformate to give pyrrolidinone 147 in 96% yield (Scheme 2.50).98 
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Scheme 2.50 
It was therefore decided to attempt the same conditions as in Scheme 2.49 using N-Boc 
methyl pyrrolidinone 148. First, N-Boc methyl pyrrolidinone 149 was synthesised by 
reaction of methyl pyrrolidinone 148 with Boc2O for 16 h at rt in 85% yield. The Claisen 
condensation was then attempted using KHMDS. Changing from N-methyl pyrrolidinone 
140 to N-Boc pyrrolidinone 149 proved successful with the reaction proceeding in 33% yield 
(Scheme 2.51). Pyrrolidinones 150 were obtained as a 67:33 mixture of diastereomers with 
diagnostic methyl signals at 1.42-1.36 and 1.33-1.27 ppm in the 1H NMR spectrum. The two 
diastereomers proved inseparable by chromatography and we were unable to assign which 
diastereomer of pyrrolidine 150 was the major product.  
 
Scheme 2.51 
The reaction was next attempted using the conditions described by Dixon et al., which 
involved LHMDS as base, a 5-minute reaction time and addition of the pyrrolidinone to the 
base as opposed to the base being added to the pyrrolidinone. This resulted in a substantial 
increase in yield of pyrrolidinones 150 (90%) (Scheme 2.52). The diastereomeric ratio 
(67:33) was the same as when using KHMDS. 
 
Scheme 2.52 
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With pyrrolidinones 150 in hand, the next step was to attempt the chemoselective reduction 
of the lactam carbonyl. BH3•DMS had recently been used in the group to prepare one of the 
other fragments on this project. In that case, pyrrolidinone 115, with the methyl and methyl 
ester groups transposed compared to our system, had been reacted with BH3•DMS to give 
pyrrolidine 151 in 66% yield (Scheme 2.53).  
 
Scheme 2.53 
These conditions were then attempted with pyrrolidinones 150, with BH3•DMS being added 
to pyrrolidinone 150 and heated at 70 °C in THF. The reaction was performed over 20 h, 
with TLCs being carried out to check the reaction progress. However, after 20 h, only the 
starting pyrrolidinones 150 were recovered (Scheme 2.54). 
 
Scheme 2.54 
Alternative conditions were then explored for the reduction. A two-step process involving 
reduction of pyrrolidinone 153 to an aminal intermediate with LiBHEt3 and then further 
reduction with Et3SiH and BF3•Et2O was used successfully by Schneider et al.
101 to give 
pyrrolidine 154 in 84% yield (Scheme 2.55). 
 
Scheme 2.55 
Therefore, LiBHEt3 was reacted with pyrrolidinones 150 in THF at –78 ºC for 30 min. After 
quenching with NaHCO3(aq) and work-up with H2O2, the presumed intermediate aminal was 
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further reduced with Et3SiH and BF3•Et2O at –78 ºC. However, only starting pyrrolidinones 
150 were recovered. This reaction was also tried using similar conditions with sodium 
borohydride in the initial step. The reaction yielded a complex mixture of products, with 1H 
NMR spectroscopy showing many doublets corresponding to the methyl group at δ 0.92-
0.82 ppm (Scheme 2.56). 
 
Scheme 2.56 
The final reduction conditions considered used Meerwein’s salt followed by sodium 
cyanoborohydride to reduce the pyrrolidinone. An example of this chemistry is shown in 
Scheme 2.42.91 These conditions were therefore attempted on pyrrolidinones 150. Treatment 
of pyrrolidinones 150 with TFA (to remove the Boc group) then trimethyloxonium 
tetrafluoroborate appeared by 1H NMR spectroscopy to have alkylated 150 to give 
intermediate 155, evidenced by pairs of singlets that integrated to a total of 3H each at 3.764 
and 3.758 ppm and 3.69 and 3.68 ppm. It was not possible to tell whether this was due to O- 
or N-alkylation. Subsequent treatment with sodium cyanoborohydride at acidic pH gave a 
complex mixture of products by 1H NMR spectroscopy (Scheme 2.57).   
 
Scheme 2.57 
With this reduction proving so difficult and the route giving a mixture of diastereomers that 
had so far proved impossible to separate, it was decided to investigate an alternative route to 
fragments cis-37 and trans-37. 
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2.2.3 Tandem Michael Addition/Dieckmann Cyclisation Route 
With the lack of success with the Claisen condensation route, an alternative route to 
fragments trans-37 and cis-37 was considered. The new route proposed for the synthesis of 
fragments trans-37 and cis-37 involved the hydrogenation of dihydropyrrole 157 to give 
pyrrolidines 152. Dihydropyrrole 157 would be formed from the reduction and elimination 
of β-ketoester 158, which would in turn be formed from a tandem Michael 
addition/Dieckmann cycisation of N-Boc alanine methyl ester 159 and methyl acrylate 
(Scheme 2.58). A similar cyclisation was used to prepare β-ketoester 100 (see Section 2.1.3) 
 
Scheme 2.58 
Although this route was quite a few steps, there was good precedent for each step. For 
example, the synthesis of a dihydropyrrole from an oxopyrrolidine very similar to 158 had 
been performed by Wang et al.70 Reaction of oxopyrrolidine 73 with NaBH3CN in MeOH 
gave alcohol 160. The alcohol was then eliminated using Mitsunobu-type conditions to give 
dihydropyrrole 74 in 90% yield over two steps (Scheme 2.59).  
 
Scheme 2.59 
The tandem Michael/Dieckmann step in the proposed synthesis of fragments trans-37 and 
cis-37 had only been carried previously on glycine derivatives. Boc protection of alanine 
methyl ester proceeded smoothly using NaHCO3, Boc2O and NaCl in CHCl3–H2O.
102 Work-
up yielded N-Boc alanine 159 in quantitative yield which required no purification (Scheme 
2.60). Using the same tBuOK conditions as for N-Boc glycine 101 (see Scheme 2.32), the 
desired 2-methyl oxopyrrolidine 158 was isolated in 50% yield after purification by 
chromatography (Scheme 2.60). Characterisation of oxopyrrolidine 158 by 1H and 13C NMR 
spectroscopy was problematic due to the mixture of tautomers, rotamers and diastereomers 
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present. Mass spectrometry and IR spectroscopy indicated that the reaction was successful 
and subsequent reactions of 158 showed that oxopyrrolidine 158 had indeed been formed. 
 
Scheme 2.60 
The next steps in the synthesis to be attempted were ketone reduction and alcohol 
elimination. For this study, we used the simpler oxopyrrolidine 100. The procedure from 
Wang et al.70 (see Scheme 2.59) was followed, starting with reaction of oxopyrrolidine 100 
with NaBH3CN in MeOH at rt at pH ~4. After work-up, the crude product was reacted with 
PPh3 and DIAD in toluene. Unfortunately, the reaction resulted in a complex mixture of 
products that were inseparable by chromatography (Scheme 2.61). Alternative conditions 
were explored for the reduction step. The reaction was attempted using NaBH(OAc)3. 
However, only starting oxopyrrolidine 100 was recovered. Luche reduction of the ketone 
using group conditions was also attempted, adding NaBH4 to a stirred solution of 
oxopyrrolidine 100 and CeCl3•H2O in MeOH at –60 ºC.
103 However, after quenching and 
work-up the reaction yielded only the starting oxopyrrolidine 100 (Scheme 2.61). 
 
Scheme 2.61 
With the reduction seemingly not working, a different strategy was devised. It was proposed 
that pyrrolidines 152 could come from hydrogenation of enol triflate 161. Palladium 
catalysts would oxidatively insert into the vinyl triflate bond and then undergo reductive 
elimination to give dihydropyrrole 157, which would undergo alkene hydrogenation 
(Scheme 2.62). If this did not proceed in one step then stepwise reduction of the triflate 
followed by hydrogenation of dihydropyrrole 157 could be performed. Triflate 161 would 
be derived from oxopyrrolidine 158. 
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Scheme 2.62 
The first step in this route involved conversion of oxopyrrolidines 158 into enol triflate 161. 
Reaction of oxopyrrolidines 158 with Hünig’s base and triflic anhydride at –78 °C and then 
at rt gave enol triflate 161 in 82% yield (Scheme 2.63). Characterisation by 1H NMR 
spectroscopy showed triflate 161 to be pure, confirming that the previous step to synthesise 
oxopyrrolidine 158 had indeed proceeded cleanly. 
 
Scheme 2.63 
The detriflation-hydrogenation of enol triflate 161 could now be explored. Standard 
hydrogenation conditions of H2 and Pd/C in MeOH at rt were explored first and the expected 
N-Boc pyrrolidines 152 were not formed. In fact, the 1H NMR spectrum of the crude product 
obtained after catalyst removal (by filtration over Celite) and solvent evaporation displayed 
two broad signals at 7.7 and 8.2 ppm and no diagnostic signal for the Boc group at ~1.5 ppm. 
This led to the realisation that the Boc group had been removed. The 1H NMR spectrum also 
showed signals for six ring protons, indicating that triflate removal and alkene hydrogenation 
had both occurred. It was thus realised that reaction of enol triflate 161 with Pd/C and H2 
had yielded a 65:35 mixture of diastereomeric pyrrolidine salts trans-156•TfOH and cis-
156•TfOH in 67% yield (Scheme 2.64). The assignment of pyrrolidine trans-156•TfOH as 
the major diastereomer is based on work that is described later in this Section. The ratio of 
diastereomers was determined by integration of the multiplets at 2.45 and 2.50 ppm in the 
1H NMR spectrum. Unfortunately, for reasons still unknown, the conversion of enol triflate 
161 into triflate salts trans-156•TfOH and cis-156•TfOH was irreproducable despite several 
attempts. 
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Scheme 2.64 
Nevertheless, with triflate salts 156•TfOH in hand, a way of separating the cis- and trans-
diastereomers was explored. Thus, Boc and Cbz groups were attached to the nitrogen to see 
if the products would be separable. Reaction of the 65:35 mixture of trans-156•TfOH and 
cis-156•TfOH with Boc2O and CbzCl gave protected compounds 152 and 162 in 52% and 
70% yield respectively (Scheme 2.65). However, the diastereomers of each compound were 
inseparable by flash column chromatography. 
 
Scheme 2.65 
The 65:35 mixture of triflate salts cis-156•TfOH and trans-156•TfOH was also subjected to 
the group’s standard N-methylation conditions in order to access the desired 3-D fragments 
cis-37 and trans-37. Thus, reductive amination with formaldehyde and sodium 
triacetoxyborohydride gave a 65:35 mixture of pyrrolidine fragments cis-37•AcOH and 
trans-37•AcOH in 23% yield (Scheme 2.66). These products were isolated as acetic acid 
salts due to volatility issues encountered with similar amines of such low molecular weight. 
As a result, we had successfully synthesised both target fragments cis-37 and trans-37, albeit 
as a mixture. 
 
Scheme 2.66 
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As the direct triflate hydrogenation with Pd/C shown in Scheme 2.64 could not be repeated, 
alternative hydrogenation conditions were considered. It was decided to attempt the 
hydrogenation in the presence of base, which would neutralise any triflic acid that was 
generated in the detriflation step. Treatment of enol triflate 161 with Pd/C, H2 and Et3N 
generated a complex mixture of products by 1H NMR spectroscopy. However, after column 
chromatography, dihydropyrrole 157 was isolated in 17% yield (Scheme 2.67). Despite the 
low yield, the isolation of dihydropyrrole 157 was at least encouraging evidence that the 
stepwise process of removing the triflate group followed by hydrogenation could be 
successful. Isolating dihydropyrrole 157 was surprising given that such a compound would 
be expected to hydrogenate quickly under these conditions. It is possible that Et3N was 
poisoning the catalyst and reducing the rate of the hydrogenation reaction. The reaction was 
therefore attempted using K2CO3 and this also gave a complex mixture of products by 
1H 
NMR spectroscopy. However, a single diastereomeric pyrrolidine, cis-152, was isolated in 
8% yield (Scheme 2.67). Interestingly, the reaction gave the opposite major diastereomer to 
hydrogenation of enol triflate 161 in the absence of base (see Scheme 2.64). 
 
Scheme 2.67 
With the direct hydrogenation of enol triflate 161 proving difficult, the stepwise approach 
was considered to the desired pyrrolidines 152. Sieburth et al. had shown that a triflate group 
could be removed from an α,β-unsaturated-β-triflate ester using Pd(PPh3)4 and Et3SiH on a 
pyrone substrate.104 In this reaction, the Et3SiH acts as a hydride donor to the palladium, 
while the palladium oxidatively inserts into the vinyl triflate bond and then undergo es 
reductive elimination to give the desired product. Using these conditions, the triflate group 
of enol triflate 161 was selectively removed using Pd(PPh3)4 and Et3SiH to give 
dihydropyrrole 157 in 56% yield (Scheme 2.68).104 Frustratingly, the product was isolated 
as an 85:15 mixture of 157 and Et3SiH, which despite work-up with sources of fluoride and 
chromatography could not be removed. However, 1H NMR spectroscopy after all subsequent 
hydrogenations showed no remaining Et3SiH and its presence caused no issues during these 
reactions. 
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Scheme 2.68 
The next step was the hydrogenation of dihydropyrrole 157 and the results are summarised 
in Table 2.1. Hydrogenation of dihydropyrrole 157 using Pd/C and H2 in MeOH at rt for 42 
h gave, after filtration through Celite, a 29% yield of an 85:15 mixture of pyrrolidines cis-
152 and trans-152 (entry 1). A similar result was obtained with an 18 h reaction time (entry 
2). In contrast, use of Pd(OH)2/C gave an 81% yield of a 55:45 mixture of cis-152 and trans-
152 (entry 3). Although Pd(OH)2 gave a poor diastereoselectivity, the yield was much higher 
than that for Pd/C (entry 1). It was postulated that the low diastereoselectivity of the reaction 
with Pd(OH)2 might due to the long reaction time, allowing for epimerisation of the product. 
The reaction was therefore repeated with a reduced reaction time of 1 h. The 
diastereoselectivity did not change, but the shorter reaction time did improve the yield to 
97% (entry 4). Finally, hydrogenation using PtO2 as the catalyst was explored but this 
returned only starting material (entry 5).  
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a % Yield of crude product 
b Ratio of cis-152 and trans-152 determined by 1H NMR spectroscopy of the crude product 
 
Table 2.1: Investigation of the hydrogenation of dihydropyrrole 157  
The cis stereochemistry of the major product, cis-152, was ascertained later in the project 
(see Section 2.2.4). The difference in diastereoselectivity caused by changing catalyst from 
Pd/C to Pd(OH)2 was substantial, and surprising given that both catalysts involve the 
hydrogenation step occurring on a heterogeneous palladium surface. However, the low yield 
of the Pd/C catalysed hydrogenations (entries 1 and 2) indicates that other processes may be 
occurring in the reaction. Our attempt to explain the cis-diastereoselectivity is shown in 
Figure 2.5. It is postulated that the planar N-Boc group forces the α-methyl group into a 
pseudo-axial position. This causes steric clashing between the methyl group and the 
palladium, which results in hydrogenation of the opposite face being favoured and the ester 
group being pushed into a cis position relative to the methyl group. The difference in the 
levels of cis-selectivity between the Pd/C and Pd(OH)2/C catalysts is difficult to explain 
without further studies into the surface of the catalysts. 
 
Figure 2.5: Postulated transition state during the hydrogenation of 157. 
Next, we wanted to find an N-substituent that would allow for the separation of the 
diastereomers. Boc and Cbz groups had already been shown not to work, so other common 
Entry Conditions Time (h) Yield (%)a cis:transb 
1 Pd/C, MeOH 42 29 85:15 
2 Pd/C, MeOH 18 27 75:25 
3 Pd(OH)2/C, MeOH 18 81 55:45 
4 Pd(OH)2/C, MeOH 1 97 55:45 
5 PtO2, AcOH 18 0 N/A 
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nitrogen-protecting groups were considered. A 55:45 mixture of N-Boc pyrrolidines cis-152 
and trans-152 was deprotected using TFA. Then, reaction with PhCHO and NaBH(OAc)3 
gave N-benzyl derivatives 163 in 41% yield (over two steps). Reaction with 2-NsCl gave N-




Chromatography of the nosyl derivatives 164 showed some separation of the diastereomers 
but not enough to fully separate them. Chromatography of the benzyl derivatives 163 proved 
more successful, and a 10% yield of pure cis-163 was isolated. However, the diastereomers 
were indistinguishable by TLC and the only way to determine that a single diastereomer was 
present in the fraction was to perform 1H NMR spectroscopy on each one. This was possible 
but very time consuming. At this point, the route had substantially increased in steps and 
still lacked diastereoselectivity in the hydrogenation step or an easy way to separate the 
diastereomers. Therefore, this route was abandoned and it was decided to move on to a new 
route. 
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2.2.4 Nitrile Hydrogenation Route 
A route that would number no more than six steps and had the potential to be 
diastereoselective was sought to synthesise the target fragments. A hydrogenation route was 
proposed that would involve pyrrolidine 156 being obtained from hydrogenation of keto 
nitrile 165. The required keto nitrile 165 could be formed using an enolate alkylation 
approach with methyl cyanoacetate 166 and chloroacetone 167 (Scheme 2.71). 
 
Scheme 2.71 
The mechanism of the key ring-forming step is shown in Scheme 2.72. Amine 168 required 
for the cyclisation step would have to be masked in some fashion, and for this we considered 
a nitrile group. It was therefore proposed that pyrrolidine 156 could come from keto nitrile 
165, where hydrogenation would reduce keto nitrile 165 to amino ketone 168 which could 
then cyclise onto the pendant ketone. This would generate imine 169 which would also be 
hydrogenated to set the relative stereochemistry and build the ring in one step.  
 
Scheme 2.72 
This nitrile hydrogenation approach to a pyrrolidine had been first reported by Korte and 
Trautner in 1961,105 where keto nitrile 170 was subjected to hydrogen gas at high pressure 
apparently in the absence of a transition metal catalyst. Reaction at rt and 100 atm 
exclusively gave pyrrole 171 (Table 2.2, entry 1). In contrast, at 250 atm, the reaction gave 
an 80:20 mixture of pyrrole 171 and pyrrolidines 172 (diastereomeric ratio and yields not 
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Entry Pressure Catalyst 171:172 
1 100 none 100:0 
2 250 none 80:20 
 
Table 2.2: Keto nitrile hydrogenation results 
A suggested mechanism for the formation of pyrrole 171 is shown in Scheme 2.73. 
Hydrogenation of the nitrile group will give the imine, which can tautomerize to form 
enamine 173. Enamine 173 can then cyclise onto the ketone to give iminium 174. 
Tautomerization of iminium 174 then gives pyrrole 171. The relative rates of the 
hydrogenation of enamine 173 and the corresponding imine, the tautomerization between 
the imine and enamine forms of 174, and the cyclisation of enamine 173 will all affect the 
ratio of pyrrole 171 and desired pyrrolidine 172 being formed.  
 
Scheme 2.73 
The first step in this proposed route was the alkylation of methyl cyanoacetate with 
chloroacetone. Using conditions from Lee et al.,106 methyl cyanoacetate was deprotonated 
with sodium methoxide and then trapped with chloroacetone to give nitrile 165 in 62% yield 
after chromatography (Scheme 2.74). This reaction was readily scaled up to give ~3 g of 
keto nitrile 165. The hydrogenation of keto nitrile 165 was then attempted using conditions 
from an AstraZeneca patent where a similar nitrile-containing compound was hydrogenated. 
Reaction in AcOH using a balloon of H2 and 5 mol% PtO2 as catalyst at rt for 16 h and then 
filtering through Celite to remove the catalyst led to the formation of an 80:20 mixture of 
the desired pyrrolidines 156•AcOH (as an 85:15 mixture of cis and trans diastereomers) and 
pyrrole 175 (Scheme 2.74). The product was isolated as the acetic acid salt due to the 
volatility of pyrrolidines 156. It was difficult to determine an accurate yield for this reaction 
due to issues with completely removing the acetic acid. An acid-base work-up was attempted 
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to remove the pyrrole 175 from the crude mixture of pyrrolidines 156•AcOH. However, 
pyrrolidines 156 proved to be highly soluble in water and difficult to extract even when 





Pyrrole 175 was identified from the 1H NMR spectrum of the crude product: the spectrum 
showed two signals that integrated to 1 H each at 6.26 ppm and 7.26 ppm, corresponding to 
the two aromatic protons, and two singlet signals that integrated to 3 H each at 3.76 ppm and 
2.23 ppm, corresponding to the methyl groups in the ester and attached to the ring 
respectively. These signals matched the literature signals for pyrrole 175.107 
At this point, we decided to Cbz protect the crude mixture as we realised that this could be 
used to assign the stereochemistry of pyrrolidines 156. This was possible because N-Cbz 
ethyl ester pyrrolidine trans- was recently reported by Tanaka et al., with its stereochemistry 
being established by NOE spectroscopy.92 However, during the course of this PhD, a 
correction to the paper was issued stating that the stereochemistry had been misassigned and 
X-ray crystallography was used to prove that it was in fact cis-176. This resulted in us 
misassigning the major diastereomer of our hydrogenations as trans-156 until late in the 
project. The stereochemistry of the 2,4-disubstituted pyrrolidines in this thesis is now 
reported correctly, with verification both through the method detailed below and via our own 
X-ray crystal structure as described in Section 2.3.  
Cbz protection of pyrrolidines 156 gave protected pyrrolidines 164, still as an 85:15 mixture 
of diastereomers, in 18% yield over the 2 steps of hydrogenation and Cbz protection. The 
static ratio of diastereomers led us to believe that no epimerisation had occurred. Pyrrolidines 
164 were easily isolable by chromatography. Pyrrolidines 164 were then hydrolysed and 
esterified to give an 85:15 mixture of ethyl ester pyrrolidines cis-176 and trans-176 in 46% 
yield (Scheme 2.75).  
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Scheme 2.75 
Key signals in the 1H NMR spectrum of pyrrolidines 176 (Figure 2.6) were the dd at 3.56 
ppm corresponding to an NCH proton, the dddd at 2.94 ppm corresponding to the CHCO2Et 
proton and the ddd at 2.38 ppm corresponding to a CH2 proton, all of which integrated to 
0.85H and matched the literature data for pure cis-176. Importantly, the corresponding 
signals for the NCHCO2Et and CH2 protons in trans-176, which were noticeably broader,  
appearing at 3.14 and 2.26 ppm, both integrated to 0.15H and were absent from the 1H NMR 
spectrum of cis-176 reported in the literature.92 This gave us the proof that pyrrolidine cis-
156 was the major product of the hydrogenation and, by comparison of 1H NMR spectra, 
allowed us to assign all of the stereochemistry in Sections 2.2 and 2.3. 
 
Figure 2.6 
The formation of pyrrolidine cis-156•AcOH as the major product from the hydrogenation of 
keto nitrile 165 was consistent with results from Tanaka et al.92 They showed that a similar 
synthetic route involving hydrogenation of nitro compounds 177 to synthesise a variety of 
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2,4-disubstituted pyrrolidines 179 gave the cis-diastereomer as the sole product (see Scheme 
2.43), although they did not comment on the origin of the diastereoselectivity. Their 
hydrogenation used Pd/C in MeOH, meaning that hydrogenation of nitro compound 179 
proceeded via intermediate imine 180. Our route uses nitrile hydrogenation under acidic 
conditions and therefore proceeds via iminium intermediate 169 (Scheme 2.76). It is possible 
that the small difference in diastereoselectivity between these two routes may be caused by 
both the larger ester group and the difference between the hydrogenation of iminium 169 as 
opposed to an imine. Later work showed that the difference is not only due to sterics, as 




The diastereoselectivity likely arises from hydrogenation on the opposite face to the 
sterically bulky ester group. This gives the cis-diastereomer as the major diastereomer 
(Figure 2.7). The increased steric bulk of the ethyl ester over the methyl ester helps make 
the reaction more selective while the difference between hydrogenation of an imine and an 
iminium could be due to several factors, including small changes in shape and the availability 
of the lone pair for co-ordination. 
                            
Figure 2.7: Transition state to explain the diastereoselectivity for cis-156 
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Then next challenge was to access pyrrolidine cis-156 as a single diastereomer. In order to 
separate the diastereomers, an N-benzyl group was attached to pyrrolidines 156•AcOH. 
After standard hydrogenation of keto nitrile 165, subjection of pyrrolidines 156 to reductive 
amination conditions with benzaldehyde followed by chromatography gave pyrrolidine cis-
163 as a single diastereomer in 21% yield over 2 steps. An 80:20 mixture of pyrrolidines 
cis-163 and trans-163 was isolated in 37% yield (Scheme 2.77). Unfortunately, as discussed 
earlier, 1H NMR spectra of individual fractions had to be carried out in order to isolate just 
21% of pure cis-163, as the diastereomers did not appear separately by TLC. 
 
Scheme 2.77 
Although we were pleased to finally have access to pyrrolidine cis-163 as a single 
diastereomer, the route still required a difficult chromatography purification to obtain small 
amounts of pure cis-163. We therefore wondered if it would be possible to epimerise 
pyrrolidines 163 to give a higher percentage of the cis-diastereomer and thus make the route 
higher yielding. Epimerisation of pyrrolidines 163 might also give access to the trans 
diastereomer. 
The first series of epimerisation reactions attempted were performed using NaOMe or 
K2CO3 as base in MeOH (Table 2.3). Reactions performed at rt (entries 1 and 3) appeared 
to give very slow or no epimerisation. However, epimerisation at 60 °C showed a 
signification change in the diastereomeric ratios. Use of NaOMe gave a 55:45 mixture of 
cis-163 and trans-163 in 94% yield (entry 2), and use of K2CO3 gave a 50:50 mixture of cis-
163 and trans-163 in 22% yield (entry 4). It is possible that the low yield from the K2CO3 
reaction at 60 °C may be due to hydrolysis of the ester occurring, an issue which had been 
shown to cause significantly reduced yields in the epimerisation reactions of analogous 
piperidine compounds by another member of our group.103 
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a % Yield of crude product 
b Ratio of cis-163 and trans-163 determined by 1H NMR spectroscopy of the crude product 
 
 Table 2.3: Epimerisation of pyrrolidines 163 
Thus far, no epimerisation conditions had given pyrrolidine trans-163 as the major product 
or cis-163 in better diastereoselectivity.  Alternative epimerisation conditions were therefore 
explored. Previous work in the group on the epimerisation of piperidines had found that t-
BuOK at –78 °C in THF gave significant diastereoselectivity.108  Treatment of pyrrolidines 
163 with t-BuOK at –78 °C for 2 h in THF, followed by quenching with saturated NH4Cl(aq), 
gave a 40:50:10 mixture of pyrrolidine cis-163, pyrrolidine trans-163 and transesterified 
pyrrolidine cis-182 in quantitative yield (Scheme 2.78).  
 
Scheme 2.78 
With epimerisations of N-benzyl pyrrolidines proving unselective, it was decided to attempt 
the epimerisation of N-Boc pyrrolidines 152. First, pyrrolidines 152 were synthesised in 48% 
yield (over 2 steps) from keto nitrile 165. Pyrrolidines 152 were then subjected to the 
NaOMe and K2CO3 conditions (Table 2.4). Pleasingly, reactions at rt gave a 50:50 mixture 
of diastereomers in very high yields (entries 1 and 3) while heating gave pyrrolidine trans-
152 as the major product (entries 2 and 4). However, diastereomers cis-152 and trans-152 
Entry Base Solvent Temp. (°C) Time (h) Yield (%)a cis:transb 
1 NaOMe MeOH rt 16 98 85:15 
2 NaOMe MeOH 60 16 94 55:45 
3 K2CO3 MeOH rt 16 100 85:15 
4 K2CO3 MeOH 60 16 22 50:50 
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were inseparable and as the results were not substantially better than the N-benzyl system, 
these results were not used moving forward. 
 
 
a % Yield of crude product 
b Ratio of cis-152 and trans-152 determined by 1H NMR spectroscopy of the crude product 
 
Table 2.4: Epimerisation of N-Boc pyrrolidines 152 
The synthesis of the targeted 3-D fragment N-Me pyrrolidine cis-37 could now be carried 
out. We planned to use the sample of pure cis-156•AcOH obtained from the N-benzylation 
route to synthesise N-Me fragment cis-37. However, as this material was precious, the 
reaction was first attempted on an 85:15 mixture of diastereomers. Hydrogenation of keto 
nitrile 165 gave pyrrolidines 156, which were reacted under standard N-methylation 
conditions (Scheme 2.79). This appeared to give some product, but placing it on the high 
vacuum line to remove the remaining AcOH led to disappearance of all of the product. This 
is in contrast with the reaction shown in Scheme 2.66, although this N-methylation was done 
on smaller scale to replicate the amount of pure cis-156 available which may account for the 




Entry Base Solvent Temp. (°C) Time (h) Yield (%)a cis:transb 
1 NaOMe MeOH rt 16 100 50:50 
2 NaOMe MeOH 60 16 88 40:60 
3 K2CO3 MeOH rt 16 98 50:50 
4 K2CO3 MeOH 60 16 64 35:65 
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Despite exploring multiple routes to fragments cis-37 and trans-37, we were still unable to 
obtain either as a single diastereomer. A 65:35 mixture of fragments trans-37 and cis-37 had 
been obtained via the triflate hydrogenation route and, using the keto nitrile route, we had 
the potential to synthesise an 85:15 mixture of cis-37 and trans-37. However, we had been 
unable to either increase the diastereoselectivity or effectively separate the diastereomers in 
either route. We therefore sought to synthesise some closely related 2,4-diubstituted 
pyrrolidine fragments that could replace cis-37 and trans-37 in the library and be obtained 
as single diastereomers. 
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2.3  Design and Synthesis of t-Butyl Ester Fragments 
Although it had not yielded either fragment as a single diastereomer, the nitrile 
hydrogenation route described in Section 2.2.4 was still very attractive to us as a way of 
synthesising fragments. It contained only four straightforward steps to reach a potential N-
H fragment, which could then be further diversified. A way of increasing the 
diastereoselectivity in the key hydrogenation step to allow us to synthesise fragments from 
this route as single diastereomers was therefore sought. It was proposed that using a more 
sterically bulky t-butyl ester group would increase the cis-selectivity of the reaction and 
allow access to cis-45 as a single diastereomer (Scheme 2.80). 
 
Scheme 2.80 
The larger t-butyl ester group would have the added benefit of reducing any potential 
volatility issues. Thus, it was decided to target N-H t-butyl ester fragment cis-45, and to 
attach the other three standard groups to the nitrogen to give fragments cis-46, cis-47 and 
cis-48 (Figure 2.8). 
 
Figure 2.8: Structures of the target t-butyl ester fragments 
PMI analysis was then performed on these target fragments to check their 3-D shape before 
synthesis. Pleasingly all four fragments had good 3-D shape, particularly the N-H, N-Me and 
N-Ac fragments which had conformations with ∑NPR > 1.3 while the N-Ms fragment 
showed conformers with ∑NPR > 1.15 (Figure 2.9). All four were therefore selected for 
synthesis. 
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Figure 2.9: PMI plots of the potential t-butyl ester fragments 
The first step in the synthesis was to synthesise starting keto nitrile 183. Nitrile 185 was 
reacted with t-BuOK and chloroacetone either in THF at rt or in t-BuOH at 40 °C. Reaction 
in THF at rt gave nitrile 183 in 63% yield, whereas the same reaction performed in t-BuOH 
at 40 °C gave nitrile 183 in 76% yield (Scheme 2.81). 
 
Scheme 2.81 
The next step wa the hydrogenation of keto nitrile 183. Pleasingly, hydrogenation of 183 
under the standard conditions (PtO2, AcOH, H2) gave an 85:15 mixture of desired 
pyrrolidine cis-45 (in >95:5 dr) and pyrrole 184. The amine was then benzyl protected to 
give a single diastereomeric pyrrolidine, cis-182 in 30% yield over the two steps (Scheme 
2.82). This increased level of diastereoselectivity in the hydrogenation meant that 
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chromatography proceeded without the need to use 1H NMR spectroscopy on each fraction 
to obtain a pure diastereomer, thus making obtaining pure cis-182 quick and easily scalable. 
Scheme 2.82 
Hydrogenation of N-benzyl pyrrolidine cis-182 gave pyrrolidine cis-45•AcOH in 79% yield 
after filtration through Celite. Pyrrolidine cis-45•AcOH was then subjected to the standard 
N-methylation conditions to give pyrrolidine cis-46•AcOH in 16% yield (Scheme 2.83). It 
is not clear why this reaction is so low yielding. 
 
Scheme 2.83 
With two fragments already in hand, attention turned to the N-Ms fragment. Pyrrolidine cis-
45•AcOH was reacted with mesyl chloride and Et3N (4.0 eq) in CH2Cl2 to give the crude 
product. Inspection of the 1H NMR spectrum showed a 3H singlet at 2.05 ppm, which is 
more upfield than would be expected for an NSO2Me signal. Furthermore, the 
13C NMR also 
showed additional signals at 172.5 and 172.2 ppm, leading to the realisation that the product 
formed was in fact the N-acetyl pyrrolidine cis-48 rather than the N-mesyl pyrrolidine cis-
47. The structure was confirmed by mass spectrometry and the presence of rotamers as 
opposed to diastereomers was confirmed by variable temperature 1H NMR spectroscopy. 
This reaction gave pyrrolidine cis-48 in 52% yield with no N-mesyl pyrrolidine cis-47 
observed (Scheme 2.84). Happily, this meant that we did not need to carry out a separate 
synthesis of N-Ac fragment cis-48! 
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Scheme 2.84 
It was proposed that pyrrolidine cis-48 was being formed due to the acetate attacking the 
generated sulfonyl intermediate 185. This would lead to the formation of mixed anhydride 




The mesylation reaction was then repeated using pyridine as both the solvent and base. The 
mechanism for mesylation reactions works differently with a weaker base such as pyridine, 
as the mesyl chloride no longer undergoes elimination but the pyridine instead acts as a 
nucleophilic catalyst. Subjection of pyrrolidine cis-45•AcOH to mesyl chloride in neat 




Crystals of fragment cis-47 suitable for X-ray crystallography were then successfully grown. 
The X-ray crystal structure of cis-47 is shown in Figure 2.10 and clearly shows that the 
methyl and t-butyl ester groups are cis to each other. The identification of the 
stereochemistry of cis-47 by X-ray crystallography was important as it fully supported the 
assignment of stereochemistry of the 2,4-disubstituted compounds in Section 2.2. We felt it 
reasonable to assume that the major products of the methyl ester keto nitrile hydrogenation 
(85:15 dr) and the t-butyl ester keto nitrile hydrogenation (95:5 dr) had the same relative 
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stereochemistry and this fitted with the stereochemical assignment by comparison with 
literature 1H NMR spectroscopy data detailed in Section 2.2.3. As such, we felt confident to 
add these fragments to our library as the cis-diastereomers. 
 
Figure 2.10: X-ray crystal structure of fragment cis-47 
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2.4  Conclusions 
Although we had not been successful in synthesising all of the four fragments initially 
targeted at the beginning of this Chapter, we did successfully synthesise six new 3-D 
fragments to add to the library (Figure 2.11). These included initial targets cis-42 and cis-
43, synthesised via a 1,3-dipolar cycloaddition route, as well as four 2,4-disubstituted 
fragments: cis-45, cis-46, cis-47 and cis-48 which were synthesised via a nitrile 
hydrogenation route.  
 
Figure 2.11: 3-D Fragments synthesised in this Chapter 
Work towards fragments cis-42 and cis-43 included both a 1,3-dipolar cycloaddition route 
and the enol triflate Michael addition route. Although the Michael addition route proved 
unsuccessful, the triflate intermediate provided the inspiration for the design of our 2nd 
generation fragments, and the work done on the synthesis of triflate 99 ensured that 2nd 
generation fragments could be accessed quickly without optimisation of the synthesis of the 
key intermediate being needed (Scheme 2.87). 
 
Scheme 2.87 
Routes to access target fragments trans-37 and cis-37 were even more varied, with work 
done on a Claisen condensation route (Section 2.2.2), a triflate hydrogenation route (Section 
2.2.3) and a nitrile hydrogenation route (Section 2.2.4). All three routes came very close to 
synthesising the target fragments, but none were able to synthesise either as a single 
diastereomer. However, the triflate hydrogenation route did give access to a 65:35 mixture 
of fragments trans-37 and cis-37, while the short, diastereoselective nitrile hydrogenation 
route ultimately resulted in the synthesis of the four t-butyl ester fragments (Scheme 2.88). 
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Scheme 2.88 
With the 1st generation of fragments now complete, we sought to apply our learnings from 
the selection and synthesis  
of this initial fragment library to guide the creation of a 2nd generation of 3-D fragments that 
would expand our collection. This work is detailed in Chapter 3. 
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DESIGN AND SYNTHESIS OF 2nd GENERATION 3-D 
FRAGMENTS 
 
After the completion of the synthetic work detailed in Chapter 2, it was decided that an 
alternative approach to the synthesis of 3-D fragments should be explored. Although the 1st 
generation fragments possessed both the requisite 3-D shape and properties, each 
substitution pattern required its own synthetic route, meaning that it took a long time to 
synthesise a significant number of 3-D fragments.  A new strategy was therefore explored 
which would allow for rapid access to a large number of fragments whilst mantaining good 
physicochemical properties and interesting 3-D shape. The new strategy, presented in detail 
in Section 3.1, involved trapping a selection of β-ketoesters 187 as enol triflates 188 followed 
by Suzuki-Miyaura coupling with aryl boronic acids to give substituted alkenes 189 and then 
hydrogenation and derivatisation to give 3-D fragments cis-44 (Scheme 3.1). 
 
Scheme 3.1 
After reviewing the relevant literature (Section 3.2), the synthesis of enol triflates 188 and 
the scope of the Suzuki-Miyaura coupling is described (Section 3.3). Then, optimisation of 
the hydrogenation is presented (Section 3.4). In Section 3.5, initial ester diversification work 
on a pyrrolidine system and synthesis of two 3-D fragments are presented. The learnings 
from this were then used to divide the diversification into two discrete routes, a reduction 
route (Section 3.6) and a hydrolysis route (Section 3.7) which were used to synthesise a 
further 22 fragments.  
  
Results and Discussion 
 97  
3.1  Issues with the 1st Generation Fragments and Introduction of the the New 
Strategy for 2nd Generation Fragment Synthesis 
Those fragment libraries whose synthesis are detailed in the literature (see Section 1.3) show 
one feature in common: they are directed by a synthetic strategy as opposed to being 
designed exclusively based on criteria such as 3-D shape or physicochemical properties. 
While our group’s strategy of selecting fragments primarily on 3-D shape had resulted in a 
shape-diverse set of attractive 3-D fragments, it had taken significant time and effort to 
synthesise the 35 fragments. We therefore sought to access the benefits of using a single 
synthetic strategy while continuing to prioritise diverse functionality and 3-D shape. It was 
decided to target 25 new 3-D fragments by using a single synthetic route, which is the focus 
of this chapter.  
When designing the 2nd generation fragments, several new design features were included 
whilst continuing to work on disubstituted saturated heterocycles. To aid with both screening 
and protein binding, an aromatic group was included in each fragment. This would increase 
both the molecular weight and lipophilicity as well as providing potential new binding 
modes and making protein screening by 1H NMR spectroscopy easier. We also wanted to 
introduce greater variation of pharmacophore. Previously, only esters and primary alcohols 
had been used in combination with the differentially functionalised amino group. In the new 
approach, the pendant pharmacophore as well as the core saturated heterocycle would be 
diversified to add greater diversity in the synthesised fragments.  
During work on the synthesis of fragments cis-42, cis-43 and cis-37, vinyl triflates 99 and 
161 had been synthesised as intermediates (Figure 3.1). Although the routes to the 3-D 
fragments involving vinyl triflates 99 and 161 were ultimately unsuccessful, the compounds 
themselves appeared to have potential as building blocks towards other fragments.  
 
Figure 3.1: Previously synthesised vinyl triflates 
Enol triflates 99 and 161 contain three points of diversification: the vinyl triflate, the amino 
substituent and the ester group. The vinyl triflate group in 99 could be used in Suzuki-
Miyaura cross-coupling to introduce an aryl group to give alkenes 190. Hydrogenation of 
alkenes 190 would give the cis stereochemistry in 3-D fragments cis-191. Diversification of 
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the amino group had already been established in the synthesis of the 1st generation fragments 
and esters are versatile and could be diversified to groups such as alcohols, alkyl fluorides, 
amines or acids to give fragments cis-192. (Scheme 3.2).  
 
Scheme 3.2 
The core heterocycle also had the potential to be varied. If different β-ketoesters (Figure 
3.2), the precursors to the vinyl triflates, could be obtained, then it should be possible to 
synthesise a diverse set of 3-D fragments. The availability of β-keto esters 100 and 193-196 
(Figure 3.2) was therefore investigated. Cyclopentane ester 193 and the NH precursor to 
piperidine ester 196 are commercially available. The synthesis of esters 194 and 195 has 
been reported109–111 and the synthesis of pyrrolidine ester 100 was carried out in Chapter 2 
(see Scheme 2.32). With ready access to these β-keto esters, the route shown in Scheme 3.3 
looked to be a viable strategy for the synthesis of 2nd generation 3-D fragments. 
 
Figure 3.2: The proposed β-ketoester starting materials 
 
Scheme 3.3 
Before their synthesis, potential fragments were subjected to PMI analysis to assess their 3-
D shape. Only fragments with at least one conformation less than 1.5 kcalmol–1 above the 
ground state energy with ∑NPR ≥ 1.15 were selected for synthesis. Detailed 3-D shape 
analysis of the synthesised fragments is presented in Section 4.3. 
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3.2 Overview of Previous Syntheses of 3,4-Disubstituted Saturated Cyclic Compounds 
using the Triflate Coupling Route 
There are a handful of reported examples of the synthesis of cis-3,4-disubstituted cyclic 
compounds using the proposed triflate coupling route. For example, Zhang et al.112  showed 
that enol triflate 197 could be easily prepared from cyclopentyl β-ketoester 193. Subsequent 
Suzuki-Miyaura coupling with phenylboronic acid gave disubstituted cyclopentene 198 in 
85% yield. Hydrogenation then gave cyclopentane ester cis-199 in 95% yield (Scheme 3.4). 
 
Scheme 3.4 
Much work in this general area has focussed on the synthesis of 3,4-disubstituted 
piperidines. This is due to the development of Paroxetine, a successful antidepressant 
discovered in 1973 and launched by SmithKline Beecham in 1992.113 Although Paroxetine 
is a trans-3,4-disubstituted piperidine, attempts to create analogues have involved the 
synthesis of cis-3,4-disubstituted piperidines. A patent from 2016 reported the deprotonation 
of β-ketoester 196 with NaH and trapping with PhNTf2 to give enol triflate 200 in 75% yield. 
Suzuki-Miyaura coupling with phenylboronic acid and Pd(PPh3)4 worked well to give 
piperidine 201.114 Hydrolysis of the ester in piperidine 202 with NaOH at 70 °C and 
hydrogenation at high pressure with Pd/C as the catalyst gave acid cis-203 in 78% yield over 
2 steps (Scheme 3.5). 
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Scheme 3.5 
Work has also been reported on the synthesis of cis- and trans-3,4-disubstituted THFs. Chen 
et al. have synthesised a number of 3,4-disubstituted THFs and tetrahydrothiophenes as 
potential melanocortin-4 receptor ligands.115 In one example, THF β-ketoester 194 was 
triflated using NaH and Tf2O to give enol triflate 204 in 23% yield. Then, Suzuki-Miyaura 
coupling with 4-chlorophenyl boronic acid gave dihydrofuran 205 in 40% yield. 
Dihydrofuran 205 was reduced using NaBH4 and NiCl2 to give an 85:15 mixture of THFs 
trans-206 and cis-206 in 76% yield (Scheme 3.6).  
 
Scheme 3.6 
Together, NiCl2 and NaBH4 typically form Ni(BH4)2 in situ, which could perform a 1,4-
conjugate addition of hydride into the alkene to give an enolate. The high trans-selectivity 
of this reduction is interesting as the kinetic product could be expected to be cis-206, with 
protonation of the enolate occurring on the opposite face to the aromatic ring. Therefore, it 
Results and Discussion 
 101  
is possible that epimerisation to trans-206 occurred after the reduction under these 
conditions. Unfortunately, the stereoselectivity of this reaction is not commented on in the 
paper. 
The examples shown in Schemes 3.5 and 3.6 indicated that the proposed new route to 3-D 
fragments was appropriate. We planned to use the literature knowledge to act as a starting 
point for identifying a single set of conditions for each step in the route that could be applied 
to all substrates and easily performed. Once conditions had been established, around 25 3-D 
fragments would be synthesised using the synthetic route set out in Scheme 3.3. 
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3.3 Synthesis of Enol Triflates and Investigation of Suzuki-Miyaura Cross-Couplings 
To start with, the required enol triflates were prepared. In some cases, it was also necessary 
to prepare the β-ketoesters. Using literature conditions,81 cyclopentene enol triflate 197 was 
synthesised in 92% yield from β-ketoester 193 (Scheme 3.7). Piperidine enol triflate 200 
was synthesised in a similar manner. Boc protection of the commercially available salt 
207•HCl proceeded in 95% yield to give the enol tautomer of β-ketoester 196a.116 Then, 
triflation of N-Boc piperidine enol ester 196a using i-PrNEt2 and Tf2O gave triflate 200 in 




The final two enol triflates to be synthesised were the THF and THP enol triflates. Neither 
THF β-ketoester 194 nor THP β-ketoester 195 are commercially available. They were each 
synthesised by another group member.83 Following a literature procedure, THF β-ketoester 
194 was prepared in 53% yield from hydroxyester 208 and methyl acrylate. A different route 
was used for THP β-ketoester 195. Reaction of ketone 209 with LHMDS and trapping with 
an imidazole-containing electrophile gave β-ketoester 195 in 45% yield (Scheme 3.8). 
 
Scheme 3.8 
With each of β-ketoesters 194 and 195 in hand, their triflation was explored. The synthesis 
of THF triflate 204 was attempted using our standard conditions of i-PrNEt2 and Tf2O. The 
triflation appeared to be successful by 1H NMR spectroscopy of the product obtained after 
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chromatography (Scheme 3.9). However, THF enol triflate 204 proved to be unstable, with 
the sample physically degrading after 1-2 days. 
 
Scheme 3.9 
The decision was therefore made to prepare fresh enol triflate 204 and then carry out the 
Suzuki-Miyaura reaction immediately after purification by chromatography. It was decided 
to use the same process with THP β-ketoester 195, even though we had no information on 
the stability of THP enol triflate. This was because the electrophile required in the synthesis 
of THP β-ketoester 195 had to be synthesised separately and purification of THP β-ketoester 
195 proved difficult, meaning that synthesis of THP β-ketoester 195 was very time-
consuming.  
With the starting enol triflates now available, the next step to explore was the Suzuki-
Miyaura couplings. Coupling of pyrrolidine enol triflate 99 with phenylboronic acid was 
attempted first. Using similar conditions to those used by Zhang et al.,112 reaction using 
Pd(PPh3)4 as catalyst and THF as solvent and heating to 65 °C for 18 h gave the desired 
dihydropyrrole 210 in only 33% yield (Scheme 3.10). To attempt to improve the yield, the 
solvent was changed since much of the material appeared not to dissolve. Use of 4:1 THF–
H2O resulted in complete dissolution of all reagents and a substantial increase in yield of 
210 to 83% (Scheme 3.10). The increase in yield may also be due in part to water increasing 
the amount of the intermediate oxo-palladium species available, which is the active species 
in the transmetallation step.117 
 
Scheme 3.10 
With suitable cross-coupling conditions identified, each enol triflate was cross-coupled with 
a selection of boronic acids. A variety of arylboronic acids, including some 
heteroarylboronic acids, were chosen to ensure that the 3-D fragments would have a range 
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of protein binding modes and physicochemical properties. Couplings of pyrrolidine enol 
triflate 99 were performed first (Table 3.1), with 2-furanboronic acid giving 211 in 72% 
yield (entry 2) and 2-fluorophenylboronic acid giving 212 in 57% yield (entry 3). 
 










 aYield after chromatography 
Table 3.1: Pyrrolidine Suzuki-Miyaura cross-couplings 
Cross-couplings were then attempted with cyclopentyl enol triflate 197. Heteroarylboronic 
acids were chosen for the cross-couplings to compensate for the lack of heteroatoms in the 
core scaffold. The results with four different boronic acids are shown in Table 3.2. 
Medicinally relevant heteroaromatic boronic acids were chosen to add a second binding 
mode, as the cyclopentane core was unlikely to form key interactions The reactions all 
proceeded successfully although 3-pyridineboronic acid gave 213 in only 35% yield (entry 
1). In contrast, pyrimidine, pyrazole and thiophene boronic acids all reacted in yields of over 
80% to give 214, 215 and 216 respectively (entries 2-4). 
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a Yield after chromatography 
Table 3.2: Cyclopentane Suzuki-Miyaura cross-couplings 
Next, cross-couplings with piperidine enol triflate 200 were carried out (Table 3.3). Cross-
coupling with phenylboronic acid (using Pd(PPh3)4, conditions A) proceeded smoothly to 
give 201 in 86% yield (entry 1). However, when the reaction was attempted with pyrimidine 
boronic acid, 1H NMR spectroscopy of the crude product showed only starting material 
(entry 2). Use of Pd(dppf)Cl2 as catalyst (conditions B) resulted in product 217 being visible 
in the 1H NMR spectrum of the crude product, but none was isolated after column 
chromatography (entry 3). It was reasoned that either the product was degrading or the 
presence of two basic amines in the molecule was causing the product to bind to the silica. 
The reaction was therefore repeated, but the column was basified with Et3N before elution 
of the crude product. This resulted in the isolation of the desired product 217 in 57% yield 
(entry 4). 
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Entry Boronic Acid Conditions Compound Yield/%a 
1 
 
A 201 86 
2 
 
A 217 0 
3 
 
B 217 0 
4 
 
Bb 217 57 
a Yield after chromatography 
b Column basified with Et3N before purification 
Table 3.3: Piperidine Suzuki-Miyaura cross-couplings 
The final enol triflates to be coupled were THF 204 and THP 218 (Table 3.4). Starting THF 
β-ketoester 194 was reacted overnight with i-PrNEt2 and Tf2O to give crude THF enol triflate 
204. Triflate 204 was then purified by chromatography and subjected to the Suzuki-Miyaura 
cross-coupling on the same day to minimise degradation of the enol triflate. Cross-coupling 
with 4-fluorophenylboronic acid gave the desired product 219 in 53% yield over two steps 
(entry 1). However, coupling with 2-fluorophenylboronic acid (entry 2) and o-tolylboronic 
acid (entry 3) gave mixtures of product and boronic acid that proved very difficult to 
separate. Further reactions of these mixtures did allow access to 3-D fragments as described 
in Section 3.5. Coupling with 3-pyridylboronic acid was successful but gave 222 in only 
23% yield (entry 4). The only attempted coupling with THP β-ketoester 195 was with 3-
methoxyboronic acid and this gave 223 in 52% yield (entry 5). 
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a Yield over two steps after chromatography 
b Isolated as an inseparable 60:40 mixture of product 220 and boronic acid 
c 16% of pure 221, 28% obtained as a 60:40 mixture of 221 and the arylboronic acid 
Table 3.4: THF and THP Suzuki-Miyaura cross-couplings 
In total, 14 Suzuki-Miyaura cross-coupled products were synthesised using a range of cores 
and arylboronic acids. With the exception of the pyrimidine-coupled piperidine 217, all the 
cross-couplings used the same reaction conditions.  
Now that the Suzuki-Miyaura cross-couplings had been successfully performed, the next 
step was the hydrogenation of the alkenes to introduce the cis-stereochemistry in the 3-D 
fragments. Reaction of dihydropyrrole 210 with Pd/C under H2 in MeOH gave the desired 
product, cis-224, as a single diastereomer in 97% yield (Scheme 3.11). The stereochemistry 
of cis-224 was proven by changing the N-Boc group into an N-Ac group and comparison of 
the NMR spectroscopic data with N-Ac trans-227, which was independently synthesised by 
another member of the group. This proof of stereochemistry is discussed later (see Scheme 
3.19).  
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Scheme 3.11 
The next hydrogenation attempted was phenyl-coupled piperidine 201 (Table 3.5). Reaction 
with Pd/C under H2 in MeOH for 16 h gave almost complete conversion to piperidine cis-
225 (entry 1). Changing the catalyst to PtO2 reduced conversion to only 25% (entry 2), but 
use of Pd(OH)2/C resulted in complete conversion (entry 3). Transfer hydrogenation using 
Pd(OH)2/C and NH4
+HCO2
– also gave complete conversion to cis-225 (entry 4). The crude 
mass recovery in all four reactions was greater than 85% 
 
a Ratio determined by 1H NMR spectroscopy of the crude product 
Table 3.5 Screening of conditions for the hydrogenation of 201 
The cis stereochemistry of piperidine 225 was confirmed using X-ray crystallography 
(Figure 3.2). 
 
Figure 3.2: X-ray crystallography of piperidine cis-225 
Entry Conditions cis-225:201a 
1 Pd/C, H2, MeOH, rt, 16 h 95:5 
2 PtO2, H2, MeOH, rt, 16 h 25:75 
3 Pd(OH)2/C, H2, MeOH, rt, 16 h 100:0 
4 Pd(OH)2/C, NH4
+HCO2
-, MeOH, 60 °C, 3 h 100:0 
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The hydrogenation of compounds containing heteroaryl groups was then attempted. 
Cyclopentyl alkenes 213, 214 and 215 were chosen for hydrogenation as the resulting 
products would all be 3-D fragments. However, hydrogenation of these compounds using 
the transfer hydrogenation conditions gave complex mixtures of products in all cases 
(Scheme 3.12). Frustrated by this result, it was postulated that the reaction was not working 
due to the basic heteroaromatic nitrogens forming formate salts. It was decided to perform a 
second hydrogenation optimisation based on what was anticipated to be the most difficult 
Suzuki-Mitaura product to hydrogenate, pyrimidine-coupled piperidine 217.  
 
Scheme 3.12 
The results of the hydrogenation of piperidine alkene 217 are summarised in Table 3.6. Both 
Pd/C and Pd(OH)2/C (entries 1 and 2) showed 90% conversion and, although not attempted, 
it was postulated that leaving either of these reactions for longer would likely result in 
complete conversion to the final product. Mass recovery in both of these systems was good 
with 80% recovery for Pd/C and 90% recovery for Pd(OH)2/C. Pd(OH)2/C hydrogenation 
with 3 equivalents of acetic acid added to prevent potential poisoning of the catalyst by the 
basic nitrogens proved unsuccessful (entry 3). In this case, the 1H NMR spectrum of the 
crude product lacked peaks in the aromatic region, indicating that the pyrimidine ring had 
likely been hydrogenated. Interestingly, the transfer hydrogenation conditions (entry 4) were 
more successful than they had been with cyclopentenes 213-215 (see Scheme 3.12), with a 
65:35 ratio of starting material 217 and product cis-226 identifiable by 1H NMR 
spectroscopy of the crude. However, the crude mass recovery was only 70% and the 
conversion was still much worse than it had been with phenyl substituted piperidine 201 (see 
entry 4, Table 3.6).  
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a Ratio determined by 1H NMR spectroscopy of the crude product 
b No aromatic peaks visible by 1H NMR spectroscopy 
Table 3.6: Screening of conditions for the hydrogenation of 217 
From the two hydrogenation optimisations, we concluded that use of Pd/C or Pd(OH)2/C as 
catalyst with H2 in MeOH (Table 3.6, entries 1 and 3) were the best conditions to proceed 
with. Reactions would be monitored by TLC and allowed to continue to completion. 
  
Entry Conditions cis-226:217a 
1 Pd/C, H2, MeOH, rt, 16 h 90:10 
2 Pd(OH)2/C, H2, MeOH, rt, 16 h 90:10 




-, MeOH, 60 °C, 3 h 35:65 
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3.4 Initial Ester Diversification Work 
With two suitable conditions for the hydrogenation step identified, a strategy for the 
diversification of the ester group was proposed. Pyrrolidine cis-224 was selected as a 
representative example to test the toolkit of reactions and our initial plans are shown in 
Scheme 3.13. First, the Boc group would be replaced with an acetyl group to give the first 
fragment, cis-227. The strategy then involved three reactions on ester cis-227: ester 
reduction to give alcohol cis-228, ester hydrolysis to give acid cis-229 or direct amidation 
to give amide cis-230. It was anticipated that acid cis-229 and alcohol cis-228 could be 
further diversified to give other functional groups. However, this would be dependent on our 
ability to synthesise the alcohol and acid fragments. 
 
Scheme 3.13 
Synthesis began with the deprotection and acetylation of pyrrolidine cis-224. Deprotection 
was performed using TFA. Subsequent acylation using AcCl and Et3N at rt followed by 
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3.4.1 Investigation of the Pyrrolidine Ester Reduction 
Diversification started with the reduction of ester cis-227 to give alcohol cis-228. Ester cis-
227 was reacted with LiAlH4 at 0 °C for 2 h. 
1H NMR spectroscopy of the crude product 
showed that the reaction was unsuccessful, with a mixture of products formed that contained 
pyrrolidine cis-231 as the major product. Pyrrolidine cis-231 had been formed due to both 
the ester and the amide groups bring reduced, giving an N-ethyl group (Scheme 3.15). 
Unfortunately, pyrrolidine cis-231 proved difficult to purify by column chromatography, 
which prevented its addition to the fragment library. 
 
Scheme 3.15 
The use of LiBH4 was then explored as it would be less likely to reduce the N-Ac group. 
Reaction of ester cis-227 with LiBH4 at 0 °C for 2 h gave no reaction (Table 3.7, entry 1). 
However, increasing the reaction temperature to rt and time to 16 h gave a 50:50 mixture of 
desired alcohol cis-228 and starting ester cis-227. A selection of times, temperatures and 
equivalents were then tested to attempt to improve the conversion of ester cis-227 into 
alcohol cis-228, with the ratio of products being determined by 1H NMR spectroscopy of the 
crude product. Heating the reaction to 65 °C gave a complex mixture of products, with small 
amounts of cis-227 and cis-228 present (entry 3). Increasing the reaction time to 64 h at rt 
showed no improvement in conversion (entry 4), but use of 4 eq. of LiBH4 gave an 
improvement to a 75:25 ratio (entry 5), with the reaction being monitored by TLC. 
Importantly, none of these conditions showed any indication of epimerisation.  
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a Ratio of cis-227 and cis-228 determined from the 1H NMR spectrum of the crude product 
 b Some evidence of cis-227 and cis-228 by 1H NMR spectroscopy amidst other products 
Table 3.7: Optimisation of the reduction of pyrrolidine cis-227 
The reduction of ester cis-227 to alcohol cis-228 was then performed on larger scale using 4 
eq. of LiBH4. The reduction gave alcohol cis-228 in 37% yield after chromatography to 
separate it from the starting ester cis-227 (Scheme 3.16). 
 
Scheme 3.16 
Ideally, the next steps would have been to attempt the further diversification of alcohol cis-
228 by hydroxyl substitution. However, insufficient amounts of alcohol cis-228 were 
synthesised to both continue the diversification and add alcohol cis-228 to the library. It was 
therefore decided to add alcohol cis-228 to the 3-D fragment library and investigate the 
synthesis of alcohol cis-228 via a different route. 
We proposed that performing the reduction on dihydropyrrole 210 could prevent the over-
reduction issues. The reduction was therefore performed on dihydropyrrole 210 using 
LiAlH4 at 0 °C (Scheme 3.17). However, the 
1H NMR of the crude reaction mixture showed 
a complex mixture of products, with neither starting material 210 nor product 232 being 
evident. 
Entry Time/h Eq. of LiBH4 Temp./ °C cis-227:cis-228 a 
1 2 2 0 100:0 
2 16 2 rt 50:50 
3 5 2 65 -b 
4 64 2 rt 50:50 
5 64 4 rt 25:75 
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Scheme 3.17 
This was surprising as the reduction of the corresponding tetrahydropyridine system 201  to 
alcohol 233 under very similar conditions was reported by Kanai et al. (Scheme 3.18).114 
We therefore decided to stop work on the synthesis of alcohol cis-228 here but to apply the 
learnings from this route to other 3-D fragment syntheses. First, we would perform 
reductions after the hydrogenation as these were shown to work quickly and effectively (see 
Scheme 3.19). For pyrrolidine and piperidine fragments, ester reduction would be performed 
on the N-Boc compound which would then be deprotected to give NH fragments. Acetyl 
groups would not be used as they caused issues with chemoselectivity of the reduction if 
attached beforehand, or chemoselectivity issues with the acetylation potentially occurring 




3.4.2 Investigation of the Pyrrolidine Ester Hydrolysis  
The next diversification route to be attempted was the synthesis of acid cis-229 via 
hydrolysis of ester cis-227 (Table 3.8). Basic hydrolysis using LiOH at rt for 16 h gave a 
mixture of products containing an 85:15 mixture of diastereomeric pyrrolidines 229 as 
determined by the 1H NMR spectrum of the crude product (entry 1). Shortening the reaction 
time to 2 h also resulted in epimerisation to a 75:25 mixture of pyrrolidines 229 (entry 2). 
Interestingly shortening the reaction time gave lower diastereoselectivity, indicating that 
epimerisation may be occurring to give trans-229 as the major product. This also 
substantially increased the mass recovery, with only small amounts of other products visible 
in the 1H NMR spectrum. Acidic hydrolysis with sulfuric acid at rt had no effect (entry 3), 
while heating resulted in decomposition (entry 4). 
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a Ratio of trans-229 and cis-229 determined by 1H NMR spectroscopy 
b Full recovery of cis-227 
c Complex mixture of products obtained 
Table 3.8: Hydrolysis of ester cis-227 
The identity of cis-229 and trans-229 were proven by the synthesis of acid trans-229 by 
another group member using the cycloaddition strategy shown in Scheme 3.19.83  
 
Scheme 3.19 
The cycloaddition is stereospecific (see Scheme 2.1)46 and therefore comparison of the 1H 
NMR spectra allowed us to confirm which diastereomer of acid 229 was the major product. 
Figure 3.3 shows the areas of the 1H NMR spectrum corresponding to the ring proton 
adjacent to the acid group (left) and the N-Ac protons (right). The 1H NMR spectrum of the 
85:15 mixture from Table 3.8 entry 1 is shown above, and comparison with the 1H NMR 
spectrum of pure trans-229 below for each signal shows trans-229 to be the major product 
from the basic hydrolyses.  
 
Entry Reagent Solvent Temp/° C Time/h trans-229:cis-229a 
1 LiOH 4:1:1 
 THF-H2O-MeOH 
rt 16 h 85:15 
2 LiOH 4:1:1  
THF-H2O-MeOH 
rt 2 h 75:25 
3 H2SO4 1:1 THF-H2O rt 16 h –
b 
4 H2SO4 1:1 THF-H2O 65 °C 16 h –
c 
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Figure 3.3: Key signals in the 1H NMR spectra of the 85:15 mixture of trans-229 and cis-
229 (above) and pure trans-229 (below) 
The synthesis of ester trans-227 was also useful for proving the stereochemistry since ester 
cis-227 had been synthesised previously (see Scheme 3.14). Comparison of the ring and 
ester proton region (3.15-4.10 ppm) of the 1H NMR spectra of cis-227 (Figure 3.4, left) and 
trans-227 (Figure 3.4, right) showed the two compounds to be different diastereomers, 
confirming that the hydrogenation of the dihydropyrrole proceeded with complete cis-
diastereoselectivity (see Scheme 3.11). In particular, the rotameric methyl groups of the 
methyl esters were clearly visible at significantly different ppm values.  
  
Figure 3.4: Comparison of the 1H NMR spectra of esters cis-227 and trans-227 
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As ester cis-227 and/or acid cis-229 was prone to epimerisation, we attempted the hydrolysis 
of dihydropyrrole 210. Performing the hydrolysis earlier in the route on dihydropyrrole 210 
could potentially avoid any potential epimerisation issues. Using LiOH, hydrolysis gave a 
complex mixture of products with neither starting material 210 nor desired acid 235 being 
detected by 1H NMR spectroscopy (Scheme 3.20).  
 
Scheme 3.20 
This was particularly surprising as harsher hydrolysis conditions have been shown to work 
on the corresponding tetrahydropyridine 201.  Metcalf and Li reported the hydrolysis of 
tetrahydropyridine 201  with NaOH at 70 °C to give acid 236 (Scheme 3.21).118 
 
Scheme 3.21 
With dihydropyrrole 210 proving unstable to both hydrolysis and reduction, it was 
concluded that the difficulties with the reductions and hydrolyses detailed in this section 
were due to the pyrrolidine system that had been chosen as opposed to a flaw in the overall 
strategy. It was therefore decided to perform hydrolysis at the alkene stage on other systems 
and to only synthesise pyrrolidine fragments via the alcohol route. This would ensure that 
no epimerisation could occur during ester hydrolysis. 
 
3.4.3 Investigation of the Direct Amidation of Pyrrolidine cis-227 
The final strategy involved bypassing acid cis-229 and the potential epimerisation issues by 
attempting to synthesise an amide via direct amidation of an ester. Woodward et al. have 
reported that by using a DABCO•AlMe3 adduct 237 known as ‘DABAL’, amides can be 
formed directly from the ester and amine with no requirement to form the carboxylic acid.119 
Scheme 3.22 shows an example of this chemistry from Woodward et al. where n-butylamine 
was first reacted with the DABAL at 40 °C for 1 h before the ester was added and the reaction 
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stirred at reflux for 18 h. Quenching with 2 M HCl(aq) gave the desired amide 238 in 99% 
yield. In our hands, the same reaction proceeded in high yield, confirming that the process 
and reagents would not be an issue in future reactions. 
 
Scheme 3.22 
The reaction was therefore attempted on ester cis-224. Butylamine, one of the examples from 
the original paper,119 was chosen as the amine partner to test the reaction. Treatment of 
DABAL with butylamine at 40 °C for 1 h followed by addition of ester cis-224 and heating 
at 65 °C for 18 h frustratingly returned only starting material cis-237 (Scheme 3.23).  
 
Scheme 3.23 
The reaction was also attempted on the dihydropyrrole as the dihydropyrrole does not have 
an acidic enol proton. Although the literature shows that the reaction does tolerate enolisable 
centres, the yields did tend to be lower.119 However, repeating the reaction shown in Scheme 
3.24 on dihydropyrrole 210 also gave only starting material (Scheme 3.24). With the reaction 
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3.5 Diversification via the Ester Reduction Route 
Now that the potential issues with the diversification steps were better understood, we 
proposed to break down the diversification into two discrete routes from the Suzuki-Miyaura 
coupling products 189. The first route (Scheme 3.25) would initially involve hydrogenation 
to form esters cis-44, which would be 3-D fragments. Fragments cis-44 would then be 
reduced using LiAlH4 to give alcohol fragments cis-241. Unlike pyrrolidine cis-227, we 
would ensure that the ester group was the only group present that could be reduced. Alcohols 
cis-227 could then be further developed in one of two ways: use of a fluorination reagent 
such as PyFluor or DAST would substitute the alcohol group for a fluorine to give cis-242, 
or the alcohol would be treated with mesyl chloride, substituted with sodium azide and then 
reduced in a Staudinger reaction to give primary amines cis-243 (Scheme 3.25). 
 
Scheme 3.25 
In total, 16 3-D fragments were proposed to be synthesised using this ester reduction 
approach and their structures are shown in Figure 3.5. These fragments would be synthesised 
from the Suzuki-Miyaura products detailed in Tables 3.1-3.4. 
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Figure 3.5: Proposed fragments to be synthesised using the ester reduction route  
The 3-D shape of the proposed fragments was analysed using PMI plots to ensure that all 
fragments had at least one conformation with ∑NPR ≥ 1.15. The PMI plot of these fragments 
is shown in Figure 3.6 and demonstrates an excellent spread of points with no conformers 
near the rod-disc axis and all compounds qualifying for synthesis. 
 
Figure 3.6: PMI plot of the 16 proposed ester reduction fragments 
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Fragments cis-252, cis-253 and cis-254 were selected for synthesis first to test this route. 
Hydrogenation of cyclopentene 215 had been unsuccessfully attempted previously (see 
Scheme 3.12). However, using Pd/C as the catalyst, hydrogenation this time proceeded to 
give fragment cis-254 in 92% yield, albeit with a very long reaction time (Scheme 3.26).  
 
Scheme 3.26 
With the first fragment now in hand, the diversification to give alcohol cis-252 and fluoro-
cyclopentane cis-253 could now be attempted. Reduction using LiAlH4 at 0 °C for 2 h 
proceeded uneventfully and gave the desired alcohol cis-252 in 98% yield (Scheme 3.27). 
 
Scheme 3.27 
The conversion of alcohol cis-252 into fluoro-cyclopentane cis-253 was also studied. A 
variety of fluorinating reagents are commercially available120–122 and, of these, we chose 
PyFluor due to its availability, ease of handling and the literature precedent for using it on 
similar systems to ours.122 Scheme 3.28 shows examples where a hydroxyproline ester, 
trans-116 was converted into cis-118 in 73% yield and heteroaromatic-containing compound 
260 was converted into 261 in 64% yield. The conditions for the two reactions are slightly 
different, with the proline alcohol trans-116 requiring heating to improve the reaction rate 
and the heteroaromatic compound 260 used a different base to reduce elimination. However, 
the latter reaction still proceeded in 41% yield when DBU was used as the base and it was 
reasoned that a functioning set of conditions could be found to work on our desired system.  
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Scheme 3.28 
The first fluorination was attempted using DBU as the base at rt, due to the potential for 
elimination to form the alkene at higher temperatures. The reaction was allowed to run until 
TLC showed that there was no more starting material remaining. As per the literature 
procedure, the reaction mixture was loaded directly on to a column following completion. 
However, purification by flash column chromatography yielded only 12% of the desired 
product cis-253 (Scheme 3.29). 
 
Scheme 3.29 
The reaction was then repeated with an aqueous work-up inserted before chromatographic 
purification. The crude mixture was analysed using 1H NMR spectroscopy and it showed 
that starting alcohol cis-252 was completely consumed. However, after purification by 
column chromatography no products were recovered (Scheme 3.30). Another member of the 
group who was carrying out the same type of reaction on a similar compound, isolated a 
sulfonate intermediate, the analogue of cis-262, when performing the reaction at rt.103 We 
therefore proposed that sulfonate cis-262 was forming in our reaction but was too polar to 
elute from the column. 
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Scheme 3.30 
The 1H NMR spectrum of the crude product showed evidence for the formation of sulfonate 
intermediate cis-262. Intermediate cis-262 is derived from successful attack of alcohol cis-
252 into the sulfonyl fluoride.  However, the second step, substitution of the sulfonate group 
by fluoride, was not occurring at rt. Raising the reaction temperature was therefore 
considered. Initial attempts from the group member working on a similar system had shown 
that the sulfonate intermediate remained when the reaction was performed at 50 °C for 2 
days, but none remained from a reaction at 70 °C.103 The reaction was therefore attempted 
at 70 °C. Monitoring by TLC showed that sulfonate cis-262 was still present after 2 days, 
but after 3 days it had been consumed. The reaction was then stopped and analysed by 1H 
NMR spectroscopy. The 1H NMR spectrum of the crude product showed an 80:20 mixture 
of desired fluoro-cyclopentane cis-253 and the alkene 263, the product of an elimination 
reaction (Scheme 3.31). Alkene 263 could be identified by diagnostic broad singlets in the 
1H NMR spectrum at 4.91 and 4.70 ppm, corresponding to the exocyclic alkene protons, and 
a broad dd signal at 3.46 ppm corresponding to the proton next to the aromatic ring. Column 
chromatography to separate the two was challenging, but a 22% yield of fragment cis-253 
was obtained. This gave 56 mg of fragment cis-253, which was enough to add the fragment 
to the library. 
 
Scheme 3.31 
The other cyclopentane fragments to be synthesised using this route were pyridine-
containing ester cis-250, alcohol cis-249 and fluoro-cyclopentane cis-248. Hydrogenation of 
cyclopentene 213 using Pd/C was successfully performed in 63% yield to give the first of 
these fragments, cis-250. Ester cis-250 was then reduced using LiAlH4 in 83% yield to give 
fragment cis-249 (Scheme 3.32). 
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Scheme 3.32 
The final step explored was the fluorination of alcohol cis-249. Due to our experience with 
the fluorination of alcohol cis-252 which had led to competing elimination, it was decided 
to perform the reaction at a temperature lower than 70 °C. However, the reaction still needed 
to be performed at elevated temperature to ensure that the fluoride displacement step 




Small amounts of pure dihydrofurans 222 and 221 were available and therefore it was 
decided to hydrogenate these to give 3-D ester fragments directly. Both reactions worked 
well to give single diastereomers. Hydrogenation of dihydrofuran 222 gave fragment cis-
259 in 96% yield and hydrogenation of dihydrofuran 221 gave fragment cis-258 in 64% 
yield (Scheme 3.34). 
 
Scheme 3.34 
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The other two THF fragments to be synthesised were alcohol cis-257 and primary amine cis-
256. As described previously (see Table 2.4 entry 2), the Suzuki-Miyaura cross-coupling 
gave an inseparable 60:40 mixture of the desired product 220 and the boronic acid after 
chromatography (28% yield of alkene 220). This mixture was hydrogenated in the hope that 
ester cis-264 would be separable from the boronic acid. However, ester cis-264 also proved 
to be inseparable from the boronic acid by column chromatography (66% yield of cis-264). 
The 60:40 mixture of ester cis-264 and boronic acid was therefore reduced with LiAlH4 to 
give alcohol cis-257 in 79% yield, which was separated from the boronic acid by column 
chromatography. This sequence gave fragment cis-257 in an overall 15% yield from β-
ketoester 194 over four steps (Scheme 3.35). 
 
Scheme 3.35 
Amine 3-D fragment cis-256 was then synthesised from alcohol cis-257 in a three-step 
process. First, alcohol cis-257 was treated with mesyl chloride to give mesylate cis-265 in 
63% yield. Then, mesylate cis-265 was heated with sodium azide in DMF at 120 °C, 
resulting in the successful substitution of the mesyl group to give azide cis-266 in 89% yield. 
The final step was the Staudinger reduction of the azide group to the amine. Treatment of 
azide cis-266 with PPh3 at 65 °C in a mixture of water and THF gave the desired 3-D 
fragment, amine cis-256 in 87% yield (Scheme 3.36). 
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Scheme 3.36 
The next fragments whose synthesis was attempted were piperidines cis-244 and cis-245 and 
pyrrolidines cis-246 and cis-247. Hydrogenation of piperidine 217 had already been 
optimised (see Table 3.6, entries 1 and 2) and using Pd/C for 16 h, the reaction proceeded in 
99% yield. Some of compound cis-226 was subjected to Boc group removal using HCl in 
Et2O. This gave the desired ester fragment cis-244•HCl in 92% yield (Scheme 3.37). 
 
Scheme 3.37 
The synthesis of alcohol cis-245 was also explored. The plan was to reduce ester cis-226 
using LiAlH4 and then remove the Boc group to give fragment cis-245•HCl. However, 
treatment of ester cis-226 with LiAlH4 at 0 °C resulted in a complex mixture of products 
(Scheme 3.38) and other reducing agents were not investigated. 
 
Scheme 3.38 
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The pyrrolidine fragments selected for synthesis were analogous to piperidines cis-244 and 
cis-245. Both the hydrogenation using Pd/C and the Boc group removal with HCl proceeded 
in quantitative yield to give the desired pyrrolidine ester fragment cis-246 (Scheme 3.39). 
 
Scheme 3.39 
The final fragment to be synthesised using this route was alcohol cis-247. In contrast to the 
issues encountered with the reduction of N-acetyl pyrrolidine cis-227, reduction of N-Boc 
protected ester cis-268 with LiAlH4 proceeded relatively smoothly. The reaction gave 
alcohol cis-269 in 56% yield. Final deprotection with HCl in Et2O gave desired fragment 
cis-247•HCl in 97% yield (Scheme 3.40). 
 
Scheme 3.40 
The other Suzuki-Miyaura coupling products to be hydrogenated were THP 223 and 
cyclopentene 216. Each was successfully hydrogenated using Pd/C to give THP cis-255 in 
82% yield and cyclopentane cis-251 in 69% yield (Scheme 3.41). 
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Scheme 3.41 
The synthesis of tetrahydropyran cis-255 was important as it was the first 6-membered ring 
product that had distinct signals in the 1H NMR spectrum and thus allowed full analysis of 
coupling constants. This enabled us to provide proof that cis-255 had been generated in the 
hydrogenation step. We expected the stereochemistry of the hydrogenation to be cis and 
THP 255 could adopt one of two possible cis-conformations, with one group axial and one 
group equatorial (Figure 3.7). Therefore, we initially set out to see if the 1H NMR spectrum 
matched with either conformation cis-255A or cis-255B. The key area of the 1H NMR 
spectrum (Figure 3.8) was analysed to see if it was possible to determine which of these 
conformations 255 had adopted. 
 
 
Figure 3.7: Possible conformations of fragment cis-255 
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Figure 3.8: 1H NMR spectrum of THP cis-255 
Starting with the most downfield signals, the signals at 4.27 and 4.18 ppm were assigned as 
H1’ and H5’ with the determination of which of these signals was which being performed 
using 2D NMR spectra. Both were next to an oxygen and would be expected to show a single 
large 2J value coupling to H1 or H5 and either one (H5’) or two (H1’) small couplings to 
protons on the adjacent carbon. The next two signals, at 3.75 ppm and 3.55 ppm were 
expected to belong to H1 and H5, and the HMQC NMR spectrum confirmed this. H1 was 
expected to show two large J values: a geminal coupling with H1’ and an axial-axial 
3J 
coupling with H2. As only one of these signals contained two large couplings, it was assigned 
to the signal at 3.55 ppm. The signal at 3.75 ppm, H5, had only one large coupling. This 
provided evidence that the conformation was cis-255A, as in cis-255B, proton H4 is 
equatorial and would therefore not cause a second large coupling. 
The next signals at 3.05 and 2.90 ppm further confirmed this hypothesis. Using the HMBC 
NMR spectrum, the signal at 3.05 ppm was assigned as H3. This signal showed as a ddd with 
one large and two small coupling constants. Conformation cis-255A would show one large 
axial-axial coupling and two small axial-equatorial couplings. Conformation cis-255B 
would show three small couplings, adding to the evidence that cis-255A was the preferred 
conformation. This signal also allowed us to confirm that the hydrogenation had proceeded 
with cis-diastereoselectivity and had not given either conformation of ester trans-255 
(Figure 3.9).  
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Figure 3.9: Possible conformations of fragment trans-255 
For the signal at 3.05 ppm, conformation trans-255C would show two large couplings and 
one small and conformation trans-255D would show no large couplings. Neither of these fit 
with the one large and two small couplings shown in Figure 3.8. Finally, the signal at 2.90 
ppm, belonging to H4, showed no large coupling values. In both cis-255B and trans-255C 
that proton is axial and would show at least one large J value, whereas in cis-255A the proton 
is equatorial and shows no large couplings. We were therefore confident in confirming that 
the hydrogenation had proceeded with complete cis-diastereoselectivity, based on the 1H 
NMR spectroscopic assignments that showed cis-255A to be the conformation adopted by 
cis-255. 
We had now proved that the hydrogenation proceeded with complete cis-diastereoselectivity 
in both the THP and pyrrolidine systems. Furthermore, the CHAr proton signal in the 1H 
NMR spectrum of piperidine ester cis-244 showed very similar coupling constants to the 
CHAr proton in THP cis-255, providing some evidence that it too had cis-stereochemistry. 
With the stereochemistry proved in both a 5-and 6-membered ring system, we felt 
comfortable to assign the stereochemistry of the other hydrogenation products by analogy. 
3.6 Diversification via the Ester Hydrolysis Route 
The second route, which would be used to create acid-, amide- and secondary amine-
containing 3-D fragments (Scheme 3.42), would begin with the hydrolysis of esters 189 to 
give acids 270. Hydrolysis at the unsaturated stage would hopefully avoid any epimerisation 
issues. Acids 270 would then be hydrogenated using either Pd/C or Pd(OH)2/C to acid 
fragments cis-271. Acids cis-271 could then undergo either amide coupling with aqueous 
ammonia to give amides cis-272 or Curtius rearrangement to give secondary amines cis-273. 
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Scheme 3.42 
The eight selected 3-D fragments to be synthesised via this route are shown in Figure 3.10. 
These included THP, THF and cyclopentane fragments. No pyrrolidine or piperidine 
fragments were chosen due to the previously encountered stability issues of the 
dihydropyrrole ester during hydrolysis (see Scheme 3.20) and the potential for zwitterion 
formation during Boc removal. Potential zwitterion formation was also the reason that no 
fragments with heteroaryl groups containing basic nitrogens were selected. 
 
Figure 3.10: Structures of the eight acid route fragments 
Shape analysis of the eight proposed fragments was then carried out before their synthesis. 
As the PMI plot shows (Figure 3.11), the proposed 3-D fragments have a good spread across 
the plot from ∑NPR = 1.13 to ∑NPR = 1.52. Interestingly, these fragments appeared higher 
up on the PMI plot than the 16 ester reduction fragments (see Figure 3.11), meaning that the 
combination of these two sets of fragments would give excellent coverage across the plot. 
All eight proposed fragments passed the selection criteria for synthesis (at least one 
conformation with ∑NPR ≥ 1.15). 
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Figure 3.11: PMI plot of the eight proposed ester hydrolysis 3-D fragments 
Cyclopentene ester 216 was selected as the first compound to be derivatised using this 
approach. Treatment of ester 216 with NaOH at 70 °C for 1 h hydrolysed the ester to give 
acid 282 in 84% yield. The conditions were those that Metcalf and Li used to hydrolyse 
tetrahydropyridine 201 (see Scheme 3.21).118 Acid 282 was then hydrogenated with Pd/C 




An X-ray crystal structure of acid cis-276 was obtained to prove the stereochemistry of the 
hydrogenation on a cyclopentane system (Figure 3.12) 
 
Figure 3.12: X-ray crystallography of cyclopentane acid cis-276 
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Curtius rearrangement of acid cis-276 to give amine cis-274 and amide coupling of acid cis-
276 to give amide cis-275 were then explored. The amide coupling was attempted first, with 
NH3(aq) and T3P as the coupling agent. However, an initial attempt gave no reaction. It was 
speculated that the ammonia in the reaction may be evaporating and being absorbed into the 
suba seal. Therefore, the reaction was reattempted using a glass stopper. This resulted in the 
reaction proceeding successfully in 48% yield to give amide cis-275 (Scheme 3.44). 
 
Scheme 3.44 
Next, acid cis-276 was treated with DPPA and benzyl alcohol at 85 °C in an attempt to form 
the Cbz protected amine cis-283. However, after column chromatography only a very small 
amount of what appeared from the 1H NMR spectrum to be product mixed with some 
impurities was isolated (Scheme 3.45). Due to the lack of material, it was decided not to 
further explore the synthesis of fragment cis-274. 
 
Scheme 3.45 
Dihydropyran 223 was then selected for derivatisation. Hydrolysis using NaOH at 70 °C 
gave acid 284 in 86% yield. Hydrogenation of acid 284 using Pd/C gave the desired acid 
fragment cis-280 as a single diastereomer in 98% yield (Scheme 3.46). Analysis of the 1H 
NMR spectrum in the same manner as the corresponding ester cis-255 (see Figure 3.8) 
showed that the reaction proceeded with complete cis-diastereoselectivity. 
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Scheme 3.46 
Acid cis-280 was then split three ways. A sample was added to the 3-D fragment library, 
some was taken on for amide coupling and the rest was used in a Curtius rearrangement. The 
amide coupling was performed with T3P and ammonia in a flask with a glass stopper and 
proceeded smoothly to give cis-279 as a single diastereomer in 41% yield (Scheme 3.47). 
We were pleased that 1H NMR spectroscopic analysis of fragments cis-280 and cis-279 
confirmed the cis-diastereoselectivity of both reactions as this allowed us to assign the other 
acid hydrogenations as cis and that epimerisation of the acid had not occurred under the 
amide coupling conditions. 
 
Scheme 3.47 
The last THP fragment to be synthesised was the Curtius rearrangement product cis-278. 
The previous attempt at a Curtius rearrangement on acid cis-276 (see Scheme 3.45) had been 
largely unsuccessful, although a small amount of product had been detected. It was decided 
to perform this reaction in neat benzyl alcohol, as opposed to using 5 eq. of benzyl alcohol 
in toluene as solvent. Reaction of THP acid cis-280 with DPPA in benzyl alcohol at 85 °C 
pleasingly gave Cbz-protected amine cis-285 in 62% yield after chromatography. The Cbz 
group was then removed by hydrogenation with Pd(OH)2 as catalyst to give 3-D fragment 
cis-278 in quantitative yield (Scheme 3.48).  
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Scheme 3.48 
The final two fragments to be synthesised were THF acids cis-277 and cis-281. Using the 
hydrolysis conditions from Scheme 3.20, the hydrolysis of THF 219 was successfully 
performed to give acid 286 in 78% yield (Scheme 3.49). 
 
Scheme 3.49 
The next step in the synthesis of fragment cis-277 was the hydrogenation, using Pd/C as the 
catalyst. The 1H NMR spectrum of the crude product appeared to show no starting material 
remaining, but a mixture of three products. Purification by column chromatography allowed 
fragment cis-277 to be isolated in 58% yield (Scheme 3.50). In addition, a mixture of two 
other compounds was isolated, which appeared from their 1H NMR spectrum to be an 85:15 
mixture of isomerised starting material 287 and oxidised furan 288. 
 
Scheme 3.50 
An X-ray crystal structure of THF cis-277 was obtained to prove the cis stereochemistry 
(Figure 3.13). With this X-ray crystal structure, the stereochemistry of the hydrogenation 
step had been proven on an example of each of the five fragment cores. 
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Figure 3.13: X-ray crystal structure of THF acid cis-277 
The product of the Suzuki-Miyaura coupling to give dihydrofuran 221 had been a mixture 
of the desired product and the tolyl boronic acid. Hydrolysis was performed on the mixture 
using the NaOH conditions from Metcalf and Li.118 The crude reaction mixture still showed 
traces of tolyl boronic acid, but purification by flash column chromatography allowed for 
the isolation of dihydrofuran acid 289 in 78% yield. Subsequent hydrogenation using 
Pd(OH)2 as catalyst for 64 h and purification by flash column chromatography gave desired 
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3.7 Conclusions 
The addition of the seven fragments synthesised via the ester hydrolysis route gave 24 3-D 
fragments in total (Figure 3.12). It was pleasing that these 2nd generation, diverse 3-D 
fragments had taken just under a year to synthesise. This compared very favourably with the 
time taken to synthesise the 1st generation fragments, validating our new approach. 
Furthermore, the fragments synthesised using the new approach showed much more 
functional group diversity than the 1st generation fragments, as demonstrated structures 
shown in Figure 3.12. The 24 synthesised fragments were combined with a set of 26 
fragments synthesised using a different route by another group member (see Section 4.5), to 
form a larger library of 50 2nd generation fragments. 
 
Figure 3.12: The 24 fragments synthesised using the new approach 
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It was anticipated that the methodology and toolkit of reactions we had optimised could 
easily be applied to other β-ketoesters (cyclohexane and 5- and 6-membered cyclic sulfones, 
for example) and other boronic acids to further increase the number of potential products 
from this approach if desired. The approach did have some limitations, particularly the 
inability to attach acid, amine and amide groups to pyrrolidines and piperidines and the 
stability issues with the pyrrolidines and dihydropyrroles, but most fragment syntheses 
proved to be straightforward and achieved in 3-5 steps from the β-ketoesters.  
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PROPERTY ANALYSIS OF THE SYNTHESISED 
FRAGMENT LIBRARIES, CONCLUSIONS AND FUTURE WORK 
 
With the synthetic work now completed, an analysis of the properties of all of the 3-D 
fragments that have been synthesised in the group was carried out. Section 4.1 sets out the 
properties that will be analysed. These include 3-D shape analysis by principal moments of 
inertia (PMI) and plane of best fit (PBF) as well as molecular weight (MW), heavy atom 
count (HAC), cLogP, rotatable bonds, H-bond acceptors and H-bond donors. The 3-D 
fragments were split up into four subsets for analysis. Analysis of the initial 32 pyrrolidine 
and piperidine fragments whose selection is described in Section 1.4 and the larger group of 
1st generation fragments which these compounds formed part of is described in Section 4.2. 
The properties of the fragments whose synthesis is described in Chapter 2 are highlighted in 
these sections. Then, the properties of the 24 fragments whose synthesis is detailed in 
Chapter 3 and the larger group which these fragments formed part of (2nd generation 
fragments) are presented (Section 4.3). Some representative examples of 1st and 2nd 
generation fragments are shown in Figure 4.1, including fragments synthesised in the results 
presented in Chapters 2 and 3 (cis-37, cis-45, cis-278, cis-253 and cis-247). 
     
Figure 4.1: Examples of 1st and 2nd generation fragments 
Throughout this chapter, the 3-D shape of our subset libraries is compared to a selection of 
commercially available fragment libraries. Furthermore, the physicochemical properties of 
our fragments are compared to industry-recommended guidelines to assess their suitability 
for screening. Conclusions drawn from the project and potential future work are detailed in 
Section 4.4 
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4.1 Identification of Properties for Analysis 
Guidelines on fragment properties in the literature are relatively varied, with many 
pharmaceutical companies having their own definition of what constitutes a fragment. The 
broadest definition of a fragment, and the most accepted one, is a molecule with a MW of 
≤300. This definition comes from the fragment ‘rule of three’,12 an adapted version of 
Lipinski’s ‘rule of five’ for drug-like compounds.13 The ‘rule of three’ also gives guidelines 
for the lipophilicity, number of hydrogen bond donors and acceptors and rotatable bonds for 
fragment molecules. These guidelines are, however, very broad, and pharmaceutical 
companies will typically target a narrower range of properties. Astex published an updated 
list of guidelines for fragment properties in 2016 based on their own library and what had 
succeeded and failed in drug discovery programmes.123 They suggested a narrower band of 
molecular weight that was significantly lower than the 300 suggested in the ‘rule of three’, 
as well as giving a tighter restriction on lipophilicity that contained a lower limit of cLogP 
≥ 0. However, it is worth noting the following quotation in the paper: ‘These are the 
properties we currently aspire to and are based on over a decade of FBDD research. Note 
that there are many examples of fragments outside of these guidelines that have been 
progressed into useful leads’.  
Analysis of the properties of our libraries will therefore use both the ‘rule of three’ and the 
updated guidelines (Table 4.1) as points of comparison. The properties analysed will be MW, 
HAC, cLogP and number of rotatable bonds, H-bond acceptors and H-bond donors. Ideally, 
fragments will fit both the updated guidelines and the ‘rule of three’, but fragments will only 
be omitted from the 3-D fragment library if they significantly flout the ‘rule of three’. 
Property ‘Rule of Five’ ‘Rule of Three’ Updated Guidelines 
Molecular Weight (Da.) ≤ 500 ≤ 300 140-230 
Heavy Atom Count (HAC) N/A N/A 10-16 
cLogP ≤ 5 ≤ 3 0-2 
Rotatable Bonds N/A ≤ 3 N/A 
H-Bond Donors ≤ 5 ≤ 3 N/A 
H-Bond Acceptors ≤ 10 ≤ 3 N/A 
Table 4.1: Summary of the suggested properties for drug molecules and fragments  
The 3-D shape of the fragments will also be analysed. As explained in Section 1.4, PMI plots 
have been used in this project to quantify 3-D shape and to select fragments for synthesis. 
The 3-D fragments have therefore been analysed using two types of plots: normal PMI plots 
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and cumulative PMI plots. Normal PMI plots (Figure 4.2, left) give an indication of both the 
shape and shape-diversity of the fragments in the library. Clustering indicates that molecules 
have similar shapes, which would ideally be avoided, while the spread towards the top right 
corner (∑NPR = 2.0) indicates the most spherical molecules.  
 
Figure 4.2: Example PMI plot (left) and cumulative PMI plot (right) 
Cumulative PMI plots (Figure 4.2, right), show the percentage of conformations of the 
library that have a ∑NPR below a certain value. The advantage of cumulative PMI plots is 
that they allow for easier comparison of different libraries. Six fragment libraries from both 
commercial and academic sources have been selected and analysed for their 3-D shape.83 
These include Maybridge, Chembridge and Enamine ‘rule of three’ libraries, which are not 
specifically designed for their 3-D shape, and Life Chemicals, ChemDiv and Enamine 
libraries which were specifically designed to have interesting 3-D shape.  
One of the difficulties of using cumulative PMI plots is that not all compounds have the 
same number of conformations. For example, a compound with 10 conformations will affect 
the cumulative PMI plot 10 times as much as a compound with a single low energy 
conformer. Therefore, when plotting cumulative plots an average ∑NPR value, taken from 
the equally weighted average of the ∑NPR values of all low energy conformations of a 
compound, was used instead of adding each conformation individually. Figure 4.3 shows 
the difference between plotting the average ∑NPR values and all the ∑NPR values of each 
molecule in a dataset. These two plots show significant difference in shape, accounted for 
by the fact that some compounds in the selection display as many as 29 low energy 
conformations while others display as few as two. 
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Figure 4.3: Averaged and non-averaged cumulative PMI plots 
Each library or subset of compounds will therefore be analysed using the physicochemical 
properties detailed in Table 4.1 and PMI and cumulative PMI plots to assess 3-D shape. 
Where available, PBF data will also be analysed. 
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4.2 Property Analysis of the 56 1st Generation York 3-D Fragments 
At the outset of the project, 33 pyrrolidine and piperidine 3-D fragments were selected for 
synthesis (see Section 1.4). Of these, 31 were successfully synthesised since we were unable 
to synthesise the 2,4-disubstituted pyrrolidines (see Chapter 2). However, the t-butyl ester 
analogue, fragment cis-46, was synthesised, taking the total up to 32 3-D fragments (Figure 
4.4). Physicochemical and 3-D shape analysis was carried out on all of these compounds 
and, in addition, a PBF analysis was recorded for the initial 33 target fragments.  
 
Figure 4.4: Structures of the 32 synthesised initial fragments 
The properties of the 32 3-D fragments shown in Figure 4.4 are shown in Table 4.2. Since 
the properties of all the potential fragments had previously been calculated during the design 
and selection process (see Section 1.4), the values were expected to be in line with the 
fragment guidelines. These 32 compounds fit the ‘rule of three’ completely, with only ten 
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fragments not completely meeting the stricter updated guidelines. Nine of these were either 
too small (MW of 129, HAC of 9), too polar (cLogP between –0.18 and 0) or both and one 
fragment failed due to having four H-bond acceptors. A potential criticism of these 
fragments is that they are relatively small and polar, which could make hit detection difficult. 
Property ‘Rule of Three’ Updated 
Guidelines 
32 3-D Fragments 
Molecular Weight (Da.) ≤ 300 140-230 158 ± 26 
Heavy Atom Count (HAC) N/A 10-16 10.8 ± 1.6 
cLogP ≤ 3 0-2 0.54 ± 0.46 
Rotatable Bonds ≤ 3 N/A 1.53 ± 0.61 
H-Bond Donors ≤ 3 N/A 1.28 ± 0.71 
H-Bond Acceptors ≤ 3 N/A 1.81 ± 0.85 
 
Table 4.2: Analysis of the physicochemical properties of 32 3-D fragments 
The 3-D shape properties of these fragments were then analysed using PMI plots. The PMI 
plot of all conformations up to 1.5 kcalmol–1 in energy above the ground state is shown in 
Figure 4.5. The plot showed an even spread of conformations all the way up to ∑NPR = 1.7. 
 
Figure 4.5: PMI plot of the 32 3-D fragments 
The individual PMI plots of the three fragments that form part of this set and whose synthesis 
was decribed in Chapter 2 are shown in Figure 4.6. Notably, the t-butyl ester analogue 
fragment still fits the shape selection criteria by having a low energy conformation with 
∑NPR ≥ 1.36. 
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Figure 4.6: PMI plots of the target fragments whose synthesis is described in this thesis 
A plane of best fit (PBF) analysis was conducted on the 33 initially selected 3-D fragments. 
This was done to confirm that PMI was a valid way of analysing the 3-D shapes of these 
molecules. As described in Section 1.2, the PBF score measures the deviation of a molecule 
from its plane of best fit. Like PMI plots, there are many definitions of whether a molecule 
is 3-D as measured by PBF. For example, Astex define molecules with PBF ≥ 0.05 as 3-
D,124 whereas AstraZeneca use PBF ≥ 0.25 as their criterium.50 The 31 fragments of those 
initial 33 that were synthesised would all be classified as 3-D, with each fragment having a 
PBF value > 0.67. 
The library of the first 32 York 3-D fragments was then compared to the other libraries 
identified in Section 4.1. Using average ∑NPR values, Figure 4.7 shows the cumulative PMI 
plot of both the 32 York 3-D fragments and the six chosen other libraries. The York 3-D 
fragments are shifted substantially to the right of the other libraries, indicating much greater 
3-D character. To use one point as an example, 50% of the 32 York 3-D fragments have an 
average ∑NPR > 1.3. This contrasts with less than 10% for the Enamine 3-D library, and 
less than 5% for the other five libraries, clearly demonstrating that our compounds are more 
effective at exploring the under-represented areas of 3-D space. 
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Figure 4.7: Cumulative PMI plot of the Original 32 fragments and other libraries 
As the synthesis of the first 32 York 3-D fragments was nearing completion, it was decided 
to use some of the chemistry developed during that process to synthesise derivatives with 
different functional groups. The aim was to produce a library of at least 50 fragments while 
increasing the functional group variation. Fragments which showed good 3-D shape (based 
on PMI analysis) and had simple synthetic routes were derivatised resulting in the 24 3-D 
fragments shown in Figure 4.8. Together with the 32 compounds synthesised previously, 
this created a library of 56 1st generation 3-D fragments.  
 
Figure 4.8: Structures of 24 additional 1st generation 3-D fragments 
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The additional fragments were notable for being on average of higher MW than the original 
32 fragments, bringing the overall average MW up from 158 to 173, and for having more H-
bond acceptors (Table 4.3). The increase in both of these properties is due in part to the 
increased prevalence of mesyl groups in the new fragments. A mesyl group adds a molecular 
weight of 79 and two H-bond acceptors and half of the 24 fragments contain mesyl groups. 
Overall however, the fragments still broadly fit the criteria, with the only non-‘rule of three’ 
compliant fragments being those with four H-bond acceptors. 
Property ‘Rule of Three’ Updated 
Guidelines 
1st Generation  
Molecular Weight (Da.) ≤ 300 140-230 173 ± 38 
Heavy Atom Count 
(HAC) 
N/A 10-16 11.8 ± 2.3 
cLogP ≤ 3 0-2 0.54 ± 0.55 
Rotatable Bonds ≤ 3 N/A 1.64 ± 0.77 
H-Bond Donors ≤ 3 N/A 0.89 ± 0.70 
H-Bond Acceptors ≤ 3 N/A 2.68 ± 0.73 
 
Table 4.3: Properties of the 56 1st generation fragments 
Each of the 24 3-D fragments had been analysed for its 3-D shape using PMI plots before 
synthesis to ensure that shape diversity was maintained. The PMI plot of the 56 1st generation 
fragments (Figure 4.9) shows more clustering than the PMI plot of the original 32 (Figure 
4.5), although this is to be expected given the additional compounds. Importantly, there are 
still very few conformations with ∑NPR ≤ 1.1, showing that the library is still highly 3-D in 
character, and there are no conformations with ∑NPR ≤ 1.06. 
 
Figure 4.9: PMI plot of the 56 1st generation fragments 
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Thee synthesis of three of these 24 fragments is described in this thesis (Section 2.3). Their 
PMI plots are shown in Figure 4.10. Both the N-H and N-Ac fragments had low energy 
conformations with ∑NPR ≥ 1.3, although the N-Ms fragment had no conformations with 
∑NPR ≥ 1.2. 
    
 
Figure 4.10: PMI plots of the three additional t-butyl ester fragments 
The 56 1st generation 3-D fragments were then plotted on a cumulative PMI plot to compare 
the 3-D shape of the library with other fragment libraries. As shown in Figure 4.11, the 1st 
generation library has less 3-D character than the original 32 but still substantially more 3-
D character than the other fragment libraries that were analysed. 
 
Figure 4.11: Cumulative PMI plot of the 56 1st generation fragments and other libraries 
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4.3 Property Analysis of the 50 2nd Generation York 3-D Fragments 
As described in Section 3.1, once the 1st generation fragments had been synthesised a new 
approach was desired that put more emphasis on ease of synthesis while not compromising 
on 3-D shape. The structures of the 24 fragments synthesised by the Suzuki-hydrogenation 
route in Chapter 3 are shown in Figure 4.12. In contrast to the 1st generation fragments, these 
compounds show a wide variety of cores, functional groups and aromatics to ensure that the 
fragments covered a wide range of properties and potential binding modes. 
 
Figure 4.12: Structures of the 24 fragments synthesised by the Suzuki-hydrogenation route 
The properties of these 24 3-D fragments are shown in Table 4.4. The fragments are heavier 
than the 1st generation fragments, as expected due to the presence of the aromatic rings. 
These 24 fragments are also significantly more lipophilic, with an average cLogP value of 
1.32. However, this is still well within both sets of guidelines. The only property in which 
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some of the fragments break the ‘rule of three’ is H-bond acceptors, although no compounds 
have more than four. Overall, the 24 2nd generation York 3-D fragments were mostly 
compliant with both the updated guidelines and the ‘rule of three’ while also occupying a 
different area of chemical space to the 1st generation fragments. 
Property  ‘Rule of Three’ Updated 
Guidelines 
24 York 3-D 
Fragments  
Molecular Weight (Da.) ≤ 300 140-230 209 ± 20 
Heavy Atom Count 
(HAC) 
N/A 10-16 14.9 ± 1.6 
cLogP ≤ 3 0-2 1.32 ± 0.77 
Rotatable Bonds ≤ 3 N/A 2.13 ± 0.33 
H-Bond Donors ≤ 3 N/A 0.50 ± 0.58 
H-Bond Acceptors ≤ 3 N/A 2.67 ± 0.94 
 
Table 4.4: Physicochemical properties of the 24 2nd generation York 3-D fragments 
Although 3-D shape was not a primary selection criterion, all potential 2nd generation 
fragments were run through Pipeline Pilot and plotted on PMI plots to assess their 3-D shape 
before synthesis. Those that did not display conformers with ∑NPR ≥ 1.15 were not 
synthesised. The wide variety of possible functional group, core and aromatic group 
combinations meant that avoiding compounds with poor 3-D shape was relatively 
straightforward and this was further compounded by the fact that the substitution patterns of 
2nd generation fragments were chosen based partly on the fact that the substitution pattern 
gave high 3-D character. The PMI plot of the 24 2nd generation York 3-D fragments is shown 
in Figure 4.13. The fragments gave an excellent spread on the PMI plot from ∑NPR = 1.13 
to ∑NPR = 1.55 with minimal clustering and no conformations close to the rod-disc axis. 
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Figure 4.13: PMI plot of the 24 York 3-D fragments 
The cumulative PMI plot showed significantly more 3-D character than any of the 
commercial libraries (Figure 4.14). Only two of the synthesised compounds showed an 
average ∑NPR value below 1.2 with the half of the conformers having ∑NPR ≥ 1.24. 
 
Figure 4.14: Cumulative PMI plot of the 24 York 3-D fragments 
During work on the 24 York 3-D fragments whose synthesis was detailed in Chapter 3, 
another group member synthesised 26 fragments using a similar approach to give an overall 
library of 50 2nd generation 3-D fragments. Like the fragments detailed in Chapter 3, these 
3-D fragments were all synthesised using a single piece of methodology to give fragments 
with a range of cores, aromatic groups and functional groups. The structures of the 26 
fragments, all synthesised using α-arylation methodology, are shown in Figure 4.15. 
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Figure 4.15: Structures of the 26 additional 2nd generation fragments 
The properties of these additional 26 3-D fragments (Table 4.5) synthesised by another group 
member are very similar to those from the route described in Chapter 3, with the exception 
that on average these fragments tended to be more lipophilic. Five of the additional 26 
fragments did not fit within the ‘rule of three’ with cLogP > 3 and brought the average cLogP 
value for the 2nd generation fragments up to 1.57. However, none were excluded. Given the 
polar nature of the 1st generation fragments, the increased lipophilicity of the 2nd generation 
fragments gives good variation across the range of desirable cLogP values. Properties of the 
whole library, including all 1st and 2nd generation fragments will be discussed in Section 4.4. 
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Property ‘Rule of Three’ Updated 
Guidelines 
2nd Generation  
Molecular Weight (Da.) ≤ 300 140-230 215 ± 23 
Heavy Atom Count (HAC) N/A 10-16 15.4 ± 1.7 
cLogP ≤ 3 0-2 1.57 ± 1.03 
Rotatable Bonds ≤ 3 N/A 2.12 ± 0.32 
H-Bond Donors ≤ 3 N/A 0.56 ± 0.67 
H-Bond Acceptors ≤ 3 N/A 2.54 ± 0.90 
 
Table 4.5: Physicochemical properties of the 50 2nd generation fragments 
The PMI plot of the 50 2nd generation fragments (Figure 4.16) showed very little clustering. 
This was particularly pleasing given the similar structures of many of the compounds and 
demonstrates how difficult it is to predict 3-D shape based on the structural drawing. The 26 
α-arylation fragments did not have as many highly 3-D conformers as the first 24 3-D 
fragments – the area of the plot with ∑NPR ≥ 1.4 looks almost identical to that in Figure 
4.12 but importantly there are still no conformations with ∑NPR ≤ 1.1.  
 
Figure 4.16: PMI plot of the 50 2nd generation fragments 
As expected from the PMI plot, the cumulative PMI plot for the 50 2nd generation 3-D 
fragments (Figure 4.17) looks very similar to that of the 24 York 3-D fragments, particularly 
at lower ∑NPR values. While the profile of the 2nd generation curve is moving closer towards 
the other libraries, particularly the Enamine 3D library, the key difference is that no York 3-
D fragments have ∑NPR values close to 1.0. The lowest ∑NPR value conformer (1.12) of 
any 2nd generation fragment has a higher ∑NPR than 28% of the Enamine 3-D library 
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conformers, 64% of the ChemDiv 3-D library conformers and 72% of the Life Chemicals 3-
D library conformers, showing just how stringent our criteria for selecting fragments are. 
 
Figure 4.17: Cumulative PMI plot of the 50 2nd generation fragments 
Importantly, preliminary fragment screens have already shown 2nd generation fragments to 
have a better hit rate than the 1st generation fragments. As mentioned in Section 4.3, these 
50 fragments were designed to be more lipophilic than their 1st generation counterparts and 
to have additional potential binding modes. One of the 26 α-arylation fragments has already 
been confirmed as a hit against a key confidential protein target by NMR, SPR and X-ray 
crystallography. One of the 24 fragments synthesised in Chapter 3 has shown as a hit by 
SPR and is currently undergoing soaking to attempt to achieve an X-ray crystal structure of 
the bound compound. This is very encouraging and has started to validate this approach. We 
hope that, as these fragments are screened against more protein targets, we will be able to 
demonstrate the value of having fragments with varied 3-D shape to complement existing 
collections and ensure hits against a wider range of targets. 
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4.4 Comparison of Overall Library Properties and 1st and 2nd Generation Fragments 
With the 2nd generation York 3-D fragments complete and the combined library of the 1st 
and 2nd generations being screened currently, the combined library was briefly analysed to 
ascertain how successful the project had been in its aim: to synthesise a library of fragments 
with diverse and interesting 3-D shapes. The distribution of properties is shown in Figure 
4.18. Each graph shows the distribution of a key physicochemical property of the 106 
fragments. The ‘rule of three’ limit for MW, HAC and number of H-bond donors and 
acceptors is shown on the graphs in red, while the updated guidelines are shown in green. 
 
Figure 4.18: Distribution of the properties of the York 3-D fragment library, showing 
number of fragments against selected property 
The graphs in Figure 4.18 show that the York 3-D fragment library has an excellent profile 
of physicochemical properties. Few fragments break the ‘rule of three’, with those that do 
having one too many H-bond acceptors or being too lipophilic. Most fragments were also 
shown to fit with the more stringent updated guidelines, with more than 70% of fragments 
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being compliant in each category. Importantly, the fragments display diverse properties 
whilst also ensuring that all desired criteria are represented. 
A PMI analysis of these 106 1st and 2nd generation York 3-D fragments was performed to 
check the spread of conformers (Figure 4.19). The PMI plot shows minimal clustering and 
no compounds on or near the rod-disc axis (∑NPR ≤ 1.05). The conformations are 
distributed relatively evenly between ∑NPR = 1.1 and ∑NPR = 1.5, clearly demonstrating 
that our aim of exploring underrepresented areas of pharmaceutical space has been 
successful. 
 
Figure 4.19: PMI plot of the 106 compound York 3-D fragment library 
Finally, the cumulative PMI plot was compared to the commercial libraries. As shown in 
Figure 4.20, more than 50% of the 106 York 3-D fragments had an average ∑NPR > 1.26. 
This demonstrates the exceptional 3-D character of these fragments, particularly when 
compared to the commercial libraries. 
 
Figure 4.20: Cumulative PMI plot of the York 3-D fragment library 
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4.5 Overall Conclusions and Future Work 
In total 30 fragments were synthesised in this work, which were then added to compounds 
synthesised by others to give a library of 106 3-D fragments. All 106 fragments have been 
shown to have both excellent physicochemical properties and 3-D shape. The process began 
with the design and selection of 33 pyrrolidine and piperidine fragments (Section 1.4). Of 
these, 31 fragments including cis-42 and cis-43 were synthesised (Section 2.1) and a t-butyl 
ester analogue of fragment cis-37 was synthesised (Section 2.2). Then, an additional 24 
related 3-D fragments, including cis-45, cis-47 and cis-48 (Section 2.3) were synthesised to 
bring the total up to 56 1st generation fragments. 
As described in Chapter 2, synthesis of the initially selected 33 fragments proved difficult 
and time consuming, with unique synthetic routes having to be found for each substitution 
pattern. It was therefore decided to alter our approach to using just two synthetic routes to 
create a library of 50 2nd generation fragments. This thesis details the synthesis of 24 
fragments by a single route (Chapter 3). Each route contained three points of diversification, 
allowing us to access interesting 3-D fragments quickly. This new approach allowed us to 
access 50 new 3-D fragments in less than 12 months. A detailed property analysis was then 
carried out to compare the properties of the 106 York 3-D fragments with other available 
libraries (Chapter 4). This showed our library to have good physicochemical properties and 
that our fragments effectively explored under-represented areas of 3-D space better than 
currently available libraries. These fragments are now undergoing screening, and 
preliminary screens have shown exciting potential for these new compounds. The York 3-D 
fragment library has also been deposited at the Diamond XChem facility to allow for future 
screening and collaborations. 
In conclusion, a library of 106 highly 3-D fragments (as shown by PMI analysis) has been 
synthesised and is now undergoing screening. Lessons learned from the synthesis of the 56 
1st generation fragments have allowed us to refine our approach and led to the synthesis of 
50 2nd generation 3-D fragments in much less time.   
Future work on this project would involve the design of new synthetic routes to access 3-D 
fragments, using a similar strategy to that detailed in Chapter 3. One potential strategy would 
be to use the same methodology described in Chapter 3 but to epimerise after the 
hydrogenation step in order to access the trans-diastereomer of each fragment. Bull et al. 
showed during their work on cis-3,4-disubstiuted pyrrolidines that these systems could be 
completely epimerised to the trans-diastereomer (Scheme 4.1).72 Reaction of cis-293, with 
the aminoquinoline directing group attached, with Cs2CO3 at 100 °C gave pyrrolidine trans-
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294. Alternatively, reaction of cis-293 with NaOH and EtOH at 100 °C hydrolysed the 
carbamate and epimerisation occurred to give acid trans-295. Both these reactions proceeded 
in very high yield and would provide a good starting point for the potential epimerisation of 
our ester 3-D fragments. 
 
Scheme 4.1 
Alternatively, a new synthetic approach could be considered. Bode et al. have developed 
SnAP reagents for the rapid synthesis of saturated heterocycles and partially saturated 
bicycles.125,126 Scheme 4.2 shows two examples of the use of SnAP reagents to give products 
297 and trans-299. Both of these compounds contain ester groups that could be diversified 
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EXPERIMENTAL 
5.1 General Methods 
5.1.1 3-D Shape Analysis Protocol 
A SMILES file containing the SMILES strings for all fragment compounds was generated 
using ChemDraw 18.0. 3-D structures were generated Pipeline Pilot 8.5.0.200, 2011, 
Accelrys Software Inc. Generated conformations were used to generate the three Principal 
Moments of Inertia (I1, I2 and I3) which were then normalised by dividing the two lower 
values by the largest (I1/I3 and I2/I3) using Pipeline Pilot built-in components. Prior to 
conformer generation a wash step was performed, which involved stripping salts and 
ionising the molecule at pH 7.4. Any stereocentre created here was left with undefined 
stereochemistry. SMILES strings were converted to their canonical representation. A list of 
allowed chirality at each centre is generated and a SMILES file with all possible 
stereoisomers was written. Conformers were generated using the BEST method in Catalyst 
using the rel option, run directly on the server and not through the built-in Conformation 
Generator component with a chosen maximum relative energy threshold of 20 kcal mol-1, 
maximum of 255 conformers for each compound. Conformations were read, ones that cannot 
be represented by the canonical SMILES are discarded, with the remaining ones 
standardised to a single enantiomer. Duplicates were filtered with a RMSD threshold of 0.1. 
Minimisation with 200 steps of Conjugate Gradient minimisation with an RMS gradient 
tolerance of 0.1 was performed using the CHARMm forcefield with Momany-Rone partial 
charge estimation and a Generalised Born implicit solvent model. Duplicates were filtered 
again with a RMSD setting of 0.1. 
5.1.2 cLogP Calculations 
cLogP Values were calculated at AstraZeneca using Daylight/Biobyte software (version 
4.3.0) 
5.1.3 General Synthetic Methods 
Non-aqueous reactions were purged and back filled with Ar three times in flame dried 
glassware. Diethyl ether and THF were distilled over sodium and benzophenone 
respectively. Alkyllithiums were titrated using N-benzylbenzamide prior to use. Flash 
column chromatography was carried out using Fluka Chemie GmbH silica (220-440 mesh). 
Thin layer chromatography was carried out using commercially available Merk F254 
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aluminium backed silica plates. Proton (400 MHz) and carbon (100.6 MHz) NMR spectra 
were recorded on a Jeol ECX-400 instrument using an internal deuterium lock. For samples 
recorded in CDCl3, chemical shifts are quoted in parts per million relative to CHCl3 (δH 7.26) 
and CDCl3 (δC 77.1, central line of triplet). For samples recorded in d4-MeOH, chemical 
shifts are quoted on parts per million relative to d4-MeOH (δH 3.31, central line of quintet) 
and d4-MeOH (δC 49.15, central line of septet). Carbon NMR spectra were recorded with 
broad band decoupling and assigned using DEPT experiments. Coupling constants (J) are 
quoted in Hertz. Melting points were carried out on a Gallenkamp melting point apparatus. 
Infrared spectra were recorded on an ATI Mattson Genesis FT-IR spectrometer. Electrospray 
high and low resonance mass spectra were recorded at room temperature on a Bruker 
Daltronics micrOTOF spectrometer. 
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5.2 Synthetic Procedures 
5.2.1 General Procedures 
General Procedure A: Hydrogenation 
10% Pd/C or 10% Pd(OH)2/C (0.01-0.03 eq) was added to a stirred solution of the alkene 
(0.23-6.07 mmol, 1.0 eq) in MeOH (5-50 mL) at rt. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times. Then, the reaction flask was evacuated 
under reduced pressure and back-filled with H2 three times. After the final evacuation, H2 
was charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 2-
112 h. Then, the solids were removed by filtration through Celite and the solvent was 
evaporated under reduced pressure to give the crude product. 
General Procedure B: Formation of enol triflates 
iPr2NEt (5.0 eq) was added dropwise to a stirred solution of the β-ketoester (1.41-21.6 mmol, 
1.0 eq) in CH2Cl2 (25-200 mL) at –78 °C under Ar. The resulting solution was stirred at –78 
°C for 10 min and then trifluoromethanesulfonic anhydride (1.2 eq) was added dropwise 
over 15 min. The resulting solution was allowed to warm to rt and stirred at rt for 16 h. H2O 
(25-100 mL) and then 5% citric acid(aq) (25-200 mL) were added and the aqueous layer was 
extracted with CH2Cl2 (3 x 25-100 mL). The combined organic extracts were dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product. 
General Procedure C: Suzuki-Miyaura Coupling 
K2CO3 (2.5 eq) was added portionwise to a stirred mixture of the enol triflate (0.37-7.29 
mmol, 1.0 eq) and aryl boronic acid (1.5 eq) in THF (4-40 mL) and H2O (1-10 mL) at rt. 
The reaction flask was evacuated under reduced pressure and back-filled with Ar three times. 
Then, Pd(PPh3)4 (0.05-0.1 eq) was added and the resulting mixture was stirred and heated at 
65 °C for 16 h. The mixture was allowed to cool to rt and H2O (10-100 mL) was added. The 
aqueous layer was extracted with EtOAc (3 x 10-100 mL).  The combined organic extracts 
were dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
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5.2.2 Synthetic Procedures for Chapter 2 
N-Benzyl-1-(trimethylsilyl)methanamine 85 
 
Benzylamine (3.74 mL, 34.2 mmol, 2.1 eq) was added dropwise to a stirred solution of 
(chloromethyl)trimethylsilane (2.28 mL, 16.3 mmol, 1 eq) in DMSO (50 mL) at rt.  The 
resulting solution was stirred and heated at 80 °C for 16 h.  After being allowed to cool to rt, 
water (100 mL) was added and the mixture was extracted with EtOAc (3  100 mL).  The 
combined organic extracts were washed with 1% Na2CO3(aq) (50 mL), dried (MgSO4) and 
evaporated under reduced pressure to give the crude product.58 Purification by flash column 
chromatography on silica with 400:100:1 hexane-EtOAc-Et3N as eluent gave amine 85 (2.44 
g, 77%) as a colourless oil, RF (400:100:1 hexane-EtOAc-Et3N) 0.21; 
1H NMR (400 MHz, 
CDCl3) δ 7.39-7.20 (m, 5H, Ph), 3.79 (s, 2H, NCH2Ph), 2.05 (s, 2H, NCH2SiMe3), 1.20 (br 
s, 1H, NH), 0.03 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, CDCl3) 140.8 (ipso-Ph), 128.5 (Ph), 
128.3 (Ph), 127.0 (Ph), 58.3 (NCH2Ph), 39.7 (NCH2SiMe3), –2.4 (SiMe3); MS (ESI) m/z 194 
(M + H)+. Spectroscopic data are consistent with those reported in the literature.58  




MeOH (0.26 mL, 6.33 mmol, 1.1 eq) was added dropwise to a stirred mixture of 37% 
aqueous formaldehyde (0.47 mL, 6.33 mmol, 1.1 eq) and amine 85 (1.11 g, 5.76 mmol, 1 
eq) at 0 °C. The resulting mixture was stirred at 0 °C for 30 min and then allowed to warm 
to rt over 4 h. K2CO3 (500 mg) was added and the organic layer was decanted. K2CO3 (50 
mg) was added and the organic layer was decanted. The inorganic residue was washed with 
Et2O (2 x 10 mL) and the combined decanted layers and washings were evaporated under 
reduced pressure to give crude methoxyamine 25 (1.08 g, 79%) as a yellow oil, 1H NMR 
(400 MHz, CDCl3) δ 7.35-7.20 (m, 5H, Ph), 4.00 (s, 2H, NCH2O), 3.76 (s, 2H, NCH2Ph), 
3.24 (s, 3H, OMe), 2.18 (s, 2H, NCH2SiMe3), 0.05 (s, 9H, SiMe3); 
13C (100.6 MHz, CDCl3) 
δ 139.7 (ipso-Ph), 128.9 (Ph), 128.2 (Ph), 126.7 (Ph), 88.4 (NCH2O), 59.7 (NCH2Ph), 55.4 
(OMe), 42.9 (NCH2SiMe3), –1.5 (SiMe3). Spectroscopic data are consistent with those 
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reported in the literature.127 The crude methoxyamine 25 was sufficiently pure for use 
without further purification. 
Lab Book: TD 1/7 
 
Methyl 1-benzyl-4-methyl-2,5-dihydro-1H-pyrrole-3-carboxylate 83 
 
Methoxyamine 25 (500 mg, 2.1 mmol, 1 eq) was added dropwise to a stirred solution of 
methyl 2-butynoate (0.315 mL, 3.15 mmol, 1.5 eq) and TFA (0.015 mL, 0.21 mmol, 0.1 eq) 
in THF (25 mL) at 0 °C. The resulting solution was allowed to warm to rt and stirred at rt 
for 16 h. Then, the solvent was evaporated under reduced pressure and EtOAc (25 mL) was 
added. The solution was washed with saturated NaHCO3(aq) (2 x 20 mL) and brine (20 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave dihydropyrrole 83 (117 mg, 24%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.17; IR 
(ATR) 2789, 1714 (C=O), 1452, 1246, 853, 696 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.32-
7.20 (m, 5H, Ph), 3.75 (s, 2H, NCH2Ph), 3.69 (s, 3H, OMe), 3.67 (tq, J = 4.0, 2.0 Hz, 2H, 
NCH2), 3.54 (tq, J = 4.0, 1.0 Hz, 2H, NCH2), 2.07 (tt, J = 2.0, 1.0 Hz, 3H, CMe); 
13C (100.6 
MHz, CDCl3) δ 165.0 (C=O), 152.4 (=CMe), 139.0 (ipso-Ph), 129.0 (=CCO2Me), 128.7 
(Ph), 128.5 (Ph), 127.2 (Ph), 65.9 (NCH2Ph), 60.12 (NCH2), 60.10 (NCH2), 51.1 (OMe), 
14.1 (CMe); MS (ESI) m/z 232 [(M + H)+, 100]; HRMS (ESI) m/z calcd for C14H17NO2 (M 
+ H)+ 232.1330, found 232.1332 (+0.7 ppm error). 
Lab Book Reference: TD 1/43 
 
Smaller Scale Procedure 
Methoxyamine 25 (100 mg, 0.42 mmol, 1 eq) was added dropwise to a stirred solution of 
methyl 2-butynoate (0.063 mL, 0.63 mmol, 1.5 eq) and TFA (0.003 mL, 0.04 mmol, 0.1 eq) 
in THF (5 mL) at 0 °C. The resulting solution was allowed to warm to rt and stirred at rt for 
16 h. Then, the solvent was evaporated under reduced pressure and EtOAc (10 mL) was 
added. The solution was washed with saturated NaHCO3(aq) (2 x 10 mL) and brine (10 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
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Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave dihydropyrrole 83 (47 mg, 48%) as a yellow oil 
Lab Book Reference: TD 1/23 
Ethyl 1-benzyl-4-methyl-2,5-dihydro-1H-pyrrole-3-carboxylate 88 
 
Procedure using TFA as Activating Agent 
Methoxyamine 25 (200 mg, 0.84 mmol, 1 eq) was added dropwise to a stirred solution of 
ethyl 2-butynoate (0.15 mL, 1.26 mmol, 1.5 eq) and TFA (0.006 mL, 0.08 mmol, 0.1 eq) in 
THF (10 mL) at 0 °C. The resulting solution was allowed to warm to rt and stirred at rt for 
16 h. Then, the solvent was evaporated under reduced pressure and EtOAc (25 mL) was 
added. The solution was washed with saturated NaHCO3(aq) (2 x 20 mL) and brine (20 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave dihydropyrrole 88 (116 mg, 56%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.13; 
1H 
NMR (400 MHz, CDCl3) δ 7.36-7.22 (m, 5H, Ph), 4.16 (q, J = 7.0 Hz, 2H, OCH2), 3.76 (s, 
2H, NCH2Ph), 3.71-3.66 (m, 2H, NCH2), 3.55-3.52 (m, 2H, NCH2), 2.07-2.04 (m, 3H, Me), 
1.25 (t, J = 7.0 Hz, 3H, CH2Me); 
13C NMR (100.6 MHz, CDCl3) δ 165.4 (C=O), 151.8 
(=CMe), 137.0 (ipso-Ph), 128.9 (=CCO2Et), 128.7 (Ph), 128.5 (Ph), 127.3 (Ph), 65.8 
(NCH2), 60.1 (NCH2Ph), 59.9 (NCH2), 59.3 (OCH2), 14.6 (CH2Me), 14.1 (=CMe). 
Spectroscopic data are consistent with those reported in the literature.76  
Lab Book Reference: TD 1/13 
 
Procedure using Fluoride as Activating Agent 
A solution of DMAP (0.24 mg, 0.002 mmol, 0.01 eq) in THF (1 mL) was added dropwise 
to a stirred solution of benzoyl fluoride (25 mg, 0.2 mmol, 1 eq), methoxyamine 25 (52 mg, 
0.22 mmol, 1.1 eq) and ethyl propiolate (22 mg, 0.2 mmol, 1 eq) in THF (3 mL) at 0 °C. The 
resulting solution was stirred at 0 °C for 30 min. After being allowed to warm to rt, the 
solution was stirred at rt for 6 h. The solvent was evaporated under reduced pressure to give 
the crude product which contained a complex mixture of compounds (by 1H NMR 
spectroscopy) that were inseparable by attempted flash column chromatography. 
Lab Book Reference: TD 1/10 
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Ethyl 1-benzyl-4-phenyl-2,5-dihydro-1H-pyrrole-3-carboxylate 90 
 
A solution of DMAP (0.3 mg, 0.002 mmol, 0.01 eq) in THF (1 mL) was added dropwise to 
a stirred solution of benzoyl fluoride (25 mg, 0.2 mmol, 1 eq), methoxyamine 25 (52 mg, 
0.22 mmol, 1.1 eq) and ethyl phenylpropiolate (35 mg, 0.2 mmol, 1 eq) in THF (3 mL) at 0 
°C. The resulting solution was stirred at 0 °C for 30 min. After being allowed to warm to rt, 
the solution was stirred at rt for 6 h. The solvent was evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 75:25 
hexane-EtOAc as eluent gave dihydropyrrole 90 (53 mg, 86%) as a colourless oil, RF (75:25 
hexane-EtOAc) 0.30; 1H NMR (400 MHz, CDCl3) δ 7.48-7.16 (m, 10H, Ph), 4.10 (q, J = 
7.0 Hz, 2H, OCH2), 3.91 (br s, 4H, NCH2), 3.85 (s, 2H, NCH2Ph), 1.14 (t, J = 7.0 Hz, 3H, 
Me); 13C NMR (100.6 MHz, CDCl3) δ 164.7 (C=O, CO2Et), 150.5 (=CPh), 136.5 (ipso-Ph), 
134.8 (ipso-Ph), 129.4 (Ph), 129.1 (Ph), 128.8 (=CCO2Me or Ph), 128.6 (=CCO2Me or Ph), 
128.2 (Ph), 127.8 (Ph), 127.5 (Ph), 65.4 (NCH2), 61.5 (NCH2), 60.1 (NCH2Ph), 59.6 
(OCH2), 14.4 (Me). Spectroscopic data are consistent with those reported in the literature.
128  
Lab Book Reference: TD 1/8 
 
Methyl 1-benzylpyrrolidine-2-carboxylate (S)-94 
 
Acetyl chloride (1.90 mL, 26.07 mmol, 3 eq) was added dropwise to a stirred solution of 
(S)-proline (1.00 g, 8.69 mmol, 1 eq) in MeOH (20 mL) at rt under Ar. The resulting solution 
was stirred at rt for 16 h. The solvent was then evaporated under reduced pressure to give 
the intermediate crude product as a colourless oil. The intermediate crude product was 
dissolved in MeCN (20 mL) at rt and benzyl bromide (1.30 mL, 10.43 mmol, 1.2 eq) and 
Et3N (2.90 mL, 26.07 mmol, 3 eq) were added sequentially. The resulting suspension was 
stirred at rt for 12 h. The solvent was evaporated under reduced pressure. Saturated NH4Cl(aq) 
(50 mL) and Et2O (50 mL) were added to the residue and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 x 50 mL) and the combined organic extracts were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. Purification 
Experimental 
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by flash column chromatography on silica with 92:8 hexane-EtOAc as eluent gave N-benzyl 
pyrrolidine (S)-94 (1.04 g, 55%) as a colourless oil, RF (90:10 hexane-EtOAc) 0.15; [α]D –
70.7 (c 1.00, MeOH) [lit.,129 –61.4 (c 1.15, MeOH)]; 1H NMR (400 MHz, CDCl3) δ 7.35-
7.20 (m, 5H, Ph), 3.87 (d, J = 13.0 Hz, 1H, NCHPh), 3.63 (s, 3H, OMe), 3.56 (d, J = 13.0 
Hz, 1H, NCHPh), 3.23 (dd, J = 9.0, 6.5 Hz, 1H, NCHCO2Me), 3.07-3.00 (m, 1H, NCH), 
2.42-2.32 (m, 1H, NCH), 2.17-2.05 (m, 1H, CH), 2.00-1.81 (m, 2H, CH), 1.80-1.71 (m, 1H, 
CH); 13C NMR (100.6 MHz, CDCl3) δ 174.7 (C=O), 138.3 (ipso-Ph), 129.3 (Ph), 128.3 (Ph), 
127.2 (Ph), 65.4 (NCHCO2Me), 58.9 (NCH2Ph), 53.4 (NCH2), 51.8 (OMe), 29.5 (CH2), 23.1 
(CH2). Spectroscopic data are consistent with those reported in the literature.
129  
Lab Book Ref: TD 1/55 
 
 1-tert-Butyl-2-methyl pyrrolidine-1,2-dicarboxylate (S)-96 
 
20% Pd(OH)2/C (20 mg, 0.03 mmol) was added to a stirred solution of pyrrolidine (S)-94 
(237 mg, 1.06 mmol, 1 eq) and ammonium formate (336 mg, 5.31 mmol, 5 eq) in MeOH 
(25 mL) at rt. The resulting solution was stirred and heated at 60 ºC for 2 h. After being 
allowed to cool to rt, the solids were removed by filtration through Celite. Di-tert-butyl 
dicarbonate (231 mg, 1.06 mmol, 1 eq), Et3N (0.888 mL, 6.38 mmol, 6 eq) and DMAP (13 
mg, 0.11 mmol, 0.1 eq) were added to the filtrate at rt. The resulting solution was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography with 80:20 hexane-EtOAc as solvent 
gave pyrrolidine (S)-96 (242 mg, 99%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.27; [α]D 
–47.3 (c 1.00, CH2Cl2) [lit. 
130, –44.8 (c 1.05, CH2Cl2)]; 
1H NMR (400 MHz, CDCl3) δ (60:40 
mixture of rotamers) 4.29 (dd, J = 8.5, 3.5 Hz, 0.4H, CHCO2Me), 4.19 (dd, J = 8.5, 4.0 Hz, 
0.6H, CHCO2Me), 3.70 (s, 1.2H, OMe), 3.69 (s, 1.8H, OMe) 3.59-3.29 (m, 2H, NCH), 2.27-
2.09 (m, 1H, CH), 1.99-1.73 (m, 3H, CH), 1.43 (s, 3.6H, CMe3), 1.38 (s, 5.4H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) δ 173.9 (C=O, CO2Me), 173.6 (C=O, CO2Me), 154.5 (C=O, 
Boc), 153.9 (C=O, Boc), 80.0 (CMe3), 79.9 (CMe3), 59.2 (CHCO2Me), 58.8 (CHCO2Me), 
52.2 (OMe), 52.0 (OMe), 46.6 (NCH2), 46.4 (NCH2), 31.0 (CH2), 30.0 (CH2), 28.5 (CMe3), 
28.4 (CMe3), 24.4 (CH2), 23.8 (CH2). Spectroscopic data are consistent with those reported 
in the literature.32  
Lab Book Reference: TD 1/70 
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1-tert-Butyl-3-methyl 4-methylpyrrolidine-1,3-dicarboxylate cis-97 
 
20% Pd(OH)2/C (18 mg, 0.03 mmol) was added to a stirred solution of dihydropyrrole 83 
(200 mg, 0.87 mmol, 1 eq) and ammonium formate (273 mg, 5.31 mmol, 5 eq) in MeOH 
(10 mL) at rt. The resulting solution was stirred and heated at 60 ºC for 2 h. After being 
allowed to cool to rt, the solids were removed by filtration through Celite. Di-tert-butyl 
dicarbonate (189 mg, 0.87 mmol, 1 eq), Et3N (0.72 mL, 5.19 mmol, 6 eq) and DMAP (11 
mg, 0.09 mmol, 0.1 eq) were added to the filtrate at rt. The resulting solution was stirred at 
rt for 16 h. Then, the solvent was evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography with 80:20 hexane-EtOAc as solvent 
gave pyrrolidine cis-97 (153 mg) as a yellow oil, which contained some dihydropyrrole 83 
by mass spectrometry. The mixture was then dissolved in MeOH (10 mL) and 5% Pd/C (15 
mg, 0.01 mmol) was added to the stirred solution. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under an H2 balloon at rt for 16 h. 
The solids were removed by filtration through Celite and the filtrate was evaporated under 
reduced pressure to give crude pyrrolidine cis-97 (145 mg, 77% over 2 steps) as a yellow 
oil, RF (80:20 hexane-EtOAc) 0.31; IR (ATR) 2974, 1731 (C=O, CO2Me), 1693 (C=O, Boc), 
1400, 1171 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 3.68 (s, 1.5H, 
OMe), 3.67 (s, 1.5H, OMe), 3.66-3.56 (m, 1H, CHCO2Me), 3.52-3.42 (m, 2H, NCH), 3.20-
3.13 (m, 0.5H, NCH), 3.11-2.97 (m, 1.5H, NCH), 2.58-2.46 (m, 1H, CHMe), 1.43 (s, 9H, 
CMe3), 0.96 (d, J = 6.5 Hz, 1.5H, Me), 0.93 (d, J = 7.0 Hz, 1.5H, Me); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 172.8 (C=O, CO2Me), 172.6 (C=O, CO2Me), 154.6 (C=O, Boc), 
79.5 (CMe3), 79.4 (CMe3), 52.3 (NCH2), 52.1 (NCH2), 51.73 (OMe), 51.68 (OMe), 47.5 
(NCH2), 46.9 (NCH2), 46.7 (CHCO2Me), 46.6 (CHCO2Me), 35.8 (CHMe), 34.8 (CHMe), 
28.59 (CMe3), 28.57 (CMe3), 14.5 (Me), 14.3 (Me); MS (ESI) m/z 266 [(M + Na)
+, 100]; 
HRMS (ESI) m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1367 (–1.6 ppm 
error). 
Lab Book Ref: TD 1/75 
3-Methyl 4-methylpyrrolidine-3-carboxylate hydrochloride cis-42•HCl 
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HCl (0.206 mL of a 2M solution in Et2O, 0.411 mmol, eq) was added dropwise to a stirred 
solution of N-Boc pyrrolidine cis-97 (20 mg, 0.08 mmol,1 eq) in CH2Cl2 (2 mL) at rt under 
Ar. The resulting mixture was stirred at rt for 16 h. The solvent was evaporated under 
reduced pressure to give pyrrolidine cis-42•HCl (14 mg, 97%) as an orange oil, IR (ATR) 
2964, 1730 (C=O), 1666, 1384, 733 cm-1; 1H NMR (400 MHz, d4-MeOH) δ 3.69 (s, 3H, 
OMe), 3.59-3.51 (br s, 1H, NCH or CHCO2Me), 3.47-3.37 (br s, 2H, NCH or CHCO2Me), 
2.99-2.89 (br s, 1H, NCH or CHCO2Me), 2.76-2.62 (br s, 1H, NCH or CHCO2Me), 2.13-
1.96 (br s, 1H, CHMe), 1.00 (br s, 3H, CHMe); MS (ESI) m/z 144 [M+, 100]; HRMS (ESI) 
m/z calcd for C7H14NO2 (M + H)
+ 144.1019, found 144.1021 (–1.5 ppm error).  
Lab Book Reference: TD 1/81 
Methyl 1,4-dimethylpyrrolidine-3-carboxylate acetate cis-43•AcOH 
 
37% aqueous formaldehyde (1.534 mL, 20.6 mmol, 10 eq) was added dropwise to a stirred 
suspension of cis-42 (295 mg, 2.06 mmol, 1 eq), NaBH(OAc)3 (1.31 g, 6.18, mmol, 3 eq) 
and MgSO4 (1.53 g) in 3:1 CH2Cl2–AcOH (20 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 1 h. The solids were removed by filtration and NaHCO3(aq) was added to the 
filtrate until the mixture reached pH 9. The aqueous phase was extracted with CH2Cl2 (3 x 
20 mL) and the combined organic extracts were washed with brine (20 mL) and dried 
(Na2SO4). AcOH (0.118 mL, 1 mmol, 1 eq) was added dropwise to the filtrate which was 
stirred at rt for 30 min. The solvent was evaporated under reduced pressure to give 
pyrrolidine cis-43•AcOH (165 mg, 76%) as a yellow oil, IR (ATR) 2958, 1720 (C=O), 1379, 
1251, 1214 cm-1; 1H NMR (400 MHz, d4-MeOH) δ 3.73 (s, 3H, OMe), 3.57-3.54 (m, 1H, 
CHCO2Me), 3.51-3.44 (m, 1H, NCH), 3.29-3.27 (m, 3H, NCH, NCH, NCH), 2.89 (s, 3H, 
NMe), 2.83-2.77 (m, 1H, CHMe), 1.96-1.90 (m, 3H, MeCO2
-) 1.02 (d, J = 7.0 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, d4-MeOH) δ 175.3 (C=O,  MeCO2
-), 172.5 (C=O, CO2Me), 
60.57 (NCH2), 60.54 (NCH2), 57.1 (CCO2Me), 51.2 (OMe), 41.1 (NMe), 40.3 (CMe), 20.3 
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(Me, MeCO2
-), 12.4 (CMe); MS (ESI) m/z  158 [M+, 100]; HRMS (ESI) m/z calcd for 
C8H16NO2 158.1176 M
+, found 158.1179 (–1.8 ppm error). 
Lab Book Reference: TD 2/30 
 
N-tert-Butyloxycarbonyl glycine methyl ester 101 
 
A solution of NaHCO3 (334 mg, 3.98 mmol, 1 eq) in H2O (5 mL) was added to a stirred 
suspension of glycine methyl ester hydrochloride (500 mg, 3.98 mmol, 1 eq) in CHCl3 (5 
mL) at rt. Then, a solution of di-tert-butyl dicarbonate (869 mg, 3.98 mmol, 1 eq) in CHCl3 
(2 mL) was added, followed by the addition of NaCl (814 mg, 13.9 mmol, 3.5 eq). The 
resulting mixture was stirred vigorously and heated at reflux for 1.5 h. After being allowed 
to cool to rt, the two layers were separated and the aqueous phase was extracted with CHCl3 
(2 x 10 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give crude N-Boc glycine 101 (745 mg, 99%) as a colourless oil, 1H 
NMR (400 MHz, CDCl3) δ 5.00 (br s, 1H, NH), 3.90 (d, J = 5.5 Hz, 2H, CH2), 3.73 (s, 3H, 
OMe), 1.43 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 170.9 (C=O, CO2Me), 155.8 
(C=O, Boc), 80.1 (CMe3), 52.3 (OMe), 42.4 (NCH2), 28.4 (CMe3). Spectroscopic data are 
consistent with those reported in the literature.131 The crude N-Boc glycine 101 was 
sufficiently pure for use without further purification. 
Lab Book: TD 1/63 
 
1-tert-Butyl-4-methyl 3-oxopyrrolidine-1,4-dicarboxylate 100 
 
Methyl acrylate (0.44 mL, 4.89 mmol, 1 eq) was added dropwise to a stirred solution of dry 
t-BuOK (604 mg, 5.38 mmol, 1.1 eq) and N-Boc glycine 101 (926 mg, 4.89 mmol, 1 eq) in 
THF at 0 °C. The resulting solution was stirred at rt for 16 h and then the solvent was 
evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (50 mL) and 1 M 
HCl(aq) (10 mL) was added. The two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (Na2SO4) and 
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evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave oxopyrrolidine 100 (830 
mg, 90%) as a red oil, RF (80:20 hexane-EtOAc) 0.35; 
1H NMR (400 MHz, CDCl3) (50:50 
mixture of keto/enol tautomers) (rotamers) δ 10.01-9.99 (m, 0.5 H, enol OH), 4.25-4.13 (m, 
1H), 4.13-4.01 (m, 1.5H), 3.99-3.82 (m, 1.5H), 3.77 (s, 3H, OMe), 3.69-3.56 (m, 0.5H), 1.47 
(s, 4.5H, CMe3), 1.46 (s, 4.5H, CMe3) ; 
13C NMR (100.6 MHz, CDCl3) δ 171.9 (C=O, 
CO2Me), 167.2 (C=O, CO2Me), 154.1 (C=O, Boc), 97.2 (=C), 81.0 (CMe3), 80.2 (CMe3), 
53.1 (OMe), 51.60 (OMe or CH2), 51.55 (OMe or CH2), 51.4 (CH2), 51.1 (CH2), 48.8 (CH2), 
48.4 (CH2), 28.5 (CMe3), 28.4 (CMe3). Spectroscopic data are consistent with those reported 
in the literature.79 




Using general procedure B, β-ketoester 100 (5.0 g, 19.4 mmol, 1.0 eq), iPr2NEt (16.9 mL, 
97.2 mmol, 5.0 eq) and trifluoromethanesulfonic anhydride (3.92 mL, 23.3 mmol, 1.2 eq) in 
CH2Cl2 (200 mL) gave the crude product. Purification by flash column chromatography on 
silica with 80:20 hexane-EtOAc as eluent gave enol triflate 99 (5.18 g, 71%) as a brown 
solid, mp 59-62 °C; RF (80:20 hexane-EtOAc) 0.30; IR (ATR) 1732 (C=O, CO2Me), 1709 
(C=O, Boc), 1682 (C=C), 1211, 1111 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.40-4.32 (m, 
4H, NCH), 3.81 (s, 3H, OMe), 1.46 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 160.5 (C=O, CO2Me), 160.4 (C=O, CO2Me), 153.5 (C=O, Boc or =CO), 153.3 
(C=O, Boc or =CO), 147.5 (C=O, Boc or =CO), 147.0 (C=O, Boc or =CO), 119.4 (=C), 
118.4 (q, J = 320 Hz, CF3), 81.1 (CMe3), 52.4 (OMe), 51.4 (NCH2), 51.2 (NCH2), 50.7 
(NCH2), 50.3 (NCH2), 28.4 (CMe3); MS (ESI) m/z 398 [(M + Na)
+, 100]; HRMS (ESI) m/z 
calcd for C12H16F3NO7S (M + Na)
+ 398.0492, found 398.0497 (–1.3 ppm error). 
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1-tert-Butyl-4-methyl 3-methyl-2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 98 and 1-
tert-Butyl-4-methyl 2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 109 
 
MeLi (0.309 mL of a 1.27 M solution in Et2O, 0.39 mmol, 1.4 eq) was added dropwise to a 
stirred solution of CuCN (35 mg, 0.39 mmol, 1.4 eq) in Et2O (1.5 mL) at –50 °C under Ar. 
The resulting solution was stirred at –50 °C for 30 min. Then, a solution of enol triflate 99 
(100 mg, 0.28 mmol, 1.0 eq) in Et2O (1.5 mL) pre-cooled to –50 °C was added dropwise. 
The resulting mixture was stirred at –50 °C for 30 min. Then, saturated NH4Cl(aq) (5 mL) 
was added and the solids were removed by filtration through Celite. The resulting solution 
was extracted with EtOAc (3 x 10 mL) and the combined organic extracts were washed with 
H2O (20 mL) and then brine (20 mL), dried (Na2SO4) and evaporated under reduced pressure 
to give an 80:20 mixture (by 1H NMR spectroscopy) of dihydropyrrole 98 and 
dihydropyrrole 109, 1H NMR (400 MHz, CDCl3) (rotamers) δ 6.77-6.70 (m, 0.2H, =CH), 
4.35-4.16 (m, 4H, NCH), 3.79-3.74 (m, 3H, OMe), 2.14-2.12 (br m, 2.4H, CMe), 1.48 (br s, 
9H, CMe3). Purification by flash column chromatography on silica with 80:20 hexane-
EtOAc as eluent gave no recoverable product. 
Lab Book Reference: TD 3/33 
1-tert-Butyl-4-methyl 3-methyl-2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 98 and 1-
tert-Butyl-4-methyl 3-methylpyrrolidine-1,4-dicarboxylate cis-97 
 
MeLi (0.309 mL of a 1.27 M solution in Et2O, 1.17 mmol, 1.4 eq) was added dropwise to a 
stirred solution of CuCN (105 mg, 1.17 mmol, 1.4 eq) in Et2O (5 mL) at –50 °C under Ar. 
The resulting solution was stirred at –50 °C for 30 min. Then, a solution of enol triflate 99 
(300 mg, 0.84 mmol, 1.0 eq) in Et2O (5 mL) pre-cooled to –50 °C was added dropwise. The 
resulting mixture was stirred at –50 °C for 30 min. Then, saturated NH4Cl(aq) (20 mL) was 
added and the solids were removed by filtration through Celite. The resulting solution was 
extracted with EtOAc (3 x 20 mL) and the combined organic extracts were washed with H2O 
(40 mL) and then brine (40 mL), dried (Na2SO4) and evaporated under reduced pressure to 
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give an 80:20 mixture (by 1H NMR spectroscopy) of dihydropyrrole 98 and dihydropyrrole 
109. The mixture was dissolved in MeOH (10 mL) and 10% Pd/C (18 mg, 0.02 mmol, 0.02 
eq) was added to the solution at rt. The reaction flask was evacuated under reduced pressure 
and back-filled with Ar three times. Then, the reaction flask was evacuated under reduced 
pressure and back-filled with H2 three times. After the final evacuation, H2 was charged and 
the reaction mixture was stirred vigorously under a H2 balloon at rt for 16 h. Then, the solids 
were removed by filtration through Celite. The solvent was evaporated under reduced 
pressure to give the crude intermediate product, which showed no presence (by 1H NMR 
spectroscopy) of desired dihydropyrrole cis-97.  The mixture was dissolved in MeOH (10 
mL) and 10% Pd(OH)2/C (15 mg, 0.01 mmol, 0.01 eq) was added to the solution at rt. The 
reaction flask was evacuated under reduced pressure and back-filled with Ar three times. 
Then, the reaction flask was evacuated under reduced pressure and back-filled with H2 three 
times. After the final evacuation, H2 was charged and the reaction mixture was stirred 
vigorously under a H2 balloon at rt for 16 h. Then, the solids were removed by filtration 
through Celite. The solvent was evaporated under reduced pressure to give a complex 
mixture of products including an 85:15 mixture (by 1H NMR spectroscopy) of 
dihydropyrrole 98 and pyrrolidine cis-97 
Lab Book Reference: TD 3/54 
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Dimethyl 1,2-dimethyl-5-oxopyrrolidine-4,4-dicarboxylate 145 
 
 
KHMDS (5.83 mL of a 0.5 M solution in THF, 2.92 mmol, 1.1 eq) was added dropwise to a 
stirred solution of 1,5-dimethylpyrrolidinone 140 (0.314 mL, 2.65 mmol, 1 eq) in THF (10 
mL) at –78 ºC under Ar. The resulting solution was stirred at –78 ºC for 1 h. Then, methyl 
chloroformate (0.205 mL, 2.65 mmol, 1 eq) was added dropwise. The resulting solution was 
stirred at –78 ºC for 1 h. NaHCO3(aq) (10 mL) was added and the aqueous layer was extracted 
with EtOAc (5 x 10 mL). The combined organic extracts were washed with NaHCO3(aq) (20 
mL) and brine (20 mL), dried (Na2SO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography with 50:50 EtOAc-hexane as 
eluent gave an inseparable 73:27 mixture of starting material 140 and double addition 
product 145 (122 mg, i.e. 55 mg (9%) of double addition product 145), diagnostic 1H NMR 
signals (400 MHz, CDCl3) for 145: δ 3.81 (s, 3H, OMe), 3.79 (s, 3H, OMe), 2.82 (s, 3H, 
NMe), 1.24 (d, J = 6.5 Hz, 3H, CHMe). 
Lab Book Reference: TD 1/29  
4-Methyl-2-methyl-5-oxopyrrolidine-1-carboxylate 149 
 
A solution of di-tert-butyl dicarbonate (4.84 g, 22.2 mmol, 1.1 eq) in CH2Cl2 (5 mL) was 
added dropwise to a stirred solution of 2-methyl-5-oxopyrrolidine 148 (2.00 g, 20.2 mmol, 
1 eq), Et3N (3.10 mL, 22.2 mmol, 1.1 eq) and DMAP (123 mg, 1.0 mmol, 0.05 eq) in CH2Cl2 
(50 mL) at 0 ºC under Ar. The resulting solution was allowed to warm to rt and stirred at rt 
for 18 h. The solvent was evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 50:50 EtOAc-hexane as eluent 
gave N-Boc pyrrolidinone 149 (3.44 g, 85%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.10; 
1H NMR (400 MHz, CDCl3) δ 4.22 (dqd, J = 8.5, 6.5, 2.0 Hz, 1H, NCHMe), 2.58 (ddd, J = 
17.5, 11.0, 9.0 Hz, 1H, CHCO), 2.40 (ddd, J = 17.5, 9.5, 3.0 Hz, 1H, CHCO), 2.21-2.09 (m, 
1H, CH), 1.69-1.53 (m, 1H, CH), 1.50 (s, 9H, CMe3), 1.30 (d, J = 6.5 Hz, 3H, CHMe); 
13C 
NMR (100.6 MHz, CDCl3) δ 174.3 (C=O, NCO), 150.0 (C=O, Boc), 82.7 (CMe3), 54.1 
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(NCH), 31.4 (CH2CO), 28.1 (CMe3), 25.2 (CH2), 20.3 (Me). Spectroscopic data are 
consistent with those reported in the literature.132  
Lab Book Ref: TD 1/41 
1-tert-Butyl-4-methyl-2-methyl-5-oxopyrrolidine-1,4-dicarboxylate 150 
 
For Procedure using LHMDS 
A solution of pyrrolidinone 149 (2.465 g, 12.4 mmol, 1 eq) in THF (20 mL) was added 
dropwise to a stirred solution of LHMDS (26 mL of a 1 M solution in THF, 26.0 mmol, 2.1 
eq) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 10 min. Then, methyl 
chloroformate (1.05 mL, 13.6 mmol, 1.1 eq) was added dropwise. The resulting solution was 
stirred at –78 °C for 10 min. Then, 1 M HCl(aq) was added dropwise until pH 1 was reached 
and the mixture was allowed to warm to rt. The two layers were separated and the aqueous 
phase was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica with 75:25 hexane-EtOAc as eluent gave a 67:33 
mixture (by 1H NMR spectroscopy) of diastereomeric pyrrolidines 150 (2.865 g, 90%) as a 
yellow oil, RF (75:25 hexane-EtOAc) 0.20; IR (ATR) 2980, 1785 (C=O), 1731 (C=O), 1718 
(C=O), 1295, 1149 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.35-4.25 (m, 0.67H, NCHMe), 
4.20-4.13 (m, 0.33H, NCHMe), 3.79-3.74 (m, 3H, OMe), 3.68-3.61 (m, 0.67H, CHCO2Me), 
3.54-3.48 (m, 0.33H, CHCO2Me), 2.62-2.52 (m, 0.67H, CH), 2.47-2.36 (m, 0.33H, CH), 
2.09-2.00 (m, 0.33H, CH), 1.92-1.85 (m, 0.67H, CH), 1.54-1.47 (m, 9H, CMe3), 1.42-1.36 
(m, 1H, CHMe), 1.33-1.27 (m, 2H, CHMe); 13C NMR (100.6 MHz) δ 169.6 (C=O), 169.4 
(C=O), 168.9 (C=O), 168.6 (C=O), 149.9 (C=O, Boc), 149.7 (C=O, Boc), 83.51 (CMe3), 
83.50 (CMe3), 53.02 (OMe or CHCO2Me), 52.97 (OMe or CHCO2Me), 52.9 (OMe or 
CHCO2Me), 52.3 (OMe or CHCO2Me), 49.3 (CHMe), 48.7 (CHMe), 29.4 (CH2), 28.5 
(CH2), 28.1 (CMe3), 21.4 (Me), 20.4 (Me); MS (ESI) m/z 280 [(M + Na)
+, 100, (M + K)+, 
2]; HRMS (ESI) m/z  calcd for C12H19NO5 (M + Na)
+ 280.1155, found 280.1149 (+2.2 ppm 
error). 
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For Proceudre using KHMDS 
KHMDS (2.10 mL of a 0.5 M solution in THF, 1.05 mmol, 1.1 eq) was added dropwise to a 
stirred solution of 4-methyl-2-methyl-5-oxopyrrolidine-1-carboxylate 149 (190 mg, 0.95 
mmol, 1 eq) in THF (10 mL) at –78 ºC under Ar. The resulting solution was stirred at –78 
ºC for 1 h. Then, methyl chloroformate (0.07 mL, 0.95 mmol, 1 eq) was added dropwise. 
The resulting solution was stirred at –78 ºC for 1 h. NaHCO3(aq) (10 mL) was added and the 
aqueous layer was extracted with EtOAc (5 x 10 mL). The combined organic extracts were 
washed with NaHCO3(aq) (20 mL) and brine (20 mL), dried (Na2SO4) and the solvent 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography with 75:25 hexane-EtOAc as eluent gave a 67:33 mixture (by 1H NMR 
spectroscopy) of diastereomeric pyrrolidines 150 (77 mg, 33%) as a yellow oil. 
Lab Book Reference: TD 1/39 
N-tert-Butyloxycarbonyl alanine methyl ester 159 
 
 
A solution of NaHCO3 (301 mg, 3.58 mmol, 1 eq) in H2O (5 mL) was added to a stirred 
suspension of glycine methyl ester hydrochloride (500 mg, 3.58 mmol, 1 eq) in CHCl3 (5 
mL) at rt. Then, a solution of di-tert-butyl dicarbonate (782 mg, 3.58 mmol, 1 eq) in CHCl3 
(2 mL) was added, followed by the addition of NaCl (732 mg, 12.53 mmol, 3.5 eq). The 
resulting mixture was stirred vigorously and heated at reflux for 1.5 h. After being allowed 
to cool to rt the organic phase was collected and the aqueous phase extracted with CHCl3 (2 
x 10 mL). The combined organic extracts were dried (Na2SO4) and evaporated under reduced 
pressure to give carbamate 159 (745 mg, quant.) as a colourless oil, 1H NMR (400 MHz, 
CDCl3) δ 5.03 (br s, 1H, NH), 4.37-4.23 (m, 1H, CH), 3.73 (s, 3H, CO2Me), 1.43 (s, 9H, 
CMe3), 1.36 (d, J = 7.0 Hz, 3H, CHMe); 
13C NMR (101.6 MHz, CDCl3) δ 174.0 (C=O, 
CO2Me), 146.8 (C=O, Boc), 85.3 (OCMe3), 52.4 (OMe), 42.4 (NCH), 28.4 (CMe3) 18.8 
(CHMe). Spectroscopic data are consistent with those reported in the literature.133 The crude 
carbamate 159 was sufficiently pure for use without further purification. 
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1-tert-Butyl-4-methyl-2-methyl-3-oxopyrrolidine-1,4-dicarboxylate 158 
 
Methyl acrylate (0.876 mL, 9.74 mmol, 1 eq) was added dropwise to a stirred solution of 
dry t-BuOK (1.2 g, 10.72 mmol, 1.1 eq) and N-Boc alanine 159 (1.98 g, 9.74 mmol, 1 eq) in 
THF at 0 °C. The resulting solution was stirred at rt for 16 h and then the solvent was 
evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (100 mL) and 1 M 
HCl(aq) (20 mL) was added. The two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave pyrrolidine 158 (1.26 g, 
50%) as a red oil, RF (80:20 hexane-EtOAc) 0.27; IR (ATR) 2977, 1770 (C=O), 1736 (C=O), 
1697 (C=O), 1639 (C=O), 1391, 1161 cm-1; 1H NMR (400 MHz, CDCl3) (mixture of 
diastereomers, rotamers and tautomers) δ 10.10-9.80 (m, 0.3H), 6.17 (m, 0.03H), 5.58 (m, 
0.03H), 5.10-4.95 (m, 0.17H), 4.57-4.49 (m, 0.17H), 4.48-4.39 (m, 0.17H), 4.35-3.96 (m, 
1.8H), 3.90-3.79 (m, 0.37H), 3.76-3.72 (m, 3H), 3.72-3.58 (m, 0.57H), 3.58-3.52 (m, 0.17H), 
3.48-3.42 (m, 0.08H), 3.33 (m, 0.03H, 3.30 (m, 0.03H), 1.50-1.30 (m, 9H), 1.40-1.30 (m, 
3H); 13C NMR (100.6 MHz, CDCl3) δ 174.6, 172.53, 172.48, 172.2, 168.9, 168.7, 168.7, 
168.0, 155.0, 154.7, 154.6, 149.8, 126.7, 96.24, 96.07, 81.38, 80.75, 80.58, 61.10, 58.70, 
58.55, 58.50, 53.75, 53.65, 53.03, 52.19, 52.13, 49.83, 48.80, 48.30, 29.16, 29.08, 29.00, 
19.37, 19.05, 18.29, 14.89; MS (ESI) m/z 256 [(M - H)-, 100]; HRMS (ESI) m/z  calcd for 
C12H19NO5 (M – H)
- 256.1190, found 256.1190 (0.0 ppm error). 








Using general procedure B, iPr2NEt (1.46 mL, 8.36 mmol, 5.0 eq), β-ketoester 158 (1.46 
mL, 8.36 mmol, 5.0 eq) and trifluoromethanesulfonic anhydride (0.34 mL, 2.0 mmol, 1.2 
eq) in CH2Cl2 (30 mL) gave the crude product. Purification by flash column chromatography 
with 75:25 hexane-EtOAc as eluent gave enol triflate 161 (490 mg, 82%) as a yellow oil, RF 
(75:25 hexane-EtOAc) 0.44; IR (ATR) 1732 (C=O, CO2Me), 1707 (C=O, Boc), 1682 (C=C), 
1209, 847 cm-1; 1H NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) δ 4.78-4.70 (m, 
0.55H, NCHMe), 4.67-4.57 (m, 0.45H, NCHMe), 4.48-4.37 (m, 1H, NCH), 4.32-4.23 (m, 
1H, NCH), 3.82 (s, 3H, OMe), 1.49-1.40 (m, 12H, CMe3, CHMe); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 160.7 (C=O, CO2Me), 160.6 (C=O, CO2Me), 153.4 (C=O, Boc or 
=CO), 151.3 (C=O, Boc or =CO), 150.7 (C=O, Boc or =CO), 118.43 (=C), 118.38 (q, J = 
321 Hz, CF3), 118.3 (=C), 81.1 (CMe3), 80.9 (CMe3), 58.5 (NCHMe), 58.4 (NCHMe), 52.4 
(OMe), 50.1 (NCH2), 49.6 (NCH2), 28.5 (CMe3), 18.4 (CMe), 17.7 (CMe); MS (ESI) m/z 
412 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C13H18F3NO7S (M + Na)
+ 412.0648, found 
412.0637 (+2.8 ppm error). 
Lab Book Reference: TD 2/49 
4-Methyl 2-methylpyrrolidine-4-carboxylate 156•TfOH 
 
Using general procedure A, dihydropyrrole 161 (490 mg, 1.37 mmol) and 10% Pd/C (49 
mg, 0.05 mmol, 0.04 eq) in MeOH (25 mL) for 42 h gave the crude amine•TfOH salt 
37•TfOH (330 mg, 67%) as a yellow oil which contained a 65:35 mixture (by 1H NMR 
spectroscopy) of pyrrolidines trans-156 and cis-156, 1H NMR (400 MHz, CDCl3) δ 8.25 (br 
s, 1H, NH), 7.72 (br s, 1H, NH), 3.90-3.65 (m, 5H, OMe, NCH), 3.65-3.54 (m, 1H, NCH), 
3.39-3.24 (m, 1H, CHCO2Me), 2.57-2.48 (m, 0.35H, CH), 2.48-2.39 (m, 0.65H, CH) 2.07-
1.97 (ddd, J = 13.5, 9.5, 9.5 Hz, 0.65H, CH), 1.97-1.88 (ddd, J = 13.5, 10.0, 10.0 Hz, 0.35H, 
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CH), 1.46 (br d, J = 6.5 Hz, 3H, CHMe). The crude amine•TfOH salt 37•TfOH was 
sufficiently pure for use without further purification. To date, we have been unable to repeat 
this experiment and so full characterisation has not been possible. 
Lab Book Reference: TD 2/51 
1-Benzoyl-4-methyl 2-methylpyrrolidine-1,4-dicarboxylate 162 
 
Procedure from pyrrolidines 156•TfOH 
Et3N (0.93 mL, 0.67 mmol, 3.0 eq) was added dropwise to a stirred solution of a 65:35 
mixture of pyrrolidines trans-156•TfOH and cis-156•TfOH (65 mg, 0.22 mmol, 1.0 eq) in 
CH2Cl2 (3 mL) at 0 °C under Ar.  The resulting solution was stirred at 0 °C for 30 min then 
benzyl chloroformate (0.35 mL, 0.24 mmol, 1.1 eq) and DMAP (3 mg, 0.02 mmol, 0.1 eq) 
were added. The resulting solution was allowed to warm to rt and was stirred at rt for 16 h. 
Then, H2O (5 mL) was added and the two layers were separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL) and the combined organic extracts were dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 80:20 hexane-EtOAc as eluent gave a 65:35 mixture 
(by 1H NMR spectroscopy) of pyrrolidines trans-162 and cis-162 (43 mg, 70%) as a 
colourless oil, RF (80:20 hexane-EtOAc) 0.20; IR (ATR) 1735 (C=O, CO2Me), 1697 (C=O, 
Cbz), 1409 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43-7.27 (m, 5H, Ph), 5.19-5.02 (m, 2H, 
OCH2Ph), 4.16-4.03 (br m, 0.65H, NCHMe) 4.00-3.78 (m, 0.70H, NCHMe, NCH), 3.73-
3.50 (m, 4.65H, OMe, NCH), 3.22-3.08 (br m, 0.65H, CHCO2Me), 2.95 (dddd, J = 7.5, 7.5, 
7.5, 7.5 Hz (apparent quintet), 0.35H, CHCO2Me), 2.38 (ddd, J =13.0, 7.5, 7.5 Hz, 0.35H, 
CH), 2.32-2.17 (br m, 0.65H, CH), 1.92-1.80 (m, 1H, CH), 1.30-1.15 (m, 3H, CHMe); 13C 
NMR (100.6 MHz, CDCl3) δ (rotamers) 173.5 (C=O, CO2Me), 173.44 (C=O, CO2Me), 
173.36 (C=O, CO2Me), 154.72 (C=O, Cbz), 154.70 (C=O, Cbz), 154.5 (C=O, Cbz), 154.4 
(C=O, Cbz), 136.9 (ipso-Ph), 136.8 (ipso-Ph) , 128.6 (Ph), 128.5 (Ph), 128.01 (Ph), 127.97 
(Ph), 127.9 (Ph), 66.9 (OCH2Ph), 66.7 (OCH2Ph), 53.7 (NCHMe), 53.4 (NCHMe), 52.8 
(NCHMe), 52.2 (OMe), 48.73 (NCH2), 48.65 (NCH2), 48.2 (NCH2), 42.1 (CHCO2Me), 41.4 
(CHCO2Me), 40.7 (CHCO2Me), 37.3 (CH2), 36.7 (CH2), 36.5 (CH2), 35.7 (CH2), 21.0 
(CHMe), 20.3 (CHMe), 20.1 (CHMe); MS (ESI) m/z 300 [(M + Na)+, 100]; HRMS (ESI) 
m/z calcd for C15H19NO4 (M + Na)
+ 300.1206, found 300.1216 (–3.2 ppm error). 
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Lab Book Reference TD 2/56  
Procedure from ketonitrile 165 
PtO2 (20 mg, 0.09 mmol, 0.05 eq) was added to a stirred solution of nitrile 165 (276 mg, 
1.78 mmol, 1.0 eq) in AcOH (10 mL) at rt. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. Then, the reaction flask was evacuated under 
reduced pressure and back-filled with H2 three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 16 h. 
Then, the solids were removed by filtration through Celite. The solvent was evaporated 
under reduced pressure to give the crude product which contained an 80:20 mixture (by 1H 
NMR spectroscopy) of pyrrolidines 156 (as an 85:15 mixture of cis-156 and trans-156) and 
pyrrole 175. Et3N (0.93 mL, 0.67 mmol, 3.0 eq) was added dropwise to a stirred solution of 
the crude product in CH2Cl2 (10 mL) at 0 °C under Ar.  The resulting solution was stirred at 
0 °C for 30 min. Then, benzyl chloroformate (0.28 mL, 1.95 mmol, 1.1 eq) and DMAP (21 
mg, 0.17 mmol, 0.1 eq) were added. The resulting solution was allowed to warm to rt and 
was stirred at rt for 16 h. Then, H2O (10 mL) was added and the two layers were separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) and the combined organic extracts 
were dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave an 85:15 mixture (by 1H NMR spectroscopy) of pyrrolidines cis-162 and trans-162 (91 
mg, 18%) as a colourless oil. 
Lab Book Ref: TD 3/47 
1-tert-Butyl-4-methyl 2-methylpyrrolidine-1,4-dicarboxylate 152 
 
Hydrogenation of Alkene 157 
Using general procedure A, dihydropyrroles 157 (171 mg, 0.71 mmol, 1.0 eq) and 10% 
Pd(OH)2/C (100 mg, 0.071 mmol, 0.1 eq) in MeOH (10 mL) for 1 h gave the crude product. 
Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave a 55:45 mixture (by 1H NMR spectroscopy) of pyrrolidines cis-152 and trans-152 (168 
mg, 97%) as a colourless oil, RF (80:20 hexane-EtOAc) 0.19; IR (ATR) 1736 (C=O, 
CO2Me), 1691 (C=O, Boc), 1393, 1365, 1166 cm
–1; 1H NMR (400 MHz, CDCl3) (major 
diastereomer exists as a mixture of rotamers)  δ 4.10-3.90 (br m, 0.55 H, NCHMe), 3.91-
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3.71 (m, 1H, NCH), 3.694 (s, 1.35H, OMe), 3.688 (s, 1.65H, OMe), 3.63-3.51 (br m, 1H, 
NCH), 3.46 (dd, J = 11.0, 8.5 Hz, 0.45H, NCH), 3.20-3.04 (m, 0.55H CHCO2Me), 2.92 
(apparent quintet, J = 8.5 Hz, 0.45H CHCO2Me), 2.36 (ddd, J = 13.0, 7.5, 7.5 Hz, 0.45H, 
CH), 2.22 (br s, 0.55H, CH), 1.88-1.77 (m, 1H, CH), 1.44 (s, 9H, CMe3), 1.23 (br d, J = 6.0 
Hz, 1.35H, CHMe) 1.16 (d, J = 6.0 Hz, 1.65H, CHMe); 13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 173.8 (C=O, CO2Me), 173.6 (C=O, CO2Me), 154.2 (C=O, Boc), 79.5 (CMe3), 
79.4 (CMe3), 53.1 (NCHMe), 52.8 (NCHMe), 52.1 (OMe), 48.4 (NCH2), 42.0 (CHCO2Me), 
41.7 (CHCO2Me), 41.4 (CHCO2Me), 40.8 (CHCO2Me), 37.4 (CH2), 36.5 (CH2), 35.8 (CH2), 
28.6 (CMe3), 21.2 (CHMe), 20.9 (CHMe), 20.4 (CHMe), 20.3 (CHMe); MS (ESI) m/z 266 
[(M + Na)+, 100]; HRMS (ESI) m/z  calcd for C12H21NO4 (M + Na)
+ 266.1363, found 
266.1359 (+1.3 ppm error). 
Lab Book Ref: TD 2/81 
Boc Protection of Pyrrolidines 156•TfOH 
Et3N (0.93 mL, 0.66 mmol, 3.0 eq) was added dropwise to a stirred solution of a 65:35 
mixture of pyrrolidines trans-156•TfOH and cis-156•TfOH (65 mg, 0.22 mmol, 1.0 eq) in 
CH2Cl2 at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 30 min. Then, di-tert-
butyl dicarbonate (53 mg, 0.24 mmol, 1.1 eq) and DMAP (3 mg, 0.02 mmol, 0.1 eq) were 
added at 0 °C. The resulting mixture was allowed to warm to rt and stirred at rt for 64 h. 
Saturated NaHCO3(aq) (10 mL) was added and the aqueous layer was extracted with CH2Cl2 
(3 x 10 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column chromatography on 
silica with 80:20 hexane-EtOAc as eluent gave a 65:35 mixture (by 1H NMR spectroscopy) 
of pyrrolidines cis-152 and trans-152 (28 mg, 52%) as a colourless oil 
Lab Book Ref: TD 2/57 
Hydrogenation of Enol Triflate 161 
10% Pd/C (29 mg, 0.03 mmol, 0.05 eq) was added to a stirred solution of dihydropyrrole 
161 (200 mg, 0.56 mmol, 1.0 eq) and K2CO3 (85 mg, 0.61 mmol, 1.1 eq) in MeOH (10 mL) 
at rt. The reaction flask was evacuated under reduced pressure and back-filled with Ar three 
times. Then, the reaction flask was evacuated under reduced pressure and back-filled with 
H2 three times. After the final evacuation, H2 was charged and the reaction mixture was 
stirred vigorously under a H2 balloon at rt for 16 h. Then, the solids were removed by 
filtration through Celite. The solvent was evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 80:20 hexane-
EtOAc as eluent gave pyrrolidine cis-152 (15 mg, 8%) as a colourless oil. 
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Lab Book Ref: TD 2/64 
4-Methyl 1,2-dimethylpyrrolidine-4-carboxylate 37•AcOH 
 
37% aqueous formaldehyde (0.507 mL, 6.82 mmol, 10.0 eq) was added dropwise to a stirred 
suspension of a 65:35 mixture of pyrrolidines cis-156•TfOH and trans-156•TfOH (200 mg, 
0.682 mmol, 1.0 eq), NaBH(OAc)3 (434 mg, 2.05 mmol, 3.0 eq) and MgSO4 (507 mg, 4.21 
mmol, 6.18 eq) in 3:1 CH2Cl2–AcOH (12 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 1 h. The solids were removed by filtration and saturated NaHCO3(aq) was 
added to the filtrate until pH 9 was reached. The mixture was extracted with CH2Cl2 (3 x 10 
mL) and the combined organic extracts were washed with brine (10 mL) and dried (Na2SO4). 
Then, AcOH (0.04 mL, 0.68 mmol, 1.0 eq) was added dropwise to the filtrate which was 
stirred at rt for 30 min. The solvent was evaporated under reduced pressure to give a 75:25 
mixture (by 1H NMR spectroscopy) of AcOH and pyrrolidines 37•AcOH (65:35 mixture of 
cis-37•AcOH and trans-37•AcOH) (63 mg, 34 mg (23%) of pyrrolidines 37•AcOH) as a 
yellow oil, IR (ATR) 1729 (C=O), 1392, 1212 cm-1; 1H NMR (400 MHz, d4-MeOH) δ 3.94-
3.88 (m, 0.35H, NCH), 3.84-3.77 (m, 0.65H, NCH), 3.73-3.67 (m, 3H, OMe), 3.41-3.23 (m, 
3H, NCH, NCHMe, CHCO2Me), 2.81-2.75 (m, 3H, NMe), 2.62-2.51 (m, 0.35H, CH), 2.49-
2.41 (m, 0.65H, CH), 2.10-1.88 (m, 4H, CH, MeCO2
-), 1.38-1.34 (m, 3H, CHMe); 13C NMR 
(100.6 MHz, d4-MeOH) δ 175.7 (C=O, MeCO2
-) 173.2 (C=O, CO2Me), 172.8 (C=O, 
CO2Me), 64.4 (NCHMe), 63.4 (NCHMe), 55.8 (NCH2), 55.6 (NCH2), 51.7 (OMe), 39.3 
(CHCO2Me), 39.2 (CHCO2Me), 37.43 (NMe), 37.36 (NMe), 35.1 (CH2), 34.9 (CH2), 20.6 
(MeCO2
-), 13.7 (CHMe); MS (ESI) m/z 158 [M+, 100]; HRMS (ESI) m/z calcd for C8H16NO2 
M+ 158.1019, found 158.1016 (–1.7 ppm error). 
Lab Book Reference: TD 2/52 
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1-tert-Butyl-4-methyl 2-methyl-2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 157 
 
Detriflation with Triethylsilane and Pd(PPh3)4 
Triethylsilane (0.446 mL, 2.79 mmol, 2.0 eq) was added dropwise to a stirred solution of 
enol triflate 161 (500 mg, 1.40 mmol, 1.0 eq), tetrakis(triphenylphosphine)palladium (162 
mg, 0.1 eq, 0.14 mmol) and Et3N (0.777 mL, 5.58 mmol, 4.0 eq) in DMF (15 mL) at rt under 
Ar. The resulting mixture was stirred and heated at 75 °C for 2 h then allowed to cool to rt. 
Saturated NaHCO3(aq) and then H2O (20 mL) were added and the aqueous layer was extracted 
with Et2O (3 x 20 mL). The combined organic extracts were washed with H2O (5 x 20 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 80:20 hexane-EtOAc as eluent 
gave an 85:15 mixture of dihydropyrrole 157 and triethylsilane (190 mg, 56% of 
dihydropyrrole 157) as a yellow oil, RF (80:20 hexane-EtOAc) 0.33; IR (ATR) 2975, 1726 
(C=O, CO2Me), 1701 (C=O, Boc), 1394, 1284 cm
-1; 1H NMR (400 MHz, CDCl3) (55:45 
mixture of rotamers) δ 6.64-6.61 (m, 0.55H, =CH) 6.61-6.58 (m, 0.45H, =CH), 4.78-4.69 
(m, 0.55H, NCHMe), 4.67-4.59 (m, 0.45H, NCHMe), 4.37 (ddd, J = 15.5, 2.0, 2.0 Hz, 
0.45H, NCH), 4.31 (ddd, J = 15.5, 2.0, 2.0 Hz, 0.55H, NCH), 4.24 (m, 0.55H, NCH), 4.20 
(0.45H, m, NCH), 3.76 (s, 1.65H, OMe), 3.75 (s, 1.35H, OMe), 1.465 (s, 4.05H, CMe3), 
1.456 (s, 4.95H, CMe3), 1.33 (d, J = 6.5 Hz, 1.65H, CHMe) 1.29 (d, J = 6.5 Hz, 1.35H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 163.6 (C=O, CO2Me), 154.0 (C=O, Boc), 142.5 
(=CH), 142.3 (=CH), 130.4 (=C), 130.2 (=C), 79.9 (CMe3), 79.7 (CMe3), 60.8 (CMe), 60.6 
(CMe), 52.2 (NCH2), 51.9 (NCH2), 51.9 (OMe), 28.6 (CMe3), 20.1 (CHMe), 19.3 (CHMe); 
MS (ESI) m/z 264 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C12H19NO4 (M + Na)
+ 
264.1206, found 264.1209 (–0.9 ppm error). 
Lab Book Reference: TD 2/68 
Hydrogenation of Enol Triflate 161 with added Et3N  
10% Pd/C (90 mg, 0.08 mmol) was added to a stirred solution of enol triflate 161 (900 mg, 
2.51 mmol, 1 eq) and Et3N (0.39 mL, 2.76 mmol, 1.1 eq) in MeOH (25 mL) at rt. The 
reaction flask was evacuated under reduced pressure and back-filled with Ar three times, 
then with H2 three times. After the final evacuation, H2 was charged and the reaction mixture 
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was stirred vigorously under a H2 balloon at rt for 16 h. Then, the solids were removed by 
filtration through Celite. The solvent was evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 80:20 hexane-
EtOAc as eluent gave dihydropyrrole 157 (105 mg, 17%) as a yellow oil. 
Lab Book Reference: TD 2/60 
Methyl 1-benzyl-2-methylpyrrolidine-4-carboxylate 163 
 
Epimerisation of pyrrolidines 163 
K2CO3 (36 mg, 0.26 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
diastereomeric pyrrolidines cis-163 and trans-163 (50 mg, 0.21 mmol, 1.0 eq) in dry MeOH 
(2.5 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. Then, saturated 
NH4Cl(aq) (5 mL) was added and the mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give an 85:15 mixture of diastereomeric pyrrolidines cis-163 and trans-163 (50 mg, quant.) 
as a yellow oil, RF (80:20 hexane-EtOAc) 0.16; IR (ATR) 1734 (C=O), 1194, 1174, 737, 698 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.19 (m, 5H, Ph), 4.02 (d, J = 13.0 Hz, 0.15H, 
NCHPh), 4.01 (d, J = 13.5 Hz, 0.85H, NCHPh), 3.64 (s, 2.55H, OMe), 3.63 (s, 0.45H, OMe), 
3.22-3.10 (m, 2H, NCH, NCHPh), 2.99-2.92 (m, 0.15 H, CHCO2Me), 2.85 (dddd, J = 9.5, 
7.5, 6.5, 3.5 Hz, 0.85H, CHCO2Me), 2.58-2.44 (m, 1H, NCHMe), 2.36 (dd, J = 10.0, 9.5 Hz, 
0.85H, NCH), 2.32-2.15 (m, 1.15H, NCH, CH), 1.81 (ddd, J = 13.0, 9.5, 7.5 Hz, 0.85H, 
CH), 1.73 (ddd, J = 13.0, 11.0, 9.0 Hz, 0.15H, CH), 1.19-1.17 (m, 3H, CHMe); 13C NMR 
(100.6 MHz, CDCl3) δ 175.7 (C=O), 138.9 (ipso-Ph), 128.8 (Ph), 128.3 (Ph), 128.2 (Ph), 
127.1 (Ph), 126.9 (Ph), 59.4 (NCHMe), 58.0 (NCHMe), 57.2 (NCH2Ph), 57.0 (NCH2Ph), 
55.9 (NCH2), 51.93 (OMe), 51.86 (OMe), 40.0 (CHCO2Me), 36.6 (CH2), 36.4 (CH2), 18.9 
(CHMe), 18.4 (CHMe); MS (ESI) m/z 234 [(M + H)+, 100]; HRMS (ESI) m/z  calcd for 
C14H19NO2 (M + H)
+ 234.1489, found 234.1478 (–4.4 ppm error). 
Lab Book Reference: TD 3/26 
Boc Deprotection and Benzylaton of pyrrolidines 152 
TFA (0.165 mL, 2.16 mmol, 6.25 eq) was added dropwise to a stirred solution of a 60:40 
mixture of pyrrolidines cis-152 and trans-152 (84 mg, 0.345 mmol, 1.0 eq) in CH2Cl2 at rt 
under Ar. The resulting solution was stirred at rt for 4 h. Then, the solvent was evaporated 
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under reduced pressure to give the crude amine•TFA salt. NaBH(OAc)3 (136 mg, 0.64 
mmol, 2.0 eq) was added to a stirred solution of the crude amine•TFA salt, benzaldehyde 
(0.04 mL, 0.35 mmol, 1.1 eq) and AcOH (0.004 mL, 0.06 mmol, 0.2 eq) in dichloroethane 
(5 mL) at rt under Ar. The resulting solution was stirred at rt for 16 h. Then, saturated 
NaHCO3(aq) (10 mL) was added and the mixture was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica with 80:20 
hexane-EtOAc as eluent, with 1H NMR spectroscopy being performed on individual 
fractions to identify the fractions containing pure cis-163, gave N-benzyl pyrrolidine cis-163 
(8 mg, 10%) as a yellow oil and a 55:45 mixture (by 1H NMR spectroscopy) of pyrrolidines 
trans-163 and cis-163 (23 mg, 31%) as a yellow oil. 
Lab Book Reference: TD 2/82, 2/83 
K2CO3 (36 mg, 0.26 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
pyrrolidines cis-163 and trans-163 (50 mg, 0.21 mmol, 1.0 eq) in dry MeOH (2.5 mL) at rt 
under Ar. The resulting solution was stirred and heated at 60 °C for 16 h. Then, saturated 
NH4Cl(aq) (5 mL) was added and the mixture was extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give a 50:50 mixture of pyrrolidines cis-163 and trans-163 (11 mg, 22%) as a yellow oil. 
Lab Book Reference: TD 3/27 
4-Methyl N-(2-nitrophenyl)sulfonyl-2-methylpyrrolidine-4-carboxylate 164 
 
TFA (0.33 mL, 4.31 mmol, 6.25 eq) was added dropwise to a stirred solution of a 60:40 
mixture of pyrrolidines cis-152 and trans-152 (168 mg, 0.69 mmol, 1.0 eq) in CH2Cl2 (1.65 
mL) at rt under Ar. The resulting solution was stirred at rt for 4 h. Then, the solvent was 
evaporated under reduced pressure to give the crude amine•TFA salt. 2-Nosyl chloride (78 
mg, 0.35 mmol, 1.1 eq) was then added portionwise to a stirred solution of half of the crude 
amine•TFA salt (82 mg, 0.32 mmol, 1.0 eq) and Et3N (0.11 mL, 0.80 mmol, 2.5 eq) in 
CH2Cl2 (3 mL) at 0 °C under Ar. The resulting solution was allowed to warm to rt and stirred 
at rt for 16 h. Then, saturated NaHCO3(aq) (10 mL) was added and the two layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) and the combined 
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organic extracts were dried (Na2SO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 50:50 hexane-
EtOAc as eluent gave a 60:40 mixture (by 1H NMR spectroscopy) of pyrrolidines cis-164 
and trans-164 (23 mg, 20%) as a yellow oil, RF (50:50 hexane-EtOAc) 0.27; IR (ATR) 1732 
(C=O), 1542, 1162 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.05-7.98 (m, 1H, Ar), 7.73-7.55 
(m, 3H, Ar), 4.22-4.13 (m, 0.4H, NCHMe), 4.09-3.99 (ddq, J = 7.0, 6.5, 6.5 Hz, 0.6H, 
NCHMe), 3.88 (dd, J = 11.0, 8.0 Hz, 0.6H, NCH), 3.71 (dd, J = 10.5 Hz, 7.5 Hz, 0.4H, 
NCH), 3.68 (s, 1.8H, OMe) 3.66-3.60 (m, 1H, NCH), 3.59 (s, 1.2H, OMe), 3.17 (dddd, J = 
7.5, 7.5, 7.5, 7.5 Hz (apparent quintet), 0.4H, CHCO2Me), 2.97-2.87 (m, 0.6H, CHCO2Me), 
2.40 (ddd, J = 13.0, 7.5, 7.0 Hz, 0.6H, CH), 2.28-2.19 (ddd, J = 13.0, 8.0, 8.0 Hz, 0.4H, CH) 
1.91-1.81 (m, 1H, CH) 1.26 (d, J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 
172.7 (C=O), 172.5 (C=O), 148.4 (ipso-Ar), 148.3 (ipso-Ar), 133.8 (Ar), 133.7 (Ar), 133.0 
(Ar), 132.2 (Ar), 131.8 (Ar), 131.6 (Ar), 131.0 (Ar), 130.9 (Ar), 124.2 (Ar), 124.1 (Ar), 56.6 
(NCHMe), 56.4 (NCHMe), 52.31 (OMe), 52.28 (OMe), 50.6 (NCH2), 50.4 (NCH2), 42.4 
(CHCO2Me), 41.5 (CHCO2Me), 37.5 (CH2), 36.9 (CH2), 22.2 (CHMe), 21.7 (CHMe); MS 
(ESI) m/z 351 [(M + Na)+, 100], 329 [(M + H)+, 4%]; HRMS (ESI) m/z calcd for 
C13H16N2O6S (M + Na)
+ 351.0621, found 351.0604 (+4.9 ppm error). 
Lab Book Reference: TD 2/82, 2/84 
 
Methyl 2-cyano-5-oxopentanoate 165 
 
NaOMe (1.635 g, 30.27 mmol, 1.0 eq) was added to a stirred solution of methyl cyanoacetate 
(2.68 mL, 30.27 mmol, 1.0 eq) in MeOH (30 mL) at 0 °C under Ar. The resulting solution 
was stirred at 0 °C for 10 min. Then, chloroacetone (2.41 mL, 30.27 mmol, 1 eq) was added 
dropwise. The resulting solution was allowed to warm to rt and stirred at rt for 5 h. Saturated 
NH4Cl(aq) (20 mL) was added and the aqueous layer was extracted with EtOAc (3 x 20 mL). 
The combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica with 80:20 
hexane-EtOAc as eluent gave keto nitrile 165 (2.91 g, 62%) as a brown oil, RF (50:50 
hexane-EtOAc) 0.33; IR 2255 (C≡N), 1746 (C=O, CO2Me), 1716 (C=O, ketone), 1267, 
1167 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.95 (dd, J = 7.0, 5.5 Hz, 1H, CHCN), 3.82 (s, 
3H, OMe), 3.20 (dd, J = 18.5, 7.0 Hz, 1H, CHC(O)Me), 3.00 (dd, J = 18.5, 5.5 Hz, 1H, 
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CHC(O)Me), 2.24 (s, 3H, C(O)Me); 13C NMR (100.6 MHz, CDCl3) δ 202.5 (C=O, ketone), 
165.9 (C=O, CO2Me), 116.0 (C≡N), 54.0 (OMe), 42.1 (CH2), 31.3 (CH), 29.5 (C(O)Me); 
MS (ESI) m/z 156 [(M + H)+, 100]; HRMS (ESI) m/z  calcd for C7H9NO3 (M + H)
+ 156.0655, 
found 156.0654 (–1.0 ppm error). 
Lab Book Reference: TD 2/99 
1-Benzoyl-4-methyl 2-methylpyrrolidine-1,4-dicarboxylate 176 
 
LiOH (22 mg, 1.08 mmol, 3.0 eq) was added to a stirred solution of an 85:15 mixture of 
pyrrolidines cis-162 and trans-162 in 4:1:1 THF-H2O-MeOH (6 mL) at rt under Ar. The 
resulting solution was stirred at rt for 16 h. Then, 2 M HCl(aq) (10 mL) was added and the 
mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
basified to pH 9 with saturated NaHCO3(aq) and the mixture was washed with CH2Cl2 (2 x 
10 mL). The mixture was then acidified to pH 3 with 2 M HCl(aq) and extracted with CH2Cl2 
(3 x 10 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude acid intermeditae. Thionyl chloride (0.044 mL, 0.605 
mmol, 1.75 eq) was added to a stirred solution of the acid intermediate (91 mg, 1.0 eq) in 
EtOH (10 mL) at rt under Ar. The resulting mixture was stirred at rt for 16 h and then the 
solvent was evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (10 
mL) and washed with saturated NaHCO3(aq) (2 x 10 mL). The organic layer was dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica with 80:20 hexane-EtOAc as eluent gave an 85:15 
mixture of pyrrolidines cis-176 and trans-176 (44 mg, 46%) as a colourless oil, RF (80:20 
hexane-EtOAc) 0.17; 1H NMR (400 MHz, CDCl3) δ 7.38-7.24 (m, 5H, Ph), 5.18-5.03 (m, 
2H, OCH2Ph), 4.18-4.10 (m, 2H, OCH2Me), 4.00-3.75 (m, 1.85H, NCHMe, NCH), 3.70-
3.60 (m, 0.3H, NCH), 3.56 (dd, J = 11.0, 8.5 Hz, 0.85H, NCH) 3.19-3.08 (m, 0.15 H, 
CHCO2Me), 2.94 (dddd, J = 8.5, 8.5, 8.5, 8.5 Hz, 0.85H, CHCO2Me), 2.38 (ddd, J = 13.0, 
8.5, 8.5 Hz, 0.85H, CH), 2.31-2.19 (m, 0.15H, CH), 1.93-1.77 (m, 1H, CH), 1.32-1.19 (m, 
6H, CHMe, OCH2Me); 
13C NMR (100.6 MHz, CDCl3) 174.5 (C=O, CO2CH2), 154.6 (C=O, 
Cbz) 139.4 (ipso-Ar), 128.7 (Ar), 128.2 (Ar), 126.8 (Ar), 80.2 (OCH2Ph), 59.4 (CO2CH2), 
57.2 (NCHMe), 56.1 (NCH), 41.3 (CHCO2), 36.6 (CH2), 28.1 (CHMe), 18.60 (CH2Me). 
Spectroscopic data for cis-176 are consistent with those reported in the literature.92 
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Lab Book Reference: TD 3/48, TD 3/49 
Methyl 1-benzyl-2-methylpyrrolidine-4-carboxylate cis-163 
 
PtO2 (14 mg, 0.06 mmol, 0.05 eq) was added to a stirred solution of nitrile 165 (191 mg, 
1.23 mmol, 1.0 eq) in AcOH (5 mL) at rt. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. Then, the reaction flask was evacuated under 
reduced pressure and back-filled with H2 three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 16 h. 
Then, the solids were removed by filtration through Celite. The solvent was evaporated 
under reduced pressure and the residue dissolved in dichloroethane (10 mL). NaBH(OAc)3 
(0.52 g, 2.46 mmol, 2.0 eq), benzaldehyde (0.14 mL, 1.36 mmol, 1.1 eq) and AcOH (0.015 
mL, 0.25 mmol, 0.2 eq) were added at rt under Ar. The resulting solution was stirred at rt 
for 16 h. Then, saturated NaHCO3(aq) (25 mL) was added and the mixture was extracted with 
CH2Cl2 (3 x 25 mL). The combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent, with 1H NMR spectroscopy 
being performed on individual fractions to identify the fractions containing pure cis-163, 
gave N-benzyl pyrrolidine cis-163 (61 mg, 21%) as a yellow oil, RF (80:20 hexane-EtOAc) 
0.16; IR (ATR) 1733 (C=O), 1194, 1174, 737 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.19 
(m, 5H, Ph), 4.01 (d, J = 13.5 Hz, 1H, NCHPh), 3.64 (s, 3H, OMe), 3.19 (dd, J = 10.0, 3.5 
Hz, 1H, NCH), 3.19 (d, J = 13.5 Hz, 1H, NCHPh), 2.85 (dddd, J = 9.5, 7.5, 6.5, 3.5 Hz, 1H, 
CHCO2Me), 2.49 (ddq, J = 9.5, 9.5, 6.0 Hz, 1H, NCHMe), 2.36 (dd, J = 10.0, 9.5 Hz, 1H, 
NCH), 2.20 (ddd, J = 13.0, 9.5, 6.5 Hz, 1H, CH), 1.81 (ddd, J = 13.0, 9.5, 7.5 Hz, 1H, CH), 
1.18 (d, J = 6.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 175.7 (C=O), 139.0 (ipso-
Ph), 128.8 (Ph), 128.2 (Ph), 126.9 (Ph), 59.4 (NCHMe), 57.3 (NCH2Ph), 55.9 (NCH2), 51.9 
(OMe), 40.1 (CHCO2Me), 36.6 (CH2), 18.4 (CHMe); MS (ESI) m/z 234 [(M + H)
+, 100]; 
HRMS (ESI) m/z  calcd for C14H19NO2 (M + H)
+ 234.1489, found 234.1478 (–4.4 ppm error) 
and an 80:20 mixture (by 1H NMR spectroscopy) of diastereomeric pyrrolidines cis-163 and 
trans-163 (106 mg, 37%) as a yellow oil. 
Lab Book Reference: TD 2/92 
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Methyl 1-benzyl-2-methylpyrrolidine-4-carboxylate cis-163, Methyl 1-benzyl-2-
methylpyrrolidine-4-carboxylate trans-163 and tert-Butyl 1-benzyl-2-
methylpyrrolidine-4-carboxylate cis-182 
 
t-BuOK (29 mg, 0.26 mmol, 1.2 eq) was added to a stirred solution of an 85:15 mixture of 
pyrrolidines cis-163 and trans-163 (50 mg, 0.21 mmol, 1.0 eq) in THF (2.5 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 2 h. Then, H2O (5 mL) was added 
and the mixture was extracted with EtOAc (3 x 10 mL). The combined organic extracts were 
dried (Na2SO4) and evaporated under reduced pressure to give a 40:50:10 mixture of 
pyrrolidines cis-163, trans-163 and cis-182 (48 mg, 98%) as a yellow oil. 
Lab Book Reference: TD 3/29 
1-tert-Butyl-4-methyl 2-methylpyrrolidine-1,4-dicarboxylate 152 
 
Preparation from ketonitrile 165 
PtO2 (36 mg, 0.16 mmol, 0.05 eq) was added to a stirred solution of nitrile 165 (500 mg, 
3.23 mmol, 1.0 eq) in AcOH (30 mL) at rt. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. Then, the reaction flask was evacuated under 
reduced pressure and back-filled with H2 three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 16 h. 
Then, the solids were removed by filtration through Celite. The solvent was evaporated 
under reduced pressure and the residue dissolved in CH2Cl2 (40 mL) at 0 °C under Ar. Et3N 
(2.25 mL, 16.15 mmol, 5.0 eq) was added dropwise to the stirred solution. The resulting 
mixture was stirred at 0 °C for 30 min. Then, di-tert-butyl dicarbonate (775 mg, 3.55 mmol, 
1.1 eq) and DMAP (20 mg, 0.16 mmol, 0.1 eq) were added at 0 °C. The resulting mixture 
was allowed to warm to rt and stirred at rt for 64 h. Saturated NaHCO3(aq) (50 mL) was added 
and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 80:20 hexane-EtOAc 
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as eluent gave a 90:10 mixture (by 1H NMR spectroscopy) of pyrrolidines cis-152 and trans-
152 (377 mg, 48%) as a colourless oil 
Lab Book Ref: TD 3/35 
Epimerisation of pyrrolidines 152 
NaOMe (14 mg, 0.25 mmol, 1.2 eq) was added to a stirred solution of a 90:10 mixture of 
pyrrolidines cis-152 and trans-152 (50 mg, 0.21 mmol, 1.0 eq) in dry MeOH (2.5 mL) at rt 
under Ar. The resulting solution was stirred at rt for 16 h. Then, saturated NH4Cl(aq) (5 mL) 
was added and the mixture was extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure to give a 50:50 mixture 
of pyrrolidines cis-152 and trans-152 (50 mg, 100%) as a yellow oil. 




Procedure in t-BuOH as solvent 
t-BuOK (500 mg, 3.54 mmol, 1.0 eq) was added to a stirred solution of tert-butyl 
cyanoacetate (0.506 mL, 3.54 mmol, 1.0 eq) in t-BuOH (30 mL) heated at 40 °C under Ar. 
The resulting solution was stirred and heated at 40 °C for 10 min. Then, chloroacetone (2.41 
mL, 30.27 mmol, 1 eq) was added dropwise under Ar. The resulting solution was stirred and 
heated at 40 °C for 5 h. Saturated NH4Cl(aq) (20 mL) was added and the aqueous layer was 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave keto nitrile 183 (530 mg, 
76%) as a brown oil, RF (50:50 hexane-EtOAc) 0.51; IR (ATR) 2982, 2253 (C≡N), 1740 
(C=O, ketone), 1722 (C=O, CO2t-Bu), 1370, 1151 cm
-1; 1H NMR (400 MHz, CDCl3) δ 3.87-
3.83 (m, 1H, CHCN), 3.14 (dd, J = 18.0, 7.5 Hz, 1H, CHC(O)Me), 2.92 (dd, J = 18.0, 5.0 
Hz, 1H, CHCO), 2.22 (s, 3H, CHC(O)Me), 1.48 (s, 9H, CMe3); 
13C NMR (100.6 MHz, 
CDCl3) δ 202.7 (C=O, ketone), 164.1 (C=O, CO2t-Bu), 116.6 (C≡N), 84.6 (CMe3), 42.1 
(CH2), 32.5 (CH), 29.6 (C(O)Me), 27.8 (CMe3); MS (ESI) m/z 220 [(M + Na)
+, 100]; HRMS 
(ESI) m/z calcd for C10H15NO3 (M + Na)
+ 220.0944, found 220.0947 (–1.5 ppm error). 
Lab Book Reference: TD 3/18 
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Procedure in THF as solvent 
t-BuOK (500 mg, 3.54 mmol, 1.0 eq) was added to a stirred solution of tert-butyl 
cyanoacetate (0.506 mL, 3.54 mmol, 1.0 eq) in THF (30 mL) at 0 °C under Ar. The resulting 
solution was stirred at 0 °C for 10 min. Then, chloroacetone (2.41 mL, 30.27 mmol, 1 eq) 
was added dropwise. The resulting solution was allowed to warm to rt and stirred at rt for 5 
h. Saturated NH4Cl(aq) (20 mL) was added and the aqueous layer was extracted with EtOAc 
(3 x 20 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column chromatography on 
silica with 80:20 hexane-EtOAc as eluent gave keto nitrile 183 (437 mg, 63%) as a brown 
oil. 
Lab Book Reference: TD 3/19 
 
tert-Butyl 1-benzyl-2-methylpyrrolidine-4-carboxylate cis-182 
 
PtO2 (103 mg, 0.45 mmol, 0.05 eq) was added to a stirred solution of nitrile 183 (1.79 g, 
9.05 mmol, 1.0 eq) in AcOH (40 mL) at rt. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. Then, the reaction flask was evacuated under 
reduced pressure and back-filled with H2 three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously under a H2 balloon at rt for 16 h. 
Then, the solids were removed by filtration through Celite. The solvent was evaporated 
under reduced pressure to give the crude product which contained an 80:20 mixture (by 1H 
NMR spectroscopy) of pyrrolidine cis-45 and pyrrole 184. NaBH(OAc)3 (3.84 g, 18.1 mmol, 
2.0 eq) was added to a stirred solution of the crude mixture of pyrrolidines cis-45•AcOH and 
pyrrole 184, benzaldehyde (1.02 mL, 9.96 mmol, 1.1 eq) and AcOH (0.10 mL, 1.81 mmol, 
0.2 eq) in dichloroethane (100 mL) at rt under Ar. The resulting solution was stirred at rt for 
16 h. Then, saturated NaHCO3(aq) (100 mL) was added and the mixture was extracted with 
CH2Cl2 (3 x 100 mL). The combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 90:10 hexane-EtOAc as eluent gave N-benzyl pyrrolidine cis-
182 (756 mg, 30%) as a yellow oil, RF (90:10 hexane-EtOAc) 0.21; IR (ATR) 2971, 1728 
(C=O), 1367, 1150 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34-7.18 (m, 5H, Ph), 4.00 (d, J = 
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13.5 Hz, 1H, NCHPh), 3.16 (d, J = 13.5 Hz, 1H, NCHPh), 3.14 (dd, J = 10.0, 3.5 Hz, 1H, 
NCH), 2.74 (dddd, J = 9.0, 7.0, 6.5, 3.5 Hz, 1H, CHCO2), 2.48 (ddq, J = 9.0, 9.0, 6.0 Hz, 
1H, NCHMe), 2.30 (dd, J = 10.0, 9.0 Hz, 1H, NCH), 2.14 (ddd, J = 13.0, 9.0, 6.5 Hz, 1H, 
CH), 1.77 (ddd, J = 13.0, 9.0, 7.0 Hz, 1H, CH), 1.40 (s, 9H, CMe3) 1.18 (d, J = 6.0 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) δ 174.5 (C=O), 139.4 (ipso-Ph), 128.7 (Ph), 128.2 
(Ph), 126.8 (Ph), 80.2 (CMe3) 59.4 (NCHMe), 57.2 (NCH2Ph), 56.1 (NCH2), 41.3 (CHCO2), 
36.6 (CH2), 28.1 (CMe3), 18.6 (CHMe); MS (ESI) m/z 276 [(M + H)
+, 100]; HRMS (ESI) 
m/z  calcd for C17H25NO2 (M + H)
+ 276.1958, found 276.1957 (0.2 ppm error). 
Lab Book Reference: TD 3/59 
 
tert-Butyl 2-methylpyrrolidine-4-carboxylate cis-45•AcOH 
 
10% Pd(OH)2/C (10 mg, 0.007 mmol, 0.01 eq) was added to a stirred solution of pyrrolidine 
cis-182 (200 mg, 0.73 mmol, 1 eq) and ammonium formate (229 mg, 3.63 mmol, 5 eq) in 
MeOH (10 mL) at rt under Ar. The resulting solution was stirred and heated to 60 °C for 2 
h. After being allowed to cool to rt, the solids were removed by filtration through Celite. 
AcOH (0.087 mL, 1.46 mmol, 2.0 eq) was added dropwise to the filtrate which was stirred 
at rt for 30 min. The solvent was evaporated under reduced pressure. Then, the residue was 
dissolved in CH2Cl2 and the solids were removed by filtration. The filtrate was evaporated 
under reduced pressure to give a 65:35 mixture (by 1H NMR spectroscopy) of AcOH and 
pyrrolidine cis-45•AcOH (198 mg (141 mg, 79% of pyrrolidines cis-45•AcOH) as a brown 
oil, IR (ATR) 2979, 1724 (C=O), 1367, 1153 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.72-3.62 
(m, 1H, NCHMe), 3.49-3.37 (m, 2H, NCH), 3.13 (dddd, J = 8.5, 8.5, 8.5, 8.5 Hz (apparent 
quintet), 1H, CHCO2), 2.40 (ddd, 13.5, 8.5, 6.5 Hz, 1H, CH), 2.03 (s, 9H, MeCO2
–), 1.81 
(ddd, J = 13.5, 8.5, 8.5 Hz, 1H, CH), 1.43 (s, 9H, CMe3), 1.38 (d, J = 6.5 Hz, CHMe); 
13C 
NMR (100.6 MHz, CDCl3) δ 177.0 (C=O, MeCO2
–), 171.3 (C=O, CO2CMe3), 82.1 (CMe3), 
55.5 (CHMe), 46.2 (NCH), 43.3 (CHCO2), 36.2 (CH2), 28.0 (CMe3), 21.7 (MeCO2
–), 17.5 
(CHMe); MS (ESI) m/z 186 [M+, 100]; HRMS (ESI) m/z calcd for C10H21NO2 M
+ 186.1489, 
found 186.1491 (–1.6 ppm error). 
Lab Book Reference: TD 3/67 
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tert-Butyl 1,2-dimethylpyrrolidine-4-carboxylate cis-46•AcOH 
 
37% aqueous formaldehyde (1.52 mL, 20.4 mmol, 10.0 eq) was added dropwise to a stirred 
suspension of pyrrolidine cis-45•AcOH (500 mg, 2.04 mmol, 1.0 eq), NaBH(OAc)3 (1.30 g, 
6.12 mmol, 3.0 eq) and MgSO4 (1.52 g, 12.6 mmol, 6.18 eq) in 3:1 CH2Cl2–AcOH (20 mL) 
at rt under Ar. The resulting mixture was stirred at rt for 1 h. The solids were removed by 
filtration and NaHCO3(aq) was added to the filtrate until pH 9 was reached. The mixture was 
extracted with CH2Cl2 (3 x 20 mL) and the combined organic extracts were washed with 
brine (20 mL) and dried (Na2SO4). AcOH (0.12 mL, 2.04 mmol, 1.0 eq) was added dropwise 
to the filtrate which was stirred at rt for 30 min. The solvent was evaporated under reduced 
pressure to give a 65:35 mixture (by 1H NMR spectroscopy) of AcOH and pyrrolidine cis-
46•AcOH  (124 mg, 85 mg (16%) of pyrrolidine cis-46•AcOH) as a yellow oil, IR (ATR) 
2977, 1726 (C=O), 1368, 1252, 1155 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.53 (dd, J = 10.5, 
5.0 Hz, 1H, NCH), 3.20-3.01 (m, 3H, NCH, NCHMe, CHCO2C), 2.56 (s, 3H, NMe), 2.38 
(ddd, J = 13.5, 9.5, 6.5 Hz, 1H, CH), 2.02 (br s, 9H, MeCO2
-), 1.95 (ddd, J = 13.5, 9.0, 7.5 
Hz, 1H, CH), 1.43 (s, 9H, CMe3), 1.27 (d, J = 6.5 Hz, 3H, CMe); 
13C NMR (100.6 MHz, 
CDCl3) δ 176.4 (C=O, MeCO2
-) 172.0 (C=O, CO2CMe3), 81.8 (CMe3), 61.8 (NCHMe), 56.0 
(NCH), 41.0 (CHCO2), 37.7 (NMe), 35.5 (CH2), 28.0 (CMe3) 21.6 (MeCO2
-), 15.2 (CHMe); 
MS (ESI) m/z 200 [M+, 100]; HRMS (ESI) m/z calcd for C11H23NO2 M
+ 200.1646, found 
200.1645 (–0.6 ppm error). 
Lab Book Reference: TD 3/52 
tert-Butyl 1-acetyl-2-methylpyrrolidine-4-carboxylate cis-48 
 
Methanesulfonyl chloride (0.474 mL, 3.0 eq, 6.12 mmol) was added dropwise to a stirred 
solution of pyrrolidine salt cis-45•AcOH (500 mg, 1.0 eq, 2.04 mmol) and Et3N (1.135 mL, 
4.0 eq, 8.16 mmol) in CH2Cl2 (20 mL) at rt. The resulting solution was stirred at rt for 3 h. 
Saturated NaHCO3(aq) (20 mL) was added and the aqueous layer was extracted with CH2Cl2 
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(3 x 20 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column chromatography on 
silica with 50:50 hexane-EtOAc, then EtOAc and then 80:20 EtOAc-MeOH as eluent gave 
pyrrolidine cis-48 (242 mg, 52%) as a red oil, RF (50:50 hexane-EtOAc) 0.16; IR (ATR) 
1724 (C=O, CO2CMe3), 1631 (C=O, NC(O)Me), 1418, 1368, 1154 cm
–1; 1H NMR (400 
MHz, CDCl3) (65:35 mixture of rotamers) δ 4.10 (ddq, J = 6.5, 6.5, 6.5 Hz, 0.65H, NCHMe), 
4.00 (dd, J = 12.5, 8.5 Hz, 0.35H, NCH), 3.97-3.90 (m, 0.35H, NCHMe), 3.70 (dd, J = 10.5, 
7.5 Hz, 0.65H, NCH), 3.60 (dd, J = 10.5, 8.0 Hz, 0.65H, NCH), 3.52 (dd, J = 12.5, 7.0 Hz, 
0.35H, NCH), 2.96-2.84 (m, 1H, CHCO2Me), 2.44-2.29 (m, 1H, CH), 2.05 (s, 1.05H, 
NC(O)Me), 2.03 (s, 1.95H, NC(O)Me), 2.00-1.94 (m, 0.35H, CH), 1.82 (ddd, J = 13.5, 7.5, 
6.0 Hz, 0.65H, CH), 1.44 (s, 5.85H, CMe3), 1.43 (s, 3.15H, CMe3), 1.22 (d, J = 6.5 Hz, 3H, 
CHMe); 13C NMR (100.6 MHz, CDCl3) (rotamers) 172.5 (C=O, NC(O)Me), 172.2 (C=O, 
NC(O)Me), 169.08 (C=O, CO2CMe3), 169.05 (C=O, CO2CMe3), 81.5 (CMe3), 81.3 (CMe3), 
53.8 (NCHMe), 52.9 (NCHMe), 49.3 (NCH2), 47.2 (NCH2), 43.5 (CHCO2), 42.2 (CHCO2), 
36.7 (CH2), 36.2 (CH2), 28.1 (CMe3), 23.2 (NC(O)Me), 21.8 (Me), 21.7 (Me), 20.0 (CMe); 
MS (ESI) m/z 228 [(M + H)+, 15], 250 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for 
C12H21NO3 (M + Na)
+ 250.1414, found 250.1425 (–4.5 ppm error). 
Lab Book Reference: TD 3/53 
tert-Butyl 1-methanesulfonyl-2-methylpyrrolidine-4-carboxylate cis-47 
 
 
Methanesulfonyl chloride (0.032 mL, 1.0 eq, 0.40 mmol) was added dropwise to a stirred 
solution of pyrrolidine salt cis-45•AcOH (100 mg, 1.0 eq, 0.40 mmol) in pyridine (10 mL) 
at 0 °C. The resulting solution was stirred at 0 °C for 1 h then allowed to warm to rt and 
stirred at rt for 16 h. The resulting mixture was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 50:50 hexane-
EtOAc as eluent gave pyrrolidine cis-47 (89 mg, 83%) as a red oil, RF (50:50 hexane-EtOAc) 
0.32; IR (ATR) 1725 (C=O), 1332, 1150 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.90 (ddq, J 
= 6.5, 6.5, 6.5 Hz, 1H, NCHMe), 3.70 (dd, J = 11.0, 8.0 Hz, 1H, NCH), 3.54 (dd, J = 11.0, 
8.5 Hz, 1H, NCH), 2.97-2.88 (m, 1H, CHCO2), 2.87 (s, 3H, SO2Me), 2.41 (ddd, J = 13.0, 
7.5, 6.5 Hz, 1H, CH), 1.88 (ddd, J = 13.0, 9.0, 6.5 Hz, 1H, CH), 1.46 (s, 9H, CMe3), 1.36 (d, 
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J = 6.5 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 171.4 (C=O), 81.7 (CMe3), 56.2 
(NCHMe), 50.2 (NCH2), 43.7 (CHCO2), 37.8 (SO2Me), 37.6 (CH2), 28.1 (CMe3), 22.0 
(CHMe); MS (ESI) m/z 286 [(M + Na)+, 100]; HRMS (ESI) m/z  calcd for C11H21NO4S (M 
+ Na)+ 286.1083, found 286.1085 (–0.5 ppm error). 
Lab Book Reference: TD 3/55 
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Table 5.1 Crystal data and structure refinement for cis-47.  
Identification code  paob1913  
Empirical formula  C11H21NO4S  
Formula weight  263.35  
Temperature/K  110.00(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  5.95574(9)  
b/Å  9.69965(14)  
c/Å  23.4296(3)  
α/°  90  
β/°  96.7003(13)  
γ/°  90  
Volume/Å3  1344.25(3)  
Z  4  
ρcalcg/cm
3  1.301  
μ/mm-1  0.244  
F(000)  568.0  
Crystal size/mm3  0.364 × 0.126 × 0.042  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.726 to 59.15  
Index ranges  -8 ≤ h ≤ 8, -13 ≤ k ≤ 13, -32 ≤ l ≤ 32  
Reflections collected  15370  
Independent reflections  3778 [Rint = 0.0278, Rsigma = 0.0248]  
Data/restraints/parameters  3778/0/159  
Goodness-of-fit on F2  1.047  
Final R indexes [I>=2σ (I)]  R1 = 0.0328, wR2 = 0.0812  
Final R indexes [all data]  R1 = 0.0392, wR2 = 0.0853  
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5.2.3 Synthetic Procedures for Chapter 3 
Methyl 2-trifluoromethylsulfonylcyclopent-1-ene-1-carboxylate 197 
 
Using general procedure B, iPr2NEt (12.9 mL, 73.9 mmol, 5.0 eq), ester 193 (2.01 g, 14.8 
mmol, 1.0 eq) and trifluoromethanesulfonic anhydride (2.98 mL, 17.7 mmol, 1.2 eq) in 
CH2Cl2 (100 mL) gave the crude product. Purification by flash column chromatography with 
70:30 hexane-Et2O as eluent gave enol triflate 197 (3.55 g, 92%) as an orange oil, RF (70:30 
hexane-Et2O) 0.24; 
1H NMR (400 MHz, CDCl3) δ 3.78 (s, 3H, OMe), 2.77-2.66 (m, 4H, 
CH2), 2.01 (tt, J = 7.5, 7.5 Hz, 2H, CH2); 
13C NMR (100.6 MHz, CDCl3) δ 162.8 (C=O), 
154.1 (=CO), 123.1 (=CCO2Me), 118.4 (q, J = 320.0 Hz, CF3), 51.9 (OMe), 32.8 (CH2), 
29.2 (CH2), 18.9 (CH2). Spectroscopic data are consistent with those reported in the 
literature.81 
Lab Book Reference: TD 4/36 
1-tert-Butyl-3-methyl 4-hydroxy-1,2,5,6-tetrahydropyridine-1,3-dicarboxylate 196a 
 
Et3N (6.33 mL, 45.5 mmol, 2.0 eq) was added dropwise to a stirred solution of methyl 4-
oxopiperidine-3-carboxylate hydrochloride (4.40 g, 22.72 mmol, 1.0 eq) in THF (100 mL) 
at rt under Ar. The resulting solution was stirred at rt for 10 min. Then, di-tert-butyl 
dicarbonate (5.46 g, 25.0 mmol, 1.1 eq) was added to the stirred solution at rt under Ar. The 
resulting solution was stirred at rt for 16 h and then the solvent was evaporated under reduced 
pressure.  The residue was dissolved in CH2Cl2 (100 mL) and washed with H2O (2 x 100 
mL). The organic layer was dried (Na2SO4) and evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 80:20 hexane-
EtOAc as eluent gave tetrahydropyridine 196a (5.57 g, 95%) as a white solid, mp 46-50 °C; 
RF (EtOAc) 0.67; 
1H NMR (400 MHz, CDCl3) δ 11.97 (s, 1H, OH), 4.05 (br s, 2H, NCH2), 
3.78 (s, 3H, OMe), 3.56 (t, J = 6.0 Hz, 2H, NCH2), 2.37 (t, J = 6.0 Hz, 2H, CH2), 1.47 (s, 
9H, CMe3); 
13C NMR (100.6 Hz, CDCl3) δ 171.4 (C=O, CO2Me), 169.8 (=COH), 154.4 
(C=O, Boc), 96.1 (=C), 80.1 (CMe3), 51.6 (OMe), 40.4 (NCH2), 39.2 (NCH2), 28.9 (CH2), 
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28.5 (CMe3). The crude material was sufficiently pure for use without further purification. 




Using general procedure B, iPr2NEt (18.9 mL, 108.2 mmol, 5.0 eq), ester 196 (5.57 g, 21.6 
mmol, 1.0 eq) and trifluoromethanesulfonic anhydride (4.37 mL, 26.0 mmol, 1.2 eq) in 
CH2Cl2 (200 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane-EtOAc as eluent gave enol triflate 200 (7.57 g, 90%) as a yellow solid, mp 42-
45 °C; RF (80:20 hexane-EtOAc) 0.27; IR (ATR) 1722 (C=O, CO2Me), 1701 (C=O, Boc), 
1609 (C=C), 1421, 1207 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.26 (br s, 2H, NCH2), 3.82 
(s, 3H, OMe), 3.61 (t, J = 5.5 Hz, 2H, NCH2), 2.50 (tt, J = 5.5, 2.5 Hz, 2H, CH2), 1.46 (s, 
9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 162.9 (C=O, CO2Me), 154.1 (C=O, Boc), 
150.9 (=CO), 120.5 (=C), 118.3 (q, J = 320 Hz, CF3), 81.1 (CMe3), 52.5 (OMe), 43.1 
(NCH2), 39.4 (NCH2), 29.0 (CH2), 28.4 (CMe3); MS (ESI) m/z 412 [(M + Na)
+, 100]; HRMS 
(ESI) m/z calcd for C13H18F3NO7S (M + Na)
+ 412.0648, found 412.0648 (+0.2 ppm error). 
Lab Book Reference: TD 3/99 
1-tert-Butyl 4-methyl 3-phenyl-2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 210 
 
Procedure with THF as solvent 
K2CO3 (1.84 g, 13.3 mmol, 2.5 eq) was added portionwise to a stirred mixture of enol triflate 
99 (2.00 g, 5.33 mmol, 1.0 eq) and phenylboronic acid (975 mg, 7.99 mmol, 1.5 eq) in THF 
(50 mL) at rt. The reaction flask was evacuated under reduced pressure and back-filled with 
Ar three times. Then, Pd(PPh3)4 (616 mg, 0.53 mmol, 0.1 eq, 10 mol%) was added and the 
resulting mixture was stirred and heated at 65 °C for 40 h. The mixture was allowed to cool 
to rt and H2O (100 mL) was added. The aqueous layer was extracted with EtOAc (3 x 100 
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mL).  The combined organic extracts were dried (Na2SO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on silica 
with 90:10 hexane-EtOAc as eluent gave dihydropyrrole 210 (528 mg, 33%) as a white solid, 
mp 119-122 °C; RF (80:20 hexane-EtOAc) 0.28; IR (ATR) 1712 (C=O, CO2Me), 1693 
(C=O, Boc), 1646 (C=C), 1404, 1122 cm–1; 1H NMR (400 MHz, CDCl3) (55:45 mixture of 
rotamers) δ 7.38-7.35 (m, 5H, Ph), 4.60-4.48 (m, 4H, NCH), 3.66 (s, 3H, OMe), 1.49 (s, 
4.95H, CMe3), 1.47 (s, 4.05H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 174.0 
(C=O, CO2Me), 173.9 (C=O, CO2Me), 153.8 (C=O, Boc), 148.5 (=CPh), 132.9 (ipso-Ph), 
132.8 (ipso-Ph), 129.3 (Ph), 129.2 (Ph), 128.2 (Ph), 128.0 (Ph), 123.5 (=CCO2Me), 80.1 
(CMe3), 80.0 (CMe3), 58.4 (NCH2), 58.1 (NCH2), 54.8 (NCH2), 54.6 (NCH2), 51.7 (OMe), 
51.6 (OMe), 29.8 (CMe3), 28.6 (CMe3); MS (ESI) m/z 326 [(M + Na)
+, 100]; HRMS (ESI) 
m/z calcd for C17H21NO4 (M + Na)
+ 326.1363, found 326.1369 (–1.2 ppm error). 
Lab Book Reference: TD 3/68 
Procedure using 4:1 THF–H2O as solvent 
Using general procedure C, enol triflate 99 (1.00 g, 2.66 mmol, 1.0 eq), phenylboronic acid 
(488 mg, 4.00 mmol, 1.5 eq), Pd(PPh3)4 (308 mg, 0.266 mmol, 0.1 eq) and K2CO3 (920 mg, 
6.66 mmol, 2.5 eq) in THF (80 mL) and H2O (20 mL) gave the crude product. Purification 
by flash column chromatography with 90:10 hexane-EtOAc gave ester 210 (666 mg, 83%) 
as a white solid. 
Lab Book Reference: TD 3/86 
1-tert-Butyl-4-methyl 3-(2-furyl)-2,5-dihydro-1H-pyrrole-1,4-dicarboxylate 211 
 
Using general procedure C, enol triflate 99 (1.74 g, 4.62 mmol, 1.0 eq), 2-furylboronic acid 
(776 mg, 6.93 mmol, 1.5 eq), Pd(PPh3)4 (534 mg, 0.462 mmol, 0.1 eq) and K2CO3 (1.60 g, 
11.6 mmol, 2.5 eq) in THF (80 mL) and H2O (20 mL) gave the crude product. Purification 
by flash column chromatography with 90:10 hexane-EtOAc gave ester 211 (980 mg, 72%) 
as a white solid, mp 135-138 °C; RF 0.16 (90:10 hexane-EtOAc); IR (ATR) 1701 (C=O, 
Boc, CO2Me), 1623 (C=C), 1406, 1245; 
1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 7.78 (d, J = 3.5 Hz, 0.5H, Ar), 7.72 (d, J = 3.5 Hz, 0.5H, Ar), 7.49 (br s, 1H, Ar), 
6.56-6.52 (m, 1H, Ar), 4.78-4.74 (m, 1H, NCH2), 4.73-4.69 (m, 1H, NCH2), 4.54-4.50 (m, 
Experimental 
 199  
1H, NCH2), 4.49-4.45 (m, 1H, NCH2), 3.81 (s, 1.5H, OMe), 3.80 (s, 1.5H, OMe), 1.514 (s, 
4.5H, CMe3), 1.510 (s, 4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 163.50 
(C=O, CO2Me), 163.46 (C=O, CO2Me), 153.9 (C=O, Boc), 153.8 (C=O, Boc), 147.6 (ipso-
Ar), 144.0 (Ar), 143.7 (Ar), 136.6 (=CAr), 119.1 (=CCO2Me), 118.8  (=CCO2Me), 116.9 
(Ar), 112.5 (Ar), 112.4 (Ar), 80.0 (CMe3), 55.2 (NCH2), 54.4 (NCH2), 54.3 (NCH2), 51.7 
(OMe), 51.6 (OMe), 28.6 (CMe3); MS (ESI) m/z 316 [(M + Na), 100]; HRMS (ESI) m/z 
calcd for C15H19NO5 (M + Na)
+ 316.1155, found 316.1150 (+1.2 ppm error). 




Using general procedure C, enol triflate 99 (709 g, 1.97 mmol, 1 eq.), 2-fluorophenylboronic 
acid (414 mg, 2.96 mmol, 1.5 eq), Pd(PPh3)4 (228 mg, 0.20 mmol, 0.1 eq) and K2CO3 (681 
mg, 4.93 mmol, 2.5 eq) in THF (16 mL) and H2O (4 mL) gave the crude product. Purification 
by flash column chromatography on silica with 80:20 hexane-EtOAc as solvent gave ester 
212 (363 mg, 57%) as a yellow solid, mp 121-124 °C; RF (80:20 hexane-EtOAc) 0.24; IR 
(ATR) 1715 (C=O, CO2Me), 1692 (C=O, Boc), 1653 (C=C), 1408, 1123 cm
–1; 1H NMR 
(400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.37-7.30 (m, 1H, Ar), 7.27-7.20 (m, 1H, 
Ar), 7.17-7.11 (m, 1H, Ar), 7.11-7.05 (m, 1H, Ar), 4.57-4.46 (m, 4H, NCH2), 3.64 (s, 3H, 
OMe), 1.49 (s, 4.5H, CMe3), 1.45 (s, 4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 163.2 (C=O, CO2Me), 163.1 (C=O, CO2Me), 159.4 (d, J = 249.0 Hz, CF), 154.0 
(C=O, Boc), 153.8 (C=O, Boc), 142.7 (=CAr), 142.52 (=CAr), 130.71 (d, J = 8.5 Hz, Ar), 
130.68 (d, J = 8.5 Hz, Ar), 129.7 (d, J = 2.5 Hz, Ar), 129.5 (d, J = 2.5 Hz, Ar), 126.94 
(=CCO2Me), 126.85 (=CCO2Me), 123.9 (br s, Ar), 121.2 (d, J = 15.5 Hz, ipso-Ar), 115.8 
(d, J = 22.0 Hz, Ar), 80.1 (CMe3), 80.0 (CMe3), 57.8 (d, J = 1.5 Hz, NCH2), 57.6 (d, J = 1.5 
Hz, NCH2), 54.2 (NCH2), 53.9 (NCH2), 51.7 (OMe), 28.5 (CMe3); MS (ESI) m/z 344 [(M + 
Na), 100]; HRMS (ESI) m/z calcd for C17H20FNO4 (M + Na)
+ 344.1269, found 344.1271 (–
0.8 ppm error). 
Lab Book Reference: TD 5/23  
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Methyl 2-(3-pyridyl)-cyclopent-1-enecarboxylate 213 
 
Using general procedure C, enol triflate 197 (100 mg, 0.37 mmol, 1.0 eq), 3-pyridyl boronic 
acid (67 mg, 0.55 mmol, 1.5 eq), Pd(PPh3)4 (42 mg, 0.037 mmol, 0.1 eq) and K2CO3 (126 
mg, 0.91 mmol, 2.5 eq) in THF (4 mL) and H2O (1 mL) gave the crude product. Purification 
by flash column chromatography with 50:50 hexane-EtOAc gave ester 213 (26 mg, 35%) as 
a yellow oil, RF (50:50 hexane-EtOAc) 0.18; IR (ATR) 2950, 1709 (C=O), 1632 (C=C), 
1434, 1234 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.55 (br s, 1H, Ar), 8.51 (br d, J = 4.5 Hz, 
1H, Ar), 7.67 (ddd, J = 8.0, 2.0, 2.0 Hz, 1H, Ar), 7.26 (dd, 8.0, 4.5 Hz, 1H, Ar), 3.63 (s, 3H, 
OMe), 2.86 (m, 4H, =CCH2), 2.02 (tt, J = 8.0, 8.0 Hz, 2H, CH2); 
13C NMR (400 MHz, 
CDCl3) δ 166.0 (C=O), 150.4 (=CAr), 148.9 (Ar), 148.7 (Ar), 135.3 (Ar), 132.9 (ipso-Ar), 
130.9 (=CCO2Me), 122.7 (Ar), 51.4 (OMe), 40.0 (=CCH2), 35.1 (=CCH2), 21.9 (CH2); MS 
(ESI) m/z 204 [(M + H), 100]; HRMS (ESI) m/z calcd for C12H13NO2 (M + H)
+ 204.1019, 
found 204.1022 (–1.3 ppm error). 
Methyl 2-(5-pyrimidyl)-cyclopent-1-enecarboxylate 214 
 
Using general procedure C, triflate 197 (200 mg, 0.73 mmol, 1.0 eq), pyrimidine-5-boronic 
acid (136 mg, 1.09 mmol, 1.5 eq), Pd(PPh3)4 (84 mg, 0.073 mmol, 0.1 eq) and K2CO3 (252 
mg, 1.83 mmol, 2.5 eq) in THF (8 mL) and H2O (2 mL) gave the crude product. Purification 
by flash column chromatography with 50:50 hexane-EtOAc gave ester 214 (122 mg, 81%) 
as a white solid, mp 79-82 °C; RF (50:50 hexane-EtOAc) 0.17; IR (ATR) 1708 (C=O), 1630 
(C=C), 1416, 1254 cm–1; 1H NMR (400 MHz, CDCl3) δ 9.13 (s, 1H, Ar), 8.72 (s, 2H, Ar), 
3.66 (s, 3H, OMe), 2.88 (m, 4H, =CCH2), 2.06 (tt, J = 7.5, 7.5 Hz, 2H, CH2); 
13C NMR 
(100.6 MHz, CDCl3) δ 165.5 (C=O), 157.8 (Ar), 155.6 (Ar), 146.8 (=CAr), 132.9 
(=CCO2Me), 131.0 (ipso-Ar), 51.6 (OMe), 39.7 (=CCH2), 35.0 (=CCH2), 21.9 (CH2); MS 
(ESI) m/z 205 [(M + H), 100]; HRMS (ESI) m/z calcd for C11H12N2O2 (M + H)
+ 205.0972, 
found 205.0974 (–0.3 ppm error). 
Lab Book Ref.: TD 4/38 
Experimental 
 201  
Lab Book Reference: TD 4/41 
Methyl 2-(3-N-methylpyrazole)-cyclopent-1-enecarboxylate 215 
 
Using general procedure C, enol triflate 197 (100 mg, 0.37 mmol, 1.0 eq), 3-(N-
methylpyrazole)boronic acid (69 mg, 0.55 mmol, 1.5 eq), Pd(PPh3)4 (42 mg, 0.037 mmol, 
0.1 eq) and K2CO3 (126 mg, 0.91 mmol, 2.5 eq) in THF (4 mL) and H2O (1 mL) gave the 
crude product. Purification by flash column chromatography with 50:50 hexane-EtOAc gave 
ester 215 (66 mg, 88%) as an orange oil, RF (50:50 hexane-EtOAc) 0.19; IR (ATR) 2950, 
1708 (C=O), 1631 (C=C), 1234 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H, Ar), 7.74 
(s, 1H, Ar), 3.91 (s, 3H, NMe), 3.75 (s, 3H, OMe), 2.89 (tt, J = 8.0 Hz, 2.0 Hz, 2H, =CCH2), 
2.77 (tt, J = 8.0 Hz, 2.0 Hz, 2H, =CCH2), 1.91 (tt, J = 8.0, 8.0 Hz, 2H, CH2); 
13C NMR (100.6 
MHz, CDCl3) δ 166.8 (C=O), 145.2 (=CAr), 140.5 (Ar), 132.4 (Ar), 123.7 (=CCO2Me), 
117.2 (ipso-Ar), 51.2 (OMe), 39.1 (NMe), 38.5 (=CCH2), 34.9 (=CCH2), 21.6 (CH2); MS 
(ESI) m/z 207 [(M + H), 100], 229 [(M + Na), 66]; HRMS (ESI) m/z calcd for C11H14N2O2 
(M + H)+ 207.1128, found 207.1126 (+0.8 ppm error). 
Lab Book Ref.: TD 4/42 
Methyl 2-(3-thiophenyl)cyclopent-2-enecarboxylate 216 
 
Using general procedure C, enol triflate 197 (2.00 g, 7.29 mmol, 1 eq.), 3-thiopheneboronic 
acid (1.40 g, 10.94 mmol, 1.5 eq), Pd(PPh3)4 (842 mg, 0.73 mmol, 0.1 eq) and K2CO3 (2.52 
g, 18.23 mmol, 2.5 eq) in THF (0 mL) and H2O (10 mL) gave the crude product. Purification 
by flash column chromatography on silica with 90:10 hexane–Et2O as eluent gave ester 216 
(1.23 g, 81%) as a yellow oil, RF (90:10 hexane–Et2O) 0.22; IR (ATR) 2948, 1711 (C=O), 
1196 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 3.0, 1.5 Hz, 1H, Ar), 7.36 (dd, J = 
5.0, 1.5 Hz, 1H, Ar), 7.24 (dd, J = 5.0, 3.0 Hz, 1H, Ar), 3.71 (s, 3H, OMe), 2.89 (tt, J = 7.5, 
2.0 Hz, 2H, =CCH2), 2.80 (tt, J = 7.5, 2.0 Hz, 2H, =CCH2), 1.93 (tt, J = 7.5, 7.5 Hz, 2H, 
CH2); 
13C NMR (100.6 MHz, CDCl3) δ 167.0 (C=O), 146.6 (=CAr), 136.7 (ipso-Ar), 128.4 
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(Ar), 127.4 (=CCO2Me), 125.9 (Ar), 124.4 (Ar), 51.4 (OMe), 39.6 (=CCH2), 35.6 (=CCH2), 
21.8 (CH2); MS (ESI) m/z 231 [(M + Na)
+, 100]; HRMS (ESI) m/z calcd for C11H12SO2 (M 
+ Na)+ 231.0450, found 231.0448 (+0.8 ppm error). 
Lab Book Reference: TD 4/81 
1-tert-Butyl-4-methyl  3-phenyl-1,2,3,6-tetrahydropyridine-1,4-dicarboxylate 201 
 
Using general procedure C, enol triflate 200 (200 mg, 0.51 mmol, 1 eq.), phenylboronic acid 
(94 mg, 0.77 mmol, 1.5 eq), Pd(PPh3)4 (59 mg, 0.05 mmol, 0.1 eq) and K2CO3 (178 mg, 1.29 
mmol, 2.5 eq) in THF (10 mL) and H2O (2.5 mL) gave the crude product. Purification by 
flash column chromatography on silica with 80:20 hexane–EtOAc as eluent gave ester 201 
(140 g, 86%) as an orange oil, RF (70:30 hexane-EtOAc) 0.19; IR (ATR) 1705 (C=O, 
CO2Me), 1696 (C=O, Boc) 1628 (C=C) cm
–1; 1H NMR (400 MHz, CDCl3) (rotamers) δ 
7.35-7.29 (m, 3H, Ph), 7.14-7.10 (m, 2H, Ph), 4.24 (br s, 2H, NCH2), 3.60 (br t, J = 5.5 Hz, 
2H, NCH2CH2), 3.47 (s, 3H, OMe), 2.53-2.46 (m, 2H, CH2), 1.49 (m, 9H, CMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 167.2 (C=O, CO2Me), 154.8 (C=O, Boc) , 146.7 (=CAr), 
141.8 (ipso-Ar), 129.7 (Ar), 128.32 (Ar), 128.25 (Ar), 127.7 (Ar), 126.7 (Ar), 120.7 (Ar), 
115.4 (=CCO2Me), 80.3 (CMe3), 51.5 (OMe), 44.0 (NCH2), 43.8 (NCH2), 38.88 
(NCH2CH2), 38.85 (NCH2CH2), 32.9 (CH2), 32.8 (CH2), 28.6 (CMe3); MS (ESI) m/z  318 
[(M + H)+, 5], 340 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C18H23NO4 (M + Na)
+ 
340.1519, found 340.1520 (+0.1 ppm error). 
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1-tert-Butyl-4-methyl  3-(5-pyrimidyl)-1,2,3,6-tetrahydropyridine-1,4-dicarboxylate 
217 
 
KHCO3 (1.07 g, 10.7 mmol, 2.5 eq) was added portionwise to a stirred mixture of enol triflate 
200 (2.00 g, 5.36 mmol, 1.0 eq) and 5-pyrimidylboronic acid (790 mg, 6.43 mmol, 1.5 eq) 
in THF (75 mL) and H2O (25 mL) at rt. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. Then, Pd(dppf)Cl2 (198 mg, 0.27 mmol, 0.05 
eq) was added and the resulting mixture was stirred and heated at 65 °C for 2 h. The mixture 
was allowed to cool to rt and the solids were removed by filtration through Celite. H2O (100 
mL) was added and the aqueous layer was extracted with EtOAc (3 x 100 mL).  The 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica that had been 
washed with 99:1 EtOAc–Et3N with EtOAc as eluent gave ester 217 (976 mg, 57%) as a 
brown oil, RF (EtOAc) 0.26; IR (ATR) 1710 (C=O, CO2Me), 1694 (C=O, Boc), 1625 (C=C); 
1H NMR (400 MHz, CDCl3) (rotamers) δ 9.14 (s, 1H, Ar), 8.52 (s, 2H, Ar), 4.29 (br s, 2H, 
NCH2), 3.63 (br t, J = 5.5 Hz, 2H, NCH2CH2), 3.55 (s, 3H, OMe), 2.53-2.45 (m, 2H, CH2), 
1.49 (m, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 167.5 (C=O, CO2Me), 
158.8 (Ar), 158.4 (Ar), 157.8 (=CAr), 155.6 (=CAr), 155.2 (Ar), 154.6 (Ar), 140.1 (ipso-
Ar), 139.3 (ipso-Ar), 125.2 (=CCO2Me), 84.0 (CMe3), 53.0 (NCH2), 52.7 (NCH2), 51.8 
(OMe), 37.8 (NCH2), 28.4 (CH2), 28.1 (CMe3); MS (ESI) m/z  319 [(M + H)
+, 100]; HRMS 
(ESI) m/z calcd for C16H21N3O4 (M + Na)
+ 319.1532, found 319.1529 (–0.9 ppm error). 
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Methyl 3-(4-fluorophenyl)-2,5-dihydrofuran-4-carboxylate 219 
 
Using general procedure B, β-ketoester 194 (203 mg, 1.41 mmol, 1 eq), iPr2NEt (1.23 mL, 
7.05 mmol, 5 eq) and trifluoromethanesulfonic anhydride (0.285 mL, 1.69 mmol, 1.2 eq) in 
CH2Cl2 (25 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane–EtOAc as eluent gave enol triflate 204 (331 mg) as a brown oil, 1H NMR (400 
MHz, CDCl3) for enol triflate 204: δ 4.89 (t, J = 5.0 Hz, 2H, OCH2), 4.77 (t, J =5.0 Hz, 2H, 
OCH2), 3.81 (s, 3H, OMe). Using general procedure C, enol triflate 204 (331 mg, 1.20 mmol, 
1 eq), 4-fluorophenylboronic acid (252 mg, 1.80 mmol, 1.5 eq), Pd(PPh3)4 (138 mg, 0.12 
mmol, 0.1 eq) and K2CO3 (414 mg, 3.00 mmol, 2.5 eq) in THF (16 mL) and H2O (4 mL)  
gave the crude product. Purification by flash column chromatography on silica with 90:10 
hexane-EtOAc as eluent gave ester 219 (168 g, 53% over two steps) as a white solid, mp 68-
70 °C, RF (90:10 hexane-EtOAc) 0.18; IR (ATR) 1725 (C=O), 1645 (C=C), 830 cm
–1; 1H 
NMR (400 MHz, CDCl3) δ 7.53-7.45 (m, 2H, Ar), 7.09-7.03 (m, 2H, Ar), 5.05-4.99 (m, 4H 
OCH2), 3.70 (s, 3H, OMe); 
13C NMR (100.6 MHz, CDCl3) δ 163.3 (C=O), 163.2 (d, J = 250 
Hz, CF), 148.3 (=CAr), 130.5 (d, J = 8.5 Hz, Ar), 127.4 (d, J = 3.5 Hz, ipso-Ar), 124.3 
(=CCO2Me), 115.3 (d, J = 21.5 Hz, Ar), 79.8 (OCH2), 77.5 (OCH2), 51.7 (OMe); MS (ESI) 
m/z  245 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C12H11O3F (M + Na)
+ 245.0584, found 
245.0580 (+1.9 ppm error). 
Lab Book Reference: TD 4/50 
Methyl 3-(2-tolyl)-2,5-dihydrofuran-4-carboxylate 220 
 
Using general procedure B, β-ketoester 194 (522 mg, 3.62 mmol, 1 eq), iPr2NEt (3.15 mL, 
18.1 mmol, 5 eq) and trifluoromethanesulfonic anhydride (0.731 mL, 4.34 mmol, 1.2 eq) in 
CH2Cl2 (50 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane–EtOAc as eluent gave enol triflate 204 (831 mg) as a brown oil. Using general 
Experimental 
 205  
procedure C, enol triflate 204 (831 mg, 3.01 mmol, 1 eq), 2-tolylboronic acid (613 mg, 4.51 
mmol, 1.5 eq), Pd(PPh3)4 (347 mg, 0.30 mmol, 0.1 eq) and K2CO3 (1.04 g, 7.52 mmol, 2.5 
eq) in THF (40 mL) and H2O (10 mL) gave the crude product. Purification by flash column 
chromatography on silica with 80:20 hexane-EtOAc as eluent gave a 60:40 mixture (by 1H 
NMR spectroscopy) of ester 220 and 4-fluorophenyl boronic acid (312 mg, i.e. 220 mg 
(28%) of ester 220 over 2 steps) and ester 220 (128 g, 16% over 2 steps) as an orange oil, RF 
(80:20 hexane-EtOAc) 0.10; IR (ATR) 1712 (C=O), 1648 (C=C), 1140 cm–1; 1H NMR (400 
MHz, CDCl3) δ 7.25-7.15 (m, 3H, Ar), 7.08-7.04 (m, 1H, Ar), 5.04 (d, J = 5.0 Hz, 1H, OCH), 
5.03 (d, J = 5.0 Hz, 1H, OCH), 4.91 (d, J = 5.0 Hz, 1H, OCH), 4.89 (d, J = 5.0 Hz 1H, OCH), 
3.59 (s, 3H, OMe), 2.25 (s, 3H, CMe); 13C NMR (100.6 MHz, CDCl3) δ 162.8 (C=O), 151.3 
(=CAr), 135.4 (ipso-Ar), 132.1 (ipso-Ar), 130.1 (Ar), 128.4 (Ar), 127.2 (Ar), 126.4 
(=CCO2Me), 125.6 (Ar), 80.5 (OCH2), 76.5 (OCH2), 51.5 (OMe), 19.6 (CMe); MS (ESI) 
m/z 219 [(M + H)+, 3], 241 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C13H14O3 (M + 
Na)+ 241.0835, found 241.0832 (+1.2 ppm error). 
Lab Book Reference: TD 4/91 
Methyl 3-(3-pyridyl)-2,5-dihydrofuran-4-carboxylate 221 
 
Using general procedure B, β-ketoester 194 (522 mg, 3.62 mmol, 1 eq), iPr2NEt (3.15 mL, 
18.1 mmol, 5 eq) and trifluoromethanesulfonic anhydride (0.731 mL, 4.34 mmol, 1.2 eq) in 
CH2Cl2 (50 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane–EtOAc as eluent gave enol triflate 204 (847 mg) as a brown oil. Using general 
procedure C, enol triflate 204 (847 mg, 3.07 mmol, 1 eq), 3-pyridylboronic acid (566 mg, 
4.60 mmol, 1.5 eq), Pd(PPh3)4 (354 mg, 0.30 mmol, 0.1 eq) and K2CO3 (1.06 g, 0.30 mmol, 
2.5 eq) in THF (40 mL) and H2O (10 mL) gave the crude product. Purification by flash 
column chromatography on silica with 50:50 hexane-EtOAc as eluent gave ester 221 (184 
mg, 23%) as an orange oil, RF (50:50 hexane-EtOAc) 0.14; IR (ATR) 1718 (C=O), 1638 
(C=C), 1223; 1H NMR (400 MHz, CDCl3) δ 8.62 (ddd, J = 2.0, 1.5, 1.5 Hz, 1H, Ar), 8.57 
(ddd, J = 5.0, 1.5, 1.5 Hz, 1H, Ar), 7.85 (ddd, J = 8.0, 2.0, 1.5 Hz, Ar), 7.32 (ddd, J = 8.0, 
5.0, 1.5 Hz, 1H, Ar), 5.09-5.05 (m, 2H, OCH2), 5.04-5.01 (m, 2H, OCH2), 3.69 (s, 3H, OMe); 
13C NMR (100.6 MHz, CDCl3) δ 162.9 (C=O), 150.1 (Ar), 148.8 (Ar), 146.0 (=CAr), 136.1 
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(Ar), 127.7 (ipso-Ar or =CCO2Me), 126.5 (ipso-Ar or =CCO2Me), 123.1 (Ar), 79.5 (OCH2), 
77.4 (OCH2), 51.8 (OMe); MS (ESI) m/z 206 [(M + H)
+, 100]; HRMS (ESI) m/z calcd for 
C11H11NO3 (M + H)
+ 206.0812, found 206.0813 (–0.7 ppm error). 
Lab Book Reference: TD 4/92 
Methyl 4-(3-fluorophenyl)-5,6-dihydro-2H-tetrahydropyran-3-carboxylate 223 
 
Using general procedure B, β-ketoester 195 (546 mg, 3.45 mmol, 1 eq), iPr2NEt (3.00 mL, 
17.3 mmol, 5 eq) and trifluoromethanesulfonic anhydride (0.696 mL, 4.14 mmol, 1.2 eq) in 
CH2Cl2 (50 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane–EtOAc as eluent gave enol triflate 218 (812 mg) as a brown oil, 1H NMR (400 
MHz, CDCl3) for enol triflate 218: δ 4.43 (t, J = 2.5 Hz, 2H, OCH2), 3.87 (t, J = 5.5 Hz, 
OCH2), 3.80 (s, 3H, OMe), 2.52 (tt, J = 5.0, 2.5 Hz, 2H, CH2). Using general procedure C, 
enol triflate 218 (812 mg, 2.80 mmol, 1 eq.), 3-methoxyphenylboronic acid (637 mg, 4.20 
mmol, 1.5 eq), Pd(PPh3)4 (243 mg, 0.21 mmol, 0.05 eq) and K2CO3 (966 mg, 7.00 mmol, 
2.5 eq) in THF (40 mL) and H2O (10 mL) gave the crude product. Purification by flash 
column chromatography on silica with 80:20 hexane-EtOAc as eluent gave ester 223 (447 
mg, 52%) as a yellow oil, RF (80:20 hexane-EtOAc) 0.15; IR (ATR) 1711 (C=O), 1642 
(C=C), 1413 1H NMR (400 MHz, CDCl3) δ 7.25 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 6.83 (ddd, J 
= 8.0, 2.5, 1.0 Hz, 1H, Ar), 6.74-6.71 (m, 1H, Ar), 6.68 (dd, J = 2.5, 1.5 Hz, 1H, Ar), 4.43 
(t, J = 2.5 Hz, 2H, OCH2), 3.88 (t, J = 5.5 Hz, 2H, OCH2CH2), 3.79 (s, 3H, ArOMe), 3.49 
(s, 3H, CO2Me), 2.49 (tt, J = 5.5, 2.5 Hz, 2H, CH2); 
13C NMR (100.6 MHz, CDCl3) δ 166.6 
(C=O), 159.4 (ipso-Ar), 146.0 (=CAr), 142.9 (ipso-Ar), 129.3 (Ar), 126.08 (=CCO2Me), 
119.3 (Ar), 113.0 (Ar), 112.5 (Ar), 65.8 (OCH2CH2), 64.2 (OCH2), 55.3 (ArOMe), 51.5 
(CO2Me), 32.4 (CH2); MS (ESI) m/z 271 [(M + Na)
+, 100]; HRMS (ESI) m/z calcd for 
C14H16O4 (M + Na)
+ 271.0941, found 271.0941 (+0.1 ppm error). 
Lab Book Reference: TD 5/14 
  
Experimental 
 207  
1-tert-Butyl 4-methyl 3-phenylpyrrolidine-1,4-dicarboxylate cis-224 
 
Using general procedure A, dihydropyrrole 210 (258 mg, 0.84 mmol) and 10% Pd/C (26 
mg, 0.02 mmol, 0.03 eq) in MeOH (10 mL) for 16 h gave pyrrolidine cis-224 (260 mg, 97%) 
as a yellow oil, RF (80:20 hexane-EtOAc) 0.27; IR (ATR) 1735 (C=O, CO2Me), 1691 (C=O, 
Boc), 1398, 1161 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.33-
7.27 (m, 2H, Ph), 7.26-7.22 (m, 1H, Ph), 7.20-7.14 (m, 2H, Ph), 3.85-3.62 (m, 5H, NCH, 
CHPh), 3.45-3.36 (m, 4H, OMe, CHCO2Me), 1.51 (s, 4.5H, CMe3), 1.50 (s, 4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 171.8 (C=O, CO2Me), 171.7 (C=O, CO2Me), 
154.4 (C=O, Boc), 138.6 (ipso-Ph), 138.4 (ipso-Ph), 128.6 (Ph), 127.6 (Ph), 127.4 (Ph), 
79.84 (CMe3), 79.80 (CMe3), 51.6 (OMe), 50.4 (NCH2), 50.3 (NCH2), 48.9 (CHCO2Me), 
48.0 (CHCO2Me), 47.1 (NCH2), 47.0 (NCH2), 46.5 (CHPh), 45.5 (CHPh), 28.6 (CMe3); MS 
(ESI) m/z 328 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C17H23NO4 (M + Na)
+ 328.1519, 
found 328.1520 (–0.6 ppm error).  
Lab Book Reference: TD 3/69 
1-tert-Butyl-3-methyl 4-phenylpiperidine-1,3-dicarboxylate cis-225 
 
Using general procedure A, tetrahydropyridine 201 (85 mg, 0.27 mmol) and 10% Pd(OH)2/C 
(9 mg, 0.006 mmol, 0.02 eq) in MeOH (10 mL) for 16 h gave piperidine cis-225 (85 mg, 
quant.) as a yellow oil, IR (ATR) 1731 (C=O, CO2Me), 1693 (C=O, Boc), 1423, 761 cm
–1; 
1H NMR (400 MHz, CDCl3) δ 7.30-7.24 (m, 2H, Ph), 7.23-7.16 (m, 3H, Ph), 4.56-4.16 (m, 
2H, NCH), 3.45 (s, 3H, OMe), 3.25-3.05 (m, 1H, NCH), 2.97 (ddd, J = 12.5, 4.0, 4.0 Hz, 
1H, CHPh), 2.93-2.78 (m, 2H, NCH, CHCO2Me), 2.70-2.57 (m, 1H, CH), 1.76-1.67 (m, 1H, 
CH), 1.44 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 172.1 (C=O, CO2Me), 
155.0 (C=O, Boc), 154.9 (C=O, Boc) 137.43 (ipso-Ph), 137.37 (ipso-Ph), 128.8 (Ph), 127.6 
Experimental 
 208  
(Ph), 127.5 (Ph), 127.0 (Ph), 79.7 (CMe3), 52.0 (OMe), 46.1 (NCH2), 45.9 (NCH2), 44.7 
(NCH2), 43.2 (CHCO2Me), 37.6 (CHPh), 28.1 (CMe3), 25.0 (CH2); MS (ESI) m/z 320 [(M 
+ H)+, 6], 342 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C18H25NO4 (M + Na)
+ 342.1676, 
found 342.1678 (–0.7 ppm error). 
Lab Book Reference: TD 4/47 
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Table 4.2 Crystal data and structure refinement for cis-225.  
Identification code  TD 4/47 
Empirical formula  C18H25NO4  
Formula weight  319.39  
Temperature/K  110.00(10)  
Crystal system  orthorhombic  
Space group  Pca21  
a/Å  19.7482(5)  
b/Å  5.66608(19)  
c/Å  30.5147(11)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  3414.43(19)  
Z  8  
ρcalcg/cm
3  1.243  
μ/mm-1  0.708  
F(000)  1376.0  
Crystal size/mm3  0.339 × 0.048 × 0.015  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.956 to 134.144  
Index ranges  -23 ≤ h ≤ 17, -6 ≤ k ≤ 6, -35 ≤ l ≤ 36  
Reflections collected  11627  
Independent reflections  5473 [Rint = 0.0390, Rsigma = 0.0472]  
Data/restraints/parameters  5473/1/423  
Goodness-of-fit on F2  1.076  
Final R indexes [I>=2σ (I)]  R1 = 0.0863, wR2 = 0.2119  
Final R indexes [all data]  R1 = 0.0942, wR2 = 0.2244  
Largest diff. peak/hole / e Å-3  1.07/-0.30  
Flack parameter 0.1(3) 
 
Experimental 
 210  
3-Methyl-1-tert-butyl 4-(5-pyrimidyl)piperidine-1,3-dicarboxylate cis-226 
 
Using general procedure A, tetrahydropyridine 217 (1.94 g, 6.07 mmol) and 10% Pd/C (46 
mg, 0.04 mmol, 0.01 eq) in MeOH (50 mL) for 40 h gave piperidine cis-226 (1.93 g, 99%) 
as a yellow oil, IR (ATR) 1733 (C=O, CO2Me), 1687 (C=O, Boc), 1415, 1156 cm
–1; 1H 
NMR (400 MHz, CDCl3) δ 9.07 (s, 1H, Ar), 8.64 (s, 2H, Ar) 4.67-4.16 (m, 2H, NCH), 3.52 
(s, 3H, OMe), 3.27-3.05 (m, 1H, NCH), 3.27-3.05 (m, 1H, NCH), 2.98 (ddd, J = 12.5, 4.0, 
4.0 Hz, 1H, CHAr), 2.94-2.77 (m, 2H, NCH, CHCO2Me), 2.77-2.60 (m, 1H, CH), 1.76-1.68 
(m, 1H, CH), 1.44 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 171.4 (C=O, CO2Me), 
157.3 (Ar), 156.4 (Ar), 155.3 (C=O, Boc), 135.7 (ipso-Ar), 80.1 (CMe3), 51.8 (OMe), 46.8 
(NCH2), 45.0 (NCH2 or CHCO2Me) , 44.7 (NCH2 or CHCO2Me), 39.4 (CHAr), 28.4 
(CMe3), 24.8 (CH2); MS (ESI) m/z 322 [(M + H)
+, 12], 344 [(M + Na)+, 100]; HRMS (ESI) 
m/z calcd for C16H23N3O4 (M + Na)
+ 344.1581, found 344.1573 (+2.1 ppm error). 
Lab Book Reference: TD 5/25 
Methyl 1-acetyl-3-phenylpyrrolidine-4-carboxylate cis-227 
 
TFA (2.0 mL, 26.1 mmol, 32.0 eq) was added dropwise to a stirred solution of pyrrolidine 
cis-224 (253 mg, 0.83 mmol, 1.0 eq) in CH2Cl2 (10 mL) at rt under Ar. The resulting solution 
was stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure to give 
the crude amine•TFA salt. Et3N (1.16 mL, 8.29 mmol, 10.0 eq) was then added dropwise to 
a stirred solution of the crude amine•TFA salt in CH2Cl2 (10 mL) at rt under Ar. The resulting 
solution was stirred at rt for 10 min. Then, acetyl chloride (0.18 mL, 2.49 mmol, 3.0 eq) was 
added dropwise and the resulting solution was stirred at rt for 16 h. Then, the solvent was 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with EtOAc and then 80:20 EtOAc-MeOH as eluent gave 
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pyrrolidine cis-227 (101 mg, 49%) as a colourless oil, RF (EtOAc) 0.10; IR (ATR) 1731 
(C=O, CO2Me), 1639 (C=O, NC(O)Me), 1420, 1209 cm
–1; 1H NMR (400 MHz, CDCl3) 
(50:50 mixture of rotamers) δ 7.33-7.20 (m, 3H, Ph), 7.17-7.08 (m, 2H, Ph), 3.99-3.83 (m, 
3H, NCH or CHPh), 3.79-3.67 (m, 2H, NCH or CHPh), 3.50 (ddd, J = 7.5, 7.5, 7.5 Hz, 0.5 
H, CHCO2Me), 3.43-3.36 (m, 3.5H, CHCO2Me, CO2Me), 2.13 (s, 1.5H, NC(O)Me), 2.12 
(s, 1.5H, NC(O)Me); 13C NMR (100.6 MHz, CDCl3) (rotamers) 171.8 (C=O, NC(O)Me), 
171.2 (C=O, NC(O)Me), 169.42 (C=O, CO2Me), 169.38 (C=O, CO2Me), 138.2 (ipso-Ph), 
137.6 (ipso-Ph), 128.72 (Ph), 128.66 (Ph), 127.7 (Ph), 127.6 (Ph), 127.42 (Ph), 127.39 (Ph), 
51.73 (OMe), 51.65 (OMe), 51.4 (NCH2), 50.2 (NCH2), 49.1 (CHCO2Me), 48.0 (NCH2), 
47.6 (CHCO2Me), 47.4 (NCH2), 46.7 (CHPh), 44.9 (CHPh), 22.6 (NC(O)Me), 22.50 
(NC(O)Me); MS (ESI) m/z 248 [(M + H)+, 14], 270 [(M + Na)+, 100]; HRMS (ESI) m/z 
calcd for C14H17NO3 (M + Na)
+ 270.1101, found 270.1103 (–1.1 ppm error). 
Lab Book Reference: TD 3/72 
1-Ethyl-4-hydroxymethyl-3-phenylpyrrolidine cis-231 
 
A suspension of LiAlH4 (22 mg, 0.57 mmol, 2.0 eq.) in THF (2 mL) was added dropwise to 
a stirred solution of ester cis-227 (70 mg, 0.28 mmol, 1.0 eq.) in THF (5 mL) at 0 °C under 
Ar. The resulting mixture was stirred at 0 °C for 2 h. Then, H2O (0.1 mL), 2 M NaOH(aq) 
(0.2 mL) and H2O (0.1 mL) were added sequentially. The solids were removed by filtration 
through Celite and the filtrate was dried (MgSO4) and evaporated under reduced pressure to 
give a mixture of products containing alcohol cis-231 (28 mg). Diagnostic signals for cis-
231: 1H NMR (400 MHz, CDCl3) δ 7.35-7.26 (m, 4H, Ph), 7.22-7.17 (m, 1H, Ph), 3.56 (ddd, 
J = 8.5, 8.5, 8.5 Hz, 1H, CHPh), 3.39 (br s, 1H, OH), 3.37 (dd, J = 10.5, 5.5 Hz, 1H, HOCH), 
3.20 (dd, J = 10.5, 5.5 Hz, 1H, HOCH), 2.96-2.89 (m, 3H, NCH), 2.68 (dd, J = 11.0, 5.5 Hz, 
1H, NCH2) 2.57 (q, J = 7.0 Hz, 2H, NCH2Me), 2.56-2.48 (m, 1H, CHPh), 1.13 (t, J = 7.0 
Hz, 3H, NCH2Me). 
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1-Acetyl-4-hydroxymethyl-3-phenylpyrrolidine cis-228 
 
LiBH4 (1.21 mL of a 4 M solution in THF, 4.85 mmol, 4.0 eq.) was added dropwise to a 
stirred solution of ester cis-227 (300 mg, 1.21 mmol, 1.0 eq) in THF (5 mL) at 0 °C under 
Ar. The solution was allowed to warm to rt and then stirred at rt for 16 h. Then, H2O (0.3 
mL) and 2 M NaOH(aq) (0.6 mL) were added sequentially and the mixture was evaporated 
under reduced pressure. The residue was dissolved in EtOAc (10 mL) and then washed with 
H2O (2 x 10 mL), dried (Na2SO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 50:50 hexane-EtOAc 
as eluent gave alcohol cis-228 (97 mg, 37%) as an orange oil, RF (50:50 hexane-EtOAc) 
0.16; IR (ATR) 3371 (OH), 2936, 1621 (C=O), 1456, 1423 cm–1; 1H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 7.37-7.27 (m, 3H, Ph), 7.20-7.14 (m, 2H, Ph), 3.89-
3.85 (m, 1H, NCH), 3.82-3.62 (m, 2H, NCH), 3.62-3.47 (m, 1.5H, CHPh, NCH), 3.47-3.40 
(m, 1H, NCH, CHHO), 3.33-3.29 (m, 1H, HOCH), 3.27-3.21 (m, 0.5H, HOCH), 2.78 
(ddddd, J = 7.0, 7.0, 7.0, 7.0, 7.0 Hz, 0.5H, CHCH2OH), 2.70 (ddddd, J = 7.0, 7.0, 7.0, 7.0, 
7.0 Hz, 0.5H, CHCH2OH), 2.14 (s, 1.5 H, NC(O)Me), 2.13 (s, 1.5 H, NC(O)Me); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 169.8 (C=O), 169.7 (C=O), 139.1 (ipso-Ph), 138.9 (ipso-
Ph), 128.9 (Ph), 128.8 (Ph), 127.8 (Ph), 127.7 (Ph), 127.3 (Ph), 127.2 (Ph), 61.6 (HOCH2), 
61.4 (HOCH2), 52.9 (NCH2), 50.2 (NCH2), 49.2 (NCH2), 47.5 (NCH2), 45.7 (CHCH2OH), 
45.5 (CHCH2OH), 44.1 (CHPh), 44.0 (CHPh), 22.5 (NC(O)Me); MS (ESI) m/z 220 [(M + 
H)+, 15], 242 [(M + Na)+, 100], 258 [(M + K)+, 9]; HRMS (ESI) m/z calcd for C13H17NO2 
(M + Na)+ 242.1151, found 242.1152 (–0.2 ppm error). 
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1-Acetyl-3-phenylpyrrolidine-4-carboxylic acid trans-229 and cis-229 
 
LiOH (12 mg, 0.61 mmol, 3.0 eq) was added portionwise to a stirred solution of ester cis-
227 (50 mg, 0.20 mmol, 1 eq) in 4:1:1 THF–H2O–MeOH (3 mL) at rt under Ar. The resulting 
mixture was stirred at rt for 16 h. Then, the solvent was evaporated under reduced pressure 
and H2O (5 mL) was added. The mixture was washed with CH2Cl2 (5 mL) and then 1 M 
HCl(aq) (5 mL) was added. The mixture was extracted with CH2Cl2 (2 x 10 mL) and the 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give a mixture of products containing a 85:15 mixture by 1H NMR spectroscopy of 
pyrrolidines trans-229 and cis-229 (13 mg) as a yellow oil. Diagnostic signals for 85:15 
mixture of trans-229 and cis-229, 1H NMR (400 MHz, CDCl3) (55:45 mixture of rotamers 
for trans-229, 50:50 mixture of rotamers for cis-229) δ 7.35-7.19 (m, 5H, Ar), 4.05-3.67 (m, 
3.55H, NCH, CHPh), 3.64 (ddd, J = 7.5, 7.5, 7.5 Hz, 0.45H, CHPh), 3.55-3.48 (m, 1H, 
NCH), 3.40 (ddd, J = 7.5, 7.5, 5.0 Hz, 0.15H, CHCO2H), 3.25 (ddd, J = 8.5, 8.5, 8.5 Hz, 
0.40H, CHCO2H), 3.18 (ddd, J = 8.5, 8.5, 8.5 Hz, 0.45H, CHCO2H), 2.11 (s, 0.22H, 
NC(O)Me), 2.10 (s, 0.23H, NC(O)Me), 2.07 (s, 1.2H, NC(O)Me), 2.04 (s, 1.35H, 
NC(O)Me). Spectroscopic data for trans-229 were consistent with a sample independently 
synthesised by another group member.83 
Lab Book reference: TD 3/73 
LiOH (12 mg, 0.58 mmol, 3.0 eq) was added portionwise to a stirred solution of ester cis-
227 (48 mg, 0.19 mmol, 1 eq) in 4:1:1 THF–H2O–MeOH (3 mL) at rt under Ar. The resulting 
mixture was stirred at rt for 2 h. Then, the solvent was evaporated under reduced pressure 
and H2O (5 mL) was added. The mixture was washed with CH2Cl2 (5 mL) and then 1M 
HCl(aq) (5 mL) was added. The mixture was extracted with CH2Cl2 (2 x 10 mL) and the 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give a mixture of products containing a 75:25 mixture (by 1H NMR spectroscopy) of 
pyrrolidines trans-229 and cis-229 (39 mg) as a yellow oil. 
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Methyl 2-(3-N-methylpyrazole)cyclopentane-1-carboxylate cis-254 
 
Using general procedure A, cyclopentene 215 (830 mg, 4.02 mmol, 1.0 eq) and 10% Pd/C 
(83 mg, 0.08 mmol, 0.02 eq) in MeOH (50 mL) for 112 h gave cyclopentane cis-254 (775 
mg, 92%) as an orange oil, IR (ATR) 2949, 1727 (C=O), 1167 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.28 (s, 1H, Ar), 7.14 (s, 1H, Ar), 3.83 (s, 3H, NMe), 3.43 (s, 3H, OMe), 3.33 (ddd, 
J = 7.5, 7.5, 7.5 Hz, 1H, CHAr), 3.04 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H, CHCO2Me), 2.10-1.85 
(m, 5H, CH), 1.76-1.66 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 175.2 (C=O), 138.5 
(Ar), 128.2 (Ar), 121.9 (ipso-Ar), 51.2 (OMe), 49.5 (CHCO2Me), 39.4 (CHAr), 38.9 (NMe), 
32.7 (CH2CH) , 27.9 (CH2CH), 24.2 (CH2CH2CH2); MS (ESI) m/z 209 [(M + H)
+, 100], 231 
[(M + Na)+, 46]; HRMS (ESI) m/z calcd for C11H16N2O2 (M + H)
+ 209.1285, found 209.1285 
(–0.2 ppm error). 
Lab Book Reference: TD 4/59 
1-Hydroxymethyl-2-(3-N-methylpyrazole)cyclopentane cis-252 
 
A suspension of LiAlH4 (219 mg, 5.76 mmol, 2.0 eq.) in THF (5 mL) was added dropwise 
to a stirred solution of ester cis-254 (600 mg, 2.88 mmol, 1.0 eq.) in THF (10 mL) at 0 °C 
under Ar. The resulting mixture was stirred at 0 °C for 2 h. Then, H2O (0.6 mL), 2 M 
NaOH(aq) (1.2 mL) and H2O (0.6 mL) were added sequentially. The solids were removed by 
filtration through Celite and the filtrate was dried (MgSO4) and evaporated under reduced 
pressure to give alcohol cis-252 (503 mg, 98%) as a colourless oil, IR (ATR) 3342 (br, OH), 
2946, 2871, 1401 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.32 (s, 1H, Ar), 7.16 (s, 1H, Ar), 
3.86 (s, 3H, NMe), 3.41-3.32 (m, 2H, HOCH), 3.20 (ddd, J = 7.0, 7.0, 7.0 Hz, CHAr), 2.26 
(ddddd, J = 7.0, 7.0, 7.0, 7.0, 7.0 Hz, 1H, CHCH2OH), 2.05-1.96 (m, 1H, CH), 1.88-1.78 
(m, 2H, CH), 1.77-1.65 (m, 2H, CH), 1.48-1.37 (m, 1H, CH), 1.33 (br s, 1H, OH); 13C NMR 
(100.6 MHz, CDCl3) δ 138.7 (Ar), 128.4 (Ar), 122.4 (ipso-Ar), 64.3 (HOCH2), 45.9 
(CHCH2OH), 38.9 (NMe), 37.2 (CHAr), 32.6 (CH2CH), 27.7 (CH2CH), 23.5 
Experimental 
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(CH2CH2CH2); MS (ESI) m/z 181 [(M + H)
+, 100], 203 [(M + Na)+, 18]; HRMS (ESI) m/z 
calcd for C10H16N2O (M + H)
+ 181.1335, found 181.134 (+0.7 ppm error). 
Lab Book Reference: TD 4/61 
1-Fluoromethyl-2-(3-N-methylpyrazole)cyclopentane cis-253 
 
PyFluor (249 mg, 1.54 mmol, 1.1 eq) was added portionwise to a stirred solution of alcohol 
cis-252 (253 mg, 1.40 mmol, 1.0 eq) and DBU (0.418 mL, 2.80 mmol, 2.0 eq) in toluene (2 
mL) at rt under Ar. The resulting solution was stirred and heated at 70 °C for 64 h. The 
mixture was then allowed to cool to rt and CH2Cl2 (2 mL) was added. Purification by flash 
column chromatography on silica with 50:50 hexane-EtOAc as eluent gave cyclopentane 
cis-253 (57 mg, 22%) as a colourless oil, RF (50:50 hexane-EtOAc) 0.30; IR (ATR) 2953, 
1444, 1399, 986 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H, Ar), 7.11 (s, 1H, Ar), 4.13 
(ddd, J = 47.5, 9.0, 6.5 Hz, 1H, CHF), 4.09 (ddd, J = 47.5, 9.0, 7.0 Hz, 1H, CHF), 3.82 (s, 
3H, NMe), 3.18 (ddd, J = 7.0, 7.0, 7.0 Hz, 1H, CHAr), 2.42-2.47 (m, 1H, CHCH2F), 2.03-
1.92 (m, 1H, CH), 1.87-1.64 (m, 4H, CH), 1.53-1.42 (m, 1H, CH); 13C NMR (100.6 MHz, 
CDCl3) δ 138.7 (Ar), 128.6 (Ar), 121.6 (ipso-Ar), 85.3 (d, J = 165.5 Hz, CH2F), 43.7 (d, J = 
18.0 Hz, CHCH2F), 38.8 (NMe), 37.1 (d, J = 4.5 Hz, CHAr), 32.5 (CH2), 26.7 (d, J = 4.5 
Hz, CH2), 23.3 (CH2); MS (ESI) m/z 183 [(M + H)
+, 100], 205 [(M + Na)+, 7]; HRMS (ESI) 
m/z calcd for C10H15N2F (M + H)
+ 183.1292, found 183.1291 (+0.8 ppm error). 
Lab Book Reference: TD 4/87 
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Methyl 2-(3-pyridyl)cyclopentanecarboxylate cis-250 
 
Using general procedure A, cyclopentene 213 (197 mg, 0.97 mmol, 1.0 eq) and 10% Pd/C 
(20 mg, 0.02 mmol, 0.02 eq) in MeOH (10 mL) for 40 h gave cyclopentane cis-250 (130 
mg, 63%) as a yellow oil, RF (50:50 hexane-EtOAc) 0.33; IR (ATR) 2951, 1728 (C=O), 
1197, 1169 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.45-8.38 (m, 2H, Ar), 7.49 (ddd, J = 8.0, 
4.0, 2.0 Hz, 1H, Ar), 7.20-7.15 (m, 1H, Ar), 3.43-3.34 (m, 1H, CHAr), 3.23 (s, 3H, OMe), 
3.20-3.13 (m, 1H, CHCO2Me), 2.14-1.94 (m, 5H, CH), 1.78-1.66 (m, 1H, CH); 
13C NMR 
(100.6 MHz, CDCl3) δ 174.7 (C=O), 149.9 (Ar), 147.9 (Ar), 137.2 (ipso-Ar), 135.1 (Ar), 
123.0 (Ar), 51.2 (OMe), 49.6 (CHCO2Me), 46.5 (CHAr), 31.1 (CH2), 28.7 (CH2), 24.8 
(CH2); MS (ESI) m/z 206 [(M + H)
+, 100]; HRMS (ESI) m/z calcd for C12H15NO2 (M + H)
+ 
206.1176, found 206.1172 (+1.6 ppm error). 
Lab Book Reference: TD 5/1 
1-Hydroxymethyl-2-(3-pyridyl)cyclopentane cis-249 
 
A suspension of LiAlH4 (37 mg, 0.97 mmol, 2.0 eq.) in THF (2 mL) was added dropwise to 
a stirred solution of ester cis-250 (100 mg, 0.487 mmol, 1.0 eq.) in THF (3 mL) at 0 °C under 
Ar. The resulting mixture was stirred at 0 °C for 2 h. Then, H2O (0.1 mL), 2 M NaOH(aq) 
(0.2 mL) and H2O (0.1 mL) were added sequentially. The solids were removed by filtration 
through Celite and the filtrate was dried (MgSO4) and evaporated under reduced pressure to 
give alcohol cis-249 (72 mg, 83%) as a colourless oil, IR (ATR) 3269 (OH), 2950, 2871, 
1425 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.42 (br s, 1H, Ar), 8.37 (br s, 1H, Ar), 7.50 (d, J 
= 8.0 Hz, 1H, Ar), 7.23-7.15 (m, 1H, Ar), 3.28 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H, CHAr), 3.22 
(dd, J = 10.5, 7.5 Hz, 1H, HOCH), 3.17 (dd, J = 10.5, 7.5 Hz, 1H, HOCH), 2.39 (ddddd, J 
= 7.5, 7.5, 7.5, 7.5, 7.5 Hz, 1H, CHCH2OH), 2.14 (br s, 1H, OH), 2.11-2.02 (m, 1H, CH), 
1.97-1.83 (m, 3H, CH), 1.79-1.68 (m, 1H, CH), 1.60-1.50 (m, 1H, CH); 13C NMR (100.6 
MHz, CDCl3) δ 149.8 (Ar), 147.3 (Ar), 138.4 (ipso-Ar), 135.9 (Ar), 123.2 (Ar), 63.5 
(HOCH2), 46.3 (CHCH2OH), 44.7 (CHAr), 31.0 (CH2), 28.2 (CH2), 23.9 (CH2); MS (ESI) 
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m/z 178 [(M + H)+, 100]; HRMS (ESI) m/z calcd for C11H15NO (M + H)
+ 178.1226, found 
178.1226 (+0.4 ppm error). 
Lab Book Reference: TD 5/9 
1-Fluoromethyl-2-(3-pyridyl)cyclopentane cis-248 
 
PyFluor (68 mg, 0.31 mmol, 1.1 eq) was added portionwise to a stirred solution of alcohol 
cis-249 (68 mg, 0.282 mmol, 1.0 eq) and DBU (0.115 mL, 0.564 mmol, 2.0 eq) in toluene 
(1 mL) at rt under Ar. The resulting solution was stirred and heated at 50 °C for 40 h. The 
mixture was then allowed to cool to rt and CH2Cl2 (2 mL) was added. Purification by flash 
column chromatography on silica with 50:50 hexane-EtOAc as eluent gave cyclopentane 
cis-248 (18 mg, 36%) as a colourless oil, RF (70:30 EtOAc-hexane) 0.46; IR (ATR) 2956, 
2873, 1424 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.50-8.40 (m, 2H, Ar, Ar), 7.54-7.50 (m, 
1H, Ar), 7.22 (dd, J = 8.0, 5.0 Hz, 1H, Ar), 4.06 (ddd, J = 47.5, 9.5, 6.0 Hz, 1H, CHF), 4.00 
(ddd, J = 47.5, 9.5, 6.0 Hz, 1H, CHF), 3.30 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHAr), 2.61-2.46 
(m, 1H, CHCH2F), 2.12-2.02 (m, 1H, CH), 2.02-1.86 (m, 2H, CH), 1.80-1.70 (m, 2H, CH), 
1.68-1.58 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 150.0 (Ar), 147.8 (Ar), 137.3 (ipso-
Ar), 135.8 (Ar), 123.2 (Ar), 84.7 (d, J = 167.5 Hz, CH2F), 44.8 (d, J = 4.0 Hz, CHAr), 44.2 
(d, J = 18.0 Hz, CHCH2F), 31.0 (CH2), 27.4 (d, J = 5.5 Hz, CH2), 24.1 (CH2); MS (ESI) m/z 
180 [(M + H)+, 100]; HRMS (ESI) m/z calcd for C11H14NF (M + H)
+ 180.1183, found 
180.1183 (+0.3 ppm error). 
Lab Book Reference: TD 5/12 
Methyl 2-(3-pyridyl)tetrahydrofurancarboxylate cis-259 
 
Using general procedure A, dihydrofuran 222 (184 mg, 0.89 mmol, 1.0 eq) and 10% Pd/C 
(18 mg, 0.02 mmol, 0.02 eq) in MeOH (10 mL) for 40 h gave tetrahydrofuran cis-259 (177 
mg, 96%) as an orange oil, IR (ATR) 2952, 2880, 1730 (C=O), 1200, 1173 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 8.46 (br s, 2H, Ar), 7.63-7.58 (m, 1H, Ar), 7.25-7.21 (m, 1H, Ar), 4.29 
(dd, J = 9.0, 7.0 Hz, 1H, OCH), 4.17-4.07 (m, 3H, OCH), 3.74-3.68 (m, 1H, CHAr), 3.55 
Experimental 
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(ddd, J = 8.5, 8.5, 7.0 Hz, 1H, CHCO2Me), 3.31 (s, 3H, OMe); 
13C NMR (100.6 MHz, 
CDCl3) δ 171.4 (C=O), 149.6 (Ar), 148.5 (Ar), 135.5 (Ar), 134.9 (ipso-Ar), 123.5 (Ar), 73.5 
(OCH2), 69.0 (OCH2), 51.7 (OMe), 49.8 (CHCO2Me), 45.6 (CHAr); MS (ESI) m/z 208 [(M 
+ H)+, 100], 230 [(M + Na)+, 11]; HRMS (ESI) m/z calcd for C11H13NO3 (M + H)
+ 208.0968, 
found 208.0969 (–0.5 ppm error). 
Lab Book Reference: TD 5/2 
Methyl 2-(2-tolyl)tetrahydrofurancarboxylate cis-258 
 
Using general procedure A, dihydrofuran 221 (69 mg, 0.32 mmol, 1.0 eq) and 10% Pd/C (7 
mg, 0.006 mmol, 0.02 eq) in MeOH (5 mL) for 64 h gave tetrahydrofuran cis-258 (45 mg, 
64%) as an orange oil, IR (ATR) 2950, 1734 (C=O), 1200, 1173 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.20-7.08 (m, 4H, Ar), 4.33 (dd, J = 9.5, 6.0 Hz, 1H, OCH), 4.20-4.09 (m, 3H, 
OCH), 3.93-3.86 (m, 1H, CHAr), 3.53 (ddd, J = 9.5, 8.0, 6.0, 1H, CHCO2Me), 3.17 (s, 3H, 
OMe), 2.37 (s, 3H, CMe); 13C NMR (100.6 MHz, CDCl3) δ 172.4 (C=O), 136.9 (ipso-Ar), 
136.4 (ipso-Ar), 130.2 (Ar), 127.0 (Ar), 126.5 (Ar), 126.1 (Ar), 72.6 (OCH2), 70.0 (OCH2), 
51.3 (OMe), 48.6 (CHCO2Me), 44.2 (CHAr), 20.0 (CMe); MS (ESI) m/z 243 [(M + Na)
+, 
100]; HRMS (ESI) m/z calcd for C13H16O3 (M + Na)
+ 243.0992, found 243.0991 (–0.1 ppm 
error). 
Lab Book Reference: TD 5/5 
3-Hydroxymethyl-4-(2-fluorophenyl)tetrahydrofuran cis-257 
 
Using general procedure B, β-ketoester 194 (3.00 g, 20.8 mmol, 1 eq), iPr2NEt (18.1 mL, 
104 mmol, 5 eq) and trifluoromethanesulfonic anhydride (4.20 mL, 25.0 mmol, 1.2 eq) in 
CH2Cl2 (200 mL) gave the crude product. Purification by flash column chromatography with 
80:20 hexane–EtOAc as eluent gave enol triflate 204 (3.10 g) as a brown oil. Using general 
procedure C, triflate 204 (3.10 g, 11.2 mmol, 1 eq), 2-fluorophenylboronic acid (2.36 mg, 
16.9 mmol, 1.5 eq), Pd(PPh3)4 (1.30 mg, 1.12 mmol, 0.1 eq) and K2CO3 (3.88 g, 28.1 mmol, 
2.5 eq) in THF (160 mL) and H2O (40 mL) gave the crude product. Purification by flash 
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column chromatography on silica with 80:20 hexane-EtOAc as eluent gave a 60:40 mixture 
(by 1H NMR spectroscopy) of alkene 220 and 2-fluorophenylboronic acid (2.13 g (i.e. 1.31 
g (28%) over 2 steps) of alkene 220). 1H NMR (400 MHz, CDCl3) of alkene 220: δ 7.38-
7.27 (m, 2H, Ar), 7.18-7.12 (m, 1H, Ar), 7.12-7.06 (m, 1H, Ar), 5.02-5.00 (m, 4H, OCH2), 
3.66 (s, 3H, OMe). Using general procedure A, the 60:40 mixture of alkene 220 (2.13 g i.e. 
1.31 g (5.90 mmol) of alkene 220) and 10% Pd(OH)2/C (65 mg, 0.04 mmol, 0.01 eq) in 
MeOH (50 mL) for 40 h gave the crude product. Purification by flash column 
chromatography with 80:20 hexane-EtOAc as eluent gave a 60:40 mixture (by 1H NMR 
spectroscopy) of ester cis-264 and 2-fluorophenylboronic acid (1.42 g (i.e. 870 mg (66%) of 
ester cis-264)). 1H NMR of ester cis-264: δ 7.26-7.17 (m, 2H, Ar), 7.10-7.04 (m, 1H, Ar), 
7.04-6.98 (m, 1H, Ar), 4.29 (dd, J = 9.0, 6.0 Hz, 1H, OCH), 4.15-4.09 (m, 3H, OCH2), 4.06-
3.99 (m, 1H, CHAr), 3.59-3.52 (m, 1H, CHCO2Me), 3.28 (s, 3H, OMe). A stirred solution 
of the 60:40 mixture of ester cis-264 and 2-fluoroboronic acid (1.42 g (i.e. 870 mg (3.88 
mmol, 1.0 eq) of ester cis-264) in THF (10 mL) at 0 °C was added dropwise to a stirred 
suspension of LiAlH4 (295 mg, 7.76 mmol, 2.0 eq) in THF (10 mL) at 0 °C under Ar. The 
resulting mixture was stirred at 0 °C for 2 h. Then, H2O (0.2 mL), 2 M NaOH(aq) (0.4 mL), 
and H2O (0.2 mL) were added dropwise sequentially. The solids were removed by filtration 
through Celite and the filtrate was dried (MgSO4) and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography with 50:50 hexane-
EtOAc as eluent gave alcohol cis-257 (598 mg, 79%, 15% over 4 steps) as a colourless oil, 
RF (50:50 hexane-EtOAc) 0.20; IR (ATR) 3393 (br, OH), 1491, 759 cm
–1; 1H NMR (400 
MHz, CDCl3) δ 7.36-7.32 (m, 1H, Ar), 7.26-7.21 (m, 1H, Ar), 7.16-7.11 (m, 1H, Ar), 7.09-
7.02 (m, 1H, Ar), 4.17-4.08 (m, 3H, OCH), 3.89-3.82 (m, 1H, CHAr), 3.78 (dd, J = 8.5, 7.5 
Hz, 1H, OCH), 3.44-3.36 (m, 1H, HOCH), 3.33-3.24 (m, 1H, HOCH), 2.87 (ddddd, J = 7.5, 
7.5, 7.5, 7.5, 7.5 Hz, 1H, CHCH2OH), 1.44 (br s, 1H, OH); 
13C NMR (100.6 MHz, CDCl3) 
δ 160.9 (d, J = 244.0 Hz, CF), 129.0 (d, J = 4.0 Hz, Ar), 128.5, (d, J = 8.0 Hz, Ar), 126.6 (d, 
J = 14.5 Hz, ipso-Ar), 124.6 (d, J = 3.5 Hz, Ar), 115.2 (d, J = 23.0 Hz, Ar), 73.0 (OCH2), 
70.3 (OCH2), 62.0 (HOCH2), 45.6 (CHCH2OH), 38.8 (CHAr); MS (ESI) m/z 219 [(M + 
Na)+, 100]; HRMS (ESI) m/z  calcd for C11H13O2F (M + Na)
+ 219.0792, found 219.0790 
(+0.8 ppm error).  
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3-(O-Methanesulfonyl)hydroxymethyl-4-(2-fluorophenyl)tetrahydrofuran cis-265 
 
Methanesulfonyl chloride (0.265 mL, 3.43 mmol, 1.2 eq) was added dropwise to a stirred 
solution of alcohol cis-257 (560 mg, 2.85 mmol, 1.0 eq) and Et3N (0.796 mL, 5.71 mmol, 
2.0 eq) in CH2Cl2 (10 mL) at rt. The resulting solution was stirred at rt for 16 h. Then, H2O 
(10 mL) was added and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give mesylate cis-265 (492 mg, 63%) as a yellow oil, RF (50:50 hexane-EtOAc) 0.30; IR 
(ATR) 1491, 1355 (S=O), 1174 (S=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 7.34-7.29 (m, 
1H, Ar), 7.29-7.24 (m, 1H, Ar), 7.15 (dddd, J = 7.5, 7.5, 1.0, 1.0 Hz, 1H, Ar), 7.10-7.04 (m, 
1H, Ar), 4.20-4.12 (m, 3H, OCH), 3.96 (dd, J = 10.0, 6.0 Hz, 1H, OCH), 3.91 (m, 1H, 
CHAr), 3.87-3.79 (m, 2H, OCH), 3.09 (ddddd, J = 7.5, 7.5, 7.5, 7.5, 7.5 Hz, CHCH2OS), 
2.84 (s, 3H, SO2Me); 
13C NMR (100.6 MHz, CDCl3) δ 160.8 (d, J = 245.0 Hz, CF), 129.1-
128.9 (m, Ar), 125.4 (d, J = 14.5 Hz, ipso-Ar), 124.8 (d, J = 3.5 Hz, Ar), 115.5 (d, J = 22.5 
Hz, Ar), 72.8 (OCH2), 70.1 (OCH2), 68.6 (OCH2), 42.2 (CHCH2OS), 38.8 (CHAr), 37.1 
(SO2Me); MS (ESI) m/z 275 [(M + H)
+, 5], 297 [(M + Na)+, 100], 313 [(M + K)+, 6]; HRMS 
(ESI) m/z  calcd for C12H15O4SF (M + Na)
+ 297.0567, found 297.0565 (+0.8 ppm error).  
Lab Book Reference: TD 5/33 
3-Azidomethyl-4-(2-fluorophenyl)tetrahydrofuran cis-266 
 
Sodium azide (350 mg, 5.38 mmol, 3.0 eq) was added portionwise to a stirred solution of 
mesylate cis-265 (492 mg, 1.79 mmol, 1.0 eq) in DMF (5 mL) at rt under Ar. The resulting 
mixture was stirred at rt for 10 min and then stirred and heated at 120 °C for 16 h. The 
solution was allowed to cool to rt. Then, H2O (25 mL) and Et2O (25 mL) were added and 
the two layers were separated. The aqueous layer was extracted with Et2O (2 x 25 mL) and 
the combined organic extracts were washed with brine (25 mL), dried (MgSO4) and 
evaporated under reduced pressure to give azide cis-266 (336 mg, 89%) as a colourless oil, 
RF (50:50 hexane-EtOAc) 0.47; IR (ATR) 2097 (N3), 1490, 758 cm
–1; 1H NMR (400 MHz, 
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CDCl3) δ 7.33-7.23 (m, 2H, Ar), 7.15 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H, Ar), 7.10-7.04 (m, 1H, 
Ar), 4.19-4.11 (m, 3H, OCH), 3.89-3.82 (m, 1H, CHAr), 3.75 (dd, J = 9.0, 6.5 Hz, 1H, 
OCH), 3.17 (br dd, J = 9.0, 6.5 Hz, 1H, CHN3), 2.93-2.81 (m, 2H, CHN3, CHCH2N3); 
13C 
NMR (100.6 MHz, CDCl3) δ 160.8 (d, J = 245.0 Hz, CF), 128.9 (d, J = 4.0 Hz, Ar), 124.7 
(d, J = 8.0 Hz, Ar), 125.9 (d, J = 14.5 Hz, ipso-Ar), 124.7 (d, J = 3.5 Hz, Ar), 115.4 (d, J = 
22.5 Hz, Ar), 72.7 (OCH2), 71.0 (OCH2), 51.3 (CH2N3), 42.7 (CHCH2N3), 39.3 (d, J = 3.0 
Hz, CHAr); MS (ESI) m/z 244 [(M + Na)+, 100]; HRMS (ESI) m/z  calcd for C11H12ON3F 
(M + Na)+ 244.0857, found 244.0856 (+0.2 ppm error). 
Lab Book Reference TD 5/34 
4-(2-Fluorophenyl)-3-aminomethyltetrahydrofuran cis-256 
 
Triphenylphosphine (832 mg, 3.17 mmol, 2.0 eq) was added portionwise to a stirred solution 
of azide cis-266 (335 mg, 1.59 mmol, 1.0 eq) in 5:1 THF-H2O (10 mL) at rt under Ar. The 
solution was stirred and heated at 65 °C for 16 h. Then, the mixture was allowed to cool to 
rt and the solvent was evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 50:50 hexane-EtOAc and then 
80:20 EtOAc-MeOH as eluent gave amine cis-256 (270 mg, 87%) as a yellow oil, RF (90:10 
EtOAc-MeOH) 0.17; IR (ATR) 2937 (NH), 2868 (NH), 1490, 759 cm–1; 7.32 (ddd, J = 7.5, 
7.5, 2.0 Hz, 1H, Ar), 7.23 (dddd, J = 8.0, 7.5, 5.5, 2.0 Hz, 1H, Ar), 7.13 (ddd, J = 7.5, 7.5, 
1.5 Hz, 1H, Ar), 7.04 (ddd, J = 10.5, 8.0, 1.5 Hz, 1H, Ar), 4.19-4.09 (m, 3H, OCH), 3.87-
3.81 (m, 1H, CHAr), 3.68 (dd, J = 8.5, 8.5 Hz, 1H, OCH), 2.72 (ddddd, J = 8.0, 8.0, 8.0, 8.0, 
8.0 Hz, 1H, CHCH2NH2), 2.49 (dd, J = 12.5, 8.0 Hz, 1H, CHNH2), 2.35 (dd, J = 12.5, 8.0 
Hz, 1H, CHNH2), 2.13 (br s, 2H, NH2); 
13C NMR (100.6 MHz, CDCl3) δ 160.8 (d, J = 244 
Hz, CF) , 129.2 (d, J = 4.0 Hz, Ar), 128.4 (d, J = 8.5 Hz, Ar), 127.0 (d, J = 14.5 Hz, ipso-
Ar), 124.6 (d, J = 3.5 Hz, Ar), 115.2 (d, J = 23.0 Hz, Ar), 73.4 (OCH2), 70.9 (OCH2), 46.6 
(CHCH2NH2), 41.0 (CH2NH2), 39.0 (d, J = 3.0 Hz, CHAr); MS (ESI) m/z 196 [(M + H)
+, 
100], 218 [(M + Na)+, 5]; HRMS (ESI) m/z  calcd for C11H14ONF (M + H)
+ 196.1132, found 
196.1128 (+2.0 ppm error).   
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Methyl 4-(3-pyrimidyl)-piperidine-3-carboxylate hydrochloride cis-244•HCl 
 
HCl (1.90 mL of a 2 M solution in Et2O, 3.80 mmol, 10.0 eq) was added dropwise to a stirred 
solution of piperidine cis-226 (122 mg, 0.38 mmol, 1.0 eq) in Et2O (5 mL) at rt under Ar. 
The resulting solution was stirred at rt for 16 h. Then, the solvent was evaporated under 
reduced pressure to give piperidine cis-244•HCl (90 mg, 92%) as a yellow oil, IR (ATR) 
2951, 1729 (C=O), 1494, 1219 cm–1; 1H NMR (400 MHz, CD3OD) δ 9.39 (br s, 1H, Ar), 
9.16 (br s, 2H, Ar), 3.85-3.78 (m, 1H, CHAr), 3.69-3.59 (m, 2H, NCH), 3.57 (s, 3H, OMe), 
3.54-3.42 (m, 3H, NCH, CHCO2Me), 2.54-2.40 (m, 1H, CH), 2.26-2.16 (m, 1H, CH); 
13C 
NMR (100.6 MHz, CD3OD) δ 170.7 (C=O), 155.9 (Ar), 151.9 (Ar), 136.7 (ipso-Ar), 51.1 
(OMe), 44.3 (NCH2), 43.1 (NCH2), 41.6 (CHAr), 35.6 (CHCO2Me), 21.3 (NCH2CH2); MS 
(ESI) m/z 222 [M+, 100]; HRMS (ESI) m/z calcd for C11H16N3O2 M
+ 222.1237, found 
222.1236 (+0.6 ppm error). 
Lab Book Reference: TD 5/39 
1-tert-Butyl-3-methyl 4-(2-fluorophenyl)pyrrolidine-1,3-dicarboxylate cis-268 
 
Using general procedure A, ester 220 (338 mg, 1.04 mmol, 1.0 eq.) and 10% Pd/C (34 mg, 
0.03 mmol, 0.03 eq.) in MeOH (10 mL) for 40 h gave ester cis-268 (339 mg, quant.) as a 
white solid, mp 96–100 °C; IR (ATR) 1736 (C=O, CO2Me), 1693 (C=O, Boc), 1401, 1165 
cm–1; 1H NMR (400 MHz, CDCl3) δ 7.23-7.18 (m, 1H, Ar), 7.17-7.11 (m, 1H, Ar), 7.05 
(ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 7.00 (br dd, J = 9.5, 9.5 Hz, 1H, Ar), 3.95 (ddd, J = 7.5, 
7.5, 7.5 Hz, 1H, CHAr or CHCO2Me), 3.83-3.60 (m, 4H, NCH, CHAr or CHCO2Me), 3.49-
3.42 (m, 1H, NCH), 3.34 (s, 3H, OMe), 1.47 (br s, 9H, CMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 172.13 (C=O, CO2Me) 172.04 (C=O, CO2Me), 160.9 (d, J = 247 Hz, 
CF), 154.4 (C=O, Boc), 128.9 (d, J = 8.5 Hz, Ar), 127.7 (d, J = 4.0 Hz, Ar), 125.2 (d, J = 
14.5 Hz, ipso-Ar), 125.0 (d, J = 14.5 Hz, ipso-Ar), 124.3 (d, J = 2.5 Hz, Ar), 124.2 (d, J = 
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2.5 Hz, Ar), 115.3 (d, J = 5.5 Hz, Ar), 115.1 (d, J = 5.5 Hz, Ar), 79.8 (CMe3) 51.5 (OMe), 
48.8 (NCH2), 48.6 (NCH2), 47.7 (NCH2), 47.5 (CHCO2Me), 46.6 (CHCO2Me), 39.1 
(CHAr), 38.3 (CHAr), 28.5 (CMe3); MS (ESI) m/z 346 [(M + Na), 100]; HRMS (ESI) m/z 
calcd for C17H22FNO4 (M + Na)
+ 346.1425, found 346.1425 (–0.1 ppm error). 
Lab Book Reference: TD 5/27 
Methyl 3-(2-fluorophenyl)-pyrrolidine-4-carboxylate hydrochloride cis-246•HCl 
 
HCl (2.03 mL of a 2 M solution in Et2O, 4.05 mmol, 10.0 eq) was added dropwise to a stirred 
solution of pyrrolidine cis-268 (131 mg, 0.405 mmol, 1.0 eq) in Et2O (5 mL) at rt under Ar. 
The resulting solution was stirred at rt for 16 h. Then, the solvent was evaporated under 
reduced pressure to give pyrrolidine cis-246•HCl (105 mg, quant.) as a white solid, mp 81-
83 °C; IR (ATR) 1723 (C=O), 1626, 1433 cm–1; 1H NMR (400 MHz, CD3OD) δ 7.39-7.30 
(m, 1H, Ar), 7.25-7.05 (m, 3H, Ar), 4.20-4.06 (m, 1H, CHAr), 3.92-3.60 (m, 5H, NCH, 
CHCO2Me), 3.28 (s, 3H, OMe); 
13C NMR (100.6 MHz, CD3OD) δ 171.3 (C=O) 160.7 (d, J 
= 246.0 Hz, CF), 129.3 (d, J = 8.5 Hz, Ar), 127.0 (d, J = 3.5 Hz, Ar), 123.7 (d, J = 3.0 Hz, 
Ar), 121.4 (d, J = 14.5 Hz, ipso-Ar), 114.6 (d, J = 22.0 Hz, Ar), 50.6 (OMe), 46.02 (NCH2), 
45.95 (NCH2), 39.3 (CHAr), 35.0 (CHCO2Me); MS (ESI) m/z 224 [M
+, 100]; HRMS (ESI) 
m/z calcd for C12H15FNO2 M
+ 224.1081, found 224.1081 (+0.3 ppm error). 
Lab Book Reference: TD 5/38 
tert-Butyl 3-(2-fluorophenyl)-4-hydroxymethylpyrrolidine-1-carboxylate cis-269 
 
A suspension of LiAlH4 (55 mg, 1.44 mmol, 2.0 eq.) in THF (5 mL) at 0 °C was added 
dropwise to a stirred solution of ester cis-268 (233 mg, 0.72 mmol, 1.0 eq.) in THF (5 mL) 
at 0 °C under Ar. The resulting mixture was stirred at 0 °C for 2 h. Then, H2O (0.1 mL), 2 
M NaOH(aq) (0.2 mL) and H2O (0.1 mL) were added sequentially. The solids were removed 
by filtration through Celite and the filtrate was dried (MgSO4) and evaporated under reduced 
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pressure to give alcohol cis-269 (166 mg, 56%) as a yellow oil, IR (ATR) 3280 (OH), 1696 
(C=O), 871 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.27-7.20 (m, 1H, Ar), 7.16-7.10 (m, 2H, 
Ar), 7.07-7.00 (m, 1H, Ar), 3.85-3.57 (m, 4H, NCH), 3.45-3.35 (m, 1H, HOCH), 3.33-3.20 
(m, 2H, CHAr, HOCH), 2.83-2.70 (m, 1H, CHCH2OH), 1.49 (s, 9H, CMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 161.0 (d, J = 236 Hz, CF), 156.2 (C=O, Boc), 129.9 (d, J 
= 8.5 Hz, Ar), 128.6 (d, J = 8.5 Hz, Ar), 128.3 (d, J = 4.5 Hz, Ar), 127.6 (d, J = 5.0 Hz ipso-
Ar), 126.4 (d, J = 5.0 Hz, Ar), 124.74 (d, J = 4.1 Hz, Ar), 124.70 (d, J = 3.9 Hz, Ar), 115.4 
(d, J = 25.4 Hz, Ar), 79.7 (CMe3), 61.9 (HOCH2), 50.0 (NCH2), 48.0 (NCH2), 47.5 (NCH2), 
44.7 (CHCH2OH), 44.0 (CHCH2OH), 36.99 (CHAr), 36.96 (CHAr), 28.6 (CMe3); MS (ESI) 
m/z 295 [(M + H), 100]; HRMS (ESI) m/z calcd for C16H22FNO3 (M + H)
+ 295.1584, found 
295.1580 (–1.0 ppm error). 
Lab Book Reference: TD 5/30 
4-Hydroxymethyl-3-(2-fluorophenyl)-pyrrolidine hydrochloride cis-247•HCl 
 
HCl (2.30 mL of a 2 M solution in Et2O, 4.60 mmol, 10.0 eq) was added dropwise to a stirred 
solution of pyrrolidine cis-269 (136 mg, 0.46 mmol, 1.0 eq) in Et2O (50 mL) at rt under Ar. 
The resulting solution was stirred at rt for 16 h. Then, the solvent was evaporated under 
reduced pressure to give pyrrolidine cis-247•HCl (106 mg, 97%) as a white solid, mp 53-55 
°C; IR (ATR) 3359 (OH or NH), 2925, 1493, 757 cm–1; 1H NMR (400 MHz, CD3OD) δ 
7.40-7.28 (m, 2H, Ar), 7.18 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 7.11 (dd, J = 10.5, 8.5 Hz, 1H, 
Ar), 4.00-3.90 (m, 1H, NCH), 3.78 (dd, J = 11.0, 11.0 Hz, 1H, NCH), 3.67-3.50 (m, 3H, 
CHAr, NCH), 3.37 (dd, J = 10.5, 4.0 Hz, 1H, HOCH), 3.19 (dd, J = 10.5, 5.5 Hz, 1H, 
HOCH), 2.78 (br s, 1H, CHCH2OH); 
13C NMR (100.6 MHz, CD3OD) δ 162.5 (d, J = 244.5 
Hz, CF), 130.6 (d, J = 8.5 Hz, Ar), 130.1 (d, J = 4.0 Hz, Ar), 125.7 (d, J = 3.5 Hz, Ar), 124.4 
(d, J = 14.5 Hz, ipso-Ar), 116.6 (d, J = 22.5 Hz, Ar), 61.5 (HOCH2), 49.6 (NCH2), 49.2 
(NCH2), 43.6 (CHCH2OH), 40.5 (d, J = 2.0 Hz, CHAr); MS (ESI) m/z 196 [M
+, 100]; HRMS 
(ESI) m/z calcd for C11H15FNO M
+ 196.1132, found 196.1131 (+0.8 ppm error). 
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Methyl 4-(3-methoxyphenyl)tetrahydropyran-3-carboxylate cis-255 
 
Using general procedure A, dihydropyran 223 (57 mg, 0.23 mmol, 1.0 eq) and 10% Pd/C (6 
mg, 0.006 mmol, 0.02 eq) in MeOH (5 mL) for 16 h gave tetrahydropyran cis-255 (47 mg, 
82%) as an orange oil, IR (ATR) 2955, 2841, 1738 (C=O), 1165 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.21 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 6.87-6.83 (m, 1H, Ar), 6.82-6.79 (m, 1H, Ar), 
6.74 (dd, J = 8.0, 2.5 Hz, 1H, Ar), 4.27 (br d, J = 11.5 Hz, 1H, OCH), 4.18 (ddd, J = 11.5, 
4.0, 1.5 Hz, 1H, OCH), 3.78 (s, 3H, ArOMe), 3.75 (dd, J = 11.5, 3.0 Hz, 1H, OCH), 3.55 
(ddd, J = 11.5, 11.5, 2.5 Hz, 1H, OCH), 3.51 (s, 3H, CO2Me), 3.05 (ddd, J = 12.5, 4.0, 4.0 
Hz, 1H, CHAr), 2.90 (br s, 1H, CHCO2Me), 2.72 (dddd, 1H, J = 12.5, 12.5, 11.5, 4.0 Hz, 
1H, OCH2CH), 1.71 (br dd, 1H, J = 12.5, 1.5 Hz, OCH2CH); 
13C NMR (100.6 MHz, CDCl3) 
172.3 (C=O), 159.6 (ipso-Ar), 144.3 (ipso-Ar), 129.3 (Ar), 119.7 (Ar), 113.5 (Ar), 111.6 
(Ar), 69.8 (OCH2CH), 68.6 (OCH2CH2), 55.2 (ArOMe), 51.5 (CO2Me), 46.5 (CHCO2Me), 
41.7 (CHAr), 26.7 (OCH2CH2); MS (ESI) m/z 251 [(M + H)
+, 11] 273 [(M + Na)+, 100]; 
HRMS (ESI) m/z calcd for C14H18O4 (M + Na)
+ 273.1097, found 273.1084 (+4.7 ppm error). 
Lab Book Reference: TD 5/18 
Methyl 2-(3-thiophenyl)cyclopentanecarboxylate cis-251 
 
Using general procedure A, cyclopentene 216 (100 mg, 0.48 mmol, 1.0 eq) and 10% Pd/C 
(10 mg, 0.009 mmol, 0.02 eq) in MeOH (10 mL) for 40 h gave cyclopentane cis-251 (70 
mg, 69%) as an orange oil, IR (ATR) 2949, 1730 (C=O), 1196, 1169 cm–1; 1H NMR (400 
MHz, CDCl3) δ 7.22 (dd, J = 5.0, 3.0 Hz, 1H, Ar), 6.99-6.97 (m, 1H, Ar), 6.94 (dd, J = 5.0, 
1.5 Hz, 1H, Ar), 3.49 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHAr), 3.33 (s, 3H, OMe), 3.16-3.09 
(m, 1H, CHCO2Me), 2.17-1.91 (m, 5H, CH), 1.76-1.64 (m, 1H, CH), 
13C NMR (100.6 MHz, 
CDCl3) 175.2 (C=O), 142.5 (ipso-Ar), 128.0 (Ar), 124.8 (Ar), 120.6 (Ar), 51.2 (OMe), 49.5 
(CHCO2Me), 44.7 (CHAr), 32.0 (CH2), 28.3 (CH2), 24.6 (CH2); MS (ESI) m/z 233 [(M + 
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Na)+, 100]; HRMS (ESI) m/z calcd for C11H14O2S (M + Na)
+ 233.0607, found 233.0604 
(+1.0 ppm error). 
Lab Book Reference: TD 4/94 
2-(3-Thiophenyl)cyclopent-1-enecarboxylic acid 282 
 
2 M NaOH(aq) (3 mL) was added dropwise to a stirred solution of ester 201 (150 mg, 0.72 
mmol, 1 eq) in MeOH (3mL) and THF (3 mL) at rt under Ar. The resulting mixture was 
stirred and heated at 70 °C for 1 h. The mixture was then allowed to cool to rt and H2O (15 
mL) was added. The mixture was washed with CH2Cl2 (10 mL) and 1 M HCl(aq) (10 mL) 
was added. The mixture was extracted with CH2Cl2 (2 x 50 mL) and the combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure to give acid 282 (115 
mg, 84%) as a white solid, mp 116-119 °C; IR (ATR) 2942, 1669 (C=O), 1648 (C=C), 1594, 
1268 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.71 (dd, J = 3.0, 1.0 Hz, 1H, Ar), 7.41 (dd, J = 
5.0, 1.0 Hz), 7.24 (dd, J = 5.0, 3.0 Hz, 1H, Ar), 2.93 (tt, J = 7.5, 2.0 Hz, 2H, =CCH2), 2.91 
(tt, J = 7.5, 2.0 Hz, 2H, =CCH2), 1.94 (tt, J = 7.5, 7.5 Hz, 2H, CH2); 
13C NMR (100.6 MHz, 
CDCl3) δ 171.3 (C=O), 149.7 (=CAr), 136.4 (ipso-Ar), 128.7 (Ar), 126.8 (Ar), 126.7 
(=CCO2H), 124.4 (Ar), 40.4 (=CCH2), 35.5 (=CCH2), 21.6 (CH2); MS (ESI) m/z 195 [(M + 
H)+, 23], 217 [(M + Na)+, 100]; HRMS (ESI) m/z calcd for C10H10O2S (M + Na)
+ 217.0294, 
found 217.0292 (+1.0 ppm error). 
Lab Book Reference: TD 4/93 
2-(3-Thiophenyl)cyclopentanecarboxylic acid cis-276 
 
Using general procedure A, cyclopentene 282 (200 mg, 1.03 mmol, 1.0 eq) and 10% Pd/C 
(20 mg, 0.014 mmol, 0.01 eq) in MeOH (10 mL) for 40 h gave cyclopentane cis-276 (188 
mg, 93%) as a white solid, mp 75-77 °C; IR (ATR) 2953 (br, OH), 1699 (C=O), 1233, 787 
cm–1; 1H NMR (400 MHz, CDCl3) δ 7.19 (dd, J = 5.0, 3.0 Hz, 1H, Ar), 6.99-6.96 (m, 1H, 
Ar), 6.93 (dd, J = 5.0, 1.0 Hz, 1H, Ar), 3.48 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHAr), 3.08 (ddd, 
J = 8.0, 8.0, 6.0 Hz, 1H, CHCO2H), 2.08-1.90 (m, 5H, CH), 1.76-1.66 (m, 1H, CH); 
13C 
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NMR (100.6 MHz, CDCl3) δ 180.1 (C=O), 142.0 (ipso-Ar), 127.9 (Ar), 125.1 (Ar), 120.8 
(Ar), 49.3 (CHCO2H), 44.6 (CHAr), 31.8 (CH2), 28.3 (CH2), 24.1 (CH2); MS (ESI) m/z 219 
[(M + Na)+, 100]; HRMS (ESI) m/z calcd for C10H12O2S (M + Na)
+ 219.0450, found 
219.0449 (+0.6 ppm error). 
Lab Book Reference: TD 4/98 
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Table 5.3 Crystal data and structure refinement for cis-276.  
Identification code  TD 4/98  
Empirical formula  C10H12O2S  
Formula weight  196.26  
Temperature/K  109.95(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  5.3862(2)  
b/Å  6.8010(3)  
c/Å  24.9772(13)  
α/°  90  
β/°  91.998(4)  
γ/°  90  
Volume/Å3  914.40(8)  
Z  4  
ρcalcg/cm
3  1.426  
μ/mm-1  2.837  
F(000)  416.0  
Crystal size/mm3  0.279 × 0.116 × 0.022  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.082 to 134.092  
Index ranges  -6 ≤ h ≤ 6, -6 ≤ k ≤ 8, -25 ≤ l ≤ 29  
Reflections collected  2995  
Independent reflections  1636 [Rint = 0.0172, Rsigma = 0.0253]  
Data/restraints/parameters  1636/0/173  
Goodness-of-fit on F2  1.032  
Final R indexes [I>=2σ (I)]  R1 = 0.0306, wR2 = 0.0731  
Final R indexes [all data]  R1 = 0.0361, wR2 = 0.0781  
Largest diff. peak/hole / e Å-3  0.32/-0.20  
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2-(3-Thiophenyl)cyclopentanecarboxamide cis-275 
 
Ammonia (0.04 mL of a 35% solution in H2O, 0.765 mmol, 3.0 eq) was added to a stirred 
solution of acid cis-276 (50 mg, 0.255 mmol, 1.0 eq), T3P (0.243 mL of a 50% solution in 
EtOAc, 0.382 mmol, 1.5 eq) and iPr2NEt (0.133 mL, 0.765 mmol, 3.0 eq) in CH2Cl2 (3 mL) 
at rt under Ar. The resulting solution was stirred at rt for 18 h. Then, 2 M HCl(aq) (5 mL) was 
added and the mixture was extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts 
were washed with NaHCO3(aq) (2 x 10 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give amide cis-275 (24 mg, 48%) as a white solid, mp 107-110 °C; IR (ATR) 
3322 (NH), 3189 (NH), 2952, 1653 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 7.23 (dd, J 
= 5.0, 3.0 Hz, 1H, Ar), 7.04-7.01 (m, 1H, Ar), 6.98 (dd, J = 5.0, 1.5 Hz, 1H, Ar), 5.16 (br s, 
1H, NH), 4.96 (br s, 1H, NH), 3.42 (ddd, J = 8.0, 8.0, 8.0 Hz, 1H, CHAr), 2.88 (ddd, J = 8.0, 
8.0, 5.5 Hz, 1HMS (ESI) m/z 196 [(M + H)+, 5], 218 [(M + Na)+, 100]; HRMS (ESI) m/z 
calcd for C10H13ONS (M + Na)
+ 218.0610, found 218.0608 (+0.8 ppm error). 
Lab Book Reference: TD 4/100 
4-(3-Methoxyphenyl)-2,3-2H-dihydropyran-3-carboxylic acid 284 
 
2 M NaOH(aq) (12 mL) was added dropwise to a stirred solution of ester 223 (590 mg, 2.38 
mmol, 1 eq) in MeOH (12 mL) and THF (12 mL) at rt under Ar. The resulting mixture was 
stirred and heated at 70 °C for 1 h. The mixture was then allowed to cool to rt and H2O (25 
mL) was added. The mixture was washed with CH2Cl2 (25 mL) and then 1 M HCl(aq) (50 
mL) was added. The mixture was extracted with CH2Cl2 (2 x 50 mL) and the combined 
organic extracts were dried (Na2SO4) and evaporated under reduced pressure to give acid 
284 (481 mg, 86%) as a white solid, mp 101-103 °C; IR (ATR) 1675 (C=O), 1446 (C=C), 
832 cm–1 1H NMR (400 MHz, CDCl3) δ 7.23 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 6.82 (ddd, J = 
8.0, 2.5, 1.0 Hz), 6.72 (ddd, J = 8.0, 1.5, 1.0 Hz, 1H, Ar), 6.67 (ddd, J = 2.5, 1.5 Hz), 4.40 
(t, J = 2.5 Hz, 2H, OCH2), 3.85 (t, J = 5.5 Hz, 2H, OCH2CH2), 3.77 (s, 3H, OMe), 2.48 (tt, 
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J = 5.5, 2.5 Hz, 2H, CH2); 
13C NMR (100.6 MHz, CDCl3) δ 170.3 (C=O), 159.4 (ipso-Ar), 
149.2 (=CAr), 142.5 (ipso-Ar), 129.4 (Ar), 125.0 (=CCO2H), 119.2 (Ar), 113.2 (Ar), 112.6 
(Ar), 65.6 (OCH2), 64.0 (OCH2CH2), 55.3 (OMe), 33.1 (CH2); MS (ESI) m/z 257 [(M + 
Na)+, 100]; HRMS (ESI) m/z calcd for C13H14O4 (M + Na)
+ 257.0784, found 257.0783 (+0.3 
ppm error). 
Lab Book Reference: TD 5/17 
4-(3-Methoxylphenyl)tetrahydropyran-3-carboxylic acid cis-280 
 
Using general procedure A, dihydropyran 284 (460 mg, 1.94 mmol, 1.0 eq) and 10% 
Pd(OH)2/C (46 mg, 0.03 mmol, 0.02 eq) in MeOH (50 mL) for 64 h gave tetrahydropyran 
cis-280 (449 mg, 98%) as a white solid, mp 111-113 °C; IR (ATR) 2965 (br, OH), 2930, 
1703 (C=O), 1165 cm–1; 1H NMR (400 MHz, CDCl3) δ 9.45 (br s, 1H, CO2H), 7.20 (dd, J = 
8.0, 8.0 Hz, 1H, Ar), 6.86-6.82 (m, 1H, Ar), 6.82-6.79 (m, 1H, Ar), 6.77-6.73 (m, 1H, Ar), 
4.32 (br dd, J = 12.0, 1.5 Hz, 1H, OCH), 4.17 (ddd, J = 11.5, 4.5, 1.5 Hz, 1H, OCH), 3.77-
3.72 (m, 4H,rOMe, OCH), 3.55 (ddd, J = 11.5, 11.5, 2.5 Hz, 1H, OCH), 3.04 (ddd, J = 12.0, 
4.0, 4.0 Hz, 1H, CHAr), 2.92-2.88 (m, 1H, CHCO2H), 2.66 (dddd, 1H, J = 12.5, 12.0, 11.5, 
4.0 Hz, 1H, OCH2CH), 1.70 (m, 1H, OCH2CH); 
13C NMR (100.6 MHz, CDCl3) δ 177.6 
(C=O), 159.5 (ipso-Ar), 143.8 (ipso-Ar), 129.3 (Ar), 119.7 (Ar), 113.4 (Ar), 111.7 (Ar), 69.7 
(OCH2CH), 68.5 (OCH2CH2), 55.1 (OMe), 46.2 (CHCO2H), 41.3 (CHAr), 26.4 
(OCH2CH2); MS (ESI) m/z 235 [(M – H)
–, 11]; HRMS (ESI) m/z calcd for C13H16O4 (M – 
H)– 235.0976, found 235.0975 (+0.4 ppm error). 
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Ammonia (0.06 mL of a 35% solution in H2O, 1.27 mmol, 3.0 eq) was added to a stirred 
solution of acid cis-280 (100 mg, 0.42 mmol, 1.0 eq), T3P (0.404 mL of a 50% solution in 
EtOAc, 0.635 mmol, 1.5 eq) and iPr2NEt (0.221 mL, 1.27 mmol, 3.0 eq) in CH2Cl2 (5 mL) 
at rt under Ar. The resulting solution was stirred at rt for 18 h. Then, 2 M HCl(aq) (5 mL) was 
added and the mixture was extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts 
were washed with NaHCO3(aq) (2 x 10 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give amide cis-279 (40 mg, 41%) as a white solid,  mp 71-73 °C; IR (ATR) 2980 
(NH), 1736 (C=O), 1180 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.25-7.20 (m, 1H, Ar), 6.84-
6.81 (m, 1H, Ar), 6.82-6.79 (m, 1H, Ar), 6.78-6.73 (m, 1H, Ar), 6.55 (br s, 1H, NH), 5.65 
(br s, 1H, NH), 4.25 (br d, J = 12.0 Hz, 1H, OCH), 4.21 (br dd, J = 12.0, 4.5 Hz, 1H, OCH), 
3.77 (s, 3H, OMe), 3.68 (dd, J = 12.0, 3.0 Hz, OCH), 3.58 (ddd, J = 12.0, 12.0, 2.5 Hz, 1H, 
OCH), 3.15-3.08 (m, 1H, CHAr), 2.64 (br s, 1H, CHCONH2), 2.42 (dddd, 1H, J = 13.0, 12.0, 
12.0, 4.5 Hz, 1H, OCH2CH), 1.76-1.68 (m, 1H, OCH2CH); 
13C NMR (100.6 MHz, CDCl3) 
δ 174.3 (C=O), 159.6 (ipso-Ar), 143.5 (ipso-Ar), 129.5 (Ar), 119.6 (Ar), 113.6 (Ar), 111.9 
(Ar), 69.4 (OCH2CH), 68.6 (OCH2CH2), 55.2 (OMe), 48.2 (CHCONH2), 42.6 (CHAr), 27.1 
(OCH2CH2); MS (ESI) m/z 236 [(M + H)
+, 25], 258 [(M + Na)+, 100]; HRMS (ESI) m/z 
calcd for C13H17O3N (M + Na)
+ 258.1101, found 258.1096 (+1.9 ppm error). 
Lab Book Reference: TD 5/28 
4-(3-Methoxyphenyl)-3-(N-benzyloxycarbonyl)aminotetrahydropyran cis-285 
 
Diphenylphosphorylazide (0.161 mL, 0.745 mmol, 1.1 eq) was added dropwise to a stirred 
solution of acid cis-280 (160 mg, 0.677 mol, 1 eq) and Et3N (0.189 mL, 1.35 mmol, 2 eq) in 
benzyl alcohol (2 mL) at rt under Ar. The resulting solution was stirred at rt for 1 h and then 
stirred and heated at 85 °C for 16 h. The resulting solution was allowed to cool to rt and the 
Experimental 
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solids were removed by filtration through Celite. The filtrate was evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography with 50:50 
hexane-EtOAc as eluent gave Cbz-protected amine cis-285 (144 mg, 62%) as a colourless 
oil, RF 0.33 (50:50 hexane-EtOAc); IR (ATR) 2954 (NH), 1709 (C=O), 1234, 696 cm
–1; 1H 
NMR (400 MHz, CDCl3) (80:20 mixture of rotamers) δ 7.35-7.15 (m, 5.6H, Ar), 6.97 (br s, 
0.4H, Ar), 6.84-6.72 (m, 3H, Ar), 5.26 (br d, J = 9.0 Hz, 1H, NH), 4.94 (d, J = 12.5 Hz, 
0.8H, OCHPh), 4.90 (d, J = 12.5 Hz, 0.8H, OCHPh), 4.85 (d, J = 12.5 Hz, 0.2H, OCHPh), 
4.42 (d, J = 12.5 Hz, 0.2H, OCHPh), 4.15-4.03 (m, 1.8H, OCH2CH2, CHNH), 4.00 (d, J = 
11.5 Hz, 0.8H, OCH2CH), 3.97-3.85 (m, 0.4H, OCH2CH2, CHNH), 3.76 (s, 2.4H, OMe), 
3.73 (s, 0.6H, OMe), 3.66 (br d, J = 11.5 Hz, 1H, OCH2CH), 3.54 (br dd, J = 12.5, 12.5 Hz, 
1H, CHNH), 3.11-3.02 (m, 1H, CHAr), 3.02-2.93 (m, 1H, CHAr), 2.26-2.12 (m, 0.2H, CH), 
2.05 (dddd, J = 12.5, 12.5, 12.5, 4.5 Hz, 0.8H, CH), 1.78-1.67 (m, 0.8H, CH), 1.63-1.57 (m, 
0.2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 159.7 (ipso-Ar), 155.8 (C=O), 142.9 (ipso-Ar), 
136.6 (ipso- Ar), 129.4 (Ar), 128.5 (Ar), 128.04 (Ar), 127.97 (Ar), 119.8 (Ar), 113.3 (Ar), 
112.0 (Ar), 72.4 (OCH2CH), 68.2 (OCH2CH2), 66.6 (OCH2Ph), 55.2 (OMe), 50.8 (CHNH), 
43.3 (CHAr), 26.1 (CH2). MS (ESI) m/z 342 [(M + H)
+, 10], 364 [(M + Na)+, 100]; HRMS 
(ESI) m/z calcd for C20H23O4N (M + Na)
+ 364.1519, found 364.1516 (+1.0 ppm error). 
Lab Book Reference: TD 5/29 
4-(3-Methoxyphenyl)-3-aminotetrahydropyran cis-278 
 
Using general procedure A, Cbz-protected amine cis-285 (144 mg, 0.42 mmol, 1.0 eq) and 
10% Pd(OH)2/C (14 mg, 0.01 mmol, 0.02 eq) in MeOH (10 mL) for 16 h gave amine cis-
278 as a yellow oil (89 mg, quant.), IR (ATR) 3362 (NH2), 3290 (NH2), 1600, 1583, 725 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26-7.21 (m, 1H, Ar), 6.82-6.74 (m, 3H, Ar), 4.18-
4.02 (m, 4H, OCH, NH2), 3.78 (s, 3H, OMe), 3.62 (br d, J = 12.0 Hz, 1H, OCH2CH), 3.47-
3.39 (m, 1H, OCH), 3.18 (br s, 1H, CHNH2), 3.05-2.99 (m, 1H, CHAr), 2.42 (dddd, J = 13.0, 
13.0, 13.0, 4.5 Hz, 1H, OCH2CH), 1.58 (br d, J = 13.0 Hz, 1H, OCH2CH2); 
13C NMR (100.6 
MHz, CDCl3) δ 160.0 (ipso-Ar), 142.6 (ipso-Ar) , 129.9 (Ar), 119.8 (Ar), 113.4 (Ar), 112.4 
(Ar), 71.5 (OCH2CH), 68.3 (OCH2CH2), 55.3 (OMe), 51.7 (CHNH2), 43.5 (CHAr), 24.2 
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(OCH2CH2); MS (ESI) m/z 208 [(M + H)
+, 100], 230 [(M + Na)+, 6], ; HRMS (ESI) m/z  
calcd for C12H17NO2 (M + H)
+ 208.1332, found 208.1329 (+1.2 ppm error). 
Lab Book Reference: TD 5/36 
3-(4-Fluorophenyl)-2,5-dihydrofuran-4-carboxylic acid 286 
 
LiOH (41 mg, 2.03 mmol, 3.0 eq) was added portionwise to a stirred solution of ester 219 
(150 mg, 0.68 mmol, 1 eq) in 4:1:1 THF–H2O–MeOH (36 mL) at rt under Ar. The mixture 
stirred at rt for 2 h. Then, the solvent was evaporated under reduced pressure and H2O (10 
mL) was added. The mixture was washed with CH2Cl2 (10 mL) and 1 M HCl(aq) (10 mL) 
was added. The mixture was extracted with CH2Cl2 (2 x 20 mL) and the combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure to give acid 286 (110 
mg, 78%) as a yellow oil, IR (ATR) 1678 (C=O), 1439 (C=C), 1220, 751 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 7.48-7.43 (m, 2H, Ar), 7.10-7.03 (m, 2H, Ar), 5.08-5.00 (m, 4H, 
OCH2); 
13C NMR (100.6 MHz, CDCl3) δ 167.7 (C=O), 163.4 (d, J = 250 Hz, CF), 151.0 
(=CAr), 130.6 (d, J = 8.5 Hz, Ar), 127.0 (d, J = 3.5 Hz, ipso-Ar), 123.7 (=CCO2H), 115.5 
(d, J = 22.0 Hz, Ar), 80.2 (OCH2), 77.4 (OCH2); MS (ESI) m/z 207 [(M – H)
–, 100]; HRMS 
(ESI) m/z calcd for C11H8FO3 (M – H)
– 207.0463, found 207.0466 (–1.4 ppm error). 
Lab Book Reference: TD 4/57 
3-(4-Fluorophenyl)tetrahydrofuran-4-carboxylic acid cis-277, 3-(4-Fluorophenyl)-2,3-
dihydrofuran-4-carboxylic acid 287 and 3-(4-Fluorophenyl)furan-4-carboxylic acid 
288 
 
Using general procedure A, dihydrofuran 286 (102 mg, 0.49 mmol, 1.0 eq) and 10% Pd/C 
(11 mg, 0.01 mmol, 0.02 eq) in MeOH (10 mL) for 16 h gave the crude product. Purification 
by flash column chromatography on silica with 69:30:1 hexane-EtOAc-AcOH as eluent gave 
tetrahydrofuran cis-277 (60 mg, 58%) as a white solid, mp 65-67 °C; RF (69:30:1 hexane-
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EtOAc-AcOH) 0.11; IR (ATR) 2959 (br, OH), 2890, 1731 (C=O), 1709, 1511, 1224 cm–1; 
1H NMR (400 MHz, CDCl3) δ 7.22-7.16 (m, 2H, Ar), 7.00-6.92 (m, 2H, Ar), 4.20 (dd, J = 
7.5, 7.5 Hz, 1H, OCH), 4.17-4.05 (m, 3H, OCH), 3.74-3.67 (m, 1H, CHAr), 3.47 (ddd, J = 
7.5, 7.5, 7.5 Hz, 1H, CHCO2H); 
13C NMR (100.6 MHz, CDCl3) δ 176.4 (C=O), 162.0 (d, J 
= 246.0 Hz, CF), 134.1 (d, J = 3.0 Hz, ipso-Ar), 129.8 (d, J = 8.0 Hz, Ar), 115.3 (d, J = 21.0 
Hz, Ar), 73.7 (OCH2), 68.9 (OCH2), 49.7 (CHAr), 47.3 (CHCO2H); MS (ESI) m/z 209 [(M 
– H)–, 100]; HRMS (ESI) m/z calcd for C11H10FO3 (M – H)
– 209.0619, found 209.0618 (+0.7 
ppm error) and an 85:15 mixture (by 1H NMR spectroscopy) of dihydrofuran 287 and furan 
288 (9 mg, i.e. 8 mg (8%) of dihydrofuran 287 and 1 mg (1%) of furan 288) as a yellow oil, 
1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 2.0 Hz, 0.15H, OCH), 7.51 (d, J = 1.5 Hz, 0.85H, 
OCH), 7.44 (d, J = 2.0 Hz, 0.15H, OCH), 7.43-7.37 (m, 0.3H, Ar), 7.19-7.13 (m, 1.7H, Ar), 
7.07-7.01 (m, 0.3H, Ar), 7.01-6.94 (m, 1.7H, Ar), 4.88 (dd, J = 10.0, 10.0 Hz, 0.85H, OCH), 
4.45 (dd, J = 10.0, 5.0 Hz, 0.85H, OCH), 4.26 (ddd, J = 10.0, 5.0, 1.0 Hz, 0.85H, CHAr). 
Lab Book Reference: TD 4/64 
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Table 5.4 Crystal data and structure refinement for cis-277.  
Identification code  TD 4/64 
Empirical formula  C11H11O3F  
Formula weight  210.20  
Temperature/K  110.00(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  5.6368(5)  
b/Å  11.7599(8)  
c/Å  15.6467(12)  
α/°  68.397(7)  
β/°  86.839(7)  
γ/°  87.855(6)  
Volume/Å3  962.71(13)  
Z  4  
ρcalcg/cm
3  1.450  
μ/mm-1  1.000  
F(000)  440.0  
Crystal size/mm3  0.189 × 0.146 × 0.096  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.088 to 142.106  
Index ranges  -6 ≤ h ≤ 6, -14 ≤ k ≤ 11, -19 ≤ l ≤ 17  
Reflections collected  6094  
Independent reflections  3610 [Rint = 0.0221, Rsigma = 0.0383]  
Data/restraints/parameters  3610/0/279  
Goodness-of-fit on F2  1.035  
Final R indexes [I>=2σ (I)]  R1 = 0.0400, wR2 = 0.0969  
Final R indexes [all data]  R1 = 0.0517, wR2 = 0.1046  
Largest diff. peak/hole / e Å-3  0.24/-0.23  
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Methyl 4-(2-methylphenyl)-2,5-dihydrofuran-3-carboxylate 289 
 
2 M NaOH(aq) (1 mL) was added dropwise to a stirred solution of a 60:40 mixture of ester 
221 and 2-tolylboronic acid (72 mg, i.e. 50 mg (0.23 mmol, 1 eq) of ester 221) in MeOH (1 
mL) and THF (1 mL) at rt under Ar. The mixture was stirred and heated at 70 °C for 1 h. 
The mixture was then allowed to cool to rt and H2O (10 mL) was added. The mixture was 
washed with CH2Cl2 (5 ml) and 1 M HCl(aq) (5 mL) was added. The mixture was extracted 
with CH2Cl2 (2 x 20 mL) and the combined organic extracts were dried (Na2SO4) and 
evaporated under reduced pressure to give acid 289 (36 mg, 78%) as a yellow oil, IR (ATR) 
2861 (br, OH), 1685 (C=O), 1272, 754 cm–1; 1H NMR (400 MHz, CDCl3) δ 9.09 (br s, 1H, 
CO2H) 7.26-7.14 (m, 3H, Ar), 7.04 (d, J = 7.5 Hz, 1H, Ar), 5.01 (t, J = 5.0 Hz, 2H, OCH2), 
4.90 (t, J = 5.0 Hz, 2H, OCH2), 2.24 (s, 3H, CMe); 
13C NMR (100.6 MHz, CDCl3) δ 167.4 
(C=O), 153.5 (=CCO2H), 135.3 (ipso-Ar or CMe), 131.6 (ipso-Ar or CMe), 130.3 (Ar), 
128.6 (Ar), 127.1 (Ar), 126.0 (=CAr), 125.7 (Ar), 80.9 (OCH2), 76.4 (OCH2), 19.6 (CMe); 
MS (ESI) m/z 195 [(M – H)– , 100]; HRMS (ESI) m/z calcd for C12H12O3 (M – H)
– 203.0714, 
found 203.0709 (+2.3 ppm error). 
Lab Book Reference: TD 5/3  
2-(2-Tolyl)tetrahydrofurancarboxylic acid cis-281 
 
Using general procedure A, dihydrofuran 289 (189 mg, 0.925 mmol, 1.0 eq) and 10% 
Pd(OH)2/C (19 mg, 0.02 mmol, 0.02 eq) in MeOH (10 mL) for 112 h gave the crude product. 
Purification by flash column chromatography with 79:20:1 hexane-EtOAc-AcOH as eluent 
gave tetrahydrofuran cis-281 (122 mg, 46%) as an orange oil, RF (80:20:1 hexane-EtOAc-
AcOH) 0.09; IR (ATR) 2980 (br, OH), 1736 (C=O), 1180 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 7.17-7.06 (m, 4H, Ar), 4.25 (dd, J = 9.0, 6.0 Hz, 1H, OCH), 4.17-4.07 (m, 3H, OCH), 3.92-
3.85 (m, 1H, CHAr), 3.52-3.45 (m, 1H, CHCO2Me), 2.35 (s, 3H, CMe); 
13C NMR (100.6 
MHz, CDCl3) δ 177.1 (C=O), 136.9 (ipso-Ar), 135.8 (ipso-Ar), 130.4 (Ar), 127.2 (Ar), 126.6 
(Ar), 126.2 (Ar), 72.7 (OCH2), 69.9 (OCH2), 48.2 (CHCO2Me), 44.2 (CHAr), 20.0 (CMe); 
Experimental 
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MS (ESI) m/z 205 [(M – H)–, 100]; HRMS (ESI) m/z calcd for C12H14O3 (M – H)
– 205.0870, 
found 205.0878 (–3.9 ppm error). 
Lab Book Reference: TD 5/19 
References 
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